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Abstract 
Abstract 
Mitochondrial disease is a significant burden on human health, at least 16.5 in 100,000 
individuals are at risk of developing a mitochondrial DNA disorder (Schaefer et al., 
2008). Early-onset mitochondrial disease affects young children and can have 
devastating consequences. One such disease, Alpers’ syndrome, is a rare, autosomal 
recessive, early-onset neurological condition, which was first described in 1931 (Alpers 
1931), characterised by refractory seizures, developmental delay, ataxia, visual 
abnormalities, and liver dysfunction and failure (Huttenlocher et al., 1976). It is primarily 
attributable to mutations in the gene POLG which encodes the only known polymerase 
to replicate mitochondrial DNA (Hance et al., 2005). POLG mutations lead to 
secondary defects of mitochondrial DNA (mtDNA), including deletion and depletion. 
There is a poor prognosis for patients diagnosed with Alpers’ syndrome with no 
effective treatments currently available and little research into this rare condition. 
The research presented here aims to understand the mechanisms leading to the 
neuropathological characteristics and clinical features in 12 patients with Alpers’ 
syndrome and sex-/age-matched controls. Four brain areas were investigated; three 
areas frequently reported to show involvement in Alpers’ syndrome and one area that 
is less frequently described. A battery of immunohistological stains and antibodies was 
used to assess the cohort. Neuropathological features identified and quantified 
included severe neuronal loss, widespread astrogliosis, reduced mitochondrial mass, 
white matter abnormalities, and microglial activation. The most severe neuropathology 
occurred in the posterior regions of the brain, yet all areas investigated exhibited 
pathology to different degrees. The expression of key respiratory chain proteins was 
quantified in neurons from different brain regions and revealed wide variation within 
and between individuals. There was a clear deficiency of complexes I and III in 
neurons, with a milder deficiency of complex IV. Assessment of mtDNA content in 
neurons revealed prominent mtDNA depletion, with a subset of neurons in older 
patients displaying high levels of mtDNA deletion. 
This study shows clear evidence of respiratory chain deficiency of complexes I and III. 
This occurs most severely in the posterior region of the brain, correlating with more 
neuropathological changes in these regions. MtDNA depletion is a central feature of 
DNA damage in neurons likely driving the development of respiratory chain deficiency. 
These findings provide a clear insight into the mechanisms of respiratory chain 
deficiency leading to the neuropathology and clinical features in patients with Alpers’ 
syndrome. 
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Chapter 1 Introduction         
Chapter 1 Introduction 
Mitochondria 
The word ‘mitochondrion’ comes from the Greek roots mito for ‘thread’ and chondrion 
for ‘small grain’, and is a reference to the shape of the mitochondria and to the size of 
the mitochondria relative to the host cell. 
It is a commonly held view that mitochondria arose from the free-living alpha-
proteobacteria which were engulfed by another cell in the environment, most probably 
an archaeal cell, to give rise to all the eukaryotic cells we see today (Margulis 1975). 
This contributed to the formation of the endosymbiotic theory of eukaryote evolution. 
Some eukaryotes do not possess mitochondria, such as the diplomonads, but it is 
thought that events in which these cells lost their mitochondria occurred separately. 
Other mitochondria-like organelles can be found in eukaryotic and prokaryotic cells. 
Hydrogenosomes and mitosomes are double-membraned organelles related to 
mitochondria. Hydrogenosomes have been shown to produce adenosine-5’- 
triphosphate (ATP) with hydrogen production as a by-product (Lindmark and Muller 
1973) and in some species hydrogenosomes may even contain their own genome 
(Akhmanova et al., 1998). Mitosomes do not produce ATP, though there is conflicting 
evidence over whether mitosomes do in fact contain their own DNA (Tovar et al., 1999; 
Léon-Avila and Tovar 2004). 
1.1 Mitochondrial Structure 
Mitochondria are traditionally considered to be oval-shaped organelles, comprised of a 
relatively permeable outer membrane, intermembrane space, selectively permeable 
inner membrane, and a matrix (Figure 1.1). 
The outer membrane is flexible compared to a eukaryotic cell’s cytoplasmic membrane, 
as the mitochondrial outer membrane does not contain sterols. This can be visualised 
through live cell imaging which shows mitochondria moving through the cytoplasm, 
changing their shape and branching off (Martz et al., 1984). The mitochondria may take 
on different morphologies, becoming elongated or corkscrew-shaped, or construct and 
deconstruct networks through fission and fusion, which can be seen in the cells of 
different tissues or even in the same cell. Mitochondrial fission and fusion enable a fine 
control over the number and size of the mitochondrial population of the cell, allowing for 
a rapid response to physiological stresses. The outer membrane contains enzymes 
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and membrane transport proteins such as porins, which act as channels to allow 
passive diffusion of medium sized molecules. 
The intermembrane space is the space between the inner and outer membranes where 
ions and molecules pass into and out of the mitochondrion. Protons are pumped into 
this space by the electron transport chain complexes to maintain the mitochondrial 
membrane potential and to create the proton gradient needed for ATP production (see 
section 1.2.2 ‘Oxidative Phosphorylation’).  
In comparison, the inner membrane is selectively permeable to small, uncharged 
molecules such as water and oxygen which diffuse across it at a rate relative to the 
membrane’s surface area. It increases its surface area by forming invaginations called 
cristae, which may form through the interactions between the inner and outer 
membrane, the actions of ATP synthase (Strauss et al., 2008), and through the 
involvement of OPA1 (Amutha et al., 2004). The mitochondrial DNA (mtDNA) 
molecules are attached to the matrix side of the inner membrane, while the complexes 
of the respiratory chain and ANT translocator, which facilitates ATP export from the 
matrix, are embedded in the inner membrane (Gautheron 1984). The density of the 
cristae is directly proportional to the energy demands of the cell as it is the site of 
oxidative phosphorylation and energy production. 
The matrix contains the mtDNA attached to the inner membrane and RNA, and it is 
where the citric acid cycle (Krebs Cycle) takes place under aerobic conditions. 
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Figure 1.1. The structure of a mitochondrion. 
Mitochondria consist of a double membrane with an intermembrane space in-between. 
The inner membrane forms the folded cristae where the electron transport chain is 
found and encloses the matrix, where the mtDNA, RNA and enzymes of the citric acid 
cycle are found. 
 
Image taken from http://www.bmb.leeds.ac.uk/illingworth/6form/mito.gif   
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1.2 Mitochondrial Dynamics 
1.2.1 Mitochondrial Fission and Fusion 
The mitochondrial population inside a cell is dynamic and can increase or decrease in 
number when necessary. They form a changeable, interconnected network which can 
quickly react to the requirements of the cell. Fission and fusion play important roles in 
cell development and normal cellular functioning and are well regulated processes. 
1.2.1.1 Fission 
Mitochondrial fission is the splitting of a single mitochondrion into two mitochondria 
(Figure 1.2). Under times of stress, increased levels of ATP may be required by the cell 
and the act of fission allows for an increase in the number of mitochondria available for 
ATP production. Fission and mtDNA replication are coordinated so that each daughter 
mitochondrion receives an adequate number of copies of the mitochondrial genome. 
A key protein involved in fission is Dynamin Related Protein 1 (Drp1). Drp1 is recruited 
by the membrane-bound protein hFis1 during fission to allow the splitting of the 
mitochondrial membranes, through the splitting of clathrin-coated pits. The function of 
Drp1 is regulated by two other proteins; hFis1 and Mff1 (Otera et al., 2010). Mitofusin 2 
(Mfn2) is known to link mitochondria to the endoplasmic reticulum (ER), which 
becomes a place where Drp1 complexes form and mitochondrial fission occurs 
(Friedman et al., 2011). 
Fission is thought to be regulated by endophilin B (Karbowski et al., 2004) and the 
sumoylation of Drp1 (Harder et al., 2004) but the exact mechanism has not yet been 
completely explained.  
1.2.1.2 Fusion 
Mitochondrial fusion is the merging of two or more mitochondria into a single 
mitochondrion (Figure 1.2). This may happen many times to form a large network of 
mitochondria merged together. Fusion is a mechanism for sharing mitochondrial 
proteins and genomes, which may rescue a subset of mitochondria that are deficient in 
certain key proteins or certain genes. 
Mitofusin 1 and 2 (Mfn1 and Mfn2) are known to be involved in the fusion of the 
mitochondrial outer membranes (Koshiba et al., 2004) while OPA1 is known to be 
involved in the fusion of the mitochondrial inner membranes (Cipolat et al., 2004). 
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There are known to be different isoforms of OPA1 and these may allow for a greater 
regulation of fusion (Song et al., 2007). 
When mitochondrial fusion is impaired, or the genes involved are affected, it can result 
in disease; it is known that defects in Mfn2 can cause Charcot-Marie-Tooth 2A 
(Züchner et al., 2004) and defects in OPA1 can cause Autosomal Dominant Optic 
Atrophy (Delettre et al., 2000; Ferraris et al., 2008). 
Mitochondrial fusion has been reported to have a protective role in neurons of the 
cerebellum (Chen et al., 2007). This makes clear the central role fusion plays in the 
health of a mitochondrial population. 
 
 
Figure 1.2. Mitochondrial fission and fusion. 
Fission and fusion of the mitochondria is a constant process, allowing fine control over 
the mitochondrial population. Mitochondrial fusion is demonstrated on the left of the 
image. OPA1 and Mfn2 play a key role in the fusion of the inner and outer membranes 
respectively. Mitochondrial fission is demonstrated on the right of the image. Fis1 and 
Drp1 facilitate the splitting of the mitochondrial membranes. Image taken and modified 
from Palaniyandi et al., (2010). 
  
5 
 
Chapter 1 Introduction         
1.2.2 Mitochondrial Transport 
Mitochondria are motile organelles, moving throughout the cytoplasm of a cell to 
provide energy where it is required. Neurons are relatively large cells with an obvious 
polarity; they have a cell soma at one extremity and a cell synapse at the other 
extremity, connected by a long, thin axon. Mitochondria must travel between these 
sites to maintain a healthy functioning of the neuron, providing energy and buffering 
calcium levels. 
This is achieved through a process known as axonal transport. Mitochondria can move 
in a bidirectional manner along a neuronal axon. They may travel in an anterograde 
movement from the cell soma to the synapse to provide energy to this highly dynamic 
site. The mitochondria may move in a retrograde movement from the synapse to the 
cell soma in order to be degraded and recycled. This occurs once the mitochondria 
have become depolarised and they are recycled as part of a normal and healthy cell 
functioning. Microtubule motor proteins aid mitochondrial transport, with kinesin motors 
allowing mitochondrial movement in an anterograde manner (Nangaku et al., 1994) 
and dynein motors allowing mitochondrial movement in a retrograde manner (Hirokawa 
et al., 1990). 
It is known that depolarised mitochondria may cluster around the cell nucleus prior to 
degradation by mitophagy. This may occur in healthy cells as part of the normal 
turnover of mitochondria; mutations in dynein have been shown to reduce perinuclear 
clustering of defective mitochondria in fibroblast cells from mice (Eschbach et al., 
2013). However, increased perinuclear clustering and movement of mitochondria away 
from the cell periphery is reported to occur after the disruption of the dynein complex in 
HeLa cells (Varadi et al., 2004). The mechanisms involved in coordinating 
mitochondrial transport and degradation are not well understood and are an area under 
current investigation.  
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1.3 Mitochondrial Function 
Mitochondria have a diverse range of functions within the cell which include energy 
generation, calcium dynamics, production of reactive oxygen species, and control over 
whether the cell enters the apoptotic pathway. 
1.3.1 Aerobic Respiration 
Mitochondria are the main sites of aerobic cellular respiration within eukaryotic cells, 
producing ATP as a source of energy for both the mitochondrion and the cell. Different 
stages of the process take place in various parts of the mitochondrion and the cell. For 
each molecule of glucose that enters glycolysis and undergoes aerobic respiration 38 
molecules of ATP are produced, though in reality fewer molecules are in fact available 
due to the energetic costs of actively transporting substrates required for aerobic 
respiration into the mitochondria. 
1.3.1.1 Glycolysis 
The first step in the process of respiration is glycolysis; a form of anaerobic respiration 
which takes place in the cytosol of the eukaryotic cell. One molecule of glucose 
(C6H12O6) splits to produce two molecules of pyruvate (CH3COCOO-), forming many 
intermediate molecules in the process and producing a net gain of two ATP molecules. 
In actuality, four ATP molecules are produced by glycolysis though two are in fact 
consumed in order to add phosphate groups to the glucose molecule during the initial 
reactions. Pyruvate may be subject to anaerobic conditions forming lactate, or aerobic 
conditions during the citric acid cycle which is mentioned in greater detail in the next 
section. Although anaerobic respiration does not produce as great a quantity of ATP as 
oxidative phosphorylation (Pfeiffer et al., 2001), it does produce it 100 times faster than 
aerobic respiration (oxidative phosphorylation), which has a significant advantage in 
the muscle tissue where rapid energy increase can be vital. 
1.3.1.2 The Citric Acid Cycle 
The second step in the process of respiration is the citric acid cycle (also known as the 
Krebs Cycle) which takes place in the matrix of the mitochondria. Pyruvate molecules 
produced during glycolysis (see section 1.2.1.1 ‘Glycolysis’ above) are oxidised to 
acetyl coenzyme-A and then enter an 8 enzyme cycle, producing intermediates 
including citrate, succinate, fumarate, and malate. During the production of these 
intermediates, NADH and FADH2 are generated and subsequently used as substrates 
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in oxidative phosphorylation while water and carbon dioxide are produced as end 
products. 
1.3.2 Oxidative Phosphorylation 
Oxidative phosphorylation is the process by which ATP is produced using the 
respiratory chain complexes, found on the inner mitochondrial membrane. Production 
of ATP can be controlled through a negative feedback mechanism, with increasing 
levels of ATP inhibiting further ATP production (Reeves and Hall 1973). 
There are four complexes that make up the electron transport chain (ETC) as well two 
electron carriers; complex I-IV with electron carriers ubiquinone and cytochrome c 
(Figure 1.3). As electrons flow along the four complexes of the ETC, hydrogen ions are 
produced which are pumped into the intermembrane space by complexes I, III, and IV. 
As the hydrogen ions accumulate they create a proton-motive force.  This proton-
motive force was first described in the chemiosmotic hypothesis (Mitchell 1961) and is 
harnessed by complex V (ATP synthase). As the hydrogen ions move down their 
electrochemical gradient they cause complex V to rotate, combining adenosine 
diphosphate (ADP) and a phosphate ion (P+) to generate ATP. 
Chemicals termed ‘uncouplers’ can act to allow the hydrogen ions to leak back across 
the inner membrane and flow down their concentration gradient without passing 
through complex V. This inefficiency may appear a wasteful action yet it can, under 
certain circumstances, be beneficial to the organism in the generation of heat (Rial and 
Nicholls 1984). This form of non-shivering thermogenesis can be used as an alternative 
to using ATP for the muscle contractions of shivering. 
1.3.2.1 The Electron Transport Chain 
The electron transport chain (ETC) is a group of multi-subunit protein complexes 
embedded in the inner mitochondrial membrane. There are five complexes in total, four 
comprising the ETC and the addition of complex V (ATP synthase) forming the 
mitochondrial respiratory chain (Figure 1.3). The most important property of the ETC is 
its capacity to permit oxidation-reduction reactions to occur in complex I-IV. This 
happens due to the iron-sulphur groups within the complexes (Page et al., 1999). The 
mitochondrial respiratory chain is encoded by both nuclear and mitochondrial genes 
(Table 1.1). The five complexes form larger supercomplexes which allow for greater 
efficiency of the mitochondrial respiratory chain, increasing the stability of the 
complexes and providing some protection from oxidative stress. Supercomplexes may 
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also play a role in shaping the inner mitochondrial membrane (Vonck and Schäfer 
2009). 
 Alternative name of the 
complex 
Subunits 
encoded by 
nuclear genes 
Subunits encoded 
by mitochondrial  
genes 
Complex I NADH dehydrogenase 37 7 (ND1-ND6, ND4L) 
Complex II Succinate dehydrogenase 4 0 
Complex III Ubiquinol cytochrome c 
reductase 
10 1 (Cytochrome b) 
Complex IV Cytochrome c oxidase 11 3 (COX I-III) 
Complex V ATP synthase 17 2 (ATP6, ATP8) 
Table 1.1. Table of the nuclear and mitochondrial location of genes coding for 
subunits of the mitochondrial respiratory chain in humans.  
All 13 polypeptides encoded by the mitochondrial genome are represented in the table. 
 
NADH and FADH2, generated by the citric acid cycle, are the initial substrates of the 
ETC which are oxidised by complex I and complex II. Electrons donated by these 
substrates are passed along the ETC allowing hydrogen ions to be pumped across the 
inner membrane and into the intermembrane space. Both complex I and complex II 
pass electrons to an electron carrier called ubiquinone. Complex III receives these 
electrons from ubiquinone and passes the electrons to another carrier, cytochrome c. 
Cytochrome c then passes the electrons to complex IV, at which the electrons react 
with oxygen (O2) and hydrogen ions (H+) to produce water. 
The process of ATP production using the respiratory chain was first proposed in 1961 
(Mitchell 1961) but their enzyme systems were first deduced much earlier, in 1948 
(Hogeboom et al., 1948). Since that time, the individual complexes of the respiratory 
chain have been investigated and characterised, with their role in human disease the 
current topic of research.   
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1.3.2.1.1 Complex I - NADH: Ubiquinone Oxidoreductase 
Complex I, NADH: ubiquinone oxidoreductase, is the largest of all of the five 
complexes in the OXPHOS system and produces much of the proton-motive force 
required for ATP synthesis. It functions to catalyse the oxidation of NADH to NAD+ and 
the simultaneous reduction of the electron carrier ubiquinone (Q) to ubiquinol (QH2). 
This results in the movement of two electrons from NADH to ubiquinone, forming 
ubiquinol which is later oxidised by complex III. As the translocation of electrons 
occurs, four hydrogen ions are pumped across the inner membrane into the 
intermembrane space; it is this build-up of hydrogen ions that will create the 
electrochemical gradient that allows the production of ATP.  
A 1MDa protein, it consists of at least 44 subunits; 37 subunits encoded by nuclear 
genes and 7 subunits encoded by mitochondrial genes (Anderson et al., 1981). There 
are 14 ‘core’ subunits that perform the redox reactions; 7 of these are encoded from 
mitochondrial DNA (ND1-6, ND4L) and 7 from nuclear DNA (NDUFS1-3, NDUFS7-8, 
NDUFV1-2). The other subunits act to stabilise this large complex. The complex takes 
on an L-shaped conformation, with the hydrophobic arm spanning the entire plasma 
membrane and the hydrophilic arm extending into the mitochondrial matrix (Figure 1.4). 
The hydrophilic domain is the part of the protein that catalyses the redox reactions, 
transferring electrons from its iron-sulphur clusters to the electron carrier ubiquinone 
(Q) to reduce it to ubiquinol (QH2). The hydrophobic domain attaches the complex to 
the inner membrane. 
The assembly of complex I requires 11 assembly factors, all encoded from nuclear 
DNA. Little is known about its process of assembly but it is thought that assembly 
progresses through intermediate stages (Antonicka et al., 2003), with the core subunits 
being assembled first, as opposed to the assembly of single subunits sequentially. It is 
thought that the hydrophobic membrane arm is assembled first, with other subunits 
assembling together and then attaching onto the arm (Vogel et al., 2007). 
Defects in complex I are the most commonly noted defects in mitochondrial disease 
(Darin et al., 2001) but may be underdiagnosed due to their heterogeneous clinical 
signs and potential for normal lactate levels (Kirby et al., 1999). The intricacy and size 
of this complex makes issues with subunit availability or subunit assembly more likely 
to occur than with other complexes. 
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Figure 1.4. Image of the respiratory chain complex I. 
The L-shaped complex is shown with labelled subunits. ND1-3 shown are 
mitochondrially-encoded subunits. Image taken and modified from Mandavilli et al., 
(2002). 
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1.3.2.1.2 Complex II - Succinate: Ubiquinone Oxidoreductase 
Complex II, succinate: ubiquinone oxidoreductase partially spans the inner 
mitochondrial membrane. It contains a hydrophobic domain within the plasma 
membrane and a hydrophilic domain that interacts with the mitochondrial matrix (Figure 
1.5). This complex plays a role in both the electron transport chain and the citric acid 
cycle, catalysing the simultaneous oxidation of succinate to fumarate and the reduction 
of ubiquinone (Q) to ubiquinol (QH2). Hydrogen ions are not transported into the 
intermembrane space by this complex and so it does not contribute directly to the 
electrochemical gradient that enables the generation of ATP. 
Complex II is a 127.5kDa protein made up of 4 subunits, all of which are encoded by 
the nuclear genome. The subunits are labelled A, B, C, and D and play a functionally 
distinct role within the complex. Subunit A is a flavoprotein to which succinate is able to 
bind. Subunit B is an iron-sulphur protein to which electrons are passed from subunit A, 
and like subunit A is hydrophilic and can interact outside of the plasma membrane. 
Subunits C and D are hydrophobic proteins within the plasma membrane, containing a 
bound haem group, anchoring the complex in the inner membrane and transferring 
electrons to ubiquinone (Sun et al., 2005). 
 
Figure 1.5. Image of the respiratory chain complex II. 
The complex is shown with labelled subunits. The electron carrier ubiquinone is shown 
as yellow circled UQ. Electrons pass from complex II to ubiquinone. Hydrophilic subunit 
A is shown as a flavoprotein and subunit B is shown as an iron protein. Hydrophobic 
subunit C and subunit D are shown within the membrane as FrdC and FrdD. Image 
taken and modified from Mandavilli et al., (2002). 
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1.3.2.1.3 Complex III - Ubiquinol Cytochrome c Reductase 
Complex III, ubiquinol cytochrome c reductase, functions to catalyse the oxidation of 
ubiquinol (QH2) and the simultaneous reduction of cytochrome c (Baum et al., 1967), 
both carrier molecules in the ETC. Four hydrogen ions are pumped across the inner 
membrane, into the intermembrane space to be harnessed by the proton-motive force 
and produce ATP. 
This complex is a 248kDa protein made up of 11 subunits (Figure 1.6); 10 subunits are 
encoded by nuclear genes and one subunit, cytochrome b, is encoded by mitochondrial 
genes. Three of the eleven subunits that make up this complex have prosthetic groups 
attached; the iron-sulphur protein (Rieske subunit), cytochrome c1, and cytochrome b 
with two haem groups attached: bL and bH.  
During electron transfer, two electrons are transferred from ubiquinol to the Rieske 
subunit and the cytochrome bL haem. In the first reaction, the Rieske subunit becomes 
reduced and it oscillates, facilitating electron transfer to cytochrome c1. In the second 
reaction, an electron transfers from the cytochrome bL haem to the bH haem, both 
reactions releasing hydrogen ions and increasing the proton-motive force.  
The ‘core’ subunits of complex III facilitate the assembly of the complex through stable 
intermediate assembly stages. The full assembly of complex III requires 2 assembly 
factors, both encoded from nuclear DNA (Smith et al., 2012). 
 
Figure 1.6. Image of the respiratory chain complex III. 
The third complex is shown with labelled subunits. The electron carrier ubiquinone is 
shown as yellow circled UQ. Electrons pass from ubiquinone, to complex III, and to the 
next electron carrier, cytochrome c, shown as aquamarine circled Cyt c. The 
mitochondrially-encoded subunit cytochrome b is shown at the centre of the complex. 
Image taken and modified from Mandavilli et al., (2002). 
14 
 
Chapter 1 Introduction         
1.3.2.1.4 Complex IV - Cytochrome c Oxidase 
Complex IV, cytochrome c oxidase, functions to catalyse the oxidation of cytochrome c 
and production of water by combining electrons with molecular oxygen and hydrogen 
ions. During this reaction, two hydrogen ions are moved across the inner membrane, 
into the intermembrane space which increases the proton-motive force. 
This complex is a 204kDa protein made up of several metal prosthetic sites and 14 
subunits; 11 subunits are encoded by nuclear genes, 3 subunits, COX I-III, are 
encoded by mitochondrial genes. COX I and COX II make up the catalytic core of the 
subunit, containing two haem groups (a and a3) and two copper groups (cuA and cuB) 
which allow electron transfer and oxygen reduction. Little is known about the enzymatic 
role of COX III subunit. Complex IV exists as a dimer to allow for functional efficiency, 
and it is the final complex in the ETC and the terminal electron acceptor (Figure 1.7). 
The assembly of complex IV occurs on both sides of the inner membrane and requires 
18 assembly factors, all encoded from nuclear DNA (Mick et al., 2011). It is suggested 
that mitochondrially-encoded COX I is directly linked to the assembly and plays a 
central role in the association of the other subunits, including COX II and COX III. 
 
Figure 1.7. Image of the respiratory chain complex IV. 
The final complex of the electron transport chain is shown with labelled subunits. 
Mitochondrially-encoded subunits COX I, II, and III are labelled in the centre of the 
complex. The electron carrier cytochrome c is shown as aquamarine circled Cyt c. 
Electrons pass from cytochrome c to complex IV where they are combined with 
molecular oxygen and hydrogen ions to form water. Image taken and modified from 
Mandavilli et al., (2002). 
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1.3.2.2 Complex V – ATP Synthase 
Complex V, ATP synthase, is made up of 19 subunits; 17 subunits are encoded by 
nuclear genes, 2 subunits are encoded by mitochondrial genes ATP6 and ATP8. It is 
the final protein of the OXPHOS system. Human ATP synthase is also termed F1Fo-
ATPase named after the two functional domains of the complex; the F1 domain, which 
contains the functional portion of the complex that synthesises ATP using the 
electrochemical gradient produced by the mitochondrial respiratory chain, and the Fo 
domain, embedded in the inner membrane (Figure 1.8).  
Complex V has an intricate structure comprising two functional domains made up of 
many subunits. The F1 domain is made up of three copies of subunits α and β, and a 
single copy of subunits γ, δ and ε. These subunits form the functional parts of the 
complex: subunits α and β form the knob, and subunits γ, δ and ε form the rod (Figure 
1.8). The membrane-bound Fo domain is made up of a subunit-c ring which forms the 
functional rotor (Figure 1.8). It also consists of a single copy of subunits a, b, d, F6, and 
OSCP which form the stator. There are four further additional subunits which associate 
with the Fo domain, including subunit a and subunit A6L encoded by the mitochondrial 
genes ATP6 and ATP8 (Anderson et al., 1981). 
The synthesis of ATP from ADP and phosphate is performed by the F1 domain, 
powered by the movement of hydrogen ions (the proton-motive force) that had been 
generated by the electron transport chain. The movement of hydrogen ions down its 
electrochemical gradient causes the subunit-c ring to rotate (Cox et al., 1984). This 
causes the rod subunits of F1 domain to also rotate, in particular the γ subunit, and a 
flow of protons through subunit α, through the subunit-c ring and into the mitochondrial 
matrix. Rotation of the γ subunit provides energy for ATP synthesis, which occurs due 
to a binding-change mechanism in the subunits (Boyer 1975). Each binding site on the 
three β subunits undergoes three conformational changes to bind ADP, phosphate, 
and then release the formed ATP molecule. Binding of the ADP and phosphate occurs 
in the open conformational state which causes a rotation of the α and β subunits by 
120o. Formation of ATP occurs in the tight conformational state with the release of a 
molecule of ATP from the loose conformational state and a return to the ability to bind 
another ADP and phosphate molecule. 
The assembly of complex V begins by attachment of the membrane-bound subunit-c 
ring. The F1 domain will then attach to this and finally the stator arm, before 
dimerization of two fully assembled complexes (Jonckheere et al., 2012). Full assembly 
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requires 4 assembly factors, all encoded from nuclear DNA (Wang et al., 2001). 
Complex V mutations and assembly abnormalities have been implicated in 
mitochondrial disease (De Meirleir et al., 2004; Mayr et al., 2010; Jonckheere et al., 
2013) but the incidence may be higher than reported as this complex is seldom 
investigated and not a regular candidate for genetic analysis. 
 
 
 
Figure 1.8. Image of complex V (ATP synthase). 
Complex V of the OXPHOS system is shown. The F1 domain comprises the part of the 
complex that synthesises ATP from ADP. The Fo domain anchors the complex to the 
inner membrane and channels hydrogen ions through. Image taken and modified from 
Nakamoto et al., (2008). 
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1.3.2.3 Supercomplexes 
The mitochondrial respiratory chain is often shown as individual, unlinked complexes in 
the mitochondrial inner membrane, electron carriers allowing the movement of 
electrons between them. However, it has now been shown that the complexes come 
together to form functionally intact supercomplexes (Schägger and Pfeiffer 2000; 
Vonck and Schäfer 2009), which have also been termed respirasomes due to their 
functional respiration (Acín-Pérez et al., 2008). 
Complex I, a large and unstable protein, has been found to associate with both 
complex III and complex IV within the supercomplex, ensuring it remains stable (Acín-
Pérez et al., 2004; Diaz et al., 2006). It has been reported that any disruption between 
complex I and complex III may increase reactive oxygen species (ROS) production 
(Maranzana et al., 2013) confirming the stabilising effect that other complexes have 
upon complex I and the beneficial properties of the supercomplex.  
In addition to a respiratory role, the supercomplexes may also be involved in shaping 
the cristae of the inner mitochondrial membrane through their presence on narrow 
cristae of the inner membrane (Vogel et al., 2006). In addition, supercomplexes allow 
for substrate channelling (Bianchi et al., 2004). 
1.3.3 Apoptosis 
Apoptosis is the programmed cell death that occurs naturally in multicellular organisms. 
It is a controlled death of the entire cell as opposed to the two other forms of cell death; 
necrosis, where cell injury results in premature cell death; and autophagy, which is the 
controlled degradation of cellular components. Apoptotic cell death is a natural process 
initiated by either extracellular or intracellular signals. The general process of apoptosis 
involves the blebbing of the cell membrane, cell shrinkage, condensation of 
chromosomes, and nuclear fragmentation. There is typically no inflammation of 
surrounding tissue or strong osmotic reaction involved. It is a process that has evolved 
to allow for the removal of individual damaged cells from a multicellular organism, so 
that the organism may survive and reproduce. 
There are two main pathways of apoptosis that lead to downstream modifications of 
structural proteins. The extracellular pathway is initiated by cell surface receptors while 
the intracellular pathway involves the mitochondria (Zamzami et al., 1995). Both the 
extracellular and intracellular pathways activate caspases which then go on to activate 
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pro-apoptotic proteins in a cascade reaction that can result in many activated proteins 
from many times fewer caspase proteins.  
The extracellular pathway is mediated by membrane-bound proteins of the tumour 
necrosis factor (TNF) receptor family such as FAS or TNFR1, termed ‘death receptors’, 
on the cell’s surface. For example, immune system cells may produce the FAS ligand 
which binds to the FAS death receptor protein on the cell’s surface. Once bound, these 
receptors can bind to intracellular adaptor proteins that can activate caspase-8 
molecules. There is a downstream cascade reaction resulting in apoptosis of the cell. 
The intracellular pathway is mediated by the release of cytochrome c from the 
mitochondria (Liu et al., 1996). The cytochrome c is released into the cytosol and there 
it binds to and activates APAF-1 protein. This induces the assembly of an apoptosome 
which when it binds to caspase-9, promotes the activation of caspase-3 and apoptosis 
of the cell. The intracellular pathway is controlled by proteins from the Bcl-2 family; 
when Bcl-2 or Bcl-XL are inhibited, other pro-apoptotic members of the protein family 
such as BAX and BAK can promote the permeabilisation of the outer mitochondrial 
membrane and the release of cytochrome c. Apoptosis-inducing factor (AIF) is also 
released from mitochondria to promote apoptosis (Susin et al., 1999) in a system that 
is caspase-independent and instead causes DNA fragmentation (Susin et al., 2000). 
Apoptotic pathways have many check points to allow apoptosis to halt before it reaches 
a certain point, beyond which apoptosis is irreversible. In addition to these, it has been 
reported that OPA1 can protect the cell from apoptosis by keeping junctions in the 
cristae tight to prevent the release of cytochrome c (Frezza et al., 2006). 
1.3.4 Reactive Oxygen Species 
Reactive oxygen species (ROS) are reactive molecules that have an oxygen atom with 
a ‘free radical’ pair of electrons attached to it. This makes the oxygen molecule many 
times more likely to bind to other molecules in the cell, oxidising molecules, and 
potentially disrupting cellular systems. ROS found in the cell include hydrogen peroxide 
(H2O2), the superoxide radical (O2-) and the hydroxyl radical (.OH). Complexes I and III 
are the main producers of ROS in the mitochondria (Chen et al., 2003). Complex I 
releases ROS across the inner membrane unidirectionally into the matrix only, while 
complex III releases ROS across both sides of the inner membrane, into both the 
matrix and the intermembrane space (Muller et al., 2004). 
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ROS may play a key role in cellular signalling, functioning in the control of smooth 
muscle tone, ventilation, and autophagy. However, highly increased levels of free 
radicals can lead to damage to mtDNA, due to the close proximity of the mtDNA to the 
electron transport chain of the inner membrane where the free radicals are formed. 
ROS cause damage which contributes to the ageing process, apoptosis, and de novo 
mtDNA mutations and the rate of ROS production may in fact increase under states of 
physiological stress, including hypoxia and ischemia (Becker et al., 1999; Kevin et al., 
2003). 
1.3.5 Calcium Dynamics 
Free calcium in the cell is required for many cellular processes, including control of the 
citric acid cycle, and for signal transduction. Cellular homeostasis of calcium levels is 
required and both the endoplasmic reticulum (ER) and mitochondria perform this 
important function to avoid any damage to the cell. 
Mitochondria have the ability to sequester calcium. This is very important as the 
calcium concentration increases to potentially damaging levels inside the cell. High 
levels of calcium, per mg of protein, can be sequestered with mitochondrial function still 
intact (Rossi and Lehninger 1964). This is achieved by the mitochondrial calcium 
uniporter (MCU) protein on the inner mitochondrial membrane, which allows for the 
influx of calcium into the mitochondria (Deluca and Engstrom 1961). It is dependent 
upon mitochondrial membrane potential to function, which in turn is driven by the 
respiratory chain, as opposed to ATP-dependent active transport. The outer membrane 
is permeable to calcium through a class of porin channels, voltage-dependent anion 
channels (VDAC), that allow medium-sized molecules to pass through. As calcium 
enters the mitochondria through VDAC channels in the outer membrane and the MCU 
in the inner membrane, it has been that hypothesised through computational 
assessments that at least two distinct classes of calcium buffer may exist in the 
mitochondria (Bazil et al., 2012). 
The mechanism by which large amounts of calcium are taken up and stored is not well 
understood and is an active topic of research. 
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1.4 The Mitochondrial Genome 
The genome of the human mitochondrion was fully sequenced in 1981; it is a circular 
molecule of 16,569Kb in length and coding for a total of 37 genes (Anderson et al., 
1981) (Figure 1.9). The two strands of mtDNA are made up of different proportions of 
purine and pyrimidine bases thus giving them different buoyancies in CsCl density 
gradients, thus earning them the names heavy strand (H strand) and light strand (L 
strand). The 37 genes (28 on the H strand and 9 on the L strand) code for 13 
polypeptide genes, 2 rRNA genes and 22 tRNA genes; there are two tRNA leucine and 
two tRNA serine genes that each recognise a different mRNA codon. The polypeptide 
genes contain no introns and its largest non-coding region is the displacement loop (D-
loop), which is the origin of replication on the H strand of mtDNA. A third strand of DNA 
holds the double stranded DNA apart, and enables replication to begin. 
All other proteins which make up the mitochondria and their metabolic processes are 
encoded by nuclear genes. These products enter the mitochondria, facilitated by a 
mitochondrial import signal. This includes the protein machinery required for mtDNA 
replication, transcription, and translation. The mitochondrial genome is able to replicate 
independently of the cell cycle (relaxed replication) and can excise misincorporated 
bases through the proof-reading ability of the polymerase.  
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Figure 1.9. The mitochondrial genome.  
The mitochondrial genome is a 16,569 base-pair circular, double-stranded molecule. 
There is both a heavy strand and a light strand composed of different proportions of 
purine and pyrimidine bases. These strands have their own origins of replication shown 
on the image: OH on the heavy strand and OL on the light strand. There are 37 genes; 
22 tRNAs (black), 2 rRNAs (purple), and 13 polypeptides which consist of 7 subunits of 
complex I (blue), 1 subunit of complex III (green), 3 subunits of complex IV (red), and 2 
subunits of complex V (orange). The displacement loop (D-loop) is the initiation site of 
replication of the H strand and of transcription. 
Used by kind permission of Professor Robert Taylor, Newcastle University.  
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1.4.1 Mitochondrial DNA Replication 
Mitochondria contain their own DNA (Nass and Nass 1963) and it is replicated 
independently of the cell cycle by a unique DNA polymerase, encoded by the nuclear 
gene POLG (Hance et al., 2005). Many other proteins are involved in the process of 
replication which are encoded by nuclear genes and transported into the mitochondria. 
These include Twinkle, a helicase that unwinds double-stranded DNA to single-
stranded DNA; TFAM, a mitochondrial transcription factor A that functions in promoter 
activation; and single-stranded binding proteins which stabilise single strand portions of 
mtDNA. Topoisomerases may also be involved in order to reverse any supercoiling of 
the genome and allow the necessary enzymes and polymerases to attach to the DNA. 
Mutations in genes involved in DNA replication, transcription and translation can lead to 
mutations in mtDNA, decreased mtDNA content, and decreased oxidative 
phosphorylation leading to mitochondrial disease. 
Three different models of mtDNA replication have been put forward to describe how 
replication of the mitochondrial genome may proceed on both the heavy strand (H 
strand) and light strand (L strand) of mtDNA. These models are termed the 
‘asynchronous strand displacement’ model (Robberson and Clayton 1972; Clayton 
1982), the ‘strand-coupled bidirectional replication’ model (Holt et al., 2000), and the 
‘RNA incorporated throughout the lagging strand (RITOLS)’ model (Yang et al., 2002; 
Yasukawa et al., 2006). A further, rare intermediate form of mtDNA replication has 
been noted in adult human heart, skeletal muscle, and placenta involving the 
replication of many mtDNA molecules linked by a four-way Holliday junction termed an 
‘X-spike’ (Kajander et al., 2001). 
1.4.1.1 The ‘Asynchronous Strand Displacement’ Model 
This model for mtDNA replication proposed that covalently-closed circular molecules 
are formed through a process of displacement replication (Robberson and Clayton 
1972). Replication is initiated at the D-loop region on the H strand (OH) and proceeds in 
a clockwise fashion. The L strand is dissociated from the H strand during replication 
and almost two thirds of the H strand is replicated until the origin of replication on the L 
strand (OL) is then exposed. This allows replication to be initiated in the opposite 
direction on the L strand until the entire strand is replicated (Clayton 1982). The strands 
are covalently closed once replication is complete to form a circular molecule, and they 
dissociate from the template strand. 
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1.4.1.2 The ‘Strand-Coupled Bidirectional Replication’ Model 
This model for mtDNA replication states that replication is initiated at the D-loop region 
(OH) on the H strand in a clockwise fashion, followed shortly afterwards by replication 
initiation on the L strand in the opposite direction. Both the leading and lagging strands 
are replicated at the same time in a bidirectional fashion. The L strand is not replicated 
as a single chain however; it is replicated in short segments termed Okazaki fragments. 
The strands are covalently closed and they dissociate from the template strands (Holt 
et al., 2000).  
It was considered that this ‘strand-coupled bidirectional replication’ model may occur in 
cells that are under steady-state conditions, whereas the ‘asynchronous strand 
displacement’ model may occur in cells where accelerated mtDNA replication may be 
advantageous (Fish et al., 2004). 
1.4.1.3 The ‘RNA Incorporated Throughout the Lagging Strand (RITOLS)’ Model 
This model agrees with the ‘strand-coupled bidirectional replication’ model that 
replication is initiated at the D-loop region (OH) on the H strand in a clockwise fashion, 
followed by replication on the L strand. However, this model proposed that the lagging 
strand is replicated through segments of RNA that are first incorporated onto the 
leading strand, later replaced by DNA (Yang et al., 2002; Yasukawa et al., 2006). Using 
two-dimensional agarose gel electrophoresis, it was shown that RNA was not only 
used to initiate the short DNA Okazaki fragments on the lagging strand, but that RNA 
could in fact extend across an entire strand of mtDNA (Yasukawa et al., 2006). 
Transmission electron microscopy (TEM) and immunopurification has further 
corroborated the evidence of large regions of RNA on one of the replicating mtDNA 
strands (Pohjoismäki et al., 2010) and the use of interstrand cross-linking techniques 
has shown these DNA/RNA hybrid tracts present in living tissue prior to study 
methodology and that they are not due to adventitious factors (Reyes et al., 2013). It 
has been suggested that mature RNA transcripts that are already present in the matrix 
may hybridise to the lagging strand as DNA synthesis of the leading strand occurs in a 
‘bootlace mechanism’, where the RNA strand is not continuous (Reyes et al., 2013). 
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1.4.2 Transcription 
Transcription of mitochondrial genes is a complex process requiring all proteins 
involved to be imported into the mitochondria. Efficient transcription of mitochondrial 
genes is vital to the production of ATP. Key components of transcription are 
mitochondrial RNA polymerase (POLRMT), TFAM, Twinkle helicase, SSBP1, TFB2M 
and MTERF1.  
Transcription occurs on each strand of the mtDNA, with a large polycistronic RNA 
molecule being synthesised. On the L strand this is initiated from the light-strand 
promoter, LSP, while on the H strand this is initiated from two promoters, HSP1 and 
HSP2 (Montoya et al., 1982). This large RNA transcript is then processed to produce 
individual mRNA, tRNA, and rRNA molecules, with each mRNA and rRNA transcript 
bordered by at least one tRNA transcript. These tRNA transcripts are thought to be a 
key substrate in the mechanism of RNA processing, known as the ‘tRNA punctuation 
model’ (Ojala et al., 1981). 
POLRMT is the mitochondrial RNA polymerase which synthesises the mRNA 
transcripts of mitochondrial genes. The gene shows high sequence homology to the 
genes of RNA polymerases found in yeast and to the C-terminal region of the RNA 
polymerase in bacteriophages (Tiranti et al., 1997). It was considered to interact with 
both mitochondrial transcription factors TFB1M and TFB2M to enhance transcription 
(Rantanen et al., 2003) though more recently TFB1M has been reported to function as 
the primary 12S rRNA methyltransferase for the biogenesis of the 28S ribosomal 
subunit (Cotney et al., 2007; Metodiev et al., 2009). TFAM encodes the mitochondrial 
transcription factor A protein which facilitates mitochondrial promoter recognition and 
initiation of transcription through structural changes to the DNA, allowing POLRMT to 
bind and begin transcription. Twinkle helicase protein uncoils the mtDNA and single 
strand binding protein (SSBP1) maintains the uncoiled state of the mtDNA to allow for 
TFAM protein to interact with the DNA. MTERF1 acts to terminate transcription through 
binding to a short region at the 3’-end of the tRNA leucine (UUR) gene (Kruse et al., 1989) 
and the clarification of other termination sites is under investigation. 
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1.4.3 Translation 
Translation of processed mitochondrial RNA transcripts requires the action of 
mitoribosomes, in addition to aminoacyl-tRNA synthetases and methionyl-tRNA 
transformylase which are essential to the production of charged tRNA molecules that 
are able to produce a peptide strand. Mitoribosomes are made up of 81 nuclear-
encoded proteins and two mitochondrially-encoded rRNAs. The 28S small subunit is 
made up of 12S RNA and 33 proteins, and the 39S large subunit is made up of 16S 
RNA and 48 proteins (Anderson et al., 1981; Smits et al., 2007). These nuclear-
encoded proteins are directed into the mitochondrial matrix via protein complexes 
known as translocase of the outer membrane (TOM) proteins and translocase of the 
inner membrane (TIM) proteins. 
Translation of RNA transcripts occurs on the mitoribosome in the separate stages of 
initiation, elongation, and termination of the synthesised strand. Initiation is performed 
by two initiation factors: mtIF1 and mtIF3 (Koc and Spremulli 2002) which recognise 
the codons AUG, AUA and AUU. They act to allow assembly of the initiation complex 
which ensures the start codon of the RNA transcript is bound to the peptidyl site (P-
site) of the mitoribosome where peptide elongation is instigated. The elongation step of 
translation is tightly controlled by nuclear factors mtEFTu, mtEFTs, mtEFG1 and 
mtEFG2. It is proposed that termination of the peptide is by mitochondrial release 
factor 1a (mtRF1a) (Zhang and Spremulli 1998) which recognises stop codons at the 
acceptor site and terminates further translation to allow detachment of the protein 
(Soleimanpour-Lichaei et al., 2007). 
The codons AGA and AGG conventionally encode arginine in the human genome but 
human mitoribosomes do not recognise these codons. It was considered that they may 
act as translation termination codons in addition to the termination codons UAA and 
UAG. However, mitoribosomes do not recognise the AGA and AGG codons as 
termination codons and this can induce -1 frameshift mutations caused by stalling of 
the mitoribosomes. The frameshift mutation then allows the mitoribosome to recognise 
a UAA or UAG codon and subsequently mitochondrial release factors are able to 
terminate and release the peptide (Temperley et al., 2010). 
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1.5 Mitochondrial Genetics 
The genetics of mitochondria are exceptionally different to the genetics of their host 
eukaryotic cell. Many of their unique traits are described in the following sections. 
1.5.1 Mitochondrial Inheritance 
Uniparental inheritance of mitochondria is found in most animals, plants and fungi, 
when the fusion of gametes from two donors occurs. Mitochondrial inheritance is 
usually from the maternal donor, although famous exceptions to this rule exist, 
including mussels (Mytilus edulis) (Hoeh et al., 1991) and fruit flies (Drosophila) (Kondo 
et al., 1992; Wolff et al., 2013), where a mixed inheritance of mtDNA has been 
demonstrated from both the maternal and paternal donors. In mammals, there is 
normally a strict maternal inheritance of mtDNA to the offspring, although exceptions 
here have been documented in humans (Schwartz and Vissing 2002) and mice 
(Gyllensten et al., 1991). 
This uniparental inheritance is thought to prevent a mixed and competing population of 
mtDNA genomes in the cell. It has been noted in rodents that when mtDNA from both 
parents enter the oocyte, the paternal population is eliminated (Shalgi et al., 1994). 
This prevents the transmission of deleterious mitochondrial genome mutations by 
preventing cytoplasmic mixing of different mitochondrial populations (Hastings 1992; 
Hurst 1996). A deleterious mutation could spread throughout the mitochondrial 
population if it has a replication advantage, even if it is harmful to the host. Uniparental 
inheritance may have evolved to prevent deleterious mutations spreading throughout 
the entire host population and as a result, allow a greater efficiency of oxidative 
phosphorylation.  
1.5.2 Heteroplasmy and the Threshold Effect 
Mitochondria contain multiple copies of their genome which replicate independently of 
the cell cycle (relaxed replication) (Bogenhagen and Clayton 1977). Heteroplasmy 
(“heterogeneity of the cytoplasm”) describes the state of mixed populations of 
mitochondria with different genomes within a tissue. Homoplasmy describes the state 
in which the mitochondria in the tissue will have identical genomes but as mtDNA 
accumulates mutations throughout an individual’s lifetime (Wallace 1992) this leads to 
populations of mitochondria with varying oxidative phosphorylation capacities (Figure 
1.10). 
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Mutations can occur in a single DNA molecule in a variety of ways, as de novo events 
or through the action of mutated proteins such as POLG, and mutations may be 
propagated to be found in a higher proportion of mtDNA molecules. The mtDNA 
turnover of a cell has been estimated to have a half-life of between 6 days in cardiac 
cells and 31 days in the brain cells of rats (Gross et al., 1969) but recent investigations 
suggest the turnover may be much faster; 1.83 days in hepatocytes of mice (Miwa et 
al., 2008). With quick mtDNA replacement happening in cells, it is important to 
understand the mechanisms by which a mutation may reach high levels in a cell.  
Clonal expansion of mtDNA mutations can explain how mutations are propagated in 
cell populations (Nekhaeva et al., 2002). Segregation of mutations at different 
proportions in the cell’s progeny can result in a mutation being propagated at higher 
levels in some daughter progeny and then the subsequent effect of random genetic 
drift may lead to fixation of a mutation over time. 
In this way, mtDNA mutations can expand to be found at very high levels and may lead 
to impaired oxidative phosphorylation and disease (Moslemi et al., 1998). This high 
level is termed the ‘threshold level’ (Sciacco et al., 1994). Once the amount of mtDNA 
with a mutation reaches a threshold value of between 70% - 90% (Rossignol et al., 
2003), the cell may start to show the signs of impaired oxidative phosphorylation. 
However, the exact threshold level may be dependent on where in the mitochondrial 
genome the mutation occurs; whether structural subunits or core functional subunits 
are affected. Heteroplasmy of mutations in structural subunits will typically have a lower 
threshold level than mutations in tRNA genes due to their link with ATP production. 
It is currently unknown how mitochondria with impaired function accumulate in the cell, 
and it is a current topic of research in the fields of ageing and neurodegenerative 
disease. 
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Figure 1.10. Homoplasmy and heteroplasmy.  
Following cell division and mtDNA replication, the distribution of normal and mutated 
mitochondria may differ. Mitochondria segregate randomly into daughter cells and 
replicate. Some cells may exhibit homoplasmy, having all mitochondria with identical 
genomes. Other cells may exhibit heteroplasmy, having mitochondria with different 
genomes, some of which may contain mutations. Low levels of heteroplasmy do not 
usually affect the functions of the mitochondria. High levels of heteroplasmy can result 
in impaired oxidative phosphorylation, once a threshold level is reached, leading to 
signs of mitochondrial disease. Light blue mitochondria represent those containing wild 
type mtDNA. Red mitochondria represent those containing mutated mtDNA. 
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1.5.3 Clonal Expansion 
Clonal expansion is the process by which mutations and deletions in the mtDNA can be 
expanded and the mutated mtDNA passed on to daughter mitochondria. This is a 
common process happening in normal tissues at the average rate of one expanded 
mtDNA point mutation per cell (Nekhaeva et al., 2002) but once the heteroplasmy 
threshold has been reached, impaired oxidative phosphorylation may lead to a clinical 
disease phenotype (Moslemi et al., 1998). If the mutation in question is not deleterious, 
it may form part of the natural genetic variation in an individual. 
There have been a number of theories to explain how clonal expansion may lead to 
accumulation of mutated mtDNA molecules in multiple cells of a tissue. It has been 
proposed that a faster replication of small mtDNA molecules that contain deletions 
could lead to the accumulation of these mutated molecules (Wallace 1992). However 
this theory has been disregarded as mtDNA replication is not rate-limiting and there are 
long stages in-between mtDNA replication events (Shadel and Clayton 1997). The 
‘Vicious Cycle’ hypothesis suggests that as mtDNA is more sensitive to damage by free 
radicals, more mtDNA mutations will occur (Bandy and Davison 1990). In tissues with a 
high oxygen consumption, such as the brain, there are high levels of mtDNA mutations 
(Arnheim and Cortopassi 1992). Therefore, there are more initial mtDNA mutations and 
a greater probability of a proportion of these reaching the threshold level. The ‘survival 
of the slowest’ hypothesis (De Grey 1997) is linked to the ‘free radical hypothesis of 
ageing’ first proposed in 1956 (Harman 1956). This early hypothesis stated that the 
damage inflicted on molecules by free radicals will result in the effect of ageing. This 
was later refined to include mitochondria as the main producers of free radicals. The 
‘survival of the slowest’ hypothesis takes this further to state that those mitochondria 
with impaired oxidative phosphorylation will be subject to less degradation as their 
production of free radicals is slower. However, this theory is not considered to be 
consistent with known theories of mitochondrial fission and fusion and the preferential 
degradation of dysfunctional mitochondria (Kim and Lemasters 2011). 
The most satisfactory theory currently being investigated is the theory of random 
genetic drift, whereby a mutation may reach very high levels or very low levels due to 
stochastic events (Chinnery and Samuels 1999; Elson et al., 2001). Computational 
modelling has shown that mutation loads can increase to levels seen in human 
biological samples due to random genetic drift alone through relaxed replication (Elson 
et al., 2001). However, random genetic drift is not a general explanation because in 
computer simulations with short-lived animals the results do not match the observed 
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heteroplasmy levels (Kowald and Kirkwood 2013). Random genetic drift may not 
represent a stand-alone theory and other mechanisms may be at work in other animal 
species. 
1.5.4 Mitochondrial DNA Mutation Rates 
The mitochondrial genome is a circular construct attached to the inner mitochondrial 
membrane. This makes it prone to damage by free radicals produced by the inner 
membrane’s mitochondrial respiratory chain by their proximity to each other. It has 
been estimated that the mtDNA mutation rate in higher primates is ten times higher 
than for single-copy nuclear DNA, using cleavage mapping with restriction 
endonucleases (Brown et al., 1979). This higher mutation rate may be contributed to by 
the fact that the mitochondrial genome is not protected by histone proteins and does 
not contain introns (Margulis 1975) as well as the high error rate of the sole 
mitochondrial DNA polymerase, POLG (Kunkel and Loeb 1981). To counter this, the 
polymerase has DNA proof-reading abilities and the mitochondria have a DNA repair 
system that can repair damaged sections of mtDNA. It is thought this could occur by 
base excision repair (Pinz and Bogenhagen 1998). 
The rate of mtDNA mutation accumulation depends upon the type of mutation and its 
location in the mitochondrial genome. The mutation rate is not equal for all areas of the 
mitochondrial genome and in areas of high percentages of purine bases there is a 
greater rate of mutation. This unequal mutation rate has been used in slower mutating 
regions, such as the D-loop control region of the mtDNA, for phylogenetic analyses and 
studies into sequence divergence (Richards et al., 2000; Howell et al., 2003). 
1.5.5 Mitochondrial DNA Mutations 
MtDNA mutations may occur sporadically in an individual or they may be inherited 
through the maternal germ cell line. These mutations can be associated with defective 
oxidative phosphorylation, ageing and neurodegeneration. There are different types of 
mutation that may occur in the mitochondrial genome; these include point mutations, 
rearrangements and deletions. In addition, the total copy number of mtDNA can be 
depleted within the cell and may itself lead to clinical disease. 
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1.5.5.1 Point Mutations 
Point mutations are single base changes in the DNA sequence. These mutations may 
be described as synonymous, resulting in the same amino acid being translated 
despite a genetic alteration or as non-synonymous, with a genetic mutation resulting in 
a different amino acid being translated. Synonymous mutations are possible due to the 
redundancy of the genetic code and its property of different codons coding for the 
same amino acid, and also owing to the ability of a tRNA molecule to allow ‘wobble’ in 
the third base of the anti-codon matching to the codon. 
The alteration of a single base can lead to amino acid substitution and changes to the 
protein’s conformation, resulting in loss of function. For example, various mtDNA point 
mutations can cause mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
episodes (MELAS), a devastating, multisystemic illness that will be later described in 
section 1.6.3.1 ‘Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like 
Episodes (MELAS)’. MELAS is an example of genetic heterogeneity and the capability 
of different mutations in different genes to result in clinically similar symptoms. 
Currently there are over 20 mutations reported in different mitochondrial genes leading 
to MELAS. Examples include the common single point mutation m.3243A>G in the 
tRNA leucine(UUR) gene (MT-TL1) (Goto et al., 1990) and recently a case of MELAS in a 
35-year-old woman which was reported due to the pathogenic point mutation 
m.6597C>A in the MT-COI gene (Lamperti et al., 2012). 
Myoclonic epilepsy with ragged red fibres (MERRF) is a rare condition that will be later 
described in section 1.6.3.2 ‘Myoclonic Epilepsy with Ragged Red Fibres (MERRF)’. 
The eponymous ‘ragged red fibres’ are due to damaged mitochondria aggregating in 
the subsarcolemmal region of the muscle fibres, which can be visualised as red clumps 
when stained with modified Gömöri trichrome stain. As in MELAS, there is a genetic 
heterogeneity in MERRF with mutations in different mitochondrial genes giving rise to 
clinically similar symptoms. The most common single point mutation m.8344A>G in the 
tRNA lysine gene (MT-TK) (Shoffner et al., 1990) occurs in 80-90% of cases and the 
mutations m.8356T>C and m.8363G>A occur in most other reported cases. However 
novel mutations such as m.661G>A in tRNA phenylalanine (Mancuso et al., 2004) 
demonstrate the clinical overlap that can occur between mutations in different genes. 
In addition to point mutations in tRNA genes, mutations in protein-coding mitochondrial 
genes have been reported. These include the mutation m.8993T>G in complex V, 
leading to symptoms of neuropathy, ataxia, and retinitis pigmentosa (NARP) (Holt et 
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al., 1990) and the mutations m.11778G>A, m.3460G>A, and m.14484T>C in complex I 
leading to Leber’s hereditary optic neuropathy (LHON) (Wallace et al., 1988; Howell et 
al., 1991; Johns et al., 1992). 
1.5.5.2 Rearrangements 
Mitochondrial rearrangements are sporadic and can include several genes. The types 
of rearrangement that can occur include large-scale deletions, microdeletions, and 
duplications. 
1.5.5.2.1 Duplications 
Mitochondrial DNA duplications have been associated with disease, with the first 
reported duplication being implicated in a mitochondrial disease in 1989 (Poulton et al., 
1989). MtDNA duplications have been associated with Kearns-Sayre syndrome 
(Poulton et al., 1994; Fromenty et al., 1997), mitochondrial myopathy (Brockington et 
al., 1993), and diabetes mellitus (Ballinger et al., 1994). 
It has been suggested that both duplications and deletions on mtDNA molecules are 
part of the same process, and that duplications are an intermediate stage in the 
formation of a deletion (Poulton et al., 1993). This is supported by the observation that 
both duplication and deletion rearrangements can occur at the same time in the same 
patient (Manfredi et al., 1997; Kajander et al., 2000), though this relationship is still not 
clear and warrants further investigation. 
1.5.5.2.2 MtDNA Deletions 
Deletions found in mtDNA may be of two forms; microdeletions of <5bp, or large-scale 
deletions encompassing many genes. Both can result in mitochondrial disease 
depending on the exact size and location of the deletion. MtDNA deletions have been 
implicated in many mitochondrial diseases and in ageing, with post-mitotic tissues 
accumulating deletions over time leading to impaired oxidative phosphorylation. It has 
been noted that post-mitotic tissues with high oxygen consumption, such as the brain 
and skeletal muscle, acquire higher levels of mtDNA deletion (Arnheim and Cortopassi 
1992) and that different areas of the brain may have different levels of deletion (Soong 
et al., 1992). 
Deletions have been reported in association with disease and ageing. In the major arc 
of the mitochondrial genome there is a 5Kb section that can often be found to harbour 
deletions (Hayakawa et al., 1992). A deletion over 5Kb section can encompass many 
33 
 
Chapter 1 Introduction         
genes, including tRNAs and those that code for subunits of complex I and complex IV 
that are vital to the function of the mitochondrial respiratory chain. 
MtDNA deletions have been reported in numerous disorders including Kearns-Sayre 
syndrome (Zeviani et al., 1988) and adPEO (Van Goethem et al., 2001) in the form of 
single deletions thought to have occurred sporadically. In addition, mtDNA deletions 
have been associated with ageing. Both mtDNA deletions and duplications, as well as 
tissue mosaicism of these rearrangements, have been observed in human ageing 
(Kovalenko et al., 1998). 
1.5.5.3 MtDNA Depletion 
MtDNA depletion is caused by a quantitative loss of mtDNA content leading to impaired 
oxidative phosphorylation in affected tissues due to insufficient production of the core 
respiratory chain components. 
MtDNA depletion is often caused by nuclear gene defects in the replication machinery 
(POLG, c10orf2) and in mtDNA maintenance genes (TYMP, TK2, SUCLA2, SUCLG1, 
RRM2B, DGUOK, ANT1). These mutations may result in fewer replicated mtDNA 
molecules, or a lower dNTP pool of one or more dNTPs so that there is limited 
availability for incorporation during mtDNA replication. 
MtDNA depletion syndromes often occur in early life and can be described in four 
different categories: myopathic syndromes, encephalopathic syndromes, 
hepatocerebral syndromes, and neurogastrointestinal syndromes. However, clinical 
disorders may be placed in overlapping categories. Mutations in genes of the 
replication machinery such as POLG have been reported to result in mtDNA depletion 
in Alpers’ syndrome (Naviaux et al., 1999) through replication stalling. Mutations in 
genes involved in mtDNA maintenance such as ANT1 can lead to mtDNA depletion in 
adPEO (Napoli et al., 2001). Mutations in TYMP can lead to MNGIE (Nishino et al., 
1999), as can mutations in RRM2B (Shaibani et al., 2009). 
Treatments and therapies of mtDNA depletion are usually symptomatic. Experimental 
studies have shown a rescue of cells with mtDNA depletion with the addition of excess 
dNTPs (Cámara et al., 2013) or the addition of deoxynucleoside monophosphates 
(dNMP) to cell culture medium (Bulst et al., 2009). Addition of inhibitors of dNTP 
catabolism may be another possible therapy. A greater understanding of the structural 
and functional consequences of mutations upon these genes is essential to realising 
their full effect in mtDNA depletion syndromes. 
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1.6 Mitochondrial Disease 
Mitochondrial diseases may be sporadic, with a single proband in a family, or there 
may demonstrable familial inheritance with a clear pattern of inheritance. The first 
human mitochondrial disease was described by Luft in 1962, of a patient suffering 
severe hypermetabolism with increased perspiration, polydipsia, polyphagia, a 
decrease in body weight, and muscle weakness (Luft et al., 1962). Since then, there 
have been hundreds of different mitochondrial diseases described in the scientific 
literature. These may be described as a primary mtDNA disease if the condition is due 
to a mutation or deletion of the mtDNA, or a secondary mtDNA disease if the condition 
is due to a mutation or deletion of a nuclear gene which has a direct effect on mtDNA 
maintenance. 
1.6.1 Mitochondrial Disease Prevalence 
Mitochondrial disorders are an underdiagnosed group of diseases that create a 
significant burden of disease upon the population. The prevalence of these disorders is 
difficult to determine accurately due to the wide range of symptoms and gene 
mutations, but it has been estimated that at least one in every two hundred healthy 
members of the population harbours a pathogenic mitochondrial mutation (Elliott et al., 
2008). A study of the North-East of England showed that 9.2 individuals in 100,000 
people had a manifest mitochondrial disease while 16.5 individuals in 100,000 were at 
risk of developing one (Schaefer et al., 2008). In both studies, the most common 
mutation found was the m.3243A>G mtDNA mutation which can lead to MELAS. 
Mitochondrial disease is a relatively new branch of disorders and further research into 
the prevalence of mitochondrial disease in different populations is needed to increase 
our understanding. 
1.6.2 Mitochondrial Disease due to Nuclear Gene Mutations 
Mitochondrial diseases are genetic disorders affecting mitochondrial metabolism. Many 
proteins that are required for mitochondrial function are encoded by nuclear genes. 
Mutations in these genes can give rise to abnormal proteins and when the proteins are 
imported into the mitochondria, that protein may be dysfunctional and affect 
mitochondrial processes, manifesting as signs of mitochondrial disease. It is important 
that rigorous research is carried out to demonstrate whether any mutations discovered 
are actually pathogenic, or if they are merely part of natural genomic variation. The 
most common disorders arising from mutations in nuclear genes are discussed below. 
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1.6.2.1 Leigh Syndrome 
Leigh syndrome (subacute necrotising encephalopathy) is an early-onset 
neurodegenerative disease with brainstem and basal ganglia dysfunction, first 
described by neuropathologist Dr Archibald Denis Leigh in 1951 (Leigh 1951). Most 
patients present in infancy with failure to thrive, hypotonia and developmental delay. 
Involvement of the brainstem and basal ganglia is particularly characteristic and often 
leads to dystonia, dysphagia, ptosis or abnormal eye movements and breathing 
difficulties (Finsterer 2008). Other clinical features may include developmental 
regression, ataxia and seizures. 
There is a range of mutations in many genes reported to lead to Leigh syndrome, with 
the pattern of inheritance appearing to be complex. Mutations in the nuclear gene 
SURF1 have been reported to lead to a Leigh’s syndrome phenotype with autosomal 
recessive inheritance (Tiranti et al., 1998; Zhu et al., 1998). SURF1 encodes one of a 
large number of assembly factors of complex IV, which is required to maintain the 
structure of complex IV. Loss of complex IV will lead to isolated complex IV deficiency 
and a reduced OXPHOS capacity. 
1.6.2.2 Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE) 
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal 
recessive disorder clinically presenting with gastrointestinal dysmotility, cachexia, 
ophthalmoplegia, sensorimotor neuropathy, and leukoencephalopathy.  
Mutations in the gene encoding thymidine phosphorylase (TYMP) have been frequently 
implicated in MNGIE (Hirano et al., 1998; Nishino et al., 1999; Suh et al., 2013). 
Thymidine phosphorylase plays a key role in the nucleotide salvage pathway of mtDNA 
and loss of function of this gene can lead to an imbalance in the dNTP pool, causing 
mtDNA instability, mtDNA deletions and mtDNA depletion. Mutations in another gene, 
RRM2B, encoding ribonucleotide reductase have also been purported to be the genetic 
cause of MNGIE in a patient with normal levels of thymidine (Shaibani et al., 2009). 
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1.6.3 Mitochondrial Disease due to Mitochondrial Gene Mutations 
Mitochondrial disease may arise due to mutations in genes of the mitochondrial 
genome. There are 37 genes encoded by the mitochondrial genome, coding for 
essential subunits of the respiratory chain, tRNAs, and rRNAs. The disorders arising 
from mutations in mitochondrial genes are discussed below. 
1.6.3.1 Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes 
(MELAS) 
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is 
a common mitochondrial condition associated with muscle pain, fatigue, migraine, 
epilepsy, and stroke-like episodes leading to dementia. There are currently over 20 
mutations in different mitochondrial genes leading to MELAS reported on the 
MITOMAP mitochondrial genome database website 
(http://www.mitomap.org/MITOMAP).  
The most common single point mutation is m.3243A>G in the tRNA leucine(UUR) gene 
(MT-TL1) (Goto et al., 1990) which is the genetic basis of the condition in the majority 
of cases. As further research into mitochondrial disease continues, novel mutations are 
being reported in cases of MELAS. The point mutation m.6597C>A in the MT-COI 
gene for complex IV subunit I has been reported (Lamperti et al., 2012) and the point 
mutation m.12299A>C which had not previously been described in MELAS in the tRNA 
leucine(CUN) gene (Abu-Amero et al., 2006). 
MELAS is an example of a disorder with genetic heterogeneity and as further cases are 
investigated, the understanding of the genetic basis of MELAS will broaden. 
1.6.3.2 Myoclonic Epilepsy with Ragged Red Fibres (MERRF) 
Myoclonic epilepsy with ragged red fibres (MERRF) leads to muscle fatigue, myoclonic 
epilepsy, exercise intolerance, and hearing loss (Fukuhara et al., 1980). A modified 
Gömöri trichrome stain may be used to visualise ragged red fibres. These are 
damaged mitochondria that aggregate in the subsarcolemmal region of the muscle 
fibre. 
The most frequent mutation associated with MERRF is a single point mutation at 
m.8344A>G in the tRNA lysine gene (MT-TK) (Shoffner et al., 1990; Noer et al., 1991). 
It occurs in 80-90% of cases, with the other mutations m.8356T>C and m.8363G>A 
occurring in most other reported cases (Silvestri et al., 1992; Ozawa et al., 1997). In 
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addition to the common mutations, a novel mutation has been reported in the tRNA 
phenylalanine gene, m.661G>A (Mancuso et al., 2004). 
1.6.3.3 Leber’s Hereditary Optic Neuropathy (LHON) 
Leber’s hereditary optic neuropathy (LHON) is characterised by a bilateral loss of 
central vision due to retinal ganglion cell degeneration and retinal microangiopathy, 
with some patients displaying dystonia or cardiac dysrhythmia. Some patients may also 
display the cardiac pre-excitation condition of Wolff-Parkinson-White syndrome 
(Nikoskelainen et al., 1994; Finsterer et al., 2001). There is a teenage-onset to late-
onset of symptoms with incomplete penetrance of the disorder, with symptoms 
occurring in ~50% of males and ~10% of females with the mutation (Harding et al., 
1995; Riordan-Eva et al., 1995). Symptoms are predominantly reported in males 
harbouring a mutation at close to 100% homoplasmy, though females may also 
demonstrate a mutation close to 100% homoplasmy but may be asymptomatic. There 
is currently no test to accurately determine which patients with a mutation will display 
the LHON phenotype. 
There are 3 primary mutations in the mitochondrially-encoded subunits of complex I 
which have been reported to cause LHON; m.3460G>A in MT-ND1 (Howell et al., 
1991), m.11778G>A in MT-ND4 (Wallace et al., 1988), and m.14484T>C in MT-ND6 
(Johns et al., 1992), all affecting complex I which account for the genetic defect in the 
majority of cases. Many rarer mutations have been reported to cause LHON, all located 
in the mitochondrial complex I genes (Achilli et al., 2012; Caporali et al., 2013). These 
mutations are commonly reported at, or close to, 100% homoplasmy in patients, 
though not all patients will display the clinical signs. 
1.6.3.4 Maternally Inherited Leigh Syndrome 
Leigh syndrome is an early-onset neurodegenerative disease that has been described 
previously (see section 1.5.2.1 ‘Leigh Syndrome’). There is a range of mutations in 
many genes reported to lead to Leigh syndrome, with the pattern of inheritance 
appearing to be complex. Maternal inheritance of Leigh’s syndrome occurs if the 
mutation is present in a mitochondrial gene, as mtDNA is maternally inherited. Point 
mutations in the mitochondrial gene MT-ATP6 account for a large proportion of cases 
of maternally inherited Leigh syndrome and high levels of heteroplasmy are required to 
result in disease symptoms (Tatuch et al., 1992). 
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1.6.4 Complex Genetic Inheritance  
The inheritance of mitochondrial disease can be complex and a single mitochondrial 
disorder may have multiple modes of inheritance. Leigh syndrome may be maternally 
inherited through mutations in the mitochondrial gene MT-ATP6 or mitochondrial tRNA 
genes, may have autosomal recessive inheritance, or may display an X-linked 
Mendelian inheritance through pyruvate dehydrogenase deficiency due to mutations in 
the PDHA1 gene (Rahman et al., 1996). Some of these modes of inheritance in Leigh 
syndrome have been described previously in this thesis (see sections 1.5.2.1 ‘Leigh 
Syndrome’ and 1.5.3.4 ‘Maternally Inherited Leigh Syndrome’). 
1.6.4.1 Chronic Progressive External Ophthalmoplegia (cPEO) 
Chronic progressive external ophthalmoplegia (cPEO) is a late-onset disorder that may 
be diagnosed as a single condition or diagnosed in association with another disorder. It 
is characterised by bilateral ptosis, ophthalmoplegia, and muscle weakness (Laforêt et 
al., 1995) with additional signs that may include neurological involvement. It is often 
seen in association with other disorders and is assessed as part of a wider range of 
symptoms. Both single large-scale deletions and secondary mtDNA deletions due to 
mutations in POLG and c10orf2 may lead to cPEO. 
Single large-scale mtDNA deletions in muscle tissue have been previously described in 
patients with cPEO (Holt et al., 1988; Moraes et al., 1989). Mutations in nuclear genes 
which are involved in mtDNA replication and repair can lead to multiple mtDNA 
deletions. MtDNA replication genes, including c10orf2 (Twinkle) (Lewis et al., 2002), 
POLG (Van Goethem et al., 2001), and ANT1 (Kaukonen et al., 2000) have been 
implicated in cPEO. Rare mutations in POLG2 have been described which may be 
responsible for a small percentage of PEO cases in adults (Longley et al., 2006; Walter 
et al., 2010).  
Mutations in tRNA genes have also been implicated as the cause of the disease 
(Gupta et al., 1995; Laforêt et al., 1995) which highlights the range of genetic defects 
that may correlate with the same clinical signs. 
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1.7 Mitochondrial DNA Polymerase Gamma (POLG) 
Mitochondrial DNA polymerase gamma (POLG) is the only known DNA polymerase to 
replicate mtDNA in mammals and is essential for embryonic development (Hance et 
al., 2005). It comprises a large catalytic subunit and two smaller beta subunits. The 
large catalytic subunit is encoded by the nuclear gene POLG, located on chromosome 
15q25 (Walker et al., 1997), which comprises 23 exons and is 21Kb long.  
Like the catalytic subunit, the accessory subunit has also been shown to be essential 
for mammalian embryogenesis and at least one functional copy of the gene must be 
present for embryonic development (Humble et al., 2013). The smaller beta subunits 
are encoded by the nuclear gene POLG2 located on chromosome 17q23 comprising 8 
exons. Pathogenic mutations in the catalytic subunit POLG may be either dominant or 
recessive and are a major cause of mitochondrial disease, displaying a heterogeneous 
range of disease phenotypes. 
1.7.1 Structure of POLG Polymerase 
Human POLG polymerase was first cloned, sequenced and characterised using cDNA 
to sequence the gene and polyclonal antibodies to verify the findings (Ropp and 
Copeland 1996). It is comprised of two different subunits: a 140kDa catalytic α subunit 
encoded by the gene POLG and a 55kDa accessory β subunit encoded by the gene 
POLG2. These form a heterotrimer made up of one catalytic (α) subunit and two 
accessory (β) subunits to form the functional holoenzyme (Yakubovskaya et al., 2006) 
(Figure 1.11). 
Both accessory subunits bind together and bind asymmetrically to one face of the 
catalytic subunit, where they position the accessory interacting subdomain (AID) of the 
catalytic subunit to bind to DNA. Through examining the crystal structure of the POLG 
holoenzyme, it has been shown that one of the accessory subunits interacts with the 
spacer/linker domain of the catalytic α subunit to bind both accessory subunits there 
(Lee et al., 2009). 
The accessory subunits are processivity factors that enhance the function of the 
catalytic subunit and increase substrate binding (Carrodeguas et al., 1999). They can 
also confer resistance to N-ethylmaleimide (Lim et al., 1999) which can inhibit 
polymerase activity. Each of the accessory subunits has been found to have a slightly 
different function in the holoenzyme, with the proximal accessory subunit allowing 
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better interaction with the DNA strand, and the distal accessory subunit increasing the 
DNA replication rate (Lee et al., 2010). 
They also have a novel function to other polymerase processivity factors. In addition to 
accelerating the polymerisation rate, they are thought to suppress exonuclease activity 
to possibly allow for a more stable polymerase conformation (Johnson and Johnson 
2001). This will decrease the fidelity of the polymerase, as the catalytic subunit will 
extend a mismatched primer to homopolynucleotide sequences more frequently with 
the presence of the accessory subunit (Longley et al., 2001). 
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Figure 1.11. Structure of POLG. 
Image A shows the structure of POLG polymerase and the gene, and the location of 
the exonuclease, spacer, and polymerase domains in their relation to the polymerase. 
AID refers to the accessory interacting subdomain and IP refers to the intrinsic 
processivity subdomain. Images B and C show POLG in association with the proximal 
and distal POLG2 subunits, forming the functional heterotrimer. Image taken from Lee 
et al., (2009). 
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1.7.2 Functions of POLG 
POLG polymerase is a type A DNA polymerase that can perform a range of functions. 
Its primary function is 5’-3’ DNA-synthesising activity and in addition to replicating DNA, 
it also plays a role in 3’-5’ base excision repair and has 5’-dRP lyase activity for 
excision repair. Base excision repair is thought to be the only mechanism of DNA repair 
to occur in mitochondria requiring POLG and mtDNA ligase (Pinz and Bogenhagen 
1998). This mechanism repairs single base lesions; the base is excised leaving an 
abasic site and a new base is incorporated by POLG. A mitochondrial AP 
endonuclease creates a nick in the phosphodiester backbone of the DNA to allow 
incorporation of the new base while mitochondrial DNA ligase repairs the 
phosphodiester bonds after repair. The 5’-dRP lyase activity of POLG can remove the 
5’-dRP molecule left by the AP endonuclease cleavage during base excision. 
The different functions are performed by the three distinct domains of the catalytic 
subunit of the polymerase. The N-terminal domain contains an exonuclease region 
which has 3’-5’ base-excision repair activity to remove misincorporated bases. There is 
a linker/spacer region considered to be involved in binding the catalytic (α) subunit to 
the accessory (β) subunits, and a C-terminal polymerase region with 5’-3’ DNA-
synthesising activity. Based upon molecular and computer modelling data, it has been 
suggested that there are five distinct and functional domains of the polymerase where 
recessive mutations can occur and may result in disease (Euro et al., 2011). 
Understanding the effect that pathogenic mutations have upon the function of POLG is 
essential to unravelling the full effect of a mutation in the heterogeneous group of 
mitochondrial diseases. 
1.7.3 POLG Mutation Frequency 
Pathogenic mutations in the POLG gene regularly occur in the linker or polymerase 
regions and this may affect the way the catalytic subunit and accessory subunit bind or 
how the polymerase binds to the substrate. There have been over 230 mutations listed 
on The Human DNA Polymerase Gamma Mutation Database 
(http://tools.niehs.nih.gov/polg/) (Figure 1.12). There are 3 common pathogenic 
mutations in POLG that are often seen in patients with a heterogeneous range of 
symptoms, from severe, early-onset conditions, to milder, adult-onset symptoms; 
p.Ala467Thr, p.Trp748Ser and p.Gly848Ser. 
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A study to investigate POLG gene mutations in patients from around Europe examined 
38 cases of POLG disease and sequenced the POLG gene in each. They reported that 
the most common mutation in children was the p.Ala467Thr mutation (Horvath et al., 
2006). A Dutch patient cohort of 37 cases with POLG mutations reported that the 
p.Ala467Thr mutation occurred 23 times in 74 alleles in 15 patients, occurring in 31% 
of all alleles. Two hundred controls were tested and the p.Ala467Thr mutation was not 
seen (Blok et al., 2009). After analysing intronic SNPs and polymorphic dinucleotide 
markers flanking the POLG gene, it is suggested that founder effects for the 
p.Ala467Thr mutation have led to its frequency in different populations (Hakonen et al., 
2007). 
The carrier frequency of the p.Trp748Ser mutation in cis with the p.Glu1143Gly 
mutation in the Finnish population was reported to be 1:125 in patients diagnosed with 
mitochondrial recessive ataxia syndrome (MIRAS), due to a founder effect (Hakonen et 
al., 2005). That is a frequency of 1:62,500 for homozygotes for the p.Trp748Ser 
mutation from Finland (Uusimaa et al., 2008). Subsequently, founder effects have also 
been identified for the p.Trp748Ser mutation in patients diagnosed with Alpers’ 
syndrome and MIRAS in Australian and New Zealand populations (Hakonen et al., 
2007). 
A Chinese cohort of 265 patients with adult-onset ataxia was investigated for the 
p.Ala467Thr and p.Trp748Ser mutations. Interestingly, no mutations were reported in 
any of the patients, suggesting that these mutations are rare causes of adult-onset 
ataxia in Taiwan (Lee et al., 2007) and that population genetics are important to 
consider when searching for pathogenic mutations. 
There has been very little data published on the frequency of a third common POLG 
mutation, p.Gly848Ser. Many case studies report it as a recessive mutation in patients 
but population studies have not yet been fully conducted. Data on the population 
frequency of POLG mutations is an expanding field, though more investigation is 
needed into the frequency of other common mutations to further understand the impact 
of pathogenic mutations upon the population. 
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Figure 1.12. Mutations in POLG. 
Mutations in POLG have been associated with a heterogeneous range of disorders. 
Image taken from The Human DNA Polymerase Gamma Mutation Database 
at http://tools.niehs.nih.gov/polg/. Database accessed 31-03-2014. 
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1.7.4 POLG Disorders 
Mutations in POLG can lead to a large, heterogeneous group of disorders, each 
displaying a varied phenotype and age of onset (Table 1.2). These may include 
disorders on the myocerebrohepatopathy (MCHS) spectrum, such as Alpers’ syndrome 
which is mentioned in further detail in section 1.9 ‘Alpers’ Syndrome’, and myoclonic 
epilepsy myopathy sensory ataxia (MEMSA) spectrum. As further research is carried 
out, mutations in POLG are found to be the genetic cause of a growing number of 
conditions. POLG mutations may be reported in a small number of patients diagnosed 
with a condition but it is vital to recognise this phenotypic spectrum in order to 
understand the underlying mechanism of manifestation of mitochondrial disease in 
different patients.  
Both dominant and recessive mutations in POLG can lead to clinical signs of 
mitochondrial disease. An example of a condition that may be due to either dominant or 
recessive POLG mutations is PEO; autosomal dominant PEO (adPEO) is due to 
dominant mutations (Van Goethem et al., 2001; Graziewicz et al., 2004) and displays 
the phenotype of ophthalmoplegia and ptosis which may cosegregate with other 
conditions (Luoma et al., 2004), while all other forms of PEO are due to recessive 
mutations (arPEO) and may display more severe symptoms than in adPEO (Van 
Goethem et al., 2001; Van Goethem et al., 2003). When arPEO is associated with 
additional symptoms, such as neurological or multisystem abnormalities, it is termed 
PEO+. PEO has been previously described in detail in section 1.6.4.1 ‘Chronic 
progressive external ophthalmoplegia (cPEO)’. 
The role of POLG mutations in some conditions is under investigation. In some cases 
of male infertility it has been suggested that POLG mutations may be the underlying 
cause. There have been published reports of microsatellite repeat size leading to 
sperm quality defects (Rovio et al., 2001; Baklouti-Gargouri et al., 2012). However, this 
is disputed and other studies have reported that there is no correlation between the 
POLG CAG microsatellite and male infertility (Rani et al., 2009; Poongothai 2013). The 
suggestion that mutations in POLG may lead to male infertility is still unclear. Mutations 
in POLG have also been reported to affect female fertility. Premature ovarian failure 
(POF) has been associated with POLG mutations in patients with premature 
menopause. POF has been reported in association with other disorders such as PEO 
and parkinsonism (Luoma et al., 2004). The mutation p.Tyr955Cys has been reported 
to segregate with POF, PEO and mtDNA depletion in the same family lineage 
(Pagnamenta et al., 2006). 
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Where two recessive mutations cannot be found in POLG, other forms of genetic 
rearrangement may account for a disease which increases the range of known POLG 
mutations that may lead to disease. The use of quantitative multiplex PCR with short 
fluorescent fragments to detect large-scale deletions in patients can be employed to 
search for alternative aetiology. A large-scale deletion of part of intron 21 and exon 22 
in POLG was detected in a patient diagnosed with Alpers’ syndrome using this 
technique (Rouzier et al., 2013). 
There have been two reported findings of Leigh syndrome due to POLG mutations 
(Naess et al., 2009; Taanman et al., 2009). The spectrum and overlap of possible 
phenotypes is important and is highlighted in a report of a patient initially diagnosed on 
the myocerebrohepatopathy (MCHS) spectrum, which then evolved into an Alpers’ 
syndrome-like phenotype with neuropathology typical of Leigh syndrome (Scalais et al., 
2012). The possible involvement of POLG in Leigh syndrome is an area of 
investigation. 
It is currently unclear why it should be that combinations of mutations common to more 
than one disease should produce such varied phenotypes. 
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Disorder Clinical 
Phenotype 
Early/Late 
Onset 
Reported 
Mutations* 
Publication 
Alpers’ 
Syndrome 
Refractory 
seizures; 
psychomotor 
regression; 
ataxia; liver 
failure 
Early-onset p.Ala467Thr; 
p.Trp748Ser; 
p.Gly848Ser 
(Naviaux and 
Nguyen 2004) 
Ataxia-
Neuropathy 
Ataxia; loss of 
sensation 
Early to 
late-onset 
p.Pro765Thr (Bostan et al., 
2012) 
Charcot-Marie 
Tooth Disease 
Muscle wasting; 
loss of sensation 
Early-adult 
to late-
onset 
p.Arg232His; 
p.Gly737Arg 
(Harrower et 
al., 2008) 
Friedreich’s 
Ataxia 
Ataxia; muscle 
weakness; 
dysarthria; 
scoliosis 
Early-adult 
to late-
onset 
CAG repeats (Heidari et al., 
2008) 
Leigh 
Syndrome 
Seizures; ataxia; 
ophthalmoplegia 
Early-onset p.Arg232His; 
p.Trp748Ser; 
p.Gly848Ser; 
p.Arg852Cys 
(Naess et al., 
2009; Taanman 
et al., 2009) 
MIRAS Ataxia; epilepsy; 
ophthalmoplegia  
Early to 
early-adult 
onset 
p.Ala467Thr; 
p.Trp748Ser; 
p.Gln467His 
(Winterthun et 
al., 2005) 
MSCAE Ataxia; epilepsy Early to 
teenage 
onset 
p.Thr419Pro; 
p.Trp748Ser 
(Hinnell et al., 
2012) 
Parkinsonism Tremor; 
hypokinesia; 
postural rigidity 
and instability  
Early to 
late-onset 
p.Ala1105Thr; 
p.Asn468Asp; 
p.Tyr955Cys 
(Luoma et al., 
2004) 
adPEO Ophthalmoplegia; 
ptosis 
Late-onset p.Tyr955Cys; 
p.Arg943His; 
p.Gly923Asp; 
p.Ala957Ser 
(Van Goethem 
et al., 2001; 
Graziewicz et 
al., 2004) 
arPEO Ophthalmoplegia; 
ptosis 
Late-onset p.Ala467Thr; 
p.Leu304Arg; 
p.Arg627Trp 
(Van Goethem 
et al., 2001; 
Van Goethem 
et al., 2003) 
POF Premature 
menopause 
Late-onset p.Tyr955Cys (Pagnamenta 
et al., 2006) 
SANDO Dysarthria; 
ophthalmoplegia; 
ptosis 
Teenage-
Late-onset 
p.Ala467Thr (McHugh et al., 
2010) 
Testicular 
Cancer 
Tumours Late-onset CAG repeats (Nowak et al., 
2005) 
Table 1.2. Disorders arising from POLG mutations. 
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MIRAS= mitochondrial recessive ataxia syndrome, MSCAE= mitochondrial 
spinocerebellar ataxia and epilepsy, adPEO=autosomal dominant progressive external 
ophthalmoplegia, arPEO=autosomal recessive progressive external ophthalmoplegia, 
POF=premature ovarian failure, SANDO= sensory ataxic neuropathy with dysarthria 
and ophthalmoplegia. *= this is not an exhaustive list, for some conditions only the 
most common mutations have been listed. 
 
1.8 POLG Mouse Models 
There have been many mouse models produced to investigate mtDNA disease and its 
progression: transmitochondrial models (Mito-Mice), models of nuclear gene 
modifications that affect mitochondrial DNA maintenance (ANT models, POLG models, 
TFAM models, c10orf2 models), and models of increased mtDNA copy by 
overexpression of a mtDNA maintenance gene (TFAM, TK2). These models display a 
variety of phenotypes which can resemble human disease, and which can allow 
investigations into mechanisms of mitochondrial disease that are currently unknown. 
POLG is the only known polymerase to replicate mtDNA and impaired functioning due 
to mutations can introduce mtDNA deletions and depletion, leading to a range of 
disorders. Many mouse models have been created with different mutations in the three 
domains of POLG to allow studies into the many heterogeneous phenotypes that result 
from mutations in this gene. 
A homozygous POLG -/- mouse model was reported in which exon 3 was removed on 
both alleles of the gene through a beta-actin-cre system. This resulted in an embryonic 
lethal phenotype (Hance et al., 2005), proving the vital role this polymerase has in the 
cell. 
The Mutator mouse model, a homozygous p.Asp257Ala knock-in model expressing a 
proof-reading-deficient version of POLG, was reported. The expression of the defective 
polymerase resulted in mtDNA mutations and an ageing phenotype, including weight 
loss, kyphosis, alopecia, anaemia, osteoporosis, and heart enlargement (Trifunovic et 
al., 2004). The ageing phenotype has been further explored through the mechanisms 
of age-related hearing loss, using this model. Mutator model mice showing accelerated 
ageing and hearing loss through degeneration of hair cells, spiral ganglion cells and 
stria vascularis of the cochlear duct, also showed increased mtDNA mutation rates 
(Yamasoba et al., 2007). In a following paper, they reported that the accumulation of 
mtDNA mutations may cause transcriptional alterations and increased apoptosis of 
cells leading to hearing loss (Someya et al., 2008). Ageing in relation to skeletal muscle 
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loss (sarcopenia) has been investigated using the Mutator mouse model. Reports 
showed a different protein expression profile in model mice and increased 
mitochondrial fission and autophagy compared to control mice, that contributes to 
sarcopenia (Joseph et al., 2013). 
Tissue-specific transgenic mouse models have been genetically engineered to more 
closely resemble a disease phenotype. A heterozygote p.Asp181Ala transgenic mouse 
model was reported with a point mutation in the proofreading exonuclease domain of 
POLG which was expressed solely in cardiac tissue. The model showed an increased 
frequency of mtDNA mutations and deletions with normal mtDNA replication with an 
enlarged heart (Zhang et al., 2000). A subsequent study used a similar heterozygote 
p.Asp181Ala model to express defective POLG in the brain in order to look into cPEO, 
and found mood disorder-like symptoms and increased mtDNA mutations in neurons 
(Kasahara et al., 2006). 
A heterozygous p.Tyr955Cys POLG transgenic mouse model was used to investigate 
chronic progressive external ophthalmoplegia (cPEO). This is a common mutation 
found in cPEO (Van Goethem et al., 2001). The POLG polymerase was overexpressed 
in the heart and cardiac cells showed mtDNA depletion, a reduction in mtDNA 
replication, and oxidative stress (Lewis et al., 2007). 
POLG mouse models will further our understanding of disease progression and the 
effects of mutations on post-mitotic cells. The use of Cre-Lox recombination systems 
and use of specific promoters within the models allows for defective protein expression 
in specific cell types. This creates a level of control not previously known, tailoring the 
model’s use to a tissue-type of interest. However, this technique is limited because it is 
not applicable to many POLG disorders. Many of the mouse models mentioned 
previously match an ageing phenotype and may be used successfully in investigations 
into the effects of ageing. When investigating disorders such as Alpers’ syndrome, 
there is no mouse model with a matching phenotype. 
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1.9 Alpers’ Syndrome 
Alpers’ syndrome is a rare autosomal recessive hepatocerebral disorder. The majority 
of patients present with symptoms in early childhood that include refractory epilepsy, 
developmental delay, ataxia, cortical visual abnormalities and subsequently a rapidly 
occurring neurological decline with a poor prognosis. Liver dysfunction and failure often 
occurs and in some cases it is considered to be linked to the use of the anti-epileptic 
drug, sodium valproate. The syndrome is caused by mutations in the mitochondrial 
DNA polymerase gamma gene, POLG (Naviaux et al., 1999), with the p.Ala467Thr, 
p.Trp748Ser, and p.Gly848Ser mutations being commonly noted and have become 
part of routine diagnostic testing when investigating POLG disorders. However there 
are emerging reports of patients displaying clinical variability in both the age of onset 
and gene involvement.  
The syndrome was first described in 1931 through the work of Dr Bernard Alpers 
(Alpers 1931) and was later characterised to include involvement of the liver by Dr 
Peter Huttenlocher and colleagues (Huttenlocher et al., 1976). This is a rare disorder 
with The National Institute of Neurologic Disorders and Strokes estimating the 
incidence of Alpers’ syndrome at 1/100,000 (Mangalat et al., 2012) 
(http://www.ninds.nih.gov/disorders/alpersdisease/alpersdisease.htm) and the 
preschool incidence being reported as 1/51,000 (Darin et al., 2001). 
Neuropathological investigations of Alpers’ syndrome have revealed neuronal cell loss, 
spongiosis and astrogliosis (Harding et al., 1995; Wiltshire et al., 2008) in both the 
cerebellum and cerebral cortex. White matter abnormalities have been infrequently 
reported as a pathological sign (Simonati et al., 2003b; Bao et al., 2008) but are an 
important consideration. Analysis of the mitochondrial respiratory chain has shown a 
reduced capacity for OXPHOS and a tissue specificity of this defect; liver shows this 
reduced capacity (Schaller et al., 2011), while skeletal muscle can show either a 
reduced capacity (Delarue et al., 2000) or normal results (Wiltshire et al., 2008). To 
date, there have been no reports in the literature of respiratory chain investigations in 
neurons of the brain in patients with Alpers’ syndrome. 
  
51 
 
Chapter 1 Introduction         
1.9.1 Alternative Terms 
Alpers’ syndrome (OMIM 203700) is also known by its alternative terms Alpers-
Huttenlocher syndrome, progressive neuronal degeneration of childhood (PNDC), and 
progressive infantile poliodystrophy.  
The term Alpers-Huttenlocher syndrome encompasses the clinical characterisation of 
patients by Dr Bernard Alpers and Dr Peter Huttenlocher. It is a term that has come to 
mean an Alpers’ syndrome phenotype with involvement of the liver. Efforts to compare 
diagnostic techniques and genetic analyses between Alpers’ syndrome and Alpers-
Huttenlocher syndrome showed there are no important differences between the terms, 
and they should be used to describe the same condition (Harding 1990). 
Progressive neuronal degeneration of childhood (PNDC) is a term used to describe 
what was seen in patients with the phenotype of Alpers’ syndrome (Boyd et al., 1986; 
Harding et al., 1986; Egger et al., 1987; Harding 1990; Harding et al., 1995; Simonati et 
al., 2003a). Its use has endured until recent years and is used as a synonym of Alpers’ 
syndrome. A similar term to PNDC had previously been used in the literature; ‘diffuse 
cerebral degeneration’ (Blackwood et al., 1963). The term PNDC should be considered 
synonymous with Alpers’ syndrome and Alpers-Huttenlocher syndrome. 
Progressive infantile poliodystrophy is a lesser used term used to report a patient 
described with Alpers’ syndrome (Prick et al., 1982). An intermediate term of Alpers 
progressive infantile neuronal poliodystrophy has been used with the suggestion of 
naming an acute neonatal form of Alpers’ syndrome as “Alpers’ syndrome type 1” 
(Frydman et al., 1993). This did not become a commonly used term.  
These alternative terms for Alpers’ syndrome most likely arose at a time when the 
characterisation of Alpers’ syndrome was becoming more commonly reported. They 
should not immediately be confused for separate neurological conditions but care 
should be taken when considering these cases in the current definition of Alpers’ 
Syndrome. The recording of a single term to refer to this disorder should be used to 
minimise confusion. 
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1.9.2 Involvement of POLG in Alpers’ Syndrome 
The main mechanism behind the mtDNA defects in Alpers’ syndrome is known to be 
caused by mutations in the nuclear gene POLG (Naviaux and Nguyen 2004). The first 
publication of a patient with Alpers’ syndrome which linked mtDNA copy number with 
reduced activity of the POLG showed a severe mtDNA depletion with undetectable 
levels of polymerase activity (Naviaux et al., 1999). The assay used to detect the 
activity of the polymerase was the most sensitive assay available and tested on tissue 
homogenate from both liver and skeletal muscle. MtDNA copy number was assessed 
by a dual-label, slot-blot method, based on a previous method using dot blots 
hybridised with a radioactively-labelled mtDNA probe and a reference radioactively-
labelled nDNA probe and the ratio measured (Poulton et al., 1995). Electron transport 
chain and citrate synthase assays showed a reduction in the activity of all complexes. 
This was the first molecular-based explanation of the mtDNA depletion in a patient with 
Alpers’ syndrome. 
With a better understanding of the clinical signs of Alpers’ syndrome and widely-
available genetic testing, reports of alternative genetic causes have been published. 
These alternative causes are discussed in greater detail in section 1.9.3 ‘Involvement 
of non-POLG genes in Alpers’ Syndrome’. Mutations in POLG continue to be the most 
widely reported genetic defect in patients diagnosed with Alpers’ syndrome. POLG 
disorders lead to a wide, heterogeneous range of clinical symptoms and understanding 
the effects of these mutations is vital. 
1.9.2.1 Phenotype and Genotype 
The genotype of an individual is expressed as the phenotype, modified by epigenetic 
factors such as the environment. In patients with the same POLG mutations, the onset 
and progression of disease can vary and there is no obvious and proven association 
between the genotype and clinical signs of POLG disease. The common mutation 
p.Ala467Thr can occur in a range of disorders; from severe paediatric disease that 
includes Alpers’ syndrome (Nguyen et al., 2005) to milder late-onset disease that 
includes cPEO (Van Goethem et al., 2003).  
It has been reported that there is an effect on survival time depending on the POLG 
mutation in patients with Alpers’ syndrome; compound heterozygotes for the 
p.Ala467Thr /p.Trp748Ser mutations had a lower survival rate when compared to 
patients homozygous for either the p.Ala467Thr or p.Trp748Ser mutations (Tzoulis et 
al., 2006). Further observations have been reported that homozygous p.Ala467Thr 
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mutations occur more frequently in late-onset Alpers’ syndrome (Naviaux and Nguyen 
2004; Nguyen et al., 2006; Blok et al., 2009). 
In addition, patients with a similar phenotype may in fact have different POLG 
mutations or even mutations in different genes. This highlights the heterogeneous 
phenotypes of POLG disease and the difficulty in creating discrete phenotypes based 
on genotype. There has been no persuasive argument to fully explain how mutations in 
a single gene can give rise to a number of heterogeneous phenotypes. 
1.9.2.2 Common Mutations 
There are currently over 230 mutations in POLG listed on the freely accessible 
database, The Human DNA Polymerase Gamma Mutation Database. This is available 
at http://tools.niehs.nih.gov/polg/ and lists mutations in all 3 domains of POLG, 
including the mutations causing Alpers’ syndrome (Figure 1.12). Any discrepancies 
between the mutations listed in Figure 1.13 and the current database may occur due to 
the fact that The Human DNA Polymerase Gamma Mutation Database is being 
constantly updated as research findings are reported. It is an important yet difficult task 
to prove that a mutation in the POLG gene is actually pathogenic and contributes to the 
disease phenotype. In the following sections, the common mutations found in POLG in 
the linker and polymerase regions are described. There are currently no commonly 
reported mutations associated with Alpers’ syndrome in the exonuclease region, 
though they can occur in this domain in patients with Alpers’ syndrome. Exonuclease 
mutations have been reported with high frequencies of mtDNA mutations owing to 
infidelity of DNA replication (Del Bo et al., 2003). 
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Figure 1.13. Mutations in POLG leading to Alpers’ syndrome. 
Top image depicts POLG gene showing the three main domains; the exonuclease 
domain, spacer region, and polymerase domain. The positions of mutations implicated 
in Alpers’ syndrome are indicated and the colour of the box surrounding the mutation 
text refers to their inclusion in a cluster, depicted in the bottom image. NTD refers to 
the N-terminal domain, AID refers to the accessory interacting subdomain, IP refers to 
the intrinsic processivity subdomain. Bottom image illustrates POLG polymerase and 
its suggested five functional cluster groups. Image taken from Euro et al., (2011). 
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1.9.2.2.1 p.Ala467Thr Mutation 
The p.Ala467Thr mutation is found in the linker/spacer domain of the POLG gene. This 
mutation is the most commonly reported and is implicated in a wide range of POLG 
disorders. This heterogeneity and phenotype overlap has led to suggestions that POLG 
disorders, including Alpers’ syndrome, are a continuum of symptoms and not discrete 
phenotypes (Neeve et al., 2012). 
This is considered to be the most common mutation associated with Alpers’ syndrome. 
In a cohort of 15 patients and 20 published cases sequenced, the p.Ala467Thr 
mutation was the most frequent, on its own or in trans with other mutations (Nguyen et 
al., 2006). 
In vitro assays of POLG protein with the p.Ala467Thr mutation showed that this 
mutation resulted in a polymerase with roughly 4% of the wild-type polymerase activity. 
The catalytic subunit failed to interact with the accessory subunit and so exhibited low 
processivity of DNA synthesis (Chan et al., 2005). This disruption may lead to the 
mtDNA deletion and depletion that result from this POLG mutation. 
1.9.2.2.2 p.Trp748Ser Mutation 
The p.Trp748Ser mutation is found in the linker/spacer domain of the POLG gene and 
it is a frequently reported mutation in Alpers’ syndrome. It is often found in cis with the 
mutation p.Glu1143Gly but it is not thought that this mutation plays a role in disease 
progression. Polymerase containing this mutation has been shown to exhibit low levels 
of activity, low processivity, and poor DNA-binding capabilities but in fact polymerase 
containing only the p.Glu1143Gly mutation was 1.4-fold more active than wild-type 
polymerase (Chan et al., 2006). 
Monoallelic expression of the p.Trp748Ser allele in a patient hemizygous for POLG, led 
to a more severe phenotype than patients homozygous for the p.Trp748Ser mutation 
(Naess et al., 2012). It is not clear why this should be and highlights the need for 
further studies into the function of mutations and the full extent of their effects upon 
disease progression. 
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1.9.2.2.3 p.Gly848Ser Mutation 
The p.Gly848Ser mutation is found in the polymerase domain of the POLG gene. 
Mutations in the this domain have been shown to reduce polymerase activity by up to 
99% depending on where the mutation is exactly in this region (Kasiviswanathan et al., 
2009). It has also been suggested from cultured fibroblast cells that mutations in the 
polymerase or exonuclease regions result in more mtDNA depletion than when 
mutations occur in the linker region of the POLG gene (Ashley et al., 2008). 
1.9.3 Involvement of non-POLG genes in Alpers’ Syndrome 
Full sequencing of POLG can show no pathogenic mutations despite the occurrence of 
the clinical signs of Alpers’ syndrome (Nguyen et al., 2006). There have been recent 
publications reporting mutations in genes other than POLG may lead to an Alpers’ 
syndrome-like phenotype. Mutations in FARS2 (mitochondrial phenylalanyl transfer 
RNA synthetase) has been implicated in some cases of Alpers’ syndrome (Elo et al., 
2012). In addition to this, mutations in the gene coding for Twinkle helicase, C10orf2, 
have been found in cases with an Alpers-like phenotype (Hunter et al., 2011). 
It is expected that further reports will be published in future years and as the definition 
of Alpers’ syndrome evolves and is redefined, so is our understanding of the underlying 
genetic causes. 
1.9.4 Cells of the Central Nervous System 
The architecture of the CNS is highly complex and is comprised of many different cell 
types. These primarily fall under the main categories of neuronal cells and glial cells, 
which include astrocytes, microglia, and oligodendrocytes. Glial cells are specialised, 
functioning in a specific role, for example microglia function in an immunological role in 
the CNS, and oligodendrocytes produce the myelin required to support and insulate 
neuronal axons and increase the rate of impulse conductivity. The brain is estimated to 
use 20% of body’s energy sources for the production of ATP and its ATP requirements 
may fluctuate between different brain regions and under different physiological 
stresses. Mitochondria are required by each of these cell types for correct functioning. 
Mitochondrial dysfunction in glial cells has been studied less frequently than in 
neurons. A respiratory chain deficiency has been reported in astrocytes of patients with 
mitochondrial disease (Lax et al., 2012) and an abnormal mitochondrial morphology 
reported in activated microglial cells (Banati et al., 2004). In addition to the effect of 
mitochondrial dysfunction in neurons, mitochondrial dysfunction in astrocytes and 
microglia will be examined in this thesis. 
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1.9.5 Affected Tissues 
It has been observed that there is a clear tissue-selectivity in Alpers’ syndrome. Certain 
organs and tissues are more severely affected than others. 
Published scientific literature on Alpers’ syndrome frequently cites the brain and liver as 
the most severely affected organs. This is attributed to their highly ATP-dependent 
processes. Other organs are also involved to a lesser degree, including the pancreas, 
resulting in pancreatitis and diabetes mellitus, the nerves innervating the eyes causing 
blindness and ears causing deafness. Gastrointestinal pathology has also been 
reported (Kapur et al., 2011; Spiegler et al., 2011). 
However, the literature has reported a mixed effect on skeletal muscle in patients with 
Alpers’ syndrome. Reports of reduced respiratory chain activity in skeletal muscle 
(Naviaux et al., 1999) and reduced mtDNA levels (Uusimaa et al., 2008; Taanman et 
al., 2009; Scalais et al., 2012) have been published in the literature. There have also 
been reports of skeletal muscle being unaffected despite other tissues showing a 
respiratory chain or mtDNA abnormality and the patient receiving a clinical diagnosis of 
Alpers’ syndrome. In a case report of two patients with Alpers’ syndrome, mtDNA 
depletion was seen in the liver at 16% of the control value, but there was no difference 
in the skeletal muscle of both patients (Pronicka et al., 2011). A respiratory chain 
abnormality in muscle was seen in one of the patients for complex II and complex IV. A 
similar pattern of tissue specificity has been reported previously (Flemming et al., 2002; 
Simonati et al., 2003a; Simonati et al., 2003b; Wiltshire et al., 2008). 
Investigations into the effect on mitochondrial structure, using electron microscopy 
(EM) on brain and muscle samples, have revealed an increase in the size and number 
of mitochondria in muscle, and the presence of globoid inclusions within the 
mitochondria (Nolte et al., 2013). Electron-dense inclusions have also been reported in 
liver and skeletal muscle in a patient with Alpers’ syndrome (Mangalat et al., 2012). 
In muscle, pathogenic changes may be ultrastructural and not become dysfunctional 
until later in disease progression. The symptoms caused by mitochondrial dysfunction 
in other tissue types may result in disease pathology that is more obvious than the 
changes in muscle. It is currently unclear why mutations in a nuclear gene do not 
equally affect all tissues that are similarly ATP-dependent. 
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1.9.5.1 Central Nervous System Involvement 
The brain has a large involvement in Alpers’ syndrome, requiring a large amount of 
ATP to function correctly and appropriately. When ATP production is impaired, the 
brain can be severely affected because the neurons may be selectively vulnerable to 
changing levels of ATP as they cannot produce ATP through the process of glycolysis. 
MRI scans are frequently used to visualise the brain and can reveal areas of atrophy, 
oedema, inflammation or other abnormalities in patients. MR spectroscopy is 
associated with MRI scans and has been used to investigate the CNS of a patient 
diagnosed with Alpers’ syndrome, revealing oedema and increased lactate levels which 
were interpreted as respiratory chain deficiency (Flemming et al., 2002).  
Epilepsy, psychomotor regression, and cortical blindness are the key symptoms of 
Alpers’ syndrome, which all stem from neuronal dysfunction. Epilepsy in these patients 
is often difficult to control and progressive. The posterior of the brain and the 
cerebellum are typically more severely affected than the anterior and central regions of 
the cerebrum. 
1.9.5.2 Neuropathology 
It is commonly reported that the grey matter of both the cerebrum and cerebellum is 
affected by neuronal cell loss, astrogliosis, and capillary proliferation (Harding 2008). In 
the cerebellum, it is the Purkinje cells that are noticeably depleted, accompanied by 
astrogliosis (Bergmann gliosis). Different areas of the brain are affected to varying 
degrees and can alter throughout disease progression, which can typically be identified 
using MRI scans and CT scans (Figure 1.14). 
The cerebellum and posterior regions of the cerebrum, such as the occipital lobe, are 
often severely affected during the course of Alpers’ syndrome (Harding et al., 1986; 
Khan et al., 2012). It is unclear why this occurs, a possibility is that these regions are 
more active and use large amounts of energy to function. A reduction in energy 
production may result in the neurons in posterior areas being detrimentally affected 
sooner than neurons in more anterior regions. 
Neuron loss is a very commonly reported neuropathological aspect of Alpers’ 
syndrome (Wiltshire et al., 2008; Scalais et al., 2012). It can cause many of the signs 
and symptoms that are seen in the patient, and create inconsistent signalling between 
connected areas of the brain. Other pathology such as astrogliosis is reported in the 
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literature (Harding et al., 1995; Wiltshire et al., 2008), however, it is very rarely 
quantified in patients. 
White matter abnormalities are reported uncommonly in the literature (Harding et al., 
1995; Simonati et al., 2003b; Bao et al., 2008). It is unclear how frequently white matter 
abnormalities occur and to what severity. These abnormalities may be due to primary 
loss of myelin or to secondary loss of myelin due to axonal loss. 
Alpers’ syndrome is considered to be a condition on a wide spectrum of POLG 
disorders. A case of Alpers’ syndrome in a young patient with compound heterozygous 
p.Ala467Thr and p.Gly848Ser mutations was initially thought to resemble a condition 
on the myocerebrohepatopathy spectrum (Scalais et al., 2012). The neuropathology 
showed much necrosis and astrogliosis in the occipital lobe, neuron loss in the basal 
ganglia, and Purkinje cell loss in the cerebellum. In addition to the cerebellum and 
basal ganglia, the thalamus showed neuron loss and vacuolation which resembled the 
pathology of Leigh syndrome. This report highlights the wide range of neuropathology 
that can occur and the overlap between syndromes that we are beginning to recognise. 
As the neurological aspects of Alpers’ syndrome are often severe, a better 
understanding of the neuropathology and the pathological mechanisms is essential in 
order to improve the treatment of this syndrome. Genetic diagnosis of patients and their 
families is important as it gives a wider picture of the factors leading to Alpers’ 
syndrome and ultimately allows medical professionals to inform ‘at risk’ individuals of 
their choices through genetic counselling. 
 
Figure 1.14. MRI images (T2-FLAIR) showing occipital lobe and thalamic lesions 
during disease progression 
Image A is a T2-FLAIR MRI image taken on patient admission. There is a small 
hyperintense cortical lesion of the occipital lobe (arrowed). Image B is a T2-FLAIR MRI 
image taken during disease progression. There is a larger hyperintense cortical lesion 
of the occipital lobe (arrowed) and a smaller lesion of the thalamic region (arrowed). 
Images taken from Visser et al., (2010). 
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1.9.5.3 Liver Involvement 
Liver dysfunction and failure is a common feature in Alpers’ syndrome. Failure is often 
preceded by steatosis, hepatocyte cell dysfunction and dropout, bile duct proliferation, 
cholestasis, and immune cell infiltration. The first report of hypoglycaemia due to 
impaired glycogenolysis in a patient with Alpers’ syndrome has been recently reported, 
with abnormal glycogen storage in the liver (Simon et al., 2013). This patient presented 
with glucosuria without any preceding neurological or developmental symptoms. Liver 
dysfunction often occurs in the later stages of Alpers’ syndrome after initial symptoms 
of epilepsy and neurological abnormalities. However, the onset of liver complications is 
variable and there have been reports of liver dysfunction and failure occurring before 
the onset of epilepsy (Egger et al., 1987). 
1.9.5.4 Use of Sodium Valproate 
Sodium valproate is a solid compound formed from the addition of liquid valproic acid 
to a base chemical. Its primary use is as an anti-convulsant drug and as a mood 
stabiliser. 
Its use as an anti-epileptic drug for patients with mitochondrial disease is not 
recommended, as it has been reported that it can inhibit fatty acid oxidation in the 
mitochondria (Eyer et al., 2005) and inhibit oxidative phosphorylation leading to 
hepatotoxicity (Horvath et al., 2006) and the precipitation of liver failure (Bicknese et 
al., 1992). Nevertheless, the mechanisms behind how this leads to adverse effects, in 
the liver in particular, are unclear. Cases have been described in the literature where 
liver abnormalities were present before sodium valproate was given to the patients 
(Ferrari et al., 2005; Uusimaa et al., 2008), which could suggest that sodium valproate 
may quicken the onset of pre-existing liver failure in some patients. When liver 
dysfunction has been diagnosed prior to a correct diagnosis, liver transplants have 
occasionally been performed on Alpers’ syndrome patients. However, these transplants 
have been unsuccessful at preventing the course of the syndrome owing to the 
involvement of seizures (Delarue et al., 2000; Kayihan et al., 2000). A report of a 
reversal of sodium valproate toxicity has been published after cessation of the drug in a 
child with four heterozygous mutations in POLG, two of which were the common 
p.Ala467Thr and p.Trp748Ser mutations often associated with Alpers’ syndrome 
(McFarland et al., 2008). The presence of an additional two mutations in POLG, the 
p.Gln879His and p.Thr885Ser mutations, may have influenced this unusual outcome. 
61 
 
Chapter 1 Introduction         
Sodium valproate is commonly prescribed in a clinical setting to control epileptic 
seizures. It has been often recommended that testing for POLG disorders, and in 
particular Alpers’ syndrome, should be carried out before administering sodium 
valproate in order to prevent side effects (Saneto et al., 2010). This should be applied 
to all mitochondrial disorders. 
1.9.6 Therapy 
There are currently no existing treatments for Alpers’ syndrome, with relief and support 
in the form of symptomatic therapies. This section will discuss the current available 
therapies for patients with Alpers’ syndrome. 
1.9.6.1 Anticonvulsant Drugs 
Seizures are the most common sign in Alpers’ syndrome. Seizures are usually 
refractory and do not consistently respond to the anticonvulsant drugs usually used in 
treatment, such as phenytoin, carbamazepine, and levetiracetam. Use of this 
medication may result in temporary benefits but this does not last and a decline in 
health rapidly transpires. 
Sodium valproate is an anticonvulsant drug once commonly used to treat all seizures 
but more recent observations have led to the call for it not to be used where 
mitochondrial disease is suspected in the patient (Saneto et al., 2010). This was 
previously discussed further in section 1.9.5.3 ‘Use of Sodium Valproate’. 
1.9.6.2 Ketogenic Diet 
A ketogenic diet is occasionally used in the treatment of refractory epilepsy in children. 
It consists of a high fat, low carbohydrate diet. The ratio of fat to carbohydrate varies 
and is roughly of 4 parts fat to one part each protein and carbohydrate. There have 
been a range of reported effects due to this diet. 
A beneficial effect in a young patient with Alpers’ syndrome was reported, with 
twitching of the left hand stopping completely after commencing the diet, a remarkable 
improvement of electroencephalogram (EEG) tests, and a cessation of seizures for 
seven months (Joshi et al., 2009). However, reduced compliance with the diet and an 
infection led to a recurrence of seizures which could not be controlled. A separate 
study of 32 infants with intractable epilepsy though not diagnosed with Alpers’ 
syndrome, were placed on a ketogenic diet and resulted in over 50% of the patients 
having a >50% reduction in seizure frequency, and the diet was considered a safe 
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treatment for infant patients with intractable epilepsy (Nordli Jr et al., 2001). However, 
Wiltshire et al., reported that the ketogenic diet had no effect in their Alpers’ syndrome 
patient (Wiltshire et al., 2008). 
Though mechanisms have been discussed for why this diet may work as an effective 
treatment, these remain speculative. Further trial of the ketogenic diet as a treatment 
option is required. It may provide relief to some patients and should remain an option 
for families. 
1.9.6.3 Magnesium Therapy 
Magnesium therapy has been used to effectively control seizures in conditions such as 
eclampsia (Roy et al., 2013). It has also been reported to have had a positive effect in 
two patients with Alpers’ syndrome (Visser et al., 2011). In one patient, seizures 
stopped completely upon administration of magnesium and did not return, though 
unfortunately further complications led to multi-organ failure. The second patient 
showed improvement of paresis and dysphagia, and improved EEG after extubation. 
Unfortunately seizures continued in this patient. 
Magnesium therapy is not a widely used treatment and further studies into the efficacy 
of this treatment are required. The mechanisms through which magnesium therapy 
may act are unclear, though it speculated that it may act through an antagonistic effect 
on N-methyl-D-aspartate (NMDA) receptors, blocking calcium influx (Hallak 1998). 
1.9.6.4 Surgical Therapy 
Functional hemispherectomy has been described as a possible treatment for refractory 
seizures in patients with Alpers’ syndrome. This was performed in a four-year-old 
patient and halted seizures and improved quality of life for two months (Lupashko et al., 
2011). Further research is needed into the benefits of hemispherectomy in patients with 
Alpers’ syndrome, to assess whether it can be beneficial as an option to manage the 
refractory seizures seen with the condition. 
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1.10 Aims of the Study 
The aims of this study are to understand the correlation between and the mechanism 
leading to the key neurological signs and degenerative changes in post-mortem brain 
tissue. This will be achieved through: 
1. The characterisation of the neuropathology of patients diagnosed with Alpers’ 
syndrome, in comparison with age-/sex-matched controls. A quantitative 
approach will be taken to assess the grey and white matter for a range of 
characteristics, including neuron loss, astrogliosis, and white matter 
abnormalities. 
2. Achieving a genetic diagnosis in patients where one was not available. 
3. Determining the respiratory chain deficiency in patients diagnosed with Alpers’ 
syndrome, in comparison with matched controls. Complexes I to IV will be 
assessed in the cohort of patients, through the use of immunohistochemistry, to 
investigate any deficiencies or partial deficiencies in neurons. 
4. Assessing the mtDNA in single neurons and whether there is DNA damage. 
Both mtDNA deletion and mtDNA depletion are assessed separately to 
investigate which may be the more prominent feature. 
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2.1 Materials 
This section will detail all materials used during this project. 
2.1.1 Solutions 
Citrate Buffer 0.01M, pH6.0 2.94g Sodium citrate 
 1 Litre Deionised water 
Developer Solution 7.4ml Formaldehyde 40% 
 50µl Nitric acid 
 0.5g Citric acid 
 100ml Deionised water 
DNA Loading Buffer 0.125g Bromophenol blue 
 0.125g Xylene Cyanol 
 15ml Glycerol 
 35ml Deionised water 
EDTA 0.001M, pH8.0 0.416g EDTA 
 1 Litre Deionised water 
Eosin Solution 10g Eosin Yellowish 
 0.25g Phloxine B 
 0.25g Erythrosin B 
 1 Litre of 20% ethanol in tap water 
 Filter before use   
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Haematoxylin Solution 1g Haematoxylin powder 
 10ml Ethanol 
 90ml Deionised water 
 2ml Saturated lithium carbonate 
Iron Alum 4% 4g Ammonium iron(III) sulphate dodecahydrate 
 100ml Deionised water 
Lysis Buffer 50µl Tris-HCl 
 250µl 1% Tween○RE  
P
 
P5µl Proteinase K 
 195µl DEPC-treated water 
Phosphate Buffered Saline (PBS) One tablet dissolved in  
 100ml deionised water 
Scott’s Tap Water  2g Sodium bicarbonate 
  20g Magnesium sulphate 
  1 Litre tap water 
  A few crystals of thymol 
Tris Buffered Saline (TBS) pH7.4 1.2g Trisma base 
 17g Sodium chloride 
 2 Litres Deionised water 
TBST with Tween A○RE A pH7.4 1.2g Trisma base 
 17g Sodium chloride 
 1ml TweenA○RE  
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 2 Litres Deionised water 
2.1.2 Chemicals 
2.1.2.1 Histological Reagents 
Acetic Acid Analar BDH 
Ammonia Analar BDH 
Ammonium Iron(III) Sulphate Dodecahydrate Sigma 
Calcium Chloride  Sigma 
Catalase  Sigma 
Citric Acid Fisher Scientific 
Cresyl Violet Acetate Sigma 
Cytochrome c Sigma 
3, 3’ Diaminobenzidine Tetrahydrochloride (DAB) tablets and liquid Sigma 
DPXPTMP Mountant CellPath 
EDTA USB 
Eosin Yellowish Raymond Lamb 
Ethanol Analar Fisher Scientific 
Ethidium Bromide Sigma 
Erythrosin B Raymond Lamb 
Formaldehyde Solution Sigma 
Gold Chloride (Sodium Chloroaurate) Sigma 
Haematoxylin Powder Fisher Scientific 
Haematoxylin Liquid (Meyer’s) Fisher Scientific 
Histoclear PTMP National Diagnostics 
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Hydrochloric Acid ~37% Fisher Scientific 
Hydrogen Peroxide 30% (w/w) Sigma 
Lithium Carbonate BDH 
Magnesium Sulphate Sigma 
Nitric Acid BDH 
Nitro Blue Tetrazolium Sigma 
Phenazine Methosulphate Sigma 
Phloxine B Raymond Lamb 
Phosphate Buffered Saline (PBS) Tablets Oxoid 
Proteinase K Invitrogen 
Silver Nitrate Analar VWR 
Sodium Azide Sigma 
Sodium Acetate BDH 
Sodium Bicarbonate Sigma 
Sodium Chloride Sigma 
Sodium Citrate Analar VWR 
Sodium Hydroxide Analar VWR 
Sodium Succinate Sigma 
Sodium Thiosulphate Analar BDH 
Thymol Sigma 
Trypsin Sigma 
Trisma Base Sigma 
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TweenA○RE A 20 Sigma 
 
2.1.2.2 Polymerase Chain Reaction 
Deoxynucleotide Triphosphates Rovalab 
DEPC-treated Water Ambion 
GoTaqA○RE A Polymerase Promega 
GoTaqA○RE A Hot Start Polymerase Promega 
Magnesium Chloride Promega  
5X GoTaqA○RE A PCR Buffer Promega 
5X GoTaqA○RE A Flexi PCR Buffer Promega 
TaqManA○RE AP PTAMRAPTM PND1/ND4 Probes Applied Biosystems 
TaqManA○RE AP PUniversal PCR Mastermix Applied Biosystems 
 
2.1.2.3 Gel Electrophoresis 
Agarose Powder Bioline 
Bromophenol Blue Sigma 
1Kb DNA Ladder Norgen 
GelRedPTMP Nucleic Acid Stain Biotium 
Glycerol Sigma 
Tris Acetate-EDTA (TAE) Buffer Sigma 
Xylene Cyanol VWR 
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2.1.2.4 Sequencing and Pyrosequencing 
BigDye Terminator v3.1 Cycle Sequencing Kit Applied Biosystems 
DMSO Sigma 
ExoSAP-IT GE Healthcare 
HiDi Applied Biosystems 
Pyrogold Reagents Qiagen 
 
2.1.3 Consumables 
0.2ml Thin-Walled PCR Tubes Thermo Scientific 
0.5ml PCR Tubes Thermo Scientific 
1.5ml Eppendorf Tubes Thermo Scientific 
2.0ml Eppendorf Tubes Thermo Scientific 
Aluminium Foil VWR 
Coverslips (22X20mm, 22X32mm, 22X40mm, 22X50mm) CellPath 
Coverslips HiQA (37X58mm, 48X64mm) CellPath 
NucleoSpin A○RE A Tissue Preparations Macherey-Nagel 
Medical Tissue Kimberly-Clark 
Microscope Slides (mega, supa mega 1.0-1.2mm, 76X26X1.0-1.2mm) CellPath 
Microscope Slides, SuperFrostA○RE A (76X26X1.0mm) VWR 
Microtome blades MX35 Premier Thermo Scientific 
PCR Plates (real-time PCR) Starlabs 
PCR Plate Seals (real-time PCR) Starlabs 
Pipette Tips (10ml, 20ml, 200ml, 1000ml) Starlabs 
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Polyethylene naphthalate (PEN) Membrane Slides Leica 
Slide Racks CellPath 
Sliderite 5 Mailer PTMP CellPath 
Weigh Boats Fisher Scientific 
 
2.1.4 Equipment 
AlamutPTMP Software Interactive Biosoftware 
Antigen Retrieval Unit A. Menarini Diagnostics 
ABI 3100 Genetic Analyser Applied Biosystems 
Autoclave Astell 
Balance, AdventurerPTMP Ohaus 
Centrifuge 3-15 Sigma 
Centrifuge C5418 Eppendorf 
Centrifuge PCV2400 Grant-Bio 
Cryostat OTF Bright 
Dry Heat Block Techne 
Electrophoresis Power Supply Cleaver Scientific Ltd 
Electrophoresis Power Supply Amersham Pharmacia Biotech 
EZ1 A○RE A Advanced Workstation Qiagen 
Incubator (35PoPC) Thermo Scientific 
Incubator (60PoPC) Genlab 
Microtome HM325 Microm 
Nanodrop ND-1000 Spectrophotometer Labtech International 
71 
 
Chapter 2 Materials and Methods  
Olympus BX51 Microscope Olympus 
Palm MicroBeam Laser Microdissection Microscope and Software Zeiss 
PCR Machines Applied Biosystems 
PCR Machines (real-time PCR) Applied Biosystems 
pH Meter 3510 Jenway 
Pipettes (2µl, 10µl, 20µl, 200µl, 1000µl) Gilson 
PyroMark Q24 Qiagen 
QIAmp DNA Mini Kit Qiagen 
StereoInvestigator Software MBF Bioscience 
Tweezers CellPath 
UV Biological Hood Bioair Instruments 
UV Gel Imaging System, ChemiDoc MP Bio-Rad 
UV Gel Imaging Software, Image Lab 4.1 Bio-Rad 
Zeiss Imaging System and software Zeiss  
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2.2 Methods 
This section will detail all methods followed during this project. 
2.2.1 Patient and Control Cohort 
The patients that were included in this study all had a clinical diagnosis of Alpers’ 
syndrome or Alpers-like syndrome. Patients fulfilled the criteria for Alpers’ syndrome 
based upon the presentation of defined features. These criteria are explained fully in 
section 2.2.2 ‘Definition of Alpers’ Syndrome’. The diagnosis given by the clinician and 
the presence of seizures and ataxia symptoms noted in the medical notes were used 
for inclusion of patients in the study. Patient 4 was diagnosed with mitochondrial 
disease due to a POLG mutation. This patient was the oldest patient in the cohort at 24 
years at the time of death. Patient details are summarised in Table 2.1. POLG 
mutations are stated where known. However, the full sequencing data was not 
available to me. 
Where possible, controls were used that were age-matched and sex-matched to the 
patients. Patient and control neuropathology details are summarised in Table 2.2. 
Patient material was obtained from a number of sources. The Newcastle Brain Tissue 
Resource (NBTR) provided formalin-fixed, paraffin-embedded (FFPE), frozen, and 
formalin-fixed tissue for Patients 1, 2, 4-6 and 12. The Institute of Neurology, University 
of Vienna, Austria provided FFPE tissues for Patients 7-11. The University of Bonn, 
Germany provided frozen tissue for Patient 3. Due to the rarity of the disease and the 
sensitive nature of the patient age, it was extremely difficult to obtain both patient and 
age-matched control tissue. A number of centres were approached to request tissue; 
centres that responded positively had one or two possible cases of Alpers’ syndrome. 
In order to visualise mitochondrial antibodies, it was desirable that possible cases had 
FFPE tissue blocks that had been fixed in formalin for less than 6 months. This made 
the acquisition of suitable tissue a challenging task. 
The following patient histories are taken from clinician’s reports written at the time. 
2.2.1.1 Patient 1 
Patient 1 was the first child of non-consanguineous parents and was born after an 
uneventful pregnancy. There was a family history of epilepsy on the mother’s side. 
She presented at hospital at 11 months old with continuous right focal seizures which 
were treated with the anticonvulsants diazepam and then sodium valproate. After a few 
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months with no seizures, they restarted following her MMR (measles, mumps and 
rubella) vaccination, and her development regressed as she stopped weight bearing or 
crawling. At 13 months old, she became drowsy, irritable, jaundiced, anorexic, and lost 
weight. The jaundice was accompanied by clinical evidence of abnormal clotting (easy 
bruising and bleeding gums), enterohepatic obstruction (dark urine and pale stools), 
and hypoproteinaemia (oedema).  
She was admitted to Newcastle General Hospital with encephalopathy and required 
ventilation. She had hypoglycaemia and abnormal liver function tests: bilirubin 113, 
alkaline phosphatase 243, alanine transaminase 189, albumin 31 and ammonia 70. 
She also exhibited coagulopathy: prothrombin>200, partial thromboplastin >180, 
fibrinogen <0.1, platelets 60, haemoglobin 8.9, and white cell count 6.6. In view of this 
she was transferred to Birmingham Children’s Liver Unit to be considered for liver 
transplant. A repeat CT scan at Birmingham showed mild generalised cerebral atrophy 
with a low attenuation area in the right frontal lobe.  
She was diagnosed with Alpers’ syndrome and she returned to Newcastle General 
Hospital for terminal care. She died aged 14 months due to hepatic failure.  
Molecular genetic investigations confirmed the patient was compound heterozygous for 
the p.Ala467Thr and p.Gly848Ser POLG mutations. Diagnostic biochemical 
investigations in muscle showed 50% reduced activity for complex I and 25% reduced 
activity for other complexes when compared to normal controls. Histochemistry 
revealed 20% COX-negative fibres in muscle. 
2.2.1.2 Patient 2 
Patient 2 was the first child of the family, with a clinically normal younger sister. 
He had normal development until 17 months of age when following a day of vomiting, 
fever and drowsiness he had a prolonged seizure that evolved into status epilepticus. A 
right hemiparesis resolved but hemianopia continued. An EEG some months later was 
normal. A subsequent seizure occurred at 19 months of age associated with a 
convergent squint and left-sided neurological defects, and once again there was 
spontaneous recovery with speech and motor functions returning to normal. 
Hemianopia continued. CT scan showed atrophy in left posterior region and EEG scan 
showed deterioration. The following month there was a similar readmission with visual 
loss. Patient was discharged on a ketogenic diet and with anticonvulsants that included 
sodium valproate. A couple of months later the patient’s condition deteriorated and he 
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became floppy, his feeding deteriorated and he was excessively drowsy. A respiratory 
chain disorder was suspected as the patient’s condition continued to deteriorate and he 
became unable to walk, had poor vision and had seizures in the right upper limbs. He 
died aged 27 months due to pulmonary haemorrhage and respiratory failure. 
Molecular genetic investigations confirmed the patient was compound heterozygous for 
the p.Ala467Thr and p.Thr914Pro POLG mutations. A case report of this patient was 
published describing clinical course and a partial deficiency of cytochrome c oxidase in 
muscle and activity of this enzyme was less than 30% of the mean control value 
(Morris et al., 1996). 
2.2.1.3 Patient 3 
This patient had clinical signs of epilepsia partialis continua, and sodium valproate-
induced liver failure. He died at 17 years old.  
Molecular genetic investigations confirmed the patient was homozygous for the 
p.Ala467Thr POLG mutation and clinical investigations showed COX-negative fibres in 
muscle and COX-negative areas in liver samples. Decreased complex I and complex 
IV enzyme activities in skeletal muscle were noted. Mitochondrial DNA deletion and 
depletion of copy number were seen in skeletal muscle, brain and liver samples 
(Zsurka et al., 2008). 
2.2.1.4 Patient 4 
Patient 4 had a normal childhood development. She first developed seizures at 20 
years old, at which time she was 22 weeks pregnant. The seizures were very difficult to 
control with treatment and investigations showed high levels of urinary copper. She had 
ataxia and uncoordinated eye movements. CT scan was normal and a lumbar puncture 
showed normal CSF results.  
Seizures continued and an EEG scan showed a diffuse abnormality, while an MRI scan 
showed three abnormal areas in the grey and white matter which suggested ischaemic 
changes. Her condition deteriorated and she developed striking eye movement 
abnormalities with impairment of her upgaze and horizontal gaze. A repeat MRI scan 
showed new ischaemic changes in the grey and white matter of the brain. 
There was a brief period of improvement in her condition when she was started on 
Dexamethasone, but her condition once again deteriorated and she was found to have 
signs of osteoporosis when she fell and fractured her femur. Her condition showed a 
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further decline with progressive ataxia with epilepsy and paraparesis with clonic jerks 
with a reduced level of consciousness. 
She died at 24 years old. Molecular genetic investigations confirmed the patient was 
heterozygous for the p.Ala467Thr and p.Trp748Ser POLG mutations. 
2.2.1.5 Patient 5 
Patient 5 died intrauterine at 34 weeks gestation. However, the size and weight of the 
patient suggested death at 36-38 weeks, suggesting the patient may have been older 
than 34 weeks. The mother was 31 years old with insulin-dependent diabetes. She 
presented with decreased fetal movements and intrauterine death was confirmed by an 
ultrasound scan. 
This patient was included in the study as a sibling had shown signs of a progressive 
neurological disorder, and this sibling had previously been confirmed as having the 
pathological POLG mutation p.Ala467Thr, as well as the single nucleotide 
polymorphism p.Glu1143Gly (Craig et al., 2007). POLG sequencing carried out during 
this project also found the sibling carried the p.Asp1219Glu mutation, which has 
unknown pathogenicity. Patient 5 is considered as having a possible POLG defect. 
2.2.1.6 Patient 6 
This patient first presented to hospital at 16 years old with headache, double vision and 
photophobia. The next day she developed weakness in the left arm with left-sided 
twitching, and epilepsy developed which was initially controlled with diazepam and later 
with sodium valproate. A CT scan was normal but left-sided hemiplegia continued and 
epilepsy reoccurred. 
Epilepsy persisted and a later CT scan showed ventricular dilation. She was admitted 
to hospital once again for left-sided seizures when she was thought to be about 10 
weeks pregnant. Seizures were extremely difficult to control and it was decided that the 
pregnancy should be terminated unless the seizures could be managed.  
After pregnancy termination, the seizures continued but were less severe. Local 
oedema of the larynx resulted in intubation. Her seizures continued and the patient 
remained unconscious with brief periods of responsiveness. This condition persisted 
until death from cardiac arrest at the age of 18 years old. 
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A brother survived into later life but suffered neurological problems. The brother had 
previously been confirmed as having the pathological POLG mutations p.Trp748Ser 
and p.Arg1096Cys. 
2.2.1.7 Patient 7 
She suffered epileptic seizures until death at 2.5 months old. There is very limited data 
for this patient from the Institute of Neurology, University of Austria, Vienna, and there 
was no conclusive diagnosis. 
2.2.1.8 Patient 8 
Patient 8 was the second child of the family; a sister had previously died at 4 months of 
age after a similar clinical course.  
At birth, he suffered a 20 minute bradycardia with apnoea, generalised cyanosis, and 
required resuscitation. He was diagnosed with infant respiratory distress syndrome and 
apnoeic episodes occurred which were eventually identified as a consequence of 
epileptic seizures.  
At 2 months old, he had problems swallowing, cyanosis, and epileptic seizures with 
episodes of apnoea. A CT scan showed symmetrical hydrocephalus. At 5 months old, 
he showed hypotonia, had no gaze fixation, and was developmentally similar to a one 
month old baby. He died at 5.5 months old during an epileptic seizure due to heart and 
respiratory failure. There was no conclusive diagnosis 
2.2.1.9 Patient 9 
This patient suffered epileptic seizures during the first few months of life, which 
presented as rhythmic jerks of the upper body and periorbital muscles. An EEG 
showed hypsarrhythmia and she was put on hydrocortisone therapy. 
Epileptic seizures continued to be resistant to anticonvulsants and she developed a 
generalised tremor with subsequent vomiting and fatigue. Seizures were also followed 
by episodes of apnoea and a loss of consciousness. 
She died at 6.5 months old from respiratory failure during an epileptic seizure. An 
autopsy revealed focal interstitial pneumonia and bilateral pleural emphysema. 
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2.2.1.10 Patient 10 
Patient 10 was born by caesarean section after a normal pregnancy.  
At 4 months old, his parents noticed a weak response to outside stimuli with no interest 
in toys, a rapid fatigue, and difficulties with drinking. He developed a stereotypical 
mouth movement with spasms of the upper and lower extremities.  
At the age of 9 months, he had no head or trunk control, no gripping, no lifting of the 
body, and extremely variable muscle tone. At 11 months old, he showed strabismus of 
the eyes, no gaze fixation, and showed the movement coordination of a 3 month old 
baby.  
An EEG showed hypsarrhythmia. Adrenocorticotrophic hormone (ACTH) therapy was 
started but was halted after 4 weeks due to high blood pressure, tachycardia, and 
fever. An acute neurological deficit appeared and the patient contracted pneumonia. 
Penicillin and IV therapy was started but the patient died at 13 months of age due to 
pneumonia in all lung lobes, hydropericardia, and liver steatosis. 
2.2.1.11 Patient 11 
This patient was the second child of the family with a clinically unaffected older sister. 
Birth and development were normal in the first 6 months of life, but then became 
delayed, with scar-like skin lesions appearing on the trunk of the body. As the patient 
started kindergarten, it was apparent that she was developmentally behind her peers 
and displayed a wide-based, wavy gait. Albinism was suspected due to her light hair 
and eye colour. 
At 5 years old, she had an acute episode of crying, vomiting and nausea, and a loss of 
consciousness. Within hours, left-sided jerking began in the face and arm and she was 
admitted to hospital. After being discharged from hospital, another episode of nausea, 
vomiting, and jerks on alternating sides of the body occurred. Her vision became 
impaired and she developed pneumonia which resulted in readmission to hospital. A 
neurological examination revealed impaired consciousness, right-sided spastic paresis, 
continuous focal jerks in upper right extremities, increased tendon reflexes, clonic 
muscle contractions in the lower extremities, and a tremor. An EEG showed 
asymmetric dysrhythmia in the brain with dominant delta activity in the fronto-parietal 
region and slow spike-wave variants in the occipital lobe. 
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At 6 years old, she was completely blind and could not speak and within a further 6 
months was deaf and required tube-feeding. She died at 7 years of age. 
The original account is described in a publication by Jellinger and Seitelberger 
(Jellinger and Seitelberger 1970). 
2.2.1.12 Patient 12 
Patient 12 was the first child of the family from a normal pregnancy and birth. A 
younger brother was clinically normal. 
His parents noted that he had had fever, cough, and coryzal (catarrhal inflammation) 
symptoms. At 5 years old, he then developed headaches and visual hallucination of 
colours in front of his eyes and his parents called for an ambulance. Following an 
episode of irritability and vacant staring his conscious level deteriorated. His eyes 
deviated to the left and drowsiness increased until intubation and ventilation were 
required. CSF pressure was normal with glucose 3.7mmol/l. On arrival at hospital, he 
showed left-sided convulsions and EEG showed a right posterior focal status 
epilepticus. Seizures were treated with Thiopentone but were not well controlled. He 
showed a left-sided weakness and a left-sided homonymous hemianopia. 
Subsequently, spasmodic jerks developed particularly in the ankle. The optic discs 
were pale with a ‘salt and pepper’ appearance of the retina but an electroretinography 
(ERG) was normal. Extensive investigations were performed, including metabolic and 
immunological, but all were within normal limits and there was no evidence of a viral 
infection. A muscle biopsy showed no evidence of a mitochondrial dysfunction and the 
complexes of the respiratory chain were normal with a possible lowering of complex IV.  
The patient’s consciousness gradually diminished and there were multiple left-sided 
myoclonic foci of the face and arm. Pupils were large and unresponsive with small pale 
optic discs. There were upper motor neurone signs in both upper and lower limbs, 
increased tone, hypereflexia, and a moderate bilateral ankle clonus. Patient 12 died at 
home at the age of 6 years old due to bronchopneumonia. 
POLG sequencing carried out in this project did not find the patient to carry a 
pathogenic mutation. 
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2.2.2 Definition of Alpers’ Syndrome 
Defining the condition of Alpers’ syndrome is a difficult task and requires evidence from 
multiple assessments; assessment in the clinic or hospital, neurophysiological 
assessments that include EEG scan to evaluate brainwaves, neuroimaging including 
MRI scans, and neuropathological assessment attained post-mortem. The typical 
clinical course is a developmental delay followed by the explosive onset of intractable 
epilepsy during infancy (Harding et al., 1986), though they may occur in early 
adulthood. The seizures may be of variable type including epilepsia partialis continua, 
multifocal myoclonus, and/or status epilepticus. A developmental regression usually 
follows, accompanied by visual impairment, hypotonia, ataxia and/or hemiplegia. 
Impairment of liver function and eventual liver failure often occurs in patients and the 
onset of liver failure may be quickened by the use of the antiepileptic medication, 
sodium valproate. EEG investigations may show abnormal discharges, with high 
amplitude slow waves and low amplitude polyspikes in the occipital lobe. MRI scans 
may show areas of oedema and of both localised and generalised cortical and white 
matter degeneration. Genetic confirmation of the presence of two recessive mutations 
in the gene POLG can aid in diagnosis, but confirmed mutations are not essential as 
patients have been reported with mutations in genes other than POLG. 
The patients in this cohort were defined as having Alpers’ syndrome based on the 
presence of two or more features of 1) intractable epilepsy, 2) a visual impairment 
including hemianopia, hallucinations or cortical blindness, and 3) either ataxia, 
hemiplegia or hypotonia. 
The patients in this cohort that fulfilled the criteria of Alpers’ syndrome with a 
comprehensive clinical background were Patients 1, 2, 4, 6, 11, and 12. It was not 
possible to ascertain further clinical details regarding Patient 3, though this patient was 
considered to have had Alpers’ syndrome due to a recent clinical diagnosis and 
biochemical investigations reported in a recent publication. Patient 5 was included in 
the project because signs of a mitochondrial disorder with POLG mutations were 
documented in the sibling. Patients 7-10 did not fit the criteria though they all 
resembled an Alpers’ syndrome-like phenotype. There is little clinical information on 
these patients which made it difficult to determine a diagnosis. 
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Patients 7-10 most likely had a primary mitochondrial disorder with an Alpers’-like 
phenotype, though there is insufficient clinical data to support a more accurate 
diagnosis. Patient 7 and Patient 9 displayed intractable seizures but no further 
symptoms of visual abnormalities or signs of ataxia, hemiplegia or hypotonia. Patient 8 
and Patient 10 do show further clinical signs compatible with an Alpers’-like phenotype, 
though are not conclusive. Patient 9 and Patient 10 show atypical symptoms not 
associated with Alpers’ syndrome, such as hypsarrhythmia on an EEG scan.  
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 Patient Sex Age 
at 
onset 
Age at 
death 
 Primary clinical features Reported 
POLG 
mutation 
Affected 
sibling 
Fever Headache Vomiting Drowsiness/ 
rapid fatigue 
Hypotonia/ 
ataxia/ 
hemiplegia 
Hemianopia Visual  
Problems 
Liver 
Failure 
Seizures / 
Status 
Epilepticus 
1 P a F 11m 14m   + + +   + + p.Ala467Thr; p.Gly848Ser None 
2 P a M 17m 27m +  + + + + + + + p.Ala467Thr; p.Thr914Pro 
Unaffected 
sister 
3 Pb M - 17y        + + p.Ala467Thr; p.Ala467Thr Unknown 
4 Pb F 20y 24y  +   +  +  + p.Ala467Thr; p.Trp748Ser Unknown 
5 
M - 
ID 
34weeks          N/A 
One sister 
p.Ala467Th
r; 
p.Glu1143
Gly 
p.Asp1219
Glu 
6 P a F 16y 18y  + +  +  + + + N/A 
One 
brother 
p.Trp748S
er; 
p.Arg1096
Cys 
7 P a F - 2.5m         + N/A None 
8 P a M 2m 5.5m     +    + N/A Affected sister 
9 P a F 1m 6.5m   + +     + N/A None 
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 Patient Sex Age 
at 
onset 
Age at 
death 
 Primary clinical features Reported 
POLG 
mutation 
Affected 
sibling 
Fever Headache Vomiting Drowsiness/ 
rapid fatigue 
Hypotonia/ 
ataxia/ 
hemiplegia 
Hemianopia Visual  
Problems 
Liver 
Failure 
Seizures / 
Status 
Epilepticus 
10Pa M 4m 13m    + +  + + + N/A None 
11P a F 6m 7y   +  +  +  + N/A Unaffected  sister 
               
12 
M 5y 6y + +  + + + +  + None Unaffected  brother 
Table 2.1. Clinical details for the patients. 
Clinical information for patients including: sex, age at onset, age at death, primary clinical features, reported POLG mutation, affected sibling. 
P
a
P was used to investigate mitochondrial respiratory chain complexes due to short formalin-fixation time. 
P
b 
Pfrozen tissue used to assess mtDNA copy number and mtDNA deletion. 
 
Key: ID= intrauterine death, N/A=data not available  
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 Category Sex Age at death PMI (hours) 
Length of 
fixation Cause of death 
1 Patient F 14m 12 1m Hepatic failure 
2 Patient M 27m 12 5weeks 
Pulmonary 
haemorrhage and 
respiratory failure 
3 Patient M 17y 12 N/A Unknown 
4 Patient F 24y 83 N/A Unknown 
5 Patient M ID 34weeks 72 13y Unknown 
6 Patient F 18y 24 2m Cardiac arrest 
7 Patient F 2.5m Unknown Unknown Unknown 
8 Patient M 5.5m Unknown Unknown Cardiac and respiratory failure 
9 Patient F 6.5m Unknown Unknown Respiratory failure 
10 Patient M 13m Unknown Unknown Pneumonia 
11 Patient F 7y Unknown Unknown Unknown 
12 Patient M 6y 36 1m and 14y Pneumonia 
1 Control F 13m 72 2-4weeks Occipital porencephaly 
2 Control M 2y Unknown 25y Electrocution 
3 Control M 19y 48 N/A Motor cycle accident 
4 Control M 27y Unknown N/A Suicide by hanging 
5 Control F 49days 24 4m 
Premature rupture 
of the membranes 
with signs of 
neuromuscular 
disease 
6 Control F 19y 5 18m Overdose 
7 Control F 18y 24 6m Overdose 
8 Control M 14m 72 2m 
Tumours in 
thalamus and left 
occipital 
9 Control F 6y 40 N/A Road traffic accident 
10 Control F 59y 19 2.5m Carcinoma 
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 Category Sex Age at death PMI (hours) 
Length of 
fixation Cause of death 
11 Control M 8y 11 17y Undiagnosed 
familial 
neurodegenerative 
disorder, 
suspected to be X-
linked 
12 Control M 51y 16 15y Cardiac arrest 
Table 2.2. Neuropathological details of the patients and controls used in this 
study. 
Key: ID=intrauterine death; N/A=data not available  
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2.2.3 Tissue Preparation 
Human brain tissue from Patient 1, 2, 4-6, and 12 was obtained from the Newcastle 
Brain Tissue Resource (NBTR). Brain tissue obtained from Patient 7 -11 was obtained 
from the University of Austria, Vienna. Brain tissue obtained from Patient 3 was 
obtained from the University of Bonn, Germany. Ethical approval was given for this 
project, ethical approval number ‘Newcastle and North Tyneside Local Research Ethics 
Committees 2002/205’. 
This study examined four areas of the brain. Three of these areas were previously 
reported to exhibit pathology in patients with Alpers’ syndrome; occipital lobe, parietal 
lobe, and cerebellum. The basal ganglia was less frequently reported to exhibit 
pathology in the literature.  
Tissue that had been fixed in formalin for 6 months or less was desired for use with 
mitochondrial antibodies, due to fixation in formalin masking the antigens and a 
possible risk of false negative results. Tissue fixed for longer periods of time was used 
for histological staining. 
FFPE human brain tissue was sectioned at room temperature using a microtome. 
Sections were cut at 5µm, 10µm, or 20µm thickness dependent upon which stain or 
antibody was to be used. Sections were placed in a water bath and then mounted onto 
glass slides (subbed or SuperFrostA○RE A slides) of the appropriate size. Sections were kept 
inside a 37P0PC oven for 3-5 days to ensure the sections had adhered well to the slides. 
Frozen human brain tissue was sectioned at -25P0PC using a cryostat. Sections were cut at 
10µm or 20µm thickness and mounted straight onto glass slides or polyethylene 
naphthalate (PEN) membrane slides, respectively. Sections were dried at room 
temperature for one hour and stored at -80P0PC until required. 
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2.2.4 Neurohistopathological Methods in Staining FFPE Tissue 
A number of histopathological stains were used to visualise specific tissue components 
in FFPE tissue, as detailed previously (Lax et al., 2012). 
2.2.4.1 Rehydration of FFPE Tissue 
Before each histological method was carried out, FFPE tissue sections were put in the 
60PoPC incubator for 20 minutes to melt the paraffin on the sections. Sections were 
deparaffinised in HistoclearPTMP and rehydrated in an ethanol gradient for 5 minutes in 
each pot (100%, 100%, 95%, 70% ethanol) and finally in deionised water. 
2.2.4.2 Haematoxylin and Eosin Stain 
A haematoxylin and eosin stain was used to assess general cellular morphology. 5µm-
thick sections of tissue were used. Sections were rehydrated as described in 2.2.3.1 
Rehydration of FFPE Tissue. Meyer’s haematoxylin was used for 5 minutes to stain the 
nuclei and then the sections were rinsed in tap water. Scott’s Tap Water Substitute was 
used for 2 minutes to provide rapid blueing of the nuclei before a rinse in tap water. A 
counterstain of alcohol eosin was used for 4 minutes to stain eosinophilic structures 
pink, e.g. cytoplasm, and the sections were rinsed in tap water. The slides were then 
dehydrated in a separate ethanol gradient to the gradient previously used (100%, 
100%, 95%, 70% ethanol), cleared in two changes of HistoclearPTMP and then mounted 
with a suitable coverslip using DPX mountant. 
2.2.4.3 Cresyl Fast Violet Stain 
Cresyl fast violet (CFV) stain was used to assess neuronal populations, through the 
staining of nissl substances in the neurons and cellular nuclei. 20µm-thick sections of 
tissue were used. Sections were rehydrated as described in 2.2.3.1 Rehydration of 
FFPE Tissue. Sections were placed in 1% acid alcohol for 5 minutes and then rinsed in 
4 changes of deionised water. The sections were then incubated in the CFV working 
solution at 60PoPC for 15 minutes and rinsed in deionised water. They were then placed in 
95% ethanol to differentiate the neurons from the background tissue stain. The slides 
were then dehydrated in a separate ethanol gradient to the gradient previously used 
(100%, 100%, 95%, 70% ethanol), cleared in two changes of HistoclearPTMP and then 
mounted with a suitable coverslip using DPX mountant. 
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2.2.4.4 Loyez Silver Stain 
Loyez silver stain was used to assess myelin density in the white matter. 20µm-thick 
sections of tissue were used. Sections were rehydrated as described in 2.2.3.1 
Rehydration of FFPE Tissue. Sections were placed in a 4% iron alum mordant for 6 
hours at room temperature. Sections were then washed in 5 changes of deionised 
water before staining in haematoxylin solution overnight at room temperature. The next 
day, sections were washed in deionised water. The slides were then dehydrated in a 
separate ethanol gradient to the gradient previously used (100%, 100%, 95%, 70% 
ethanol), cleared in two changes of HistoclearPTMP and then mounted with a suitable 
coverslip using DPX mountant. 
2.2.4.5 Bielschowsky Silver Stain 
Bielschowsky silver stain was used to visualise nerve fibres and axons in the white 
matter. 10µm-thick sections of tissue were used. Prior to beginning the protocol, all 
glassware to be used was washed with 50% nitric acid and all glassware and solutions 
were refrigerated. Sections were rehydrated as described in 2.2.3.1 Rehydration of 
FFPE Tissue.  
Sections were placed in 10% silver nitrate in the fridge in complete darkness for 20 
minutes and then rinsed in deionised water. An ammoniacal silver solution was made 
by adding concentrated ammonia (25%) drop by drop to the silver solution until the 
precipitate disappears. This was performed under the fume hood and the sections were 
placed in this solution in the fridge in complete darkness for 20 minutes. The sections 
were then placed in 1% ammonia solution for 5 minutes. To 100ml of the ammoniacal 
solution, 0.5ml of Developer Solution was added and the sections placed in this 
solution for 10-20 minutes, then rinsed in deionised water. Throughout this time, the 
sections were checked macroscopically for a change in colour to tan brown. The 
sections were placed in a solution of 15ml 0.2% gold chloride diluted in 100ml 
deionised water, for less than one minute. Then sections were rinsed in deionised 
water. Sections were fixed in 5% sodium thiosulphate for 5 minutes and then rinsed 
under tap water.  
The slides were then dehydrated in a separate ethanol gradient to the gradient 
previously used (100%, 100%, 95%, 70% ethanol), cleared in two changes of 
Histoclear PTMP and then mounted with a suitable coverslip using DPX mountant. 
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2.2.5 Antibody Staining in FFPE Tissue 
FFPE tissue was stained with antibodies to assess the different cell types and 
mitochondrial localisation (Table 2.3). Tissue that had been fixed in formalin for 6 
months or less was used, as a longer fixation time gave weak staining and the risk of 
false negative results. The length of formalin fixation did not appear to have an effect 
when using porin, so porin was stained and assessed in all tissues available. 
Antibody Epitope Retrieval 
Method 
Dilution 
Used 
Company Catalogue 
Number 
CD68 Lysosomal 
membrane 
protein on 
microglia 
0.1% trypsin 
and 0.1% 
calcium 
chloride in 
TBS, 37PoPC, 15 
minutes 
1:350 Dako M0876 
GFAP Glial 
fibrillary 
acidic 
protein 
0.01M citrate 
buffer, pH 6.0, 
microwave, 10 
minutes 
1:15,000 Dako Z0334 
Porin VDAC1 1mmol EDTA, 
pH 8.0, high 
pressure 
decloaker unit 
1:10,000 MitoSciences MSA03 
Table 2.3. Antibodies used for immunohistochemistry in FFPE brain tissue. 
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2.2.5.1 Respiratory Chain Antibody Staining 
Antibodies were used for various subunits of the mitochondrial respiratory chain to 
allow for assessment of the integrity and expression of the electron transfer chain 
proteins in neurons (Table 2.4). 
Antibody Epitope Retrieval 
Method 
Dilution 
Used 
Company Catalogue 
Number 
Complex I 
subunit 
NDUFA13 
Complex I 
subunit 
19kDa 
1mmol EDTA, 
pH 8.0, high 
pressure 
decloaker unit 
1:3,000 MitoSciences MS103 
Complex I 
subunit 
NDUFB8 
Complex I 
subunit 
20kDa 
1mmol EDTA, 
pH 8.0, high 
pressure 
decloaker unit 
1:300 MitoSciences MS105 
Complex I 
subunit 
NDUFS3 
Complex I 
subunit 
30kDa 
1mmol EDTA, 
pH 8.0, high 
pressure 
decloaker unit 
1:1,000 MitoSciences MS110 
Complex I 
subunit 
NDUFA9 
Complex I 
subunit 
39kDa 
1mmol EDTA, 
pH 8.0, high 
pressure 
decloaker unit 
1:100 MitoSciences MS111 
Complex II 
subunit 
70kDa Fp 
Complex II 
subunit 
70kDa 
1mmol EDTA, 
pH 8.0, high 
pressure 
decloaker unit 
1:4,000 MitoSciences MS204 
Complex III 
subunit 
Rieske  
Complex III 
subunit 
Rieske  
1mmol EDTA, 
pH 8.0, high 
pressure 
decloaker unit 
1:1,500 MitoSciences MS305 
Complex IV 
subunit I 
Complex IV 
subunit I 
1mmol EDTA, 
pH 8.0, high 
pressure 
decloaker unit 
1:10,000 MitoSciences MS404 
Complex IV 
subunit IV 
Complex IV 
subunit IV 
1mmol EDTA, 
pH 8.0, high 
pressure 
decloaker unit 
1:8,000 MitoSciences MS408 
Table 2.4. Antibodies used to visualise mitochondrial respiratory chain proteins, 
using immunohistochemistry, in FFPE brain tissue.  
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2.2.5.1.1 Complex I 
These antibodies bind to NADH: ubiquinone oxidoreductase, the first complex in the 
mitochondrial ETC. Four different antibodies were used to four subunits of complex I; 
these were CI-19 (NDUFA13), CI-20 (NDUFB8), CI-30 (NDUFS3), and CI-39 
(NDUFA9). Each of these subunits is nuclear-encoded. They antibodies were chosen 
as there are currently no mitochondrially-encoded antibodies available suitable for this 
method. These particular four antibodies were used due to their importance to the 
function of complex I. CI-19 and CI-30 are thought to be involved in the catalytic 
functions of this complex with CI-30 being one of the core subunits, while CI-20 and CI-
39 are known to play a role in mitochondrial disease. 
2.2.5.1.2 Complex II 
This antibody binds to succinate: ubiquinone oxidoreductase, the second complex in 
the mitochondrial ETC. Electrons may enter the ETC at complex I or at complex II and 
continue to flow along the respiratory chain. 
2.2.5.1.3 Complex III 
This antibody for the Rieske subunit binds to the iron sulphur protein within ubiquinol 
cytochrome c reductase, the third complex in the mitochondrial ETC. The Rieske 
subunit is nuclear-encoded. 
2.2.5.1.4 Complex IV 
This antibody binds to cytochrome c oxidase, the fourth complex in the mitochondrial 
ETC. Two different antibodies were used; these were for subunit I and subunit IV. 
Subunit I is encoded by a mitochondrial gene while subunit IV is encoded by a nuclear 
gene. 
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2.2.6 Quantitative Methods 
2.2.6.1 Neuronal Cell Counting 
Tissue sections from patients and controls were stained with cresyl fast violet (CFV) 
stain to visualise the neurons. The Olympus BX51 microscope together with 
StereoInvestigator software was used to count the neurons. A neuron was defined as a 
cell that was intensely stained with CFV nissl stain and had a visible nucleus and 
nucleolus. 
Three sections of tissue of 20µm each were taken from each brain area and stained 
with CFV stain, with an interval of 60µm between each section. Neurons were counted 
on each slide to give an indication of neuronal cell density through the tissue. This 
method is based upon previous quantitative methods for counting neurons (Lax et al., 
2012). Within the cerebellum, neurons were counted in both the superior and inferior 
regions where available. In the superior region, the anterior crescentic and ala centralis 
regions were sampled. In the inferior region, the tonsilla, biventer, posterior inferior, 
posterior superior and posterior crescentic were sampled. Focal loss of Purkinje cells 
was investigated; areas of the cerebellum known to show neuron loss in one patient 
were sampled in all patients and the controls. 
Reference spaces were randomly sampled on each slide; 21 spaces of 0.8mmP2P at X10 
magnification in the cerebellum, and 5 columns of 1mmP2P each spanning the six cellular 
layers at X100 magnification in the occipital and parietal lobes (Figure 2.1). Within the 
1mmP2P columns, every visible neuron was counted in layers I-VI. A total area of 
5mmP2 Pwas counted per slide, and a total area of 15mmP2P was counted per patient over 
the three slides. Within each 0.8mmP2P reference space, Purkinje cells were counted in 
the cerebellum. A total area of 16.8mmP2 Pwas counted per slide and a total area of 
50.4mmP2P was counted per patient over the three slides. The area of this reference 
space in the cerebellum correlates with the field of vision at X10 magnification, an 
optimal magnification in order to identify Purkinje cells. The coefficient of variation was 
calculated for each patient and control to assess the dispersion of data points around 
the mean value and so assess the accuracy of neuronal cell counting in each patient 
and control. 
The length of the single-cell-deep layer of Purkinje cells was taken in order to calculate 
the density of Purkinje cells. The total area and perimeter of the entire tissue section on 
the slide was also taken in order to be aware of the section area examined in reference 
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to the entire tissue section. Section length was used rather than section volume in 
order to calculate neuron loss for all brain areas. Section volume is commonly used for 
tissue stereological approaches to calculation of cell loss. The use of stereological 
methods requires a large thickness of tissue to be used for accurate measurements. 
The rarity of the disease and difficulty in obtaining suitable tissue samples made the 
use of large volumes of tissue as part of the calculation unsatisfactory.  
 
Figure 2.1. Reference spaces for quantification of neuronal cells. 
Reference spaces were used to count neurons in the cortical layers. According to 
stereological conventions, only neurons that were touching two of the four sides of the 
spaces were counted. Neuronal bodies touching or crossing the sides with a tick were 
counted; neuronal bodies touching or crossing the sides with a cross were not counted. 
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2.2.7 Semi-quantitative Methods 
2.2.7.1 Myelin Quantification 
Tissue sections from patients and controls were stained with Loyez silver stain to 
visualise myelin. The tissue section from each patient was assessed and assigned a 
score based upon the density of myelin judged to be intact, when compared to a 
suitable control. The method was based upon a previous semi-quantitative method for 
assessing myelin density (Smallwood et al., 2012).  
Images were taken for all brain areas at X10 magnification with the Olympus BX51 
microscope. They were assessed semi-quantitatively using the scale 0=complete 
myelin loss, 1=marked loss of myelin staining, 2=slight pallor of myelin staining, 
3=good myelin staining equivalent to controls, for assessment. 
2.2.7.2 Neuronal Cell Loss Quantification 
Tissue sections from patients and controls were stained with cresyl fast violet stain to 
visualise the neurons of the dentate nucleus. These neurons were assessed semi-
quantitatively. The Olympus BX51 microscope was used to view the neurons. 
Neuron loss was assessed semi-quantitatively using the scale -/+/++/+++ to describe 
any pathological changes. The scale is defined (-) no change, (+) mild neuron loss, 
(++) moderate neuron loss, and (+++) severe neuron loss. 
2.2.7.3 Astrogliosis Quantification 
Tissue sections from patients and controls were stained with GFAP antibody to 
visualise reactive astrocytes. The Olympus BX51 microscope was used to view the 
astrocytes. 
They were assessed semi-quantitatively using the scale -/+/++/+++ to describe any 
pathological changes. The scale is defined (-) no change, (+) mild astrogliosis, (++) 
moderate astrogliosis, and (+++) severe astrogliosis. 
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2.2.7.4 Microglial Activation Quantification 
Tissue sections from patients and controls were stained with CD68 antibody to 
visualise macrophages and activated microglial cells. The Olympus BX51 microscope 
was used to view the cells. 
They were assessed semi-quantitatively using the scale -/+/++/+++ to describe any 
pathological changes. The scale is defined (-) no change, (+) mild increase, (++) 
moderate increase, and (+++) severe increase in CD68-positive cells. 
2.2.8 Sequential COX/SDH Staining in Frozen Tissue 
Slides were defrosted for at least one hour at room temperature. Sequential staining 
was performed to assess complex IV activity using cytochrome c (COX) incubation 
medium, and to assess complex II activity using succinate dehydrogenase (SDH) 
incubation medium.  
The COX incubation medium was made by adding 200µl cytochrome c to 800µl 3, 3’ 
diaminobenzidine tetrahydrochloride (DAB) and then a small amount of catalase 
(20µg/ml). The eppendorf was vortexed and centrifuged briefly. 50-100µl medium was 
added to tissue sections to cover them and they were incubated at 37P0PC for 50 
minutes. After incubation, the sections were washed twice in phosphate-buffered saline 
(PBS) for 5 minutes each time.  
The SDH incubation medium contains a substance that is sensitive to light, so the tube 
was wrapped in foil first. To 800µl nitro blue tetrazolium (NBT) was added 100µl 
sodium succinate, 100µl phenazine methosulphate (PMS, light-sensitive), and 10µl 
sodium azide. 
Any excess PBS was wiped from the slides and 50-100µl medium was added to tissue 
sections to cover them. They were incubated at 37 P0PC for 45 minutes. After incubation, 
the sections were washed twice in PBS for 5 minutes each time. 
The slides were then dehydrated in an ethanol gradient (70%, 95%, 100%, 100%) with 
the final 100% ethanol being for 10 minutes. PEN slides were then left to dry for an 
hour at room temperature. Glass slides were taken through two changes of 
Histoclear PTMP and mounted with a suitable coverslip using DPX mountant. 
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2.2.8.1 Single Cell Isolation 
Single neurons were taken from PEN membrane slides which were subjected to 
sequential COX/SDH histochemistry or single SDH histochemistry. Samples were 
defrosted for one hour at room temperature before single neurons were laser-capture 
microdissected directly into 15µl of buffer sitting in the cap of a sterile 0.5ml PCR tube. 
The Palm MicroBeam Laser Microdissection microscope from Zeiss was used for laser-
capture microdissection. 
2.2.9 Real-time PCR 
Real-time polymerase chain reaction (PCR) was performed on DNA extracted from 
frozen human tissue as previously described (Krishnan et al., 2007). All reactions were 
set up under a UV hood and used DEPC-treated water and pipettes that had been 
under the UV hood for 30 minutes prior to PCR set up.  
Reactions were set up in a 20µl volume which consisted of 5.8µl DEPC-treated water, 
10µl TaqManA○RE A Universal Mastermix, 0.4µl 5µM ND1 probe, 0.4µl 5µM ND4 probe, 
0.6µl 10µM ND1 forward primer, 0.6µl 10µM ND1 reverse primer, 0.6µl 10µM ND4 
forward primer, 0.6µl 10µM ND4 reverse primer, and 1µl standard DNA or 4µl DNA 
lysate from single neurons. Primer sequences are shown in Table 2.5. 
Real-time 
Primers 
Primer Sequences 
MT-ND1 Forward 5’-CCCTAAAACCCGCCACATCT 
Reverse 5’-GAGCGATGGTGAGAGCTAAGGT 
VIC- labelled 
probe 
5’-CCATCACCCTCTACATCACCGCCC 
MT-ND4 Forward 5’-CCATTCTCCTCCTATCCCTCAAC 
Reverse 5’-CACAATCTGATGTTTTGGTTAAACTATATTT 
FAM-labelled 
probe 
5’-CCGACATCATTACCGGGTTTTCCTCTTG 
Table 2.5. Primer sequences used for MT-ND1 and MT-ND4 in real-time PCR. 
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2.2.10 Pyrosequencing PCR 
Pyrosequencing PCR was performed on DNA extracted from frozen human tissue or 
FFPE human tissue. All reactions were set up under a UV hood and used DEPC-
treated water and pipettes that had been under the UV hood for 30 minutes prior to 
PCR set up. 
Reactions were set up in a 25µl volume which consisted of 10.8µl DEPC-treated water, 
5µl GoTaqA○RE A Flexi buffer, 3µl MgClR2R, 2.5µl 10mM dNTPs, 1.25µl forward primer, 1.25µl 
reverse primer, 0.2µl 5U/µl GoTaqA○RE A HotStart polymerase, and 1µl DNA. DNA from a 
positive control that contained the one of the mutations and DNA from a wildtype 
control, which did not contain the mutations, were used to check the efficacy of the 
PCR. 
Either the forward or reverse primers were biotinylated, which resulted in a biotinylated 
PCR product in one direction. If the forward primer was biotinylated, the reverse 
sequence strand was used for pyrosequencing. 
2.2.11 DNA Sequencing 
DNA was extracted from 9 patients and 1 patient sibling. The other patient sibling had 
eluted DNA available. Attempts were made to elucidate any mutations in the POLG 
gene. The following sections describe this. 
2.2.11.1 DNA Extraction 
DNA was extracted from FFPE tissue in patients where a POLG diagnosis had not 
been confirmed. The NucleoSpinA○RE A Tissue Preparation kit obtained from Macherey-
Nagel was used and protocol followed as outlined below. Alternative systems of 
extraction were also used. A silica column-based method with the QIAmp DNA Mini Kit 
and the EZ1A○RE A Advanced Workstation, both from Qiagen, were additionally used on 
separate occasions during the optimisation of extracting DNA from FFPE tissue. 
Sections of tissue were cut on the microtome. A new blade was used for each separate 
patient tissue block and gloves were changed between each block. The knife holder 
and tweezers were cleaned with HistoclearPTMP, P P10% bleach, and then 70% ethanol in 
order to reduce cross contamination. A clean piece of medical tissue was used over the 
eppendorf cap when opening, to prevent contamination between eppendorf tubes 
(Greer et al., 1994). 
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Ten tissue sections of 20µm thickness were taken and deparaffinised in two changes of 
Histoclear PTM Pat 56PoPC for 20 minutes. The tissue was rehydrated in two changes each of 
100%, 95%, 70% ethanol and finally ultrapure water. Between each of the changes the 
eppendorf tubes containing the tissue were spun at 11,000g for three minutes to 
ensure the tissue was at the bottom of the tube and there would be minimal loss when 
changing the supernatant. The tubes were then left open at 37PoPC on the heat block to 
allow for the evaporation of residual ethanol. 80µl of buffer T1 and 8µl proteinase K 
were added to each tube, the tubes vortexed, and incubated at 56PoPC for 16 hours in the 
dry heat block. An increased incubation time can reverse cross-linkages between DNA 
and protein and increase PCR amplifiable DNA yield (Gilbert et al., 2007). 
The next day, 80µl of Buffer 3 from the NucleoSpinA○RE A Tissue Preparation kit was added 
to the tissue then the samples were vortexed and incubated at 70PoPC for 5 minutes. 80µl 
of 100% ethanol was then added and the samples mixed by inverting and they were 
centrifuged briefly. The tissue lysates were transferred to a NucleoSpin A○RE A Tissue XS 
column and centrifuged at 11,000g for 1 minute. It has been suggested that a silica 
column-based extraction method is beneficial to DNA extraction from FFPE tissue 
(Gilbert et al., 2007). The flow through was discarded and two washes with 50ul Buffer 
B5 was applied to each column and centrifuged at 11,000 g for 1 minute. The DNA was 
then eluted with 20ul Buffer BE to each membrane and centrifuged at 11,000 g for 1 
min. Residual ethanol removed by incubating the eluted DNA fraction in the open tube 
at 90PoPC for 5 minutes, on the heat block. 
The DNA samples were tested on the nanodrop ND-1000 spectrophotometer to check 
DNA concentration, and check for any contaminants, and then stored at -20PoPC until 
needed. 
2.2.11.2 POLG Pyrosequencing 
DNA from 7 patients (Patients 5-11) was used in order to pyrosequence for the 3 most 
common POLG mutations; p.Ala467Thr, p.Trp748Ser, and p.Gly848Ser. The primers 
used to amplify the nuclear DNA sequence for the mutation in POLG are shown in 
Table 2.6. During the optimisation process, a first round of PCR was used to amplify 
the POLG exon containing the mutation, in order to create more initial template for 
subsequent PCR. The primers used to amplify the nuclear DNA sequence for the exon 
containing the mutation are shown in Table 2.7. 
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Pyrosequencing was performed using PyroMark Gold Q24 Reagents and according to 
the standard protocol, available from Qiagen. The biotinylated products were extracted 
from the mixture using the Instrument and read using the PyroMark Q24 machine, 
Qiagen. Then the results were analysed using the PyroMark Q24 software. 
POLG 
Mutation 
Primers 
Primer Sequences Expected 
Product 
Size 
Tm 
( PoPC) 
c.1399G>A 
p.Ala467Thr 
Forward 
(biotinylated) 
5’-CCAGCGGGAGATGAAGAA 171bp 60PoPC 
Reverse 5’-TACAGAGCCAGTCCACTAGGG 
Sequencing 5’-GGCAGGCATCATTGG   
c.2243G>C 
p.Trp748Ser 
Forward 5’-CTCACAGACTGCCCGTGGT 142bp 60PoPC 
Reverse 
(biotinylated) 
5’-CAGGACAGGCCATGACCC 
Sequencing 5’-ACATCCCTGGCTGCT   
c.2542G>A 
p.Gly848Ser 
Forward 5’-CTGCCCCAAGTGGTGACT 106bp 60PoPC 
Reverse 
(biotinylated) 
5’-AGGGGCCAGAGGTACAGAG 
Sequencing 5’-CAAGTGGTGACTGCC   
Table 2.6. Primer sequences used to amplify DNA mutation regions from the 
gene POLG for pyrosequencing. 
 
 
POLG 
Mutation 
Primers 
Primer Sequences Expected 
Product 
Size 
Tm 
( PoPC) 
Exon 7 
p.Ala467Thr 
Forward 5’-
TGTAAAACGACGGCCAGTATGGG
ATGATATTGTTCCCATTT 
536bp 59PoPC 
Reverse 5’-
CAGGAAACAGCTATGACCAGTCC
ACTAGGGCAGGGCTA 
Exon 13 
p.Trp748Ser 
Forward 5’-
TGTAAAACGACGGCCAGTACAGT
TTCAGGCCCTTTTCC 
378bp 59PoPC 
Reverse 5’-
CAGGAAACAGCTATGACCTGTGC
CTGAAATCACACTCTG 
Exon 15+16 
p.Gly848Ser 
Forward 5’-
TGTAAAACGACGGCCAGTAGTGA
GGCTGGGTAATGGAG 
544bp 59PoPC 
Reverse 5’-
CAGGAAACAGCTATGACCCAGGG
TCCTTTTCATGATCC 
Table 2.7. Primer sequences used to amplify exons from the gene POLG 
containing the mutation, for pyrosequencing. 
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2.2.11.3 POLG Sequencing 
DNA from one patient and one patient sibling (Patient 12 and the sibling of Patient 5) 
was used in order to sequence the entire POLG gene. 
2.2.12 Electron Microscopy 
Transmission electron microscopy (TEM) was performed on patient and control fixed 
tissues. Formalin-fixed brain tissue was taken from control 10, control 11, and Patient 
12. This tissue had been fixed in formalin that was buffered with marble chips for 
between 14 to 17 years.  
A small piece of tissue, ~1mm x 1mm, was dissected and first fixed in 2% 
glutaraldehyde in 0.1M sodium cacodylate buffer, then post fixed in 1% osmium 
tetroxide to make the tissue electron dense. The tissue was then dehydrated through a 
series of graded acetones and embedded in epoxy resin at 60PoPC. 70nm sections were 
cut and stained with uranyl acetate and lead citrate to give contrast to the image. A 
Philips CM100 transmission electron microscope was used to view the stained 
sections. All fixing, staining, and cutting of tissues were carried out by staff at the 
Electron Microscopy Research Services, Newcastle Biomedicine Core Scientific 
Facilities, Newcastle University. All images were taken at these facilities. Method 
adapted from Hogan et al., (Hogan et al., 2009). 
Sets of images were taken at various magnifications, depending upon the structure 
being visualised; 2600X to view cellular structure, 19,000X to view mitochondria, and 
32,000X to view internal mitochondrial structure. Images were systematically and 
randomly sampled, maintaining a constant distant between each image. Images were 
then anonymised and randomly chosen for structures to be counted. Appropriate 
structures for each magnification were counted and analysed. Cellular nuclei and 
mitochondria must have a complete and intact membrane to be counted. At least 50% 
of the structure must be within the image to be counted, in order to be certain of its 
identification. Cellular nuclei and mitochondria were not counted if they were contained 
within a blood vessel structure. There must be visible cristae or remnants of cristae 
within a structure for it to be positively identified as a mitochondrion.  
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Chapter 3 Neuropathological Features of Patients with Alpers’ 
Syndrome 
3.1 Introduction 
Alpers’ syndrome is an autosomal recessive, early-onset disease often caused by 
mutations in POLG, primarily affecting the CNS and liver. Clinical features include 
refractory seizures, developmental delay, ataxia, visual abnormalities, and liver 
dysfunction and failure. There are over 230 POLG mutations, both dominant and 
recessive, listed on the National Institute of Environmental Health Sciences (NIEHS) 
website (http://tools.niehs.nih.gov/polg/). Many of these mutations are considered to be 
pathogenic and can lead to a heterogeneous group of symptoms, ranging from those 
which are mild with a late-onset, to symptoms which are severe with an early-onset. 
Alpers’ syndrome is attributed to the presence of two recessive mutations in POLG and 
many different allele mutations have been reported to be pathological. The three most 
common mutations found in patients with Alpers’ syndrome are the p.Ala467Thr 
mutation and the p.Trp748Ser mutation, found in the linker domain, and the 
p.Gly848Ser mutation, found in the polymerase domain of the gene. The p.Ala467Thr 
mutation is seen in around 40% of the mutations occurring in Alpers’ syndrome 
(Nguyen et al., 2006). 
Patients clinically diagnosed with Alpers’ syndrome have a severe, early-onset 
phenotype that can be caused by a range of mutations in POLG. Mutations in POLG 
are the cause of 95% of the reported cases of Alpers’ syndrome but there have been 
documented cases of clinical Alpers’ syndrome where no mutation in POLG was 
present (Sofou et al., 2012). Genetic studies have been performed in patients without a 
mutation in POLG and subsequently, mutations in FARS2 (Elo et al., 2012) and 
Twinkle have been reported in patients with the clinical signs of Alpers’ syndrome 
(Hunter et al., 2011). 
It is known that the Alpers’ syndrome phenotype may manifest in patients of a wider 
age range than had been previously described in the literature, with late-teenage 
patients developing the clinical signs and harbouring two recessive POLG mutations 
(Wiltshire et al., 2008; Visser et al., 2011). The broadened age range was taken into 
account when forming the cohort and is reflected in the age range of the included 
patients (0 years – 24 years).  
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The posterior of the brain shows the most severe pathology in patients (Uusimaa et al., 
2008; Khan et al., 2012). As a consequence, many key symptoms of Alpers’ syndrome 
are most likely the result of damage to these regions: pathology to the cerebellum is 
associated with nystagmus and ataxia, while pathology to the occipital lobe is 
associated with impaired vision and visual abnormalities. Pathology in other regions of 
the cerebrum and the deep grey nuclei has been reported less frequently (Wiltshire et 
al., 2008; Cardenas and Amato 2010). 
The neuropathological investigations in this study centre on four regions of the brain in 
the cohort: the cerebellum, occipital lobe, parietal lobe, and basal ganglia. The former 
two regions have been highly implicated in the neuropathology of the condition. 
Pathology of the latter two regions has been documented less frequently in the 
literature and these are areas of interest to this study. I investigated the morphology of 
the tissue (microvacuolation, capillary proliferation, and microinfarcts), neuronal cell 
loss, astrogliosis, microglial activation, and white matter abnormalities (myelin loss and 
axonal abnormalities). These criteria are commonly used to assess patient tissue, and 
aid neuropathologists in making a diagnosis. 
This chapter examines many neuropathological aspects in a large cohort of patients 
with clinically diagnosed Alpers’ syndrome. The literature on Alpers’ syndrome contains 
many case reviews of one or two patients, written in isolation of other cases, while this 
cohort brings together many patients across a large age range with known and 
unknown POLG mutations. A poor prognosis is given for patients with Alpers’ 
syndrome, increasing the importance of further investigations into the condition. 
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3.2 Aims 
The patients were categorised into groups depending on the availability of a genetic 
diagnosis: evidence of two recessive POLG mutations, no genetic diagnosis possible 
due to no suitable DNA being available, no mutation in POLG, and a single stillbirth 
with POLG mutations identified in a sibling. The aims of this work are: 
1. To achieve a genetic diagnosis in patients where one is not confirmed.  
2. To correlate the neuropathology with severe clinical signs in the patients. 
3. To quantitatively and semi-quantitatively assess the neuropathological 
characteristics in the brains of patients clinically diagnosed with Alpers’ 
syndrome, and compare the findings to those of controls. The neuropathological 
characteristics studied gave information on the severity of pathology in the 
brain; these characteristics were the degree of atrophy, microvacuolation, 
neuron loss, astrogliosis, mitochondrial localisation, white matter changes, and 
microglial activation. 
4. To investigate the differences in the neuropathology between the patient 
groups. 
3.3 Methodological Approach 
Ten patients were assessed for neuropathological characteristics (Table 3.1). 
Histological stains and antibodies were used to identify cells and cellular structures of 
interest. Standard protocols were followed for staining and antigen retrieval and the 
antibody dilutions used are listed in Chapter 2 Materials and Methods, 2.2.3 
‘Neurohistopathological Methods in Staining FFPE Tissue’ and 2.2.4 ‘Antibody Staining 
in FFPE Tissue’. 
A battery of histological stains and antibodies were used to fully investigate the 
pathology: haematoxylin and eosin stain, cresyl fast violet stain, GFAP, porin, Loyez 
silver stain, Bielschowsky silver stain, and CD68. These are detailed below, using 
images to describe the pathology seen in the brain tissue of patients. 
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Patient Age at Death Sex POLG Mutation 
1 14 months F p.Ala467Thr; 
p.Gly848Ser 
2 27 months M p.Ala467Thr; 
p.Thr914Pro 
6 18 years F 
A sibling with 
p.Trp748Ser; 
p.Arg1096Cys 
5 ID at 34 weeks M 
A sibling with 
p.Ala467Thr; 
p.Glu1143Gly; 
p.Asp1219Glu 
7 2.5 months F Unknown 
8 5.5 months M Unknown 
9 6.5 months F Unknown 
10 13 months M Unknown 
11 7 years F Unknown 
12 6 years M None 
Table 3.1. Details of the patients used in the study of neuropathological features. 
Key: ID= intrauterine death   
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3.4 Results 
 Molecular Investigations of POLG 3.4.1
DNA was extracted from the FFPE tissues from six patients, Patients 5-11, using a 
number of different methods described in Chapter 2 Methods and Materials, 2.2.10.1 
‘DNA Extraction’. It was then tested for DNA concentration and any contaminants 
present using the Nanodrop ND-1000 Spectrophotometer. A quantity of DNA in the 
range 1.1 ng/µl to 217.6 ng/µl appeared to be present but subsequent PCR reactions 
using primers for the three common mutations and their exons (see Chapter 2 Methods 
and Materials, 2.2.10.1 ‘POLG Pyrosequencing’) did not yield positive results (Figure 
3.1). This may have been attributable to contaminants of a 260/230 absorption 
spectrum, including carbohydrate, organic chemicals, or solvents. This value should be 
in the range 2.0-2.2 but was frequently seen as negative values. Many different 
extraction methods were used, all ensuring full evaporation of any ethanol present in 
the sample before commencing with subsequent steps. This did not improve PCR 
amplification of the DNA sample. 
Patient 5 and Patient 6 each had a sibling with known POLG mutations (Table 3.1). 
The reasons for the stillbirth of Patient 5 are not clear but Patient 6 was known to have 
presented with features of a POLG disorder. It was assumed that both these patients 
carried one or more of the same POLG mutations as their respective sibling. The data 
from the siblings were useful as only FFPE blocks of brain tissue were available for 
Patient 5 and Patient 6. Patients 7-11 are historical cases, diagnosed in the 1970s and 
1980s when a genetic diagnosis in Alpers’ syndrome was not considered; suitable 
material is no longer available to establish a genetic diagnosis. 
Patient 12 in the cohort did not have a reported POLG mutation in DNA extracted from 
frozen muscle tissue. The gene POLG was sequenced as described in Chapter 2 
Methods and Materials, 2.2.10.3 ‘POLG Sequencing’ and was also later submitted for 
whole exome sequencing. This has identified a potential candidate gene although 
substantial further work, outside the remit of this thesis, is required to establish a link 
between the genetic defect and cellular respiration. 
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Figure 3.1. Image of an agarose gel showing no amplification of POLG exons. 
The figure shows an image of a 1% agarose gel with 1Kb ladder, the bands are 
visualised with GelRedTM. DNA had been extracted using the NucleoSpin○RE A Tissue 
Preparation Kit (Macherey-Nagel). Two rounds of PCR performed using primers for the 
three common mutations and their exons. Lanes 1-5, 9-13, and 17-21 are repeated 
with extracted DNA from fixed tissue from Patients 7-11. A positive, wildtype, and 
negative control (water) were also tested. Lanes 1-8 are tested for the p.Ala467Thr 
mutation, lanes 9-16 are tested for the p.Trp748Ser mutation, and lanes 17-24 are 
tested for the p.Gly848Ser mutation. The positive control (lanes 6, 14, and 22) and 
wildtype DNA (lanes 7, 15, and 23) show positive for bands of amplified DNA. The 
negative control (lanes 8, 16, and 24) is clear, showing there is no contamination.  
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All introns and exons of POLG were sequenced in both Patient 12 and the female 
sibling of Patient 5. In Patient 12, seven polymorphisms were found; five within introns, 
one within exon 23, and one in the 3’-untranslated region (Table 3.2). Within exon 23, a 
single heterozygous mutation, p.Gln1236His, was found which is not considered to be 
pathogenic after a search of The Human DNA Polymerase Gamma Mutation Database 
( 34Thttp://tools.niehs.nih.gov/polg/) and using AlamutTM software to assess pathogenicity. 
No other mutations were found. In the sibling of Patient 5, nine polymorphisms were 
found; five within introns, one within exon 7, one within exon 21, one within exon 23, 
and one in the 3’-untranslated region (Table 3.2). 
It is assumed that Patient 5 carried the common POLG mutation p.Ala467Thr, the 
same as his sibling. The p.Glu1143Gly mutation is known to be a polymorphism and 
the p.Asp1219Glu mutation is a rare polymorphism with an unknown pathogenicity 
assessed by AlamutTM software. It is a conserved amino acid with PolyPhen-2 software 
predicting the mutation to be ‘probably damaging’ with a score of 0.999. 
Exon Patient 12 Sibling of Patient 5 
7  c.1399 G>A, p.Ala467Thr 
11+12 Intron 11, c.2071-22 T>C Intron 11, c.2071-22 T>C 
17 Intron 17, c. 2734+41, GTAG insert 
Intron 17, c. 2734+41, GTAG 
insert 
19+20 Intron 19, c.3105-36 A>G 
Intron 19, c.3105-11 T>C 
Intron 19, c.3105-36 A>G 
Intron 19, c.3105-11 T>C 
21  c.3428 A>G, p.Glu1143Gly 
22 Intron 21, c.3483-19 T>G Intron 21, c.3483-19 T>G 
23 c.3708 G>T, p.Gln1236His c.3657 T>G, p.Asp1219Glu 
3’-UTR c.3720+49 c.3720+49 
Table 3.2. A list of POLG mutations sequenced in Patient 12 and in the sibling of 
Patient 5. 
Table showing the mutations found in POLG in both Patient 12 and the sibling of 
Patient 5. Mutations causing amino acid changes are highlighted in the table. Patient 
12 has a heterozygous point mutation in exon 23 causing an amino acid change. This 
mutation is not thought to be pathogenic. The sibling of Patient 5 has a heterozygous 
point mutation in exon 7 causing an amino acid change that is well-known to be 
pathogenic, a heterozygous point mutation in exon 21 that is thought to be a modifying 
mutation when it segregates with the p.Trp748Ser mutation, and a heterozygous point 
mutation in exon 23 (different to that of Patient 12), at a conserved amino acid that has 
unknown pathogenicity. Key: 3’-UTR=3’-untranslated region. 
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 Patient Characteristics 3.4.2
I investigated a cohort of patients with symptoms of epilepsy and ataxia, and with a 
clinical diagnosis of Alpers’ syndrome where available. As part of the disease 
progression, 11 of the 12 patients developed seizures, 8 patients developed a 
movement disorder such as ataxia or hemiplegia, 6 patients developed visual 
problems, and 5 patients developed liver failure. Patient 5 was a stillbirth at 34 weeks 
gestation but was considered for inclusion in the cohort as a POLG defect was 
identified in a sibling. 
 Morphological Assessment of Tissue 3.4.3
A haematoxylin and eosin (H&E) stain was used to assess and quantitate general 
cellular morphology; microvacuolation, atrophy, microinfarcts, and capillary proliferation 
in four brain regions. The patients are described within their groups based upon the 
availability of a genetic diagnosis: evidence of two recessive POLG mutations, no 
genetic diagnosis possible, no mutation in POLG, and a single stillbirth with the POLG 
mutations p.Ala467Thr, p.Glu1143Gly, and p.Asp1219Glu identified in a sibling. 
3.4.3.1 Cerebellum 
The pathology in the cerebellum is summarised in Table 3.3 for patients where this 
brain region was available. 
Patients with evidence for POLG mutations (Figure 3.2; image B) show atrophy, 
microvacuolation, thinned cell layers, and eosinophilic neurons. Patient 1 shows a 
thinned granular cell layer, confirmed in the original neuropathologist’s report. Patient 2 
shows a thinned molecular layer and granular cell layer with dendrite proliferation 
throughout the molecular layer. Microvacuolation mainly in the white matter and the 
dentate nucleus is clearly seen in Patients 1 and 2.  
A single microinfarct is seen in the cerebellum of Patient 6, involving an entire sulcus in 
the posterior-inferior region. The molecular layer, Purkinje cell layer, granular cell layer, 
and white matter are all involved. The area of the microinfarct was determined to be 
15,935.2 µm2. An additional pre-motor cortex lesion was noted in the original 
neuropathologist’s report. It was suggested in this report that the pre-motor cortex 
lesion may have initiated the epilepsy and be of a different origin to other lesions. One 
other patient, Patient 4, also showed signs of a microinfarct in the cerebellar cortex. 
Both of these patients were older patients in the cohort. 
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Patients with no genetic diagnosis available show atrophy, microvacuolation, capillary 
proliferation, and eosinophilic neurons. Patient 7 shows a thinned granular cell layer 
and flattened folia in addition to atrophy. All patients show microvacuolation in the white 
matter and the dentate nucleus. Patient 8 shows microvacuolation in focal areas of the 
granular cell layer. There is limited clinical and reported neuropathological data on this 
group of patients as they are historical cases from the University of Vienna. 
The patient without a POLG mutation shows microvacuolation and eosinophilic 
neurons of the dentate nucleus only. Microvacuolation appears mainly in the white 
matter and the dentate nucleus and Patient 12 shows one the greatest degrees of 
microvacuolation of all the patients. A mild microvacuolation of the molecular layer was 
mentioned in the original neuropathologist’s report. 
The stillbirth, Patient 5 (Figure 3.2; image D) shows a severe capillary proliferation 
throughout the cerebellum, with no other abnormalities noted. The matched control 
tissue did not demonstrate a capillary proliferation. 
The cerebellum shows pathology of both the grey and white matter, affecting both 
Purkinje cells and neurons of the dentate nucleus. The morphology of the cerebellum is 
more affected where a POLG mutation is confirmed or unknown, rather than in the 
patient without a POLG mutation where pathology is restricted to the white matter and 
the dentate nucleus. Patients with evidence for POLG mutations show a wider range of 
pathology, including microinfarcts. 
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Figure 3.2. Neurodegenerative abnormalities in the cerebellum.  
A=Control 6, B=Patient 6 POLG mutation-positive group, C=Control 5, D=Patient 5 
stillbirth. Patient 6 (image B) shows a striated appearance of the molecular layer (ML) 
indicated by the blue arrow, and thinned granular cell layer (GCL) indicated by the 
black arrow. The control (image A) shows intact ML and GCL. Patient 5 shows capillary 
proliferation in the white matter (image D) whilst the control (image C) shows normal 
white matter. All sections stained with H&E. Scale bar = 100µm. 
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The brain area is unavailable for patients not listed in the table. 
POLG 
mutation Patient Atrophy MV 
Capillary 
Proliferation Microinfarct 
+ 
1 + + - - 
2 + + - - 
6 - - - + 
+ s 5 - - +++ - 
? 
7 + ++ - - 
8 + + + - 
9 - ++ + - 
10 - + + - 
11 - ++ - - 
- 12 - ++ - - 
Table 3.3. Summary of neuropathology in the cerebellum. 
Assessment is semi-quantitative using the scale -/+/++/+++, where - is the absence of 
a pathological feature and +++ is the presence of a severe pathological feature.  
Key: MV=microvacuolation, s=stillbirth  
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3.4.3.2 Occipital Lobe 
The pathology in the occipital lobe (BA19) is summarised in Table 3.4 for patients 
where this brain region was available. 
Patients with evidence for POLG mutations (Figure 3.3; images C and D) show slight 
microvacuolation, capillary proliferation, and some neurons appearing eosinophilic and 
shrunken. Patient 2 shows slight microvacuolation in the upper cortical layers II and III, 
confirmed in the original neuropathologist’s report. 
Patients with no genetic diagnosis available (Figure 3.3; images B, E and F) show 
microvacuolation throughout the grey matter and considerable capillary proliferation. 
The patient without a POLG mutation, Patient 12, shows microvacuolation in both grey 
and white matter, capillary proliferation, and eosinophilic neurons. There are small focal 
areas of necrosis in the grey matter throughout all layers, which are confirmed in the 
original neuropathologist’s report. 
The stillbirth, Patient 5, shows severe capillary proliferation throughout the occipital 
lobe and this is also noted in the cerebellum. The matched control tissue did not 
demonstrate a capillary proliferation. 
The occipital lobe shows pathology primarily of the grey matter. The morphology of this 
brain area is more consistently affected where a POLG mutation is unknown yet it is 
surprising that more severe pathology is not seen, given its involvement in the clinical 
signs of Alpers’ syndrome. Pathology is mainly seen in the grey matter; however the 
white matter is also notably affected in the patient without a POLG mutation. 
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Figure 3.3. Microvacuolation in the occipital lobe.  
A=Control 7, B=Patient 10 POLG mutation-undetermined group, C=Patient 2 POLG 
mutation-positive group, D= Patient 2 POLG mutation-positive group, E=Patient 11 
POLG mutation-undetermined group, F= Patient 11 POLG mutation-undetermined 
group. All three patient images show microvacuolation in the grey matter. Image B is at 
a higher magnification to illustrate the pathology. Image D is a higher magnification of 
image C, and image F is a higher magnification of image E which show 
microvacuolation in the grey matter.  All sections stained with H&E. Scale bar = 100µm. 
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The brain area is unavailable for patients not listed in the table. 
POLG 
mutation Patient MV 
Capillary 
Proliferation Microinfarct 
+ 
1 - + - 
2 + - - 
+ s 5 - +++ - 
? 
8 ++ ++ - 
10 ++ ++ - 
11 ++ ++ - 
- 12 + + - 
Table 3.4. Summary of neuropathology in the occipital lobe. 
Assessment is semi-quantitative using the scale -/+/++/+++, where - is the absence of 
a pathological feature and +++ is the presence of a severe pathological feature.  
Key: MV=microvacuolation, s=stillbirth 
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3.4.3.3 Parietal Lobe 
The pathology in the parietal lobe (BA40) is summarised in Table 3.5 for patients where 
this brain region was available. 
Patients with evidence for POLG mutations (Figure 3.4; images E and F) show 
microvacuolation in the deep grey matter layers, capillary proliferation and shrunken 
neurons. However, Patient 1 does not display any microvacuolation or capillary 
proliferation, and neurons appear small but possibly not shrunken, though mild 
spongiform changes are noted in the original neuropathologist’s report. 
Patients with no genetic diagnosis available show microvacuolation in the deep layers 
of the grey matter with large spaces around the neurons, and considerable capillary 
proliferation. 
The patient without a POLG mutation (Figure 3.4; images B, C and D) shows 
microvacuolation in the deep layers of the grey matter, and particularly in the 
perivascular spaces. This was noted throughout the entire parietal tissue available, with 
the areas surrounding the vessels greatly enlarged by microvacuolation, not 
commented on in the original neuropathologist’s report. This was not seen to this 
extent in any other patients. 
The stillbirth, Patient 5, shows severe capillary proliferation and moderate 
microvacuolation throughout. A severe capillary proliferation is also seen in the 
cerebellum and occipital lobe. The matched control tissue did not demonstrate a 
capillary proliferation. 
The parietal lobe shows pathology primarily of the deep grey matter layers. The 
morphology of this brain area is affected in all groups. Further comparisons between 
groups are difficult to draw due to single patients available in some groups. An 
exception is Patient 1, where no pathology is apparent. 
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Figure 3.4. Microvacuolation in the parietal lobe.  
A=Control 7, B=Patient 12 POLG mutation-absent group, C=Patient 12 POLG 
mutation-absent group, D=Patient 12 POLG mutation-absent group, E=Patient 2 POLG 
mutation-positive group, F=Patient 2 POLG mutation-positive group. All patient images 
show microvacuolation in the grey matter. Image B is at a higher magnification and 
shows microvacuolation in the perivascular space. Image D is a higher magnification of 
image C, and image F is a higher magnification of image E which show 
microvacuolation in the grey matter. All sections stained with H&E. Scale bar = 100µm.  
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The brain area is unavailable for patients not listed in the table. 
POLG 
mutation Patient MV 
Capillary 
Proliferation Microinfarct 
+ 
1 - - - 
2 + + - 
6 + + - 
+ s 5 ++ +++ - 
? 8 ++ +++ - 
- 12 ++ - - 
Table 3.5. Summary of neuropathology in the parietal lobe. 
Assessment is semi-quantitative using the scale -/+/++/+++, where - is the absence of 
a pathological feature and +++ is the presence of a severe pathological feature. 
Key: MV=microvacuolation, s=stillbirth 
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3.4.3.4 Basal Ganglia 
The pathology in the basal ganglia is summarised in Table 3.6 for patients where this 
brain region was available. All nuclei of the basal ganglia were assessed where 
available. 
Patients with evidence for POLG mutations (Figure 3.5; images C and D) show little 
pathology.  
Patients with no genetic diagnosis available (Figure 3.5; image B) show 
microvacuolation and slight capillary proliferation. 
The patient without a POLG mutation (Figure 3.5; images E and F) shows patchy 
microvacuolation confirmed in the original neuropathologist’s report, and large spaces 
around the neurons of the caudate. 
The stillbirth, Patient 5, shows severe capillary proliferation. A severe capillary 
proliferation is also seen in the cerebellum, occipital lobe, and parietal lobe. The 
matched control tissue did not demonstrate a capillary proliferation. 
The basal ganglia show a lesser degree of pathology than other brain areas. The 
morphology of this brain area is slightly affected where a POLG mutation is unknown. A 
severe capillary proliferation is seen in Patient 5, a feature that has been noted in all 
brain areas studied for this patient. Capillary proliferation was not seen in the age-
matched control, Control 5, and so is not considered a normal stage of development. 
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Figure 3.5. Microvacuolation in the caudate of the basal ganglia.  
A=Control 6, B=Patient 9 POLG mutation-undetermined group, C=Patient 1 POLG 
mutation-positive group, D=Patient 1 POLG mutation-positive group, E=Patient 12 
POLG mutation-absent group, F=Patient 12 POLG mutation-absent group. Image B is 
at a lower magnification and shows microvacuolation over a larger area. Image D is a 
higher magnification of image C which shows no microvacuolation. Image F is a higher 
magnification of image E which shows slight microvacuolation. All images are taken of 
caudate. All sections stained with H&E. Scale bar = 100µm. 
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The brain area is unavailable for patients not listed in the table. 
POLG 
mutation Patient MV 
Capillary 
Proliferation Microinfarct 
+ 
1 - - - 
2 - - - 
+ s 5 - +++ - 
? 
8 + - - 
9 + + - 
10 - - - 
11 + + - 
- 12 + - - 
Table 3.6. Summary of neuropathology in the basal ganglia. 
Assessment is semi-quantitative using the scale -/+/++/+++, where - is the absence of 
a pathological feature and +++ is the presence of a severe pathological feature. 
Key: MV=microvacuolation, s=stillbirth 
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 Neuron Loss 3.4.4
A cresyl fast violet (CFV) stain was used to assess neuronal populations in patient and 
control tissue. Suitable control tissue was extremely difficult to obtain due to the age of 
the patients. However, a number of controls were obtained for each brain area. 
In the cerebellum, both Purkinje cells and neurons of the dentate nucleus were 
assessed. Purkinje cells are one of the largest neuron types in the brain. They are the 
main efferent output of the cerebellum, ultimately controlling motor coordination, and 
have an inhibitory effect on the deep grey nuclei of the cerebellum. The dentate 
nucleus is the largest of the four deep grey nuclei within the white matter of the 
cerebellum. It has a role in motor coordination to plan and initiate voluntary movement, 
as well as a non-motor role in visuospatial functioning. 
In the occipital and parietal lobes, neurons of cortical layers I-VI were assessed. In the 
basal ganglia, neurons of the caudate, putamen, and globus pallidus (both lateral and 
medial) were assessed. 
Purkinje cells and cortical neurons were counted using reference spaces as described 
in Chapter 2 Methods and Materials, 2.2.6 ‘Quantitative Methods’. It was not possible 
to assess the neurons of the dentate nucleus or the basal ganglia fully quantitatively. 
Therefore, neurons of the dentate nucleus and the basal ganglia were assessed semi-
quantitatively using the -/+/++/+++ scale as described in Chapter 2 Methods and 
Materials, 2.2.7 ‘Semi-quantitative Methods’. Where both percentage values and semi-
quantitative date were available, they were displayed in the same table. 
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3.4.4.1 Cerebellum 
Purkinje cells of the cerebellum were assessed in representative patients from two of 
the groups and in three controls, Control 1, a 13 month old female, Control 5 which is a 
female fetal control, and Control 6, a 19 year old female. Focal neuron loss was known 
to occur in the patients. This was examined by counting areas of the cerebellum known 
to exhibit focal neuron loss in one patient and then sampled in all patients and the 
controls. 
Purkinje cells were qualitatively assessed (Figure 3.6) and quantitatively assessed 
using reference spaces and the length of the Purkinje cell layer taken to calculate for 
neuron density. A qualitative assessment only was made of neurons of the dentate 
nucleus. The results of these assessments are shown in Figure 3.7. Semi-quantitative 
assessment of both the Purkinje cells and the neurons of the dentate nucleus are 
summarised in Table 3.8. Where appropriate, both percentage values and a semi-
quantitative assessment for a patient have been displayed together. These values 
correlate well. 
The density of Purkinje cells reveal that these cells are greatly reduced in three of the 
five patients assessed when compared to controls. Patients and controls were matched 
based on age, with both non-fetal controls having a very similar average density 
(shown as ‘Average Count per mm’ in Table 3.7). The percentage of cell loss is similar 
in all three young patients; Patient 2, 64.6% loss; Patient 6, 44.4% loss; Patient 12, 
48.2% loss. Patient 5, a stillbirth, showed a 5.8% loss of Purkinje cells which was not 
considered significant. These values are summarised in Table 3.7, grouping the 
patients with the matched control that was used to assess neuron loss. 
Patients with evidence for POLG mutations (Figure 3.6; images B and D) show 
Purkinje cell loss and loss of neurons from the dentate nucleus. In patients showing 
Purkinje cell loss, this is concentrated in the biventer and tonsilla regions of the 
cerebellum which may indicate susceptible neurons in these regions. However, very 
little neuron loss is seen in Patient 1; there is no Purkinje cell loss but there is a mild 
loss of neurons from the dentate nucleus (+) (Table 3.8) which is confirmed in the 
original neuropathologist’s report describing lesser pathology in the cerebellar 
hemispheres with greater pathology in the cerebellar vermis. It is currently unclear what 
factors have spared Purkinje cell loss in this patient. Patient 2, of a similar age to 
Patient 1, shows 64.6% loss of Purkinje cells and a mild loss of neurons from the 
dentate nucleus (+) (Table 3.8). 
122 
 
Chapter 3 Neuropathological Features of Patients with Alpers’ Syndrome 
 
Patients with no genetic diagnosis available showed variable Purkinje cell and dentate 
nucleus neuron loss (not shown on Figure 3.7). Loss of Purkinje cells is not seen in two 
patients, is seen at a low level (+) in one patient, moderate level (++) in one patient, 
and severe level (+++) in one patient. Patients that show Purkinje cell loss do not 
always show a loss of neurons from the dentate nucleus (Table 3.8) suggesting that 
these groups of neurons may be affected differently in patients. 
The patient without a POLG mutation (Figure 3.6; image C) shows a 48.2% Purkinje 
cell loss and a moderate loss of neurons from the dentate nucleus (++) (Table 3.8). 
Focal Purkinje cell loss is seen in some areas of the cerebellum of this patient.  
No Purkinje cell loss is seen in Patient 5, the stillbirth, when compared to its control. 
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Figure 3.6. Neuron loss in the cerebellum.  
A=Control 6, B=Patient 1 POLG mutation-positive group, C=Patient 12 POLG 
mutation-absent group, D=Patient 6 POLG mutation-positive group. Image B does not 
show any Purkinje cell loss. Image C is at a higher magnification showing focal 
Purkinje cell loss. Image D shows an area of complete Purkinje cell loss. All sections 
stained with CFV stain. Scale bar = 100µm. 
Key: PC=Purkinje cell  
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Figure 3.7. Average number of Purkinje cells per length of cell layer (mm) in the 
cerebellum of patients and controls.  
Each column represents the average Purkinje cell count, over a total of 63 reference 
spaces over three separate microscope slides (21 reference spaces per slide). This 
value has been corrected for the length of the Purkinje cell layer assessed. Patient 12 
was averaged over two available microscope slides (error bars represent ± SEM over a 
total of 63 reference spaces).  
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The stillbirth, with a sibling that has an identified POLG mutation, does not show 
Purkinje cell loss when compared to a fetal control (Figure 3.8). There was also no loss 
of neurons from the dentate nucleus. There is a higher average number of Purkinje 
cells in both the fetal patient and fetal control. This may be due to undifferentiated 
Purkinje cells in the Purkinje cell layer. As they differentiate and connections 
throughout the brain become refined, fewer Purkinje cells will populate the layer. 
 
Figure 3.8. Average number of Purkinje cells per length of cell layer (mm) in the 
cerebellum of a stillbirth and a fetal control.  
Each column represents the average Purkinje cell count, over a total of 63 reference 
spaces over three separate microscope slides (21 reference spaces per slide). This 
value has been corrected for the length of the Purkinje cell layer assessed (error bars 
represent ± SEM over a total of 63 reference spaces). 
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Patient 
Individual 
Slide Cell 
Count 
Average Cell 
Count CoV 
Average 
Count per 
mm 
Percent 
of the 
Control 
Percent 
Purkinje 
Cell Loss 
Control 1 151, 152, 160 
154.33  
(Range: 2-13) 
0.032  
(SD=4.933) 
4.29   
Patient 1 146, 164, 158 
156 
(Range: 2-15) 
0.059 
(SD=9.165) 
4.52 101.1% 0% 
Patient 2 54, 56, 54 
54.67 
(Range: 0-10) 
0.021  
(SD=1.155) 
1.46 35.43% 64.57% 
Patient 
12 86, 74 
80 
(Range: 0-7) 
0.106 
(SD=8.485) 
2.74 51.85% 48.15% 
Control 6 137, 131, 135 
134.3 
(Range: 3-12) 
0.023 
(SD=3.055) 
4.37   
Patient 6 58, 78, 88 
74.67 
(Range: 0-11) 
0.205 
(SD=15.275) 
2.02 55.6% 44.4% 
Control 5 385, 386, 399 
390 
(Range: 7-38) 
0.020 
(SD=7.810) 
12.15   
Patient 5 435, 325, 342 
367.3 
(Range: 0-35) 
0.161 
(SD=59.214) 
12.31 94.18% 5.82% 
Table 3.7. Calculation of Purkinje cell loss in the cerebellum. 
The table shows the calculation of Purkinje cell loss from each patient. Patients are 
grouped showing the control used to calculate percentage neuron loss from. This 
control was chosen based its age and matched to the patient. The average cell count 
per microscope slide and the average cell count of all three slides are shown in the 
table, with the range of counted cells shown. The coefficient of variation and standard 
deviation are also shown. The average count when corrected for the length of the 
Purkinje cell layer (mm) is shown. 
 
Key: CoV=coefficient of variation, SD=standard deviation  
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The brain area is unavailable for patients not listed in the table. The availability of the 
dentate nucleus was dependent upon the orientation of the sample taken by the 
original pathology team. In some patients, this led to the dentate nucleus being 
unavailable for analysis. 
POLG 
Mutation Patient Purkinje Cell Loss 
Dentate Nucleus 
Neuron Loss 
+ 
1 0% (-) + 
2 64.6% (+++) + 
6 44.4% (++) N/A 
+ s 5 5.8% (-) - 
? 
7 - + 
8 + - 
9 - ++ 
10 - - 
11 +++ +++ 
- 12 48.2% (++) ++ 
Table 3.8. Summary of neuron loss in the cerebellum. 
Neuron loss of both Purkinje cells and neurons of the dentate nucleus is summarised in 
the above table. Both percentage loss values and semi-quantitative values are shown 
where appropriate. 
Semi-quantitative assessment is using the scale -/+/++/+++, where – denotes no 
neuron loss, and +++ denotes severe neuron loss. 
 
Key: N/A=data not available, s=stillbirth 
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3.4.4.2 Occipital Lobe 
Neurons within all six cortical layers of the occipital lobe (BA19) were assessed in 
representative patients from two of the groups and one control; Control 7, an 18 year 
old female, since this was the only control available for this brain region. 
Patients with evidence for POLG mutations (Figure 3.9; images B and C) show a 
moderate neuron loss. Patients 1 and 2 show over 40% neuron loss in the upper 
cortical layers I, II and III (Figure 3.10 and Table 3.9). There is less neuron loss in the 
lower cortical layers IV, V and VI. Spongiform changes and neuron loss in the 
superficial layers of Patients 1 and 2 is confirmed in the original neuropathologist’s 
report. 
Patients without a genetic diagnosis were assessed semi-quantitatively. The patients 
show variable neuron loss. Patient 8 and Patient 10 do not show neuron loss whilst 
Patient 11 shows a severe neuron loss (+++) in cortical layer V. There is limited clinical 
and reported neuropathological data on this group of patients as they are historical 
cases from the University of Vienna. 
The patient without a POLG mutation (Figure 3.9; image D) shows mild neuron loss in 
layers I, III, IV and V. There is no neuron loss in layers II and VI (Figure 3.10 and Table 
3.9). 
The occipital lobe shows overall neuronal cell loss in layers I – III, with much less 
neuron loss identified in any of the patients in layers IV, V and VI. This is not attributed 
to microvacuolation in the upper cortical layers. The neuron loss in these upper layers 
may be attributable to the fact that these neurons were difficult to distinguish with 
confidence, with low numbers being counted for all patients and control. The POLG 
mutation-positive group shows more neuron loss in the upper cortical layers than the 
POLG mutation-absent patient. The lack of neuron loss is unusual considering the 
involvement the occipital lobe has in the neuropathology of Alpers’ syndrome. As part 
of protocol, the NBTR centre processes region BA19 of the occipital lobe, the 
extrastriate cortical area. The primary visual cortex is Brodmann Area (BA) 17. This 
could explain why more pathology is not seen in these patients. Previous reports in the 
scientific literature do not regularly specify the area of occipital lobe examined. 
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Figure 3.9. Neuron loss in the occipital lobe. 
A=Control 7 cl19/20, B=Patient 1 POLG mutation-positive group cl29, C=Patient 2 
POLG mutation-positive group cl28, D=Patient 12 POLG mutation-absent group cl30. 
Images B and C do not show any neuron loss in layer V. Image D shows focal neuron 
loss in layer V. All sections stained with CFV stain. Scale bar = 100µm. 
 
Key: cl=coronal level 
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POLG 
Mutation 
 
Patient 
Percentage Neuron Loss 
  Layer I Layer II Layer III Layer IV Layer V Layer IV 
 Control 7 
CoV 0.236 0.349 0.277 0.479 0.387 0.134 
+ 
Patient 1 83.33% 55.82% 55.60% 31.41% 0% 34.74% 
CoV 0.471 0.091 0.144 0.426 0.401 0.425 
Patient 2 83.33% 68.12% 68.31% 33.61% 31.60% 5.26% 
CoV 0.471 0.044 0.420 0.187 0.303 0.294 
? 
Patient 8     -  
Patient 10     -  
Patient 11     +++  
- 
Patient 12 27.80% 5.33% 44.01% 29.20% 20.09% 9.47% 
CoV 0.762 0.171 0.150 0.212 0.140 0.201 
Table 3.9. Summary of neuron loss in the occipital lobe. 
The table shows the neuron loss from each patient. Both percentage loss values and 
semi-quantitative values are shown where appropriate. 
Semi-quantitative assessment is using the scale -/+/++/+++, where – denotes no 
neuron loss, and +++ denotes severe neuron loss. 
Percentage loss is calculated the same way as for the cerebellum and patients are 
compared to Control 7 to calculate the percentage neuron loss. This control was the 
only control available for this brain region. The coefficient of variation is also shown. 
Key: CoV=coefficient of variation 
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Figure 3.10. Neuron loss in the occipital lobe of patients and controls 
Each column represents the average neuronal cell count, over a total of 15 reference 
spaces over three separate microscope slides (5 reference spaces per slide) (error 
bars represent ± SEM over a total of 15 reference spaces).  
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3.4.4.3 Parietal Lobe 
Neurons of all six cortical layers of the parietal lobe (BA40) were assessed in 
representative patients from two of the groups and in Control 1, a 13 month old female. 
Control 1 only was available for this brain region. 
Patients with evidence for POLG mutations (Figure 3.11; images B and C) show severe 
neuron loss of over 50% in the upper cortical layers I, II, and III (Figure 3.12 and Table 
3.10).  
Patient 8 was the only patient available with no genetic diagnosis. This patient was 
assessed semi-quantitatively and shows no neuron loss.  
The patient without a POLG mutation (Figure 3.11; image D) shows moderate neuron 
loss of over 40% in layers III and VI (Figure 3.12 and Table 3.10). 
The parietal lobe shows overall neuronal cell loss in layers I – III, with less neuron loss 
identified in layers IV, V and VI. This is not attributed to microvacuolation in the upper 
cortical layers of Patient 1 and Patient 2, which showed very little microvacuolation. It 
may play a role in the neuron loss of Patient 12 however, which showed a moderate 
microvacuolation (++) and 34%-45% neuron loss in the cortical layers III - VI. The 
neurons in layer I were difficult to distinguish with confidence, with low numbers being 
counted for all patients and a slightly higher number being counted for the control. The 
POLG mutation-positive group shows a variable neuron loss, with Patient 1 showing 
loss through all layers concentrated in the upper cortical layers, while Patient 2 shows 
loss concentrated in the upper cortical layers I-III. The POLG mutation-absent group 
shows neuron loss in the lower cortical layers III and VI. This pattern between the 
POLG mutation-positive group and the POLG mutation-absent group is very similar to 
the occipital lobe. 
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Figure 3.11. Neuron loss in the parietal lobe. 
A=Control 1 cl22, B=Patient 1 POLG mutation-positive group cl28-30, C=Patient 2 
POLG mutation-positive group cl25, D=Patient 12 POLG mutation-absent group cl24. 
Images B and C do not show any neuron loss in layer V. Image D shows neuron loss in 
layer V. All sections stained with CFV stain. Scale bar = 100µm. 
 
Key: cl=coronal level 
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POLG 
Mutation 
 
Patient 
Percentage Neuron Loss 
  Layer I Layer II Layer III Layer IV Layer V Layer IV 
 Control 1 
CoV 0.354 0.104 0.219 0.035 0.230 0.034 
+ 
Patient 1 85% 55.49% 31.27% 26.99% 15.04% 8.05% 
CoV ND 0.456 0.197 0.189 0.182 0.226 
Patient 2 100% 82.45% 80.22% 15.90% 31.74% 31.03% 
CoV ND 0.137 0.216 0.199 0.264 0.156 
? Patient 8     -  
- 
Patient 12 35% 3.51% 45.39% 34.20% 39.53% 41.38% 
CoV 0.118 0.175 0.383 0.483 0.299 0.488 
Table 3.10. Summary of neuron loss in the parietal lobe. 
The table shows the neuron loss from each patient. Both percentage loss values and 
semi-quantitative values are shown where appropriate. 
Semi-quantitative assessment is using the scale -/+/++/+++, where – denotes no 
neuron loss, and +++ denotes severe neuron loss. 
Percentage loss is calculated the same way as for the cerebellum and patients are 
compared to Control 1 to calculate the percentage neuron loss. This control was the 
only control available for this brain region. The coefficient of variation is also shown. 
Key: CoV=coefficient of variation, ND=not determined 
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Figure 3.12. Neuron loss in the parietal lobe of patients and controls 
Each column represents the average neuronal cell count, over a total of 15 reference 
spaces over three separate microscope slides (5 reference spaces per slide) (error 
bars represent ± SEM over a total of 15 reference spaces).  
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3.4.4.4 Basal Ganglia 
Semi-quantitative assessments of neuron loss in the basal ganglia were carried out in 
the same manner to the dentate nucleus of the cerebellum. There is good correlation 
between quantified percentage loss and semi-quantified assessment in previous brain 
areas assessed. The results are summarised in Table 3.11. Neurons of the caudate, 
putamen, and globus pallidus were assessed in all patients available and in Control 5, 
which is a fetal control, and Control 6, a 19 year old female. 
There was no neuronal cell loss from patients with evidence for POLG mutations 
(Figure 3.13; images B and C), or from the patient without a POLG mutation (Figure 
3.13; image D), or from stillbirth Patient 5. 
There is a single patient with no genetic diagnosis available that shows neuron loss. 
Patient 9 shows mild neuron loss (+) in the caudate and moderate neuron loss (++) in 
the globus pallidus. No neuron loss is seen in any other patients of this group.  
Neuron loss is seen in the basal ganglia of a single patient, with an unknown genetic 
diagnosis. No neuron loss is present in all other patients in all other groups or in the 
controls. 
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Figure 3.13. Neuron loss in the putamen of the basal ganglia. 
A=Control 6, B=Patient 1 POLG mutation-positive group, C=Patient 2 POLG mutation-
positive group, D=Patient 12 POLG mutation-absent group. Images B, C and D do not 
show any neuron loss in layer V. All images are taken of the putamen. All sections 
stained with CFV stain. Scale bar = 100µm. 
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POLG 
Mutation Patient Caudate Putamen 
Globus 
Pallidus 
+ 
1 - - - 
2 - - - 
+ s 5 - - - 
? 
8 N/A - - 
9 + - ++ 
10 N/A - - 
11 - - - 
- 12 - - - 
Table 3.11. Summary of neuron loss in the basal ganglia. 
Neuron loss of the basal ganglia is summarised in the above table.  
Assessment is semi-quantitative using the scale -/+/++/+++, where – denotes no 
neuron loss, and +++ denotes severe neuron loss. 
 
Key: N/A=data not available, s=stillbirth 
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 Astrogliosis 3.4.5
Astrocytes are ubiquitous cells of the CNS, providing a supporting role to cells of the 
blood-brain barrier, to neurons, and they also play a role in the repair of damaged 
tissue. This gives them a vital role in the functioning of the brain. They appear spider-
like with numerous dendrite projections reaching out into the tissue, making contact 
with other cells. An antibody to the glial fibrillary acidic protein (GFAP) expressed by 
reactive astrocytes was used to assess astrocyte populations using the -/+/++/+++ 
scale as described in Chapter 2 Methods and Materials, 2.2.7 ‘Semi-quantitative 
Methods’. 
3.4.5.1 Cerebellum 
Astrocytes of the cerebellum are termed Bergmann glia and they are assessed in 
patients of the POLG groups below. Semi-quantitative assessment of a gliosis in the 
Bergmann glia of the cerebellum is summarised in Table 3.12. 
Patients with evidence for POLG mutations (Figure 3.14; image B) show no astrogliosis 
in two patients and a moderate increase (++) in Patient 6. Patient 6 also has a 
microinfarct in the cerebellum, and much of the astrogliosis is present in the region of 
the infarct. 
Patients with no genetic diagnosis available (Figure 3.14; images C and D) show a 
variable astrogliosis. Three patients show no astrogliosis, there is a mild increase (+) in 
one patient around the dentate nucleus only, and a moderate increase (++) in one 
patient. 
The patient without a POLG mutation does not show astrogliosis. 
The stillbirth, Patient 5, shows a mild astrogliosis (+) in both the grey matter and the 
white matter. 
There is variable gliosis of Bergman glia in patients where a POLG mutation is 
confirmed or unknown. In the patient without a POLG mutation there is no gliosis. 
Astrogliosis does not appear to correlate well with neuronal cell loss. 
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Figure 3.14. Bergmann glia of the cerebellum.  
A=Control 6, B=Patient 6 POLG mutation-positive group, C=Patient 8 POLG mutation-
undetermined group, D=Patient 11 POLG mutation-undetermined group. Image B 
shows widespread astrogliosis at the site of the microinfarct in the patient. The 
microinfarct is large and the entirety of it is not visible in the image. Image C does not 
show astrogliosis in the white matter. Image D shows moderate astrogliosis. All 
sections stained with GFAP antibody. Scale bar = 100µm. 
 
Key: ML=molecular layer, GCL=granular cell layer, WM=white matter 
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The brain area is unavailable for patients not listed in the table. 
POLG 
Mutation Patient Grey Matter 
White Matter / 
Dentate Nucleus 
+ 
1 - - 
2 - - 
6 ++ ++ 
+ s 5 + + 
? 
7 - - 
8 - + 
9 - - 
10 - - 
11 ++ ++ 
- 12 - - 
Table 3.12. Summary of Bergmann glia of the cerebellum. 
The increase in Bergmann glia in the cerebellum is summarised in the above table.  
Assessment is semi-quantitative using the scale -/+/++/+++, where – is defined as no 
change, + mild increase, ++ moderate increase, and +++ severe increase. 
 
Key: s=stillbirth   
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3.4.5.2 Occipital Lobe 
Suitable control tissue was extremely difficult to obtain due to the age of the patients 
and the availability of different brain regions. Control tissue was unavailable for this 
brain region. 
Semi-quantitative assessment of astrogliosis the occipital lobe (BA19) is summarised in 
Table 3.13. 
The patient with evidence for POLG mutations (Figure 3.15; images C and D), Patient 
2, shows a severe increase (+++), exhibiting swollen astrocytes. 
Patients with no genetic diagnosis available (Figure 3.15; images E and F) show a mild 
increase (+) for two patients, one showed an increase at the meninges in particular, 
and a severe increase (+++) for another patient in the grey matter in particular. 
The patient without a POLG mutation (Figure 3.15; image B) shows severe astrogliosis 
(+++). 
The stillbirth, Patient 5 (Figure 3.15; image A), shows a mild astrogliosis (+) in both the 
grey matter and the white matter. 
There is a severe astrogliosis seen in patients of three of the groups. The stillbirth 
shows a much milder astrogliosis. Some patients where POLG mutation is confirmed or 
unknown have a milder gliosis. Astrogliosis appears to correlate well with neuronal cell 
loss, with more severe astrogliosis seen in patients showing greater neuron loss. 
Despite control tissue being unavailable, there is a clear gradation of astrogliosis and a 
difference between patients. 
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1
 
Figure 3.15. Astrogliosis in the occipital lobe.  
A=Patient 5 stillbirth, B=Patient 12 POLG mutation-absent group, C=Patient 2 POLG 
mutation-positive group, D=Patient 2 POLG mutation-positive group, E=Patient 11 
POLG mutation-undetermined group, F=Patient 11 POLG mutation-undetermined 
group. Image A shows mild astrogliosis. Images B-F show severe astrogliosis, with 
swollen astrocytes in images C-F. Image D is a higher magnification of image C, and 
image F is a higher magnification of image E which show severe astrogliosis in the 
grey and white matter. All sections stained with GFAP antibody. Scale bar = 100µm. 
 
Key: GM=grey matter, WM=white matter 
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The brain area is unavailable for patients not listed in the table. The antibody stain for 
GFAP could not be performed for Patient 1 as the stain was very uneven after 
repeating. 
POLG 
Mutation Patient Grey Matter White Matter 
+ 2 +++ +++ 
+ s 5 + + 
? 
8 + + 
10 + + 
11 +++ ++ 
- 12 +++ ++ 
Table 3.13. Summary of astrogliosis in the occipital lobe. 
Astrogliosis in the occipital lobe is summarised in the above table.  
Assessment is semi-quantitative using the scale -/+/++/+++, where – is defined as no 
change, + mild increase, ++ moderate increase, and +++ severe increase. 
 
Key: s=stillbirth   
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3.4.5.3 Parietal Lobe 
Suitable control tissue was extremely difficult to obtain due to the age of the patients 
and the availability of different brain regions. Control tissue was unavailable for this 
brain region. 
Semi-quantitative assessment of astrogliosis the parietal lobe (BA40) is summarised in 
Table 3.14. 
Patients with evidence for POLG mutations (Figure 3.16; images A and B) show a 
severe increase (+++) in the grey matter. In Patient 2 there is a severe increase in the 
grey matter with many of the astrocytes appearing large and swollen. There are fewer 
astrocytes present in the white matter which is not mentioned in the original 
neuropathologist’s report. In Patient 6, the astrocytes also appear large and swollen 
and appear in particularly large numbers in the white matter, which is confirmed in the 
original neuropathologist’s report. 
There is a single patient with no genetic diagnosis available (Figure 3.16; images C 
and D) in this brain region. Patient 8 shows a mild increase (+). Astrocytes are 
particularly seen in the white matter and in the epithelial lining of the brain. 
The patient without a POLG mutation (Figure 3.16; images E and F) shows a mild 
astrogliosis (+), particularly where there is also microvacuolation in the grey matter 
layers. 
There is a severe astrogliosis in patients with a confirmed POLG mutation. Patients of 
the other two groups show a milder gliosis. However, astrogliosis does not appear to 
correlate well with neuronal cell loss. Despite control tissue being unavailable, there is 
a clear gradation of astrogliosis and a difference between patients.  
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Figure 3.16. Astrogliosis in the parietal lobe.  
A=Patient 6 POLG mutation-positive group, B=Patient 6 POLG mutation-positive 
group, C=Patient 8 POLG mutation-undetermined group, D=Patient 8 POLG mutation-
undetermined group, E=Patient 12 POLG mutation-absent group, F=Patient 12 POLG 
mutation-absent group. Image A and image B, which is at a higher magnification, show 
extreme astrogliosis. Images C and image D, which is at a higher magnification, show 
mild astrogliosis with swollen astrocytes. Images E and image F, which is at a higher 
magnification, show mild astrogliosis. All sections stained with GFAP antibody. Scale 
bar = 100µm. 
 
Key: GM=grey matter 
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The brain area is unavailable for patients not listed in the table. The antibody stain for 
GFAP could not be performed for Patient 1 as the stain was very uneven after 
repeating. 
POLG 
Mutation Patient Grey Matter White Matter 
+ 
2 +++ - 
6 +++ +++ 
? 8 + + 
- 12 + + 
Table 3.14. Summary of astrogliosis in the parietal lobe. 
Astrogliosis in the parietal lobe is summarised in the above table.  
Assessment is semi-quantitative using the scale -/+/++/+++, where – is defined as no 
change, + mild increase, ++ moderate increase, and +++ severe increase. 
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3.4.5.4 Basal Ganglia 
The availability of each of the caudate, putamen, and globus pallidus for analysis was 
dependent upon the precise location of the sample that was taken by the original 
pathology team. In some patients, this led to two of the three areas being available for 
analysis.  
Patients with evidence for POLG mutations show very mild levels of astrogliosis. 
Patient 2 does not exhibit astrogliosis. Patient 1 has a mild increase of astrocytes 
present in the globus pallidus only, where these astrocytes appear unusually large and 
swollen. 
Patients with no genetic diagnosis available (Figure 3.17; images B, C and D) show no 
increase for one patient, a mild increase (+) in the caudate and globus pallidus for one 
patient, and a severe increase (+++) for two patients. 
The patient without a POLG mutation does not show astrogliosis and nor does the 
stillbirth, Patient 5. 
Patients with a confirmed POLG mutation show a very mild astrogliosis while no 
astrogliosis is present in the patient with no POLG mutation. There is severe to 
moderate astrogliosis in Patient 8 and Patient 11, with a milder astrogliosis in Patient 9. 
Astrogliosis does appear to correlate well with neuronal cell loss, except in Patient 8 
and Patient 10, as no neuron loss was seen in any of the patients. Semi-quantitative 
assessment of astrogliosis the occipital lobe is summarised in Table 3.15. 
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Figure 3.17. Astrogliosis in the basal ganglia.  
A=Control 6 putamen, B=Patient 8 putamen POLG mutation-undetermined group, 
C=Patient 9 caudate POLG mutation-undetermined group, D=Patient 11 putamen 
POLG mutation-undetermined group. Images B, C and D show widespread 
astrogliosis. All sections stained with GFAP antibody. Scale bar = 100µm. 
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The brain area is unavailable for patients not listed in the table. 
POLG 
Mutation Patient Caudate Putamen 
Globus 
Pallidus 
+ 
1 - - + 
2 - - - 
+ s 5 - - - 
? 
8 N/A +++ ++ 
9 + - + 
10 N/A - - 
11 +++ +++ +++ 
- 12 - - - 
Table 3.15. Summary of astrogliosis in basal ganglia. 
Astrogliosis in the caudate, putamen, and globus pallidus of the basal ganglia is 
summarised in the above table.  
Assessment is semi-quantitative using the scale -/+/++/+++, where – is defined as no 
change, + mild increase, ++ moderate increase, and +++ severe increase. 
 
Key: N/A=not available, s=stillbirth   
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 Mitochondrial Localisation in Neurons 3.4.6
Mitochondria are found throughout the neuron and may move in a bidirectional manner 
along the axon towards the synaptic terminal or the cell body (soma), a process that 
occurs through mitochondrial axonal transport. A high mitochondrial density is required 
for oxidative phosphorylation that is able to respond to the physiological stresses of the 
cell. Mitochondrial density and localisation was visualised using an antibody to porin, a 
class of voltage-dependent anion channel (VDAC) on the outer membrane of 
mitochondria, involved in the passive diffusion of calcium and ions. Abnormal 
localisation was categorised as a darker ring of antibody around the periphery of the 
nucleus (perinuclear) or the periphery of the soma, or weak staining of porin at the 
periphery of the soma. The results are summarised in Table 3.16 and Table 3.17. 
Patients with evidence for POLG mutations (Figure 3.18; images B, F and H) show 
variable mitochondrial density over all brain areas. In the cerebellum, patients show 
mainly a high density of mitochondria in both the Purkinje cells and neurons of the 
dentate nucleus. There is no abnormal localisation of mitochondria in the dentate 
nucleus but both Patient 1 and Patient 2 show perinuclear localisation in Purkinje cells, 
while Patient 2 and Patient 6 show areas of low mitochondrial density at one edge of 
the soma periphery. In the occipital lobe, Patient 1 shows some neurons with a low 
mitochondrial density, and Patient 2 shows a high mitochondrial density. There is no 
abnormal localisation of mitochondria. Patients 1, 2, and 6 all show a low mitochondrial 
density in the parietal lobe, but with no abnormal localisation of mitochondria. In the 
basal ganglia, the globus pallidus shows low mitochondrial density but with no 
abnormal localisation of mitochondria. 
Patients without a genetic diagnosis (Figure 3.18; images C, D and J) show variable 
mitochondrial density over all brain areas. In the cerebellum, patients show a low 
density of mitochondria in neurons of the dentate nucleus, accompanied by perinuclear 
localisation. In Purkinje cells, Patient 7, Patient 9 and Patient 10 show a low 
mitochondrial density. In Patient 10, all of the Purkinje cells have low mitochondrial 
density. Patients 8-11 exhibit perinuclear localisation, with localisation around the 
periphery of the soma in Patient 8. In Patient 11, this abnormal perinuclear localisation 
was seen in only a single Purkinje cell. In the occipital lobe, there is a high density of 
mitochondria in all patients with no abnormal localisation of mitochondria. In the 
parietal lobe, only Patient 8 is available and shows a high density of mitochondria with 
no abnormal localisation. In the basal ganglia, Patient 9 and Patient 11 show evidence 
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of neurons with a low mitochondrial density. Patients 8, 10, and 11 show perinuclear 
localisation of mitochondria, predominantly in neurons of the globus pallidus. 
The patient without a POLG mutation shows a high mitochondrial density in most brain 
areas. In the cerebellum, neurons of the dentate nucleus show a high density of 
mitochondria with no abnormal localisation of mitochondria. The Purkinje cells show a 
low density of mitochondria, accompanied by perinuclear localisation. In the occipital 
lobe, parietal lobe, and basal ganglia there is a high mitochondrial density in neurons 
with no abnormal localisation of mitochondria.  
The stillbirth, Patient 5 shows a high density of mitochondria in neurons of the 
cerebellum and basal ganglia, with no abnormal localisation of mitochondria. The 
neurons of the occipital lobe and parietal lobe are too small and contain little cytoplasm 
to assess accurately. 
Some of the control tissues also demonstrated a ring of high density staining with porin 
around the periphery of the nucleus in some neurons. The staining around the 
periphery of the nucleus was not as intense as that seen in neurons of the patients. 
This was most noticeable in larger neurons, such as Purkinje cells of the cerebellum. 
Depolarised mitochondria are returned from the synapse to the cell soma to be 
degraded and recycled. Clustering of mitochondria around the periphery of the nucleus 
can occur as part of the normal recycling of mitochondria. Clustering of mitochondria 
may happen in all neurons but it may be happening at a greater rate or in greater 
numbers in patient neurons. This is mentioned further in the discussion at the end of 
this chapter. 
A low density of mitochondria in neurons may result in less efficient oxidative 
phosphorylation and deficiencies of electron transport chain complexes. Where this is 
accompanied by abnormal mitochondrial localisation, this may indicate physiological 
stress to the cell. Mitochondria are known to be transported from the synapse to the 
soma, retrograde transport, in order to be degraded and recycled. Depolarised 
mitochondria may cluster around the nucleus prior to degradation.  
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Figure 3.18. Mitochondrial localisation.  
A=Control 1 cerebellum, B=Patient 2 POLG mutation-positive group cerebellum, 
C=Patient 9 POLG mutation-undetermined group cerebellum, D=Patient 10 POLG 
mutation-undetermined group cerebellum, E=Control 7 occipital lobe, F=Patient 1 
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POLG mutation-positive group occipital lobe, G=Control 7 parietal lobe, H=Patient 2 
POLG mutation-positive group parietal lobe. I=Control 6 globus pallidus of the basal 
ganglia, J=Patient 10 POLG mutation-undetermined group globus pallidus of the basal 
ganglia. Image B shows low mitochondrial density at one edge of the soma periphery. 
Images C and J show perinuclear localisation of mitochondria. Images D, F, and H 
show low mitochondrial density. All sections stained with antibody to porin. Scale bar = 
100µm. 
 
  Cerebellum 
  Purkinje Cells Dentate Nucleus 
POLG 
Mutation  Density 
Abnormal 
Localisation Density 
Abnormal 
Localisation 
 Control 1 High Perinuclear circles High No 
+ 
Patient 1 High Perinuclear circles High No 
Patient 2 High 
Perinuclear 
circles and 
localisation 
away from 
the soma 
periphery 
High No 
Patient 6 Some low 
Localisation 
away from 
the soma 
periphery 
N/A N/A 
+ s Patient 5 High No High No 
? 
Patient 7 Some low No Some low Perinuclear circles 
Patient 8 High 
Perinuclear 
circles and 
around soma 
periphery 
Some low Perinuclear circles 
Patient 9 Some low Perinuclear circles Some low 
Perinuclear 
circles 
Patient 10 All low Perinuclear circles Some low 
Perinuclear 
circles 
Patient 11 High 
Perinuclear 
circles in a 
single neuron 
Too few neurons to assess 
- Patient 12 Some low Perinuclear circles High No 
Table 3.16. Summary of mitochondrial density and localisation in the cerebellum. 
Mitochondrial density and localisation in Purkinje cells and neurons of the dentate 
nucleus in the cerebellum is summarised in the above table.  
 
Key: N/A=data not available, s=stillbirth 
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   Occipital Lobe (BA19) Parietal Lobe (BA40) Basal Ganglia 
POLG 
Mutation  Density 
Abnormal 
Localisation Density 
Abnormal 
Localisation Density 
Abnormal 
Localisation 
 Control 6 N/A N/A N/A N/A High Perinuclear circles 
 Control 7 High No High No N/A N/A 
+ 
Patient 1 Some low No Some low No 
C-High 
P-High 
GP-Some low 
No 
Patient 2 High No Some low No 
C-High 
P-High 
GP-Some low 
No 
Patient 6 N/A N/A Some low No N/A N/A 
+ s Patient 5 Neurons too small to assess accurately 
C-High 
P-High 
GP-High 
No 
? 
Patient 8 High No High No P-High GP-High 
GP-Perinuclear 
circles 
Patient 9 N/A N/A N/A N/A 
C-High 
P-Some low 
GP-Some low 
No 
Patient 10 High No N/A N/A P-High GP-High Perinuclear circles 
Patient 11 High No N/A N/A 
C-Some low 
P-Some low 
GP-Some low 
GP-Perinuclear 
circles 
- Patient 12 High No High No 
C-High 
P-High 
GP-High 
No 
Table 3.17. Summary of mitochondrial density and localisation in the occipital lobe, parietal lobe, and basal ganglia. 
Mitochondrial density and localisation in neurons of the occipital lobe, parietal lobe, and basal ganglia is summarised in the above table.  
 
Key: N/A=data not available, s=stillbirth, C=caudate, P=putamen, GP=globus pallidus 
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 White Matter Abnormalities 3.4.7
A Loyez silver stain was used to assess myelin density in the white matter using the 
0/1/2/3 scale as described in Chapter 2 Methods and Materials, 2.2.7 ‘Semi-
quantitative Methods’. 
Assessing myelin density also aided investigations into axonal abnormalities, when 
investigating whether there was primary or secondary myelin loss. A Bielschowsky 
silver stain was used to assess axonal abnormalities yet this stain was difficult to 
perform and analyse. Tissue was assessed in representative patients from two of the 
groups. Myelin loss is summarised in Table 3.18 and Table 3.19. 
Patient 5 was excluded from assessment of white matter abnormalities, including loss 
of myelin, as myelin is not fully formed in patients as young as Patient 5 and its 
matched fetal control. The availability of each of the caudate, putamen, and globus 
pallidus for analysis was dependent upon the precise location of the sample that was 
taken by the original pathology team. In some patients, this led to two of the three 
areas being available for analysis. 
Patients with evidence for POLG mutations show variable myelin loss in all brain areas. 
In the cerebellum (Figure 3.19; image B), Patient 1 shows moderate areas of myelin 
loss (++) and Patient 2 shows very mild (+) myelin loss. Patient 6 shows myelin loss 
only at the area of the microinfarct. In the occipital lobe (Figure 3.19; images C and D), 
there is mild (+) loss in Patient 1 and moderate (++) loss in Patient 2. In the parietal 
lobe (Figure 3.19; image E), there is no evidence of myelin loss. In the basal ganglia 
(Figure 3.19; image H), Patient 1 shows no evidence of myelin loss while Patient 2 
shows severe loss (+++) of myelin in this area. A Bielschowsky stain shows some 
axonal loss, though myelin loss appears to be greater suggesting a primary loss of 
myelin in this group. 
No data were available for patients without a genetic diagnosis. 
The patient without a POLG mutation shows myelin loss in all brain areas. In the 
cerebellum, there is moderate (++) myelin loss that appears to be greater on one side 
of the dentate nucleus. In the occipital lobe, there is mild (+) myelin loss. In the parietal 
lobe (Figure 3.19; image F), there is pale staining of the myelin and a mild (+) loss of 
myelin. The Bielschowsky stain in the cerebellum, occipital lobe, and parietal lobe 
shows a loss of axons, indicating that the myelin loss is secondary to the axonal loss. 
In the basal ganglia, there is moderate (++) myelin loss throughout the caudate and 
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putamen and slight loss in the internal capsule. The Bielschowsky stain shows no loss 
of axons, indicating that in this region the myelin loss is primary. The length of tissue 
fixation for this patient is long-term (~14 years) for the cerebellum, parietal lobe, and 
basal ganglia, all areas which demonstrate myelin loss. However, the length of tissue 
fixation in the occipital lobe is short term (~1 month), in this area which demonstrates a 
marked myelin loss also. This suggests that the length of fixation does not have a great 
impact upon the efficacy of the loyez silver stain. 
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Figure 3.19. Myelin abnormalities.  
An asterisk indicates regions of myelin loss. Image B shows a demarcated area of focal 
myelin loss. 
A=Control 6 cerebellum, B=Patient 1 POLG mutation-positive group cerebellum, 
C=Patient 1 POLG mutation-positive group occipital lobe, D=Patient 2 POLG mutation-
positive group occipital lobe, E=Patient 6 POLG mutation-positive group parietal lobe, 
F=Patient 12 POLG mutation-absent group parietal lobe, G=Control 6 internal capsule 
of the basal ganglia, H=Patient 2 POLG mutation-positive group internal capsule of the 
basal ganglia. Images A, C, E and G do not show any myelin loss. Images B, D, F and 
H show myelin loss in the white matter. All sections stained with Loyez silver stain. 
Scale bar = 100µm.
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 POLG 
Mutation 
 Staining Quantification 
  Tonsilla Biventer Posterior Inferior 
Posterior 
Superior 
Posterior 
Crescentic 
Anterior 
Crescentic Ala Centralis 
 Control 6 N/A N/A 3, 3, 3 3, 3, 3 3, 3, 3 N/A N/A 
+ 
Patient 1 1, 1, 3 2, 3, 3 2, 3, 3 3, 3, 3 2, 3, 3 3, 3, 3 3, 3, 2 
Patient 2 3, 3, 3 3, 3, 2 3, 3, 2 3, 3, 2 2, 3, 3 3, 2, 3 3, 3, 3 
Patient 6 3, 3, 3 3, 3, 3 3, 3, 3 3, 3, 3 3, 3, 3 N/A N/A 
- Patient 12 1, 1, 2 1, 1, 2 1, 2, 2 1, 2, 2 2, 2, 2 1, 2, 2 2, 2, 3 
Table 3.18. Myelin quantification in the cerebellum. 
Loyez silver staining was performed on tissue from the cerebellum. Three images were taken for each cerebellar region at X10 magnification and 
assessed for myelin loss. Not all brain areas were available for assessment in each patient.  
Myelin Assessment Key: 0=complete myelin loss, 1=marked loss of myelin staining, 2=slight pallor of myelin staining, 3=good myelin staining 
equivalent to controls. 
 
Key: N/A=not available 
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 POLG 
Mutation  Staining Quantification 
  Occipital Lobe (BA19) 
Parietal Lobe 
(BA40) Basal Ganglia 
    Caudate Internal Capsule Putamen 
Medial 
Globus 
Pallidus 
Lateral 
Globus 
Pallidus 
 Control 6 N/A N/A 3 3 3 3 3 
+ Patient 1 2 3 1 3 3 3 2 
Patient 2 1 2 0 1 0 N/A N/A 
Patient 6 N/A 3 N/A N/A N/A N/A N/A 
- Patient 12 1 2 0 2 1 N/A N/A 
Table 3.19. Myelin quantification in the occipital lobe, parietal lobe, and basal ganglia.  
Loyez silver staining was performed on tissue from the occipital lobe, parietal lobe, and basal ganglia. Images were taken at X10 magnification and 
assessed for myelin loss.  
Myelin Assessment Key: 0=complete myelin loss, 1=marked loss of myelin staining, 2=slight pallor of myelin staining, 3=good myelin staining 
equivalent to controls.  
 
Key: N/A=not available
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 Microglial Activation 3.4.8
Microglia are glial cells of the immune system, found throughout the entire brain. Their 
function is to phagocytise foreign and unwanted material, removing it from the brain 
and preventing damage. They provide an interesting feature of neuropathology. An 
antibody to CD68, a highly glycosylated lysosomal membrane protein found on 
macrophages and activated microglia was used to assess CD68-positive cell 
populations in both grey and white matter. This was performed using the -/+/++/+++ 
scale as described in Chapter 2 Methods and Materials, 2.2.7 ‘Semi-quantitative 
Methods’. The results are summarised in Table 3.20. 
The availability of each of the caudate, putamen, and globus pallidus for analysis was 
dependent upon the precise location of the sample that was taken by the original 
pathology team. In some patients, this led to two of the three areas being available for 
analysis. Some brain areas were unavailable for patients and therefore they were not 
listed in Table 3.20 or listed specifying ‘not available’ for the brain area. 
Patients with evidence for POLG mutations show a widely varied pathology in all brain 
areas. In the cerebellum, Patient 6 shows a mild increase (+) around the region of the 
microinfarct. There is a moderate increase (++) for Patient 1 and Patient 2 (Figure 3.20; 
image B). In the occipital lobe (Figure 3.20; images C and D), there is a mild increase 
(+) in one patient, and a severe increase (+++) in one patient. In Patient 2 where there 
is a severe increase, the microglial cells appear swollen in the white matter, possibly 
due to having phagocytised any excess material. This correlates with a marked loss of 
myelin in the occipital lobe of Patient 2. In the parietal lobe (Figure 3.20; image F) there 
is a moderate increase (++) in Patients 1 and 2, and a severe increase (+++) in Patient 
6. Where there is a severe increase, there is no evidence of any swollen microglia. In 
the basal ganglia, there is no increase in Patient 2, and a moderate increase (++) in 
Patient 1. 
Patients with no genetic diagnosis available show a variable pathology. In the 
cerebellum, there is mild increase (+) in microglia in four patients, and a severe 
increase (+++) for one patient, especially in the white matter. In the occipital lobe, there 
is no increase in two patients, and a moderate increase (++) in one patient. In the 
parietal lobe, there is no increase in microglia. In the basal ganglia (Figure 3.20; image 
H), there is a mild increase throughout the basal ganglia in Patient 10. In Patient 8 
there is a mild increase (+) in the putamen in any areas of microvacuolation or around 
any vessels, and a mild increase (+) throughout the globus pallidus. Patient 11 shows a 
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range of pathology in different areas; there is a mild increase (+) in the caudate, a 
moderate (++) increase in the putamen and globus pallidus, and a severe increase 
(+++) in the internal capsule (not shown in table). Patient 9 shows a moderate to 
severe increase (++/+++) throughout the basal ganglia. 
The patient without a POLG mutation shows no increase in microglia in the cerebellum 
and basal ganglia. The parietal lobe (Figure 3.20; image E) shows a mild increase (+) 
throughout the grey and white matter, while the occipital lobe shows a severe increase 
(+++) in microglia. These are found almost entirely in the white matter, while the grey 
matter is almost free from microglia. 
The stillbirth, Patient 5, shows no increase in microglia in any brain area. 
Microglial activation correlates with myelin loss in the occipital lobe, with Patient 2 and 
Patient 12 showing a marked loss of myelin and a severe increase in microglia. 
However, this correlation does not hold for other brain areas as Patient 2 and Patient 
12 show a marked loss of myelin throughout the basal ganglia, yet there is no increase 
in microglia. 
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Figure 3.20. Microglial activation.  
A=Control 6 cerebellum, B=Patient 2 POLG mutation-positive group cerebellum, 
C=Patient 1 POLG mutation-positive group occipital lobe, D=Patient 2 POLG mutation-
positive group occipital lobe, E=Patient 12 POLG mutation-absent group parietal lobe, 
F=Patient 6 POLG mutation-positive group parietal lobe, G=Control 6 putamen of the 
basal ganglia, H=Patient 9 POLG mutation-undetermined group putamen of the basal 
ganglia. Images A, C, E and G do not show any activation. Images B, D, F and H show 
moderate to severe activation. Images A and B are taken at a lower magnification to 
illustrate microglial activation over a wide area. All sections stained with CD68 
antibody. Scale bar = 100µm. 
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   Cerebellum Occipital Lobe (BA19) Parietal Lobe (BA40) Basal Ganglia 
POLG 
Mutation Patient Grey Matter White Matter Grey Matter White Matter Grey Matter White Matter C P GP 
+ 
1 ++ ++ + + ++ ++ ++ ++ ++ 
2 ++ ++ +++ +++ ++ ++ - - - 
6 + + N/A N/A +++ +++ N/A N/A N/A 
+ s 5 - - - - - - - - - 
? 
7 + + N/A N/A N/A N/A N/A N/A N/A 
8 + - - - - - N/A + + 
9 + - N/A N/A N/A N/A +++ +++ +++ 
10 + - - - N/A N/A N/A + + 
11 +++ ++ ++ ++ N/A N/A + ++ ++ 
- 12 - - +++ + + + - - - 
Table 3.20. Summary of microglial activation. 
Microglial activation in the cerebellum, occipital lobe, parietal lobe, and basal ganglia is summarised in the above table.  
Assessment is semi-quantitative using the scale -/+/++/+++, where – is defined as no change, + mild increase, ++ moderate increase, and +++ 
severe increase. 
 
Key: N/A=data not available, s=stillbirth, C=caudate, P=putamen, GP=globus pallidus
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3.5 Electron Microscopy 
Transmission electron microscopy (TEM) was performed on patient and control fixed 
tissues. Disease Control 11, an 8 year old male with an undiagnosed familial 
neurodegenerative disorder that was suspected to be X-linked, and Control 12, a 51 
year old male, were chosen to match the formalin-fixation time of the patient. A disease 
control was examined to account for the effects of generalised neurodegenerative 
disorders on the brain so that the cellular and mitochondrial degeneration in Alpers’ 
syndrome specifically could be studied. 
The occipital lobe was sampled and processed as this region is known to be one of the 
more severely affected brain areas in Alpers’ syndrome. Systematically sampled 
random images were taken at low and high magnifications and structures were counted 
and analysed (Table 3.21).  
No intact or identifiable cells are seen at low magnification. Structures identified as 
nuclei are visible in both patients and controls (Figure 3.21). Mitochondria are identified 
at higher magnification (Figure 3.22). These mitochondria have intact outer membranes 
and cristae are visible in many of the mitochondria for Disease Control 11 and Control 
12. Patient 12 has a substantially sparser cytoplasm and fewer cellular organelles 
(Figure 3.21; image A) when compared to Disease Control 11 and Control 12 (Figure 
3.21; images B and C respectively) and this is confirmed by diminished counts of 
visible and intact mitochondria and axonal structures. 
Electron-dense inclusions were noted within mitochondria. These are visible in the 
patient and both controls (Figure 3.23). The number of electron-dense inclusions was 
counted and the majority of mitochondria contained either one or two inclusions. Both 
Disease Control 11 and Control 12 showed greater numbers of mitochondria with these 
inclusions present. However, it is important to note the highly degraded state of the 
tissue sample of Patient 12 and the low total counts of mitochondria recorded. 
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Figure 3.21. TEM images of formalin-fixed tissue taken at 2600X.  
Tissue is from the occipital lobe. Image A=Patient 12 POLG mutation-absent group, 
B=Disease Control 11, C=Control 12. Image A shows a substantially sparser cytoplasm 
and fewer internal organelles than images B and C. Arrows indicate nuclei within the 
cytoplasm. 
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Figure 3.22. TEM images of formalin-fixed tissue taken at 19,000X.  
Tissue is from the occipital lobe. A=Patient 12 POLG mutation-absent group, 
B=Disease Control 11, C=Control 12. Image A shows a substantially sparser cytoplasm 
and mitochondria with fewer internal cristae than images B and C. Arrows indicate 
mitochondria within the cytoplasm. 
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Figure 3.23. TEM images of formalin-fixed tissue taken at 34,000X.  
Tissue is from the occipital lobe. A=Patient 12 POLG mutation-absent group, 
B=Disease Control 11, C=Control 12. Image A, B and C show electron-dense 
inclusions inside the mitochondria. Arrows indicate mitochondria containing electron-
dense inclusions.
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  Low Magnification (2600X) High Magnification (19,000X) 
 Nuclei Axons Mitochondria 
Mitochondria 
containing electron-
dense inclusions 
One 
electron-
dense 
inclusion 
Two 
electron-
dense 
inclusions 
Three 
electron-
dense 
inclusions 
Four 
electron-
dense 
inclusions 
Patient 12 38 146 56 23 16 6 1 0 
Disease 
Control 11 25 1371 131 65 
48 12 4 1 
Control 12 22 3194 81 38 25 9 3 1 
Table 3.21. Summary of EM structure counts in patient and controls. 
Structures at low and high magnification were counted. Total values are given in the table for 20 images taken at each magnification for each 
patient and control. Cellular nuclei and axons were counted at a low magnification (2600X). The total number of mitochondria, the number of those 
mitochondria with electron-dense inclusions, and the number of mitochondria with one or more electron-dense inclusions were counted at a high 
magnification (19,000X). Cellular nuclei and mitochondria with a complete and intact membrane were counted. At least 50% of the structure must 
be within the image to be counted, in order to be certain of its identification.   
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3.6 Discussion 
The clinical diagnosis of Alpers’ syndrome is based upon the key triad of refractory 
seizures, psychomotor regression and cortical blindness, with posterior regions of the 
brain often reported to be affected (Uusimaa et al., 2008; Khan et al., 2012). This 
chapter has examined, in detail, the neuropathology present in a cohort of patients 
clinically diagnosed with Alpers’ syndrome. The neuropathology is examined within 
each group and between each group to explore and contrast the prominent 
neuropathological features. 
 Patient Variability 3.6.1
I examined each patient individually from the POLG mutation-positive group and the 
POLG mutation-absent group because these groups are both clinically and genetically 
well-defined. I also investigated Patient 5, the stillbirth. Patients 3 and 4 are not 
included in this discussion as only frozen tissue was available and therefore the 
neuropathology and any respiratory chain abnormalities could not be fully investigated 
in the same manner as the rest of the cohort. 
3.6.1.1 Patient 1 
Patient 1, a 14 month old female compound heterozygous for the p.Ala467Thr and 
p.Gly48Ser mutations, clinically presented with ataxia, developmental regression, 
epilepsy, and liver failure. No visual problems were reported. Previous biochemical 
investigations showed complex I and COX deficiency in skeletal muscle. This patient 
did not show any Purkinje cell loss in the cerebellum which is confirmed in the original 
neuropathologist’s report, where Purkinje cell loss was noted in the cerebellar vermis. 
Mild neuron loss was seen in the dentate nucleus and there was neuron loss in the 
upper cortical layers of the occipital lobe and parietal lobe. No neuron loss was seen in 
the caudate, putamen or globus pallidus of the basal ganglia. It is unusual that more 
neuron loss was not seen considering the aetiology of Alpers’ syndrome and the 
clinical signs seen in the patient. 
In addition, the cerebellum showed abnormal mitochondrial localisation in neurons, 
moderate microglial activation and some myelin loss. A Bielschowsky stain showed 
mild axonal loss though myelin loss is considered primary. This is surprising as there is 
no Purkinje cell loss in the cerebellum, suggesting all the axons should be intact. This 
suggests there may be some axonal damage not due to neuronal loss. However, the 
Bielschowsky silver stain is difficult to perform and analyse and therefore the results 
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are taken as a guide. The occipital lobe and parietal lobe showed little pathology with 
low mitochondrial density in neurons and neuron loss was concentrated in the upper 
cortical layers I-III. In the occipital lobe, there was mild myelin loss with some axonal 
loss, mild microglial activation, and mild capillary proliferation suggesting a milder 
pathology than expected. The basal ganglia showed little pathology with a moderate 
microglial activation and low mitochondrial density in neurons of the globus pallidus. 
The investigations suggest that the neuropathological changes represent an early 
stage in the degenerative process, agreeing with the original neuropathologist’s report. 
The neuropathology seen during these investigations suggest that other factors may 
have led to the neuronal dysfunction and the possibility of damage to other brain areas 
may have led to the clinical signs in this patient. Patient 2 is of a similar age and clinical 
course and exhibits substantially greater pathology than Patient 1, suggesting there is 
a patient-to-patient variability in the neuropathology that gives rise to the clinical 
symptoms. 
3.6.1.2 Patient 2 
Patient 2, a 27 month old male compound heterozygous for the p.Ala467Thr and 
p.Thr914Pro mutations, exhibited ataxia, visual problems that included hemianopia, 
epilepsy, and liver failure. Previous biochemical investigations showed COX deficiency 
in skeletal muscle. The patient showed severe Purkinje cell loss in the cerebellum with 
mild loss in the dentate nucleus. There was severe neuron loss in the upper cortical 
layers of the occipital lobe and parietal lobe. No neuron loss was seen in the caudate, 
putamen or globus pallidus of the basal ganglia. 
In the cerebellum, pronounced dendrites ran through the molecular layer. There was 
abnormal mitochondrial localisation in neurons, moderate microglial activation and 
some myelin loss. A Bielschowsky stain was inconclusive to detect axonal loss. The 
occipital lobe showed severe astrogliosis and severe microglial activation, a strong 
immune reaction, with severe myelin loss. In the parietal lobe, there was low 
mitochondrial density in neurons, mild capillary proliferation, mild myelin loss and 
moderate microglial activation with a severe astrogliosis in the grey matter only. No 
astrogliosis was present in the white matter of the parietal lobe. The basal ganglia 
showed no pathology but an almost compete loss of myelin. The globus pallidus 
showed low mitochondrial density in neurons. 
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There is striking pathology in Patient 2; severe neuron loss with low mitochondrial 
density and abnormal mitochondrial localisation in surviving neurons. There is marked 
myelin loss and a severe astrogliosis. This is confirmed in the original 
neuropathologist’s report, noting severe pathology of the cerebellum and occipital lobe. 
This correlates with the clinical symptoms of ataxia, visual abnormalities, and epilepsy.  
3.6.1.3 Patient 6 
Patient 6, an 18 year old female with a sibling compound heterozygous for the 
p.Trp748Ser and p.Arg1096Cys mutations, exhibited ataxia, visual problems, epilepsy, 
and liver failure. The patient showed moderate Purkinje cell loss in the cerebellum, the 
dentate nucleus was unavailable. The parietal lobe was not assessed for neuron loss 
as Patient 6 was not one of the representative patients were taken from the POLG 
mutation-positive group. The occipital lobe and basal ganglia were unavailable regions 
for this patient. 
In the cerebellum, there was a microinfarct in the posterior-inferior region measuring 
15,935.2 µm2. There was low mitochondrial density in neurons with abnormal 
mitochondrial localisation, a moderate astrogliosis, and mild microglial activation but no 
myelin loss. The original neuropathologist’s report notes vacuolation in the cerebellar 
white matter, which was not seen in the slides. The parietal lobe showed low 
mitochondrial density in neurons, mild microvacuolation and mild capillary proliferation, 
with severe astrogliosis and severe microglial activation, a strong immune reaction. 
There was no myelin loss. This parietal lobe pathology is reflected in the original 
neuropathologist’s report. 
Patient 6 shows significant neuron loss in the cerebellum but no myelin loss in any 
brain area. There is a single microinfarct in the cerebellum, contributing to the 
astrogliosis and microglial activation seen in this area. This older teenage patient had 
severe refractory epilepsy throughout the two years of disease progression, reflected 
by the severity of the neuron loss and the microinfarct.  
3.6.1.4 Stillbirth Patient 5 
Patient 5, a stillborn male with a sibling heterozygous for the p.Ala467Thr and 
p.Glu1143Gly mutations, had decreased fetal movements and died intrauterine. After 
sequencing POLG, the sibling was also found to be heterozygous for the 
p.Asp1219Glu mutation, a mutation with an unknown pathogenicity. It is still possible 
that Patient 5 carries two recessive POLG mutations, which full sequencing of the 
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parental POLG genes may reveal. This patient was included in the cohort based upon 
the POLG disorder and genotype of the sibling, who was not diagnosed with Alpers’ 
syndrome. The patient showed no Purkinje cell or dentate nucleus neuronal loss in the 
cerebellum with a high mitochondrial density. The neurons of the occipital lobe and 
parietal lobe were too small to be reliably quantified. No neuron loss was seen in the 
caudate, putamen or globus pallidus of the basal ganglia. 
Due to the age of the patient, it was not possible to compare some aspects of 
neuropathology with other patients. The average number of Purkinje cells per mm was 
much higher in Patient 5 when compared to the other patients and controls. Also, the 
myelin sheath had not fully formed in the brain areas studied and could not be 
analysed. These were both noted in the fetal control and are not signs of pathology. 
Severe capillary proliferation was noted throughout the brain of the patient, which was 
not seen in the control. In addition, the cerebellum and occipital lobe both had a mild 
astrogliosis. The severe proliferation of capillaries could suggest a pathological reaction 
to stresses on the central nervous system as it was not demonstrated in the age-
matched control. 
3.6.1.5 Patient 12 
Patient 12, a 6 year old male with no pathogenic mutation in POLG, exhibited ataxia, 
visual problems that included hemianopia and epilepsy. Previous biochemical 
investigations showed a normal respiratory chain although complex IV was slightly low 
in skeletal muscle. The patient showed moderate Purkinje cell loss with low 
mitochondrial density and abnormal mitochondrial localisation in the remaining 
neurons. There was neuronal loss from the dentate nucleus though remaining neurons 
showed a high mitochondrial density. There was moderate neuron loss in layer III of 
the occipital lobe and layers III and VI of the parietal lobe. No neuron loss was seen in 
the caudate, putamen or globus pallidus of the basal ganglia. 
In the cerebellum, there was a moderate microvacuolation and moderate myelin loss. A 
Bielschowsky stain showed some axonal loss suggesting the myelin loss is secondary. 
However, the Bielschowsky silver stain is difficult to perform and analyse and therefore 
the results are taken as a guide. The occipital lobe showed a mild microvacuolation 
and capillary proliferation, with severe astrogliosis and severe microglial activation in 
the grey matter. Milder microglial activation was present in the white matter. In the 
parietal lobe, there was a moderate microvacuolation, mild microglial activation and 
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mild astrogliosis with a mild loss of myelin. The basal ganglia showed mild 
microvacuolation and an almost compete loss of myelin in the caudate and putamen. 
As reported in the patients above, there is severe pathology in Patient 12. In addition to 
neuron loss, there is a more severe myelin loss shown over all four brain areas studied. 
The lack of a pathological mutation in POLG suggests a different course of disease 
progression to the patients in this cohort with a mutation in POLG. 
 Within-group Variation 3.6.2
Much variation has been demonstrated within the groups designated POLG mutation-
positive group and POLG mutation-undetermined group. The POLG mutation-absent 
group consisted of a single patient. The stillbirth is not included in this discussion as it 
is a single patient with relatively little pathology to report. 
The POLG mutation-positive group showed variation in age at symptom onset, clinical 
signs and neuropathological changes between patients of this group. All patients 
included in this group were compound heterozygous for one common mutation and one 
less common mutation, or had a sibling with pathogenic POLG mutations and were 
therefore assumed to have the same mutations. In this cohort, there was no correlation 
between the POLG mutation and the severity of the neuropathology. There was a 
correlation between the neuropathological changes and the age of the patient; 
microinfarcts appeared as the age of the patient increased. Both of the oldest patients 
in this group, Patient 4 and Patient 6, had microinfarcts present in the cerebellum. The 
progression of their illness lasted 4 years and 2 years, respectively. No other patients 
showed microinfarcts in any brain regions. 
The POLG mutation-undetermined group showed great variation in the 
neuropathological changes between patients of this group. This can be explained by 
the unknown range of genotypes and the range of POLG and non-POLG mutations 
that may be present in this group. There is limited clinical data from this group, as they 
came from a different university to Patients 1-6, 12, the University of Vienna. The age 
at onset is similar between patients with clinical signs becoming apparent at a young 
age, before the age of 6 months. In all but Patient 11, there was a short clinical course 
that was less than 9 months. Patient 11 had a clinical course of 6.5 years, the longest 
of any patient in the cohort. There was a correlation between the neuropathology and 
the age of the patient; Patient 11, 7 years old, showed severe neuron loss in addition to 
moderate microvacuolation, astrogliosis and microglial activation in the cerebellum and 
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occipital lobe. The parietal lobe was not available and the basal ganglia showed no 
neuron loss. 
The within-group variation is evident with a correlation of neuropathological findings 
with the age of the patient. The older patients of the POLG mutation-positive group with 
a clinical course lasting over one year showed the severe neuropathological feature of 
microinfarcts. The oldest patient of the POLG mutation-undetermined group showed 
the most severe neuropathological features of the group. There is no clear severity 
between the age and length of disease progression of the other patients. This suggests 
there is a natural variation in the clinical and neuropathological phenotypes when the 
course of disease is short and that the presence of microinfarcts is a clear factor for 
disease progression. 
 Inter-group Variation 3.6.3
There were clear differences between the POLG groups investigated. Each group 
showed signs of neuron loss, suggesting that neuron loss is a common and 
unmistakable feature of Alpers’ syndrome. The stillbirth, Patient 5, did not show any 
significant level of neuron loss. 
In the POLG mutation-positive group, the parietal lobe showed the most severe 
microglial activation and the occipital lobe showed the most severe astrogliosis 
compared to the other groups. Microglial activation and astrogliosis are reactions 
involved in immune response or to protect tissue and they often correlated with each 
other in a brain region. Low mitochondrial density was noted in the occipital lobe and 
parietal lobe, where density was high in other groups for these brain regions.  
The stillbirth showed a severe capillary proliferation in all brain areas investigated. A 
mild astrogliosis was seen in the cerebellum and occipital lobe, with no microglial 
activation seen at all. There was moderate microvacuolation in the parietal lobe. This 
patient had relatively mild neuropathology, with capillary proliferation being the most 
severe response. 
The POLG mutation-undetermined group showed a wide range of severities for each 
neuropathological feature. This reflects the unknown fixation lengths and unknown 
genotypes within this group and the possibility of a mixture of POLG and non-POLG 
mutations. The POLG mutation-undetermined group showed a more severe 
microvacuolation in 3 of the 4 brain areas. This group showed the most severe 
microglial activation and astrogliosis in the basal ganglia compared to other groups. 
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Mitochondrial density was low in both Purkinje cells and neurons of the dentate nucleus 
and frequently accompanied by abnormal mitochondrial localisation.  
The POLG mutation-absent patient showed a severe phenotype, with much neuron 
loss and myelin loss in all brain areas. This may reflect mutations in a well-conserved 
gene, leading to an Alpers’ syndrome phenotype. The POLG mutation-absent patient 
showed the most severe myelin loss in all brain areas and the occipital lobe showed 
the most severe microglial inflammation. 
The inter-group variation is clear and does seem to correlate with genotype. Reports of 
the correlation of phenotype with genotype have suggested that non-POLG patients 
have a very early-onset, partly preserved Purkinje cells, and mainly preserved white 
matter (Sofou et al., 2012). This is in disagreement with what is seen in the cohort used 
in this study. In my cohort, the non-POLG genotype has a severe phenotype but a later 
symptom onset than most of the patients with a POLG mutation-positive phenotype. In 
the published study, patients with an undetermined phenotype have a mixed range of 
neuropathology and undefined phenotypes, which reflects the range of genotypes that 
could be present in this group. This disparity may arise from many of the non-POLG 
patients being discovered to have mtDNA mutations with other childhood 
neuropathological diseases not being fully ruled out. 
 The Project’s Findings in the Context of the Literature 3.6.4
There are many case reports of patients with Alpers’ syndrome in the scientific 
literature. Previous research into Alpers’ syndrome has reported neuropathology in the 
CNS tissues of patients; atrophy, microvacuolation, capillary proliferation, neuron loss 
and astrogliosis being the most frequently reported features. 
3.6.4.1 Areas of Pathology 
This study has shown that pathology and neuron loss are most severe in the 
cerebellum, with much neuron loss in the upper layers of the occipital lobe. This is in 
agreement with studies that have shown severe pathology in the cerebellum (Harding 
2008; Uusimaa et al., 2008) and occipital lobe (Harding et al., 1986; Khan et al., 2012). 
Fewer reports have been published on the involvement of the parietal lobe and basal 
ganglia, making these areas of interest to examine whether they show comparable 
levels of pathology to more well-studied brain areas. 
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In particular, the basal ganglia showed little pathology. Previously literature has 
reported atrophy, neuronal loss, and astrogliosis in the basal ganglia (Delarue et al., 
2000; Kayihan et al., 2000; Wiltshire et al., 2008; Cardenas and Amato 2010) but this 
has not been noted for many patients in this cohort, suggesting that pathology is 
variable in patients and severe pathology of the basal ganglia is uncommon. 
The research carried out in this project is comparable with the current scientific 
literature, raising further points. There is considerable pathology in the cerebellum, with 
less pathology in the occipital lobe, parietal lobe and basal ganglia. Pathology is 
present in all brain areas studied and quantitative evidence in support of this is 
demonstrated in this chapter. 
3.6.4.2 Neuron Loss 
Neuron loss is one of the most commonly reported neuropathological findings of 
Alpers’ syndrome (Harding et al., 1995; Kayihan et al., 2000; Simonati et al., 2003a; 
Harding 2008; Wiltshire et al., 2008). Neuron loss was seen in almost all of the patients 
in this cohort; the cerebellum of Patient 1 being a notable exception. 
Neuron loss was most severe in the cerebellum, with loss of Purkinje cells and dentate 
nucleus neurons occurring either concurrently or independently of each other. This 
suggests that Purkinje cells and neurons of the dentate nucleus are equally vulnerable 
in patients, though may not be affected to the same severity.  
There was neuron loss from the occipital lobe, predominantly in the upper layers I-III. In 
those patients with a more severe neuron loss, this correlated with a more severe 
astrogliosis. Considering the widely reported pathology to the posterior of the brain in 
Alpers’ syndrome patients, it is unusual that there was not a greater neuron loss in the 
occipital lobe in this cohort. It is possible that due to the sampling protocols of the 
Newcastle Brain Tissue Resource, the extrastriate cortical area is sampled and not the 
primary visual cortex. More profound change may be seen in the primary visual cortex. 
There was neuron loss from the parietal lobe, predominantly in the upper layers I-III. In 
the occipital and parietal lobe, neuron loss is not attributed to microvacuolation in the 
upper cortical layers. However, it may have played a role in the parietal lobe neuron 
loss of Patient 12, which showed a moderate microvacuolation (++) and 34%-45% 
neuron loss in the cortical layers III - VI. Neuron loss in the upper grey matter layers 
may be partly attributable to the fact that these neurons were difficult to distinguish with 
confidence, with low numbers being counted for all patients and control. 
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Only one patient, Patient 9, showed neuron loss from the basal ganglia. This is an area 
infrequently reported to show pathology and neuron loss does not appear to be a main 
feature of neuropathology in the basal ganglia. 
3.6.4.3 Astrogliosis 
The research findings of this project agree with previous reports showing obvious 
astrogliosis in patients (Harding et al., 1995; Wiltshire et al., 2008). Severe astrogliosis 
can be correlated with severe neuron loss in the occipital lobe.  
In this cohort, many of the patients exhibit swollen astrocytes, a feature which has not 
been previously reported in the literature for patients with Alpers’ syndrome. The role of 
astrocytes in neurodegenerative conditions is not fully understood, these cells can play 
a role in the protection and preservation of neurons (Acarin et al., 2007) but may also 
play a role in the neurological aspects of other conditions, including HIV, where 
patients show astrogliosis (An and Scaravilli 1997). 
3.6.4.4 Mitochondrial Localisation 
Mitochondrial density was low in the neurons of the majority of patients and was 
frequently accompanied by an abnormal localisation of mitochondria around the 
periphery of the nucleus, the periphery of the soma, or localised away from an edge of 
the soma. This was most readily seen in large neurons, such as Purkinje cells of the 
cerebellum and the neurons of the globus pallidus of the basal ganglia. 
Typically, mitochondria have a pan-cytoplasmic distribution throughout the cell body of 
the neuron. ATP is required throughout the neuron, nodes of Ranvier and synapse. 
Axonal transport distributes mitochondria towards the synapse in anterograde 
transport, where ATP is utilised for cellular processes. Depolarised mitochondria are 
then returned to the cell soma in retrograde transport, in order to be degraded and 
recycled. Clustering of mitochondria around the nucleus was noted in the control tissue 
in this study, and this may happen naturally in all neurons but it may be happening at a 
greater rate or in greater numbers in the neurons of patients with Alpers’ syndrome. 
Depolarised mitochondria may cluster around the nucleus prior to degradation in other 
neurological disorders, and this has been documented in cell lines with mutations in 
Parkin, a gene implicated in Parkinson’s disease (Okatsu et al., 2010). In HeLa cells, 
increased perinuclear clustering and movement of mitochondria away from the cell 
periphery is reported to occur after the disruption of the dynein complex (Varadi et al., 
2004). The clear localisation of mitochondria around the periphery of the nucleus in the 
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neurons of many patients in this cohort, suggests that large numbers of mitochondria 
may be damaged and depolarised, compared to the controls. 
3.6.4.5 White Matter Abnormalities 
Involvement of the white matter in Alpers’ syndrome is infrequently mentioned in the 
literature. There have been previous reports noting abnormalities of the white matter 
and myelin loss (Harding et al., 1995; Simonati et al., 2003b; Bao et al., 2008).  
In this cohort, considerable white matter pathology was seen in the cerebellum, 
occipital lobe, and the basal ganglia in 3 of the 4 patients studied. Myelin loss was the 
most prominent pathology of the basal ganglia, as it had no neuron loss and less 
astrogliosis and microglial activation than other brain areas. This suggests that myelin 
loss may occur in the absence of other neuropathological features in patients. The 
white matter loss in Alpers’ syndrome patients is most likely to be secondary to 
neuronal loss and the loss of neuronal axons. Primary loss of myelin cannot be ruled 
out completely, as Patient 12 displayed myelin loss but no axonal loss in the basal 
ganglia. 
White matter abnormalities are a more important factor than is currently considered in 
the literature and warrants further investigation into the root cause of myelin loss, which 
could aid in the understanding of disease progression in Alpers’ syndrome. 
3.6.4.6 Microglial Activation 
Microglia are ubiquitous immune cells, usually quiescent, that become activated in 
response to a variety of pathological stimuli. They are spatially restricted and this can 
indicate the area of any continuing disease processes (Banati et al., 2004). 
Inflammation and microglial activation are not often reported as part of the 
neuropathology in patients with Alpers’ syndrome. Reactive inflammatory changes 
have been previously described in the brain tissue of patients with Alpers’ syndrome, 
though suggest that it was not involved in the disease progression (Nolte et al., 2013).  
Activated microglia were seen in every patient in at least one brain area, except the 
stillbirth, Patient 5. A moderate to severe increase in these cells was often seen and 
correlated with the severity of astrogliosis, indicating areas of pathology despite there 
being no neuron loss. Interestingly, extremely swollen microglia were seen in the 
occipital lobe of Patient 2 which corresponded with microvacuolation and severe myelin 
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loss, possible indicators of the phagocytosis of degenerating cells and large amounts of 
materials. 
3.6.4.7 Electron Microscopy 
There are very few EM studies on tissue from patients with Alpers’ syndrome. This 
project is one of the few to use the technique to examine the mitochondria in patient 
cells. This study noted a difference between the patient and disease control, with a 
greater difference between the patient and the control. Fewer cellular structures, 
including axons and mitochondria, were visible in the patient sample suggesting a 
greater extent of tissue degradation. Electron-dense inclusions were seen within the 
mitochondria of brain tissue examined from a patient diagnosed with Alpers’ syndrome. 
Control tissue was tested at the same times as patient tissue and electron-dense 
inclusions were also found to be present in this tissue. The results of control tissue 
have not been previously reported in the literature, possibly due to case reports testing 
patient tissue only. 
In agreement with the results in the patient tissue, a study noted electron-dense 
inclusions in liver and skeletal muscle mitochondria in a patient with Alpers’ syndrome 
(Mangalat et al., 2012). A separate study examined two patients with a POLG-related 
encephalopathy and reported globoid inclusions in EM of muscle and brain 
mitochondria (Nolte et al., 2013). 
A full analysis of the patient using EM techniques was difficult due to the degradation of 
the tissue sample. It is possible that the degradation was due, in part, to disease 
processes that damaged the tissue to a greater extent than was seen in either of the 
controls. The patient showed low numbers of mitochondria with few intact cristae when 
compared to the controls and this may suggest a particular vulnerability of these 
organelles. This approach is limited as cellular and mitochondrial morphology can be 
affected by post-mortem delay and fixation length. It can be difficult to obtain tissue of a 
suitable quality for EM studies and controls should be matched for age as well as 
fixation length. 
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 Novel Findings 3.6.5
This project has a large cohort of patients over a large age range and diverse range of 
genetic diagnoses, which has not been published previously in the literature. 
This study has shown that patients with Alpers’ syndrome show a more diverse range 
of features than previously thought, including astrogliosis and white matter 
abnormalities. Pathology of the white matter occurred more often than was expected 
and in all brain regions. It had a greater pathology that was not reflected in the 
literature and the results of this study suggest that white matter pathology should be 
investigated as part of the neuropathology of Alpers’ syndrome.  
Structural abnormalities of mitochondria occur at the ultrastructural level, however 
great care should be taken in interpreting these findings. Through the use of EM 
techniques, this study has shown electron-dense inclusions in both the patient and 
fixation-matched control tissue. This may indicate an artefact of the fixation process 
highlighting the limitations of this approach. 
Astrogliosis with swollen astrocytes of an abnormal morphology have not been 
previously reported in the literature. This is an interesting finding that may suggest a 
pathological role of astrocytes in the course of Alpers’ syndrome. Astrocytes can play a 
role in the neurological aspects of other conditions; HIV patients show astrogliosis (An 
and Scaravilli 1997). However, astrocytes can show neuroprotective properties and 
their presence can lead to the preservation of neurons (Acarin et al., 2007). The full 
role of astrocytes in neurodegenerative conditions is not fully understood. 
The knowledge that clinically diagnosed Alpers’ syndrome may be due to both POLG 
and non-POLG mutations is leading to new area of research. So far, few studies have 
compared these possible groups (Sofou et al., 2012) which can add new data to an 
expanding array of possible genes involved in Alpers’ syndrome. 
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3.7 Future Work  
The work performed in this study has highlighted the need for a genetic diagnosis when 
studying patients clinically diagnosed with Alpers’ syndrome. Genetic data can add 
much information and aid in the interpretation of clinical and neuropathological data. In 
the case of this cohort, current methods of DNA extraction were not successful and 
despite all efforts, a genetic diagnosis could not be made for some patients. Future 
attempts to elucidate the genetic status of the group with an undetermined POLG 
mutation may prove fruitful and allow fresh interpretations of the neuropathological 
data. 
Work to uncover the aetiology of the clinical signs seen in the POLG mutation-absent 
patient is currently on-going. Whole exome sequencing has identified a potential 
candidate gene but further work is required to prove a link between the genetic defect 
and levels of cellular respiration. Data contributing to the knowledge of mutations in 
other genes leading to Alpers’ syndrome, may vastly improve our understanding of the 
spectrum of mitochondrial disease and its impact upon the CNS. 
Further assessment of the white matter of the group with an undetermined POLG 
mutation will be interesting and add to the investigations performed during the course 
of this project. The use of fully quantitative techniques to assess white matter 
abnormalities and porin localisation may be of use, particularly densitometric 
techniques. 
This study has underlined the importance of full neuropathological, phenotypic and 
genotypic data when studying a patient cohort. The cohort in this project is the largest 
and most comprehensive that has been studied with Alpers’ syndrome. Further 
investigations will add invaluable insights into what has already been determined in this 
project.  
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Chapter 4 Respiratory Chain Deficiency in Patients with Alpers’ 
Syndrome 
4.1 Introduction 
The mitochondrial polymerase gamma enzyme (POLG) is essential for mtDNA 
replication and is the only known polymerase in mammals to perform this action 
(Hance et al., 2005). Mutations in this gene may affect its function, leading to 
secondary mtDNA abnormalities. As mtDNA encodes 13 polypeptides making up the 
respiratory chain, the effect of mutated POLG on the mtDNA can have negative 
consequences for the respiratory chain in affected tissues. 
There have been studies of respiratory chain deficiency in patients with a mitochondrial 
disease, due to mutations in POLG causing mtDNA defects. These studies have shown 
variable respiratory chain dysfunction, from normal respiratory chain activity (Milone et 
al., 2008; Isohanni et al., 2011) to a deficiency of complex I (Hakonen et al., 2008) and 
complex III (Blok et al., 2009). Normal respiratory chain functioning was seen in the 
skeletal muscle of five patients diagnosed with cPEO (Milone et al., 2008) and in the 
skeletal muscle of five patients with POLG mutations (Isohanni et al., 2011). Two 
patients diagnosed with MIRAS had complex I deficiency in neurons of the cerebellum 
and frontal cortex (Hakonen et al., 2008) while a patient with homozygous p.Ala467Thr 
mutations showed reduced complex III in the brain (Blok et al., 2009). Complex IV is 
less severely affected but has shown milder defects in neurons of patients with a 
POLG-related disorder, thought to be due to clonally expanded mtDNA deletions (Lax 
et al., 2012). 
Mitochondrial respiratory chain impairment in the CNS and liver is a prominent feature 
of Alpers’ syndrome. Studies of patients have examined respiratory chain defects in a 
variety of tissues, including liver and skeletal muscle. These have shown a loss of 
activity of multiple respiratory chain complexes (Delarue et al., 2000; Wiltshire et al., 
2008; Schaller et al., 2011). However, as mentioned above concerning patients with 
POLG disorders, there have been reports of patients with Alpers’ syndrome with 
normal respiratory chain activity in muscle, fibroblast and liver tissue samples (de Vries 
et al., 2008). Fewer studies have focussed on Alpers’ syndrome than on other POLG 
disorders and there have been no published studies examining the respiratory chain in 
the brain tissue of diagnosed Alpers’ syndrome patients. In addition, studies on Alpers’ 
syndrome generally focus on case studies of a single patient or small number of 
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patients rather than a cohort of patients. These studies focus on specific parts of the 
respiratory chain, most often on complex I and complex IV due to the mtDNA defects 
resulting in a loss of function and assembly of these complexes. 
Previous studies have mostly used homogenate tissue samples to quantify respiratory 
chain expression and activity (Hakonen et al., 2008; Blok et al., 2009), with some 
COX/SDH studies performed on single neurons (Lax et al., 2012). This study is unique 
in that it investigates the respiratory chain in single neurons in the brain of patients 
diagnosed with Alpers’ syndrome. Examining tissue at the level of the single neuron 
greatly increases the sensitivity and accuracy of the results, and gives certainty of the 
extent and severity of deficiency in neurons. Studies of respiratory chain deficiency 
often examine complex I and complex IV, which are frequently affected by acquired 
mtDNA defects. The size and complexity of complex I, and the position of complex IV 
at the end of the chain transporting electrons, make them both agents for the failure of 
the respiratory chain. This study also examines complex III, which is seldom studied in 
single cells. 
The previous chapter examined the neuropathology seen in a large cohort of patients 
with clinical Alpers’ syndrome. This chapter will investigate the integrity of mitochondrial 
respiratory chain in neurons of the cerebellum, occipital lobe, parietal lobe, and basal 
ganglia in the same cohort. 
4.2 Aims 
Patients with Alpers’ syndrome demonstrate clinical signs that correlate with areas of 
neuropathology. This chapter will investigate the pathology further by examining the 
respiratory chain in the four brain regions. The aims of this work are: 
1. To semi-quantitatively assess protein expression of different subunits of the 
respiratory chain of mitochondria in neurons. This will be performed in CNS 
tissues of patients clinically diagnosed with Alpers’ syndrome, and will compare 
the findings to those of controls. 
2. To investigate the differences in the expression of the respiratory chain 
between the patient groups. 
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4.3 Methodological Approach 
Antibodies were used to assess complexes of the respiratory chain in mitochondria in 
nine patients (Table 4.1), as described in Chapter 2 Methods and Materials, 2.2.5.1 
‘Respiratory Chain Antibody Staining’. A semi-quantitative assessment of the neurons 
was completed according to the scale – deficient/no staining, + weak staining, ++ weak 
to moderate staining, +++ intense staining. Deficiency of a respiratory chain complex 
was defined as greatly reduced expression or absence of a protein subunit. Patients 3 
and 4 could not be assessed as no FFPE tissue was available. Patient 5 had tissue 
that had been fixed in formalin for 13 years. This made the tissue unreliable for 
quantifying respiratory chain antibodies. Therefore these patients are not included in 
the results. The patient without a mutation in POLG, Patient 12, had tissue that had 
been fixed in formalin for 14 years from the cerebellum, parietal lobe, and basal 
ganglia. This made the tissue unreliable for quantifying respiratory chain antibodies and 
only the occipital lobe was suitable for this study. 
Patient Age at Death Sex POLG Mutation 
1 14 months F p.Ala467Thr; 
p.Gly848Ser 
2 27 months M p.Ala467Thr; 
p.Thr914Pro 
6 18 years F 
A sibling with 
p.Trp748Ser; 
p.Arg1096Cys 
7 2.5 months F Unknown 
8 5.5 months M Unknown 
9 6.5 months F Unknown 
10 13 months M Unknown 
11 7 years F Unknown 
12 6 years M None 
Table 4.1. Details of the patients used in the study of respiratory chain 
deficiency.   
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4.4 Results 
4.4.1 Staining Quantification 
Visualisation of antibody staining was achieved through the use of DAB, which 
produces an insoluble brown polymer upon its oxidation. Semi-quantitative assessment 
of the patients and controls was done according to the scale below (Figure 4.1). 
One hundred neurons were counted with each antibody in each patient. Neurons 
classed as weak to moderate (+) and intense (+++) were considered part of the natural 
variation of respiratory chain expression. Deficiency was defined as the combined 
numbers of neurons classed as deficient (-) and weak (+). 
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Figure 4.1. Semi-quantitative scale of antibody staining in neurons.  
Key: Image A=deficient (-), image B=weak (+), image C=weak to moderate (++), image 
D=intense (+++). The images shown are taken from the cerebellum. Arrowheads 
indicate Purkinje cells of the specified intensity. 
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4.4.2 Cerebellum 
The Purkinje cells and the dentate nucleus were examined. The availability of the 
dentate nucleus was dependent upon the orientation of the sample taken by the 
original pathology team. In some patients, this led to the dentate nucleus being 
unavailable for analysis. 
4.4.2.1 Purkinje Cells 
Recognised by Czech physiologist Jan Evangelista Purkinje in 1837, Purkinje cells are 
large, GABA-ergic, inhibitory neurons of the cerebellum. They form a single cell-thick 
layer between the molecular layer and the granular cell layer, their dendrites branching 
out into the molecular layer, where stellate cells and basket cells may act upon the 
Purkinje cell. They are acted upon by mossy climbing fibres and parallel fibres, and 
Purkinje cells themselves act upon neurons of the deep grey nuclei, including the 
dentate nucleus. They are responsible for controlling motor coordination and voluntary 
movement. 
4.4.2.1.1 Complex I – NADH: Ubiquinone Oxidoreductase 
Complex I is a multi-subunit protein made up of at least 44 subunits; 37 subunits are 
nuclear-encoded, 7 are mitochondrially-encoded. Antibodies to four different subunits 
were tested to investigate all parts of the complex: CI-19 (NDUFA13) part of the 
hydrophilic domain, CI-20 (NDUFB8) and CI-39 (NDUFA9) part of the hydrophobic 
domain, and one of the core hydrophilic domain subunits CI-30 (NDUFS3). All subunits 
investigated were nuclear-encoded, as there are no suitable antibodies currently 
available to subunits encoded by the mitochondrial DNA. 
In a subset of patients, CI-19 and CI-20 antibodies were tested only, as it became 
apparent there was little additional information being added to the investigation through 
the inclusion of CI-30 and CI-39 antibodies. 
Patients with evidence for POLG mutations (Figure 4.2; image B) show moderate 
levels of deficiency in all four of the complex I subunits tested.  
Patients with no genetic diagnosis available (Figure 4.2; images C and D) show 
moderate to high levels of deficiency in two of the complex I subunits tested. 
All patients, except Patient 2 and Patient 7, show a complex I deficiency in the Purkinje 
cells. The POLG mutation-positive group shows the greatest levels of deficiency in 
complex I-20 and complex I-30. The POLG mutation-undetermined group shows the 
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highest levels of deficiency in complex I-19. The pattern of staining appears to be 
random with either of the complex subunit antibodies showing greater deficiency than 
the other three. The control shows no evidence of deficiency. 
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Figure 4.2. Staining with antibodies for complex I in the Purkinje cells of the 
cerebellum. 
Arrowheads indicate neurons. All sections stained with complex I antibody.  
A=Control 6 CI-19, B=Patient 1 POLG mutation-positive group CI-19, C=Patient 11 
POLG mutation-undetermined group CI-19, D=Patient 10 POLG mutation-
undetermined group CI-19. Scale bar = 100µm. 
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Deficiency values for all subunits are shown in Table 4.2. The brain area is unavailable 
for patients not listed in the table. The antibody stain for CI-39 could not be performed 
for Patient 2 as the stain was very uneven after repeating. 
POLG 
mutation Patient 
Complex I-
19 
Complex I-
20 
Complex I-
30 
Complex I-
39 
+ 
1 8% 22% 0% 8% 
2 1% 1% 0% N/A 
6 11% 12% 25% 19% 
? 
7 3% 2% N/A N/A 
8 10% 3% N/A N/A 
9 61% 21% N/A N/A 
10 44% 13% N/A N/A 
11 63% 38% N/A N/A 
Table 4.2. Table of complex I deficiency in Purkinje cells of the cerebellum. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted with each antibody in each patient. 
Where FFPE tissue is unavailable or is known to have been fixed for longer than 6 
months, no values are given. 
 
Key: N/A=not available 
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4.4.2.1.2 Complex II – Succinate: Ubiquinone Oxidoreductase 
Complex II is a multi-subunit protein made up of 4 subunits; subunits A, B, C, and D 
that are all nuclear-encoded. Electrons may enter the ETC at complex I or at complex II 
and continue to flow along the respiratory chain. 
Patients with evidence for POLG mutations show little evidence of deficiency (<5%) 
(Figure 4.3; images B and C). 
Almost all the patients with no genetic diagnosis available show no deficiency. One 
patient, Patient 10, shows moderate levels of complex II deficiency at 28% in the 
Purkinje cells of the cerebellum (Figure 4.3; image D) but 0% deficiency in all other 
areas studied, including in neurons of the dentate nucleus of the cerebellum. 
In the majority of patients, there is no evidence for complex II deficiency. However, a 
single patient, Patient 10, showed moderate levels of deficiency which may have been 
due to issues that affected only the Purkinje cells. The fixation time of the tissue is 
unknown for Patient 10. The controls show no evidence of deficiency. 
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Figure 4.3. Staining with antibodies for complex II in the Purkinje cells of the 
cerebellum. 
Arrowheads indicate neurons. All sections stained with complex II subunit 70 antibody. 
A=Control 6, B=Patient 1 POLG mutation-positive group, C=Patient 6 POLG mutation-
positive group, D=Patient 10 POLG mutation-undetermined group. Scale bar = 100µm. 
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Deficiency values are shown in Table 4.3. The brain area is unavailable for patients not 
listed in the table. 
POLG 
mutation Patient Complex II-70 
+ 
1 0% 
2 1% 
6 5% 
? 
7 0% 
8 0% 
9 0% 
10 28% 
11 0% 
Table 4.3. Table of complex II deficiency in Purkinje cells of the cerebellum. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted in each patient. Where FFPE tissue is 
unavailable or is known to have been fixed for longer than 6 months, no values are 
given. 
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4.4.2.1.3 Complex III – Ubiquinol Cytochrome c Reductase 
Complex III is a multi-subunit protein made up of 11 subunits; 10 subunits are nuclear-
encoded, 1 is mitochondrially-encoded, cytochrome b. The antibody used for 
immunohistochemistry is raised against the Rieske subunit, an iron-sulphur protein that 
is nuclear-encoded with an important role in electron transfer. 
Patients with evidence for POLG mutations (Figure 4.4; images B and C) show variable 
levels of complex III deficiency. One patient shows very little evidence of deficiency 
while two further patients show moderate levels of deficiency. Patient 2 shows 
moderate levels of complex III deficiency but is the only patient not to exhibit a complex 
I deficiency in this part of the brain. 
Patients with no genetic diagnosis available (Figure 4.4; image D) show moderate to 
high levels of deficiency.  
The control shows no evidence of deficiency.  
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Figure 4.4. Staining with antibodies for complex III Rieske subunit in the Purkinje 
cells of the cerebellum. 
Arrowheads indicate neurons. All sections stained with complex III Rieske subunit 
antibody. A=Control 10, B=Patient 6 POLG mutation-positive group, C=Patient 1 POLG 
mutation-positive group, D=Patient 8 POLG mutation-undetermined group. Scale bar = 
100µm. 
  
197 
 
Chapter 4 Respiratory Chain Deficiency in Patients with Alpers’ Syndrome 
Deficiency values are shown in Table 4.4. The brain area is unavailable for patients not 
listed in the table. This antibody stain could not be performed for Patient 9 as the 
supply of tissue was depleted. 
POLG 
mutation Patient Complex III-Rieske 
+ 
1 1% 
2 39% 
6 27% 
? 
7 30% 
8 27% 
10 60% 
11 68% 
Table 4.4. Table of complex III deficiency in Purkinje cells of the cerebellum. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted in each patient. Where FFPE tissue is 
unavailable or is known to have been fixed for longer than 6 months, no values are 
given. 
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4.4.2.1.4 Complex IV – Cytochrome c Oxidase 
Complex IV is a multi-subunit protein made up of 14 subunits; 11 subunits are nuclear-
encoded, 3 are mitochondrially-encoded. 
Patients with evidence for POLG mutations show little evidence of complex IV subunit I 
deficiency (Figure 4.5; image B). They show no complex IV subunit IV deficiency 
(Figure 4.6; images C and D). 
Patients with no genetic diagnosis available show moderate levels of complex IV 
subunit I deficiency (Figure 4.5; images C and D). They show little evidence of complex 
IV subunit IV deficiency (Figure 4.6; image B). 
The control shows no evidence of deficiency for both subunits. 
It is unusual that Patient 11 shows a complex IV-IV deficiency of 14%, comparable to 
the complex IV-I deficiency of 18%. This is discussed in the Discussion section at the 
end of this chapter.  
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Figure 4.5. Staining with antibodies for complex IV subunit I in Purkinje cells of 
the cerebellum. 
Arrowheads indicate neurons. All sections stained with complex IV subunit I antibody. 
A=Control 6, B=Patient 6 POLG mutation-positive group, C=Patient 9 POLG mutation-
undetermined group, D=Patient 7 POLG mutation-undetermined group. Scale bar = 
100µm. 
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Figure 4.6. Staining with antibodies for complex IV subunit IV in Purkinje cells of 
the cerebellum. 
Arrowheads indicate neurons. All sections stained with complex IV subunit IV antibody. 
A=Control 6, B=Patient 8 POLG mutation-undetermined group, C=Patient 1 POLG 
mutation-positive group, D=Patient 6 POLG mutation-positive group. Scale bar = 
100µm. 
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Deficiency values for both subunits are shown in Table 4.5. The brain area is 
unavailable for patients not listed in the table. 
POLG 
mutation Patient Complex IV-I Complex IV-IV 
+ 
1 1% 0% 
2 0% 0% 
6 15% 0% 
? 
7 0% 0% 
8 1% 0% 
9 33% 0% 
10 10% 8% 
11 18% 14% 
Table 4.5. Table of complex IV deficiency in Purkinje cells of the cerebellum. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted with each antibody in each patient. 
Where FFPE tissue is unavailable or is known to have been fixed for longer than 6 
months, no values are given. 
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4.4.2.2 Dentate Nucleus 
Neurons of the dentate nucleus are found in the deep white matter of the cerebellum. 
The dentate nucleus is the largest of four deep cerebellar nuclei, the others being the 
fastigal nucleus, the emboliform nucleus, and the globose nucleus. These neurons 
receive input from the premotor cortex and from Purkinje cells. The deep cerebellar 
nuclei are the main output of the cerebellum, projecting to regions of the cerebrum, 
including the frontal lobe and parietal lobe. The dentate nucleus controls the planning 
and initiation of voluntary movement, as well as playing a role in visuospatial 
awareness. 
4.4.2.2.1 Complex I – NADH: Ubiquinone Oxidoreductase 
Patients with evidence for POLG mutations (Figure 4.7; image B) show little evidence 
of complex I deficiency for the majority of subunits. There is a moderate to high level of 
deficiency of complex I-30. Patient 1 shows 53% deficiency of the core subunit 
complex I-30, affecting only neurons of the dentate nucleus. Normal levels of staining 
are seen in the Purkinje cells. 
Patients with no genetic diagnosis available show a variable deficiency. Patient 7 and 
Patient 8 show no deficiency of complex I, but Patient 9 and Patient 10 show a 
moderate to high deficiency (Figure 4.7; images C and D). 
The majority of patients, except Patient 7 and Patient 8, show a complex I deficiency in 
the dentate nucleus. Patient 1 shows a high level of deficiency of a single subunit, 
complex I-30, which occurs only in the neurons of the dentate nucleus. The POLG 
mutation-undetermined group shows the greatest levels of deficiency. Although Patient 
8 does not show a deficiency in the dentate nucleus, this patient does show complex I 
deficiency in the Purkinje cells. As in the Purkinje cells, the affected subunits appear to 
be random with either of the complex subunit antibodies showing greater deficiency 
than the other three. The control shows no evidence of deficiency. 
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Figure 4.7. Staining with antibodies for complex I in neurons of the dentate 
nucleus in the cerebellum. 
Arrowheads indicate neurons. All sections stained with complex I antibody. A=Control 1 
CI-20, B=Patient 1 POLG mutation-positive group CI-20, C=Patient 9 POLG mutation-
undetermined group CI-20, D=Patient 10 POLG mutation-undetermined group CI-20. 
Scale bar = 100µm. 
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Deficiency values for all subunits are shown in Table 4.6. The brain area is unavailable 
for patients not listed in the table. The availability of the dentate nucleus was 
dependent upon the orientation of the sample taken by the original pathology team. In 
some patients, this led to the dentate nucleus being unavailable for analysis, as for 
Patient 6. 
POLG 
mutation Patient 
Complex I-
19 
Complex I-
20 
Complex I-
30 
Complex I-
39 
+ 
1 0% 10% 53% 11% 
2 0% 9% 14% 0% 
? 
7 2% 0% N/A N/A 
8 0% 0% N/A N/A 
9 68% 89% N/A N/A 
10 41% 24% N/A N/A 
Table 4.6. Table of complex I deficiency in neurons of the dentate nucleus in the 
cerebellum. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted with each antibody in each patient. 
Where FFPE tissue is unavailable or is known to have been fixed for longer than 6 
months, no values are given. 
 
Key: N/A=not available 
  
205 
 
Chapter 4 Respiratory Chain Deficiency in Patients with Alpers’ Syndrome 
4.4.2.2.2 Complex II – Succinate: Ubiquinone Oxidoreductase 
Patients with evidence for POLG mutations or with no genetic diagnosis available show 
no deficiency (Figure 4.8). The controls show no evidence of deficiency. 
There is no evidence for complex II deficiency in these patients. A single patient, 
Patient 10, showed moderate levels of deficiency in the Purkinje cells but not in the 
neurons of the dentate nucleus. 
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Figure 4.8. Staining with antibodies for complex II in neurons of the dentate 
nucleus in the cerebellum. 
Arrowheads indicate neurons. All sections stained with complex II subunit 70 antibody. 
A=Control 6, B=Patient 1 POLG mutation-positive group, C=Patient 2 POLG mutation-
positive group, D=Patient 10 POLG mutation-undetermined group. Scale bar = 100µm.  
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4.4.2.2.3 Complex III – Ubiquinol Cytochrome c Reductase 
Patients with evidence for POLG mutations show a variable deficiency. Patient 1 shows 
no deficiency while Patient 2 shows a moderate deficiency (Figure 4.9; image B). 
Patients with no genetic diagnosis available (Figure 4.9; images C and D) also show a 
variable deficiency. This ranges from no deficiency in Patient 10 to a moderate 
deficiency in Patient 7. Patient 2 shows moderate levels of complex III deficiency but is 
the only patient not to exhibit a complex I deficiency in this part of the brain. 
There is a variable complex III deficiency in the dentate nucleus across both POLG 
groups. Patient 2 and Patient 7 show a moderate deficiency whilst Patient 1 and 
Patient 10 show no deficiency at all. The control shows no evidence of deficiency. 
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Figure 4.9. Staining with antibodies for complex III Rieske subunit in neurons of 
the dentate nucleus in the cerebellum. 
Arrowheads indicate neurons. All sections stained with complex III Rieske subunit 
antibody. A=Control 10, B=Patient 2 POLG mutation-positive group, C=Patient 10 
POLG mutation-undetermined group, D=Patient 11 POLG mutation-undetermined 
group. Scale bar = 100µm. 
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Deficiency values are shown in Table 4.7. The brain area is unavailable for patients not 
listed in the table. The availability of the dentate nucleus was dependent upon the 
orientation of the sample taken by the original pathology team. In some patients, this 
led to the dentate nucleus being unavailable for analysis, as for Patient 6 and Patient 
11. This antibody stain could not be performed for Patient 9 as the supply of tissue was 
depleted. 
POLG 
mutation Patient Complex III-Rieske 
+ 
1 0% 
2 47% 
? 
7 49% 
8 10% 
10 0% 
Table 4.7. Table of complex III deficiency in neurons of the dentate nucleus in the 
cerebellum. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted in each patient. Where FFPE tissue is 
unavailable or is known to have been fixed for longer than 6 months, no values are 
given. 
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4.4.2.2.4 Complex IV – Cytochrome c Oxidase 
Patients with evidence for POLG mutations show no complex IV subunit I deficiency 
(Figure 4.10; image B) and show no complex IV subunit IV deficiency (Figure 4.11; 
image B). 
Patients with no genetic diagnosis available show a moderate complex IV subunit I 
deficiency in Patient 7 and Patient 9 only (Figure 4.10; images C and D). There is no 
complex IV subunit IV deficiency (Figure 4.11; images C and D). 
The control shows no evidence of deficiency for both subunits. 
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Figure 4.10. Staining with antibodies for complex IV subunit I in neurons of the 
dentate nucleus in the cerebellum. 
Arrowheads indicate neurons. All sections stained with complex IV subunit I antibody. 
A=Control 1, B=Patient 2 POLG mutation-positive group, C=Patient 7 POLG mutation-
undetermined group, D=Patient 9 POLG mutation-undetermined group. Scale bar = 
100µm. 
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Figure 4.11. Staining with antibodies for complex IV subunit IV in neurons of the 
dentate nucleus in the cerebellum. 
Arrowheads indicate neurons. All sections stained with complex IV subunit IV antibody. 
A=Control 1, B=Patient 2 POLG mutation-positive group, C=Patient 7 POLG mutation-
undetermined group, D=Patient 9 POLG mutation-undetermined group. Scale bar = 
100µm. 
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Deficiency values for both subunits are shown in Table 4.8. The brain area is 
unavailable for patients not listed in the table. The availability of the dentate nucleus 
was dependent upon the orientation of the sample taken by the original pathology 
team. In some patients, this led to the dentate nucleus being unavailable for analysis, 
as for Patient 6 and Patient 11. 
POLG 
mutation Patient Complex IV-I Complex IV-IV 
+ 
1 2% 0% 
2 0% 0% 
? 
7 22% 0% 
8 0% 0% 
9 17% 1% 
10 0% 0% 
Table 4.8. Table of complex IV deficiency in neurons of the dentate nucleus in the 
cerebellum. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted with each antibody in each patient. 
Where FFPE tissue is unavailable or is known to have been fixed for longer than 6 
months, no values are given. 
 
 
A summary of respiratory chain deficiency values for the cerebellum is detailed in Table 
4.9.
214 
 
   Purkinje Cells Dentate Nucleus 
POLG 
mutation Patient CI-19 CI-20 CI-30 CI-39 CII-70 CIII CIV-I 
CIV-
IV CI-19 CI-20 CI-30 CI-39 CII-70 CIII CIV-I 
CIV-
IV 
+ 
1 8% 22% 0% 8% 0% 1% 1% 0% 0% 10% 53% 11% 0% 0% 2% 0% 
2 1% 1% 0% N/A 1% 39% 0% 0% 0% 9% 14% 0% 0% 47% 0% 0% 
6 11% 12% 25% 19% 5% 27% 15% 0% N/A N/A N/A N/A N/A N/A N/A N/A 
? 
7 3% 2% N/A N/A 0% 30% 0% 0% 2% 0% N/A N/A 0% 49% 22% 0% 
8 10% 3% N/A N/A 0% 27% 1% 0% 0% 0% N/A N/A 0% 10% 0% 0% 
9 61% 21% N/A N/A 0% N/A 33% 0% 68% 89% N/A N/A 0% N/A 17% 1% 
10 44% 13% N/A N/A 28% 60% 10% 8% 41% 24% N/A N/A 0% 0% 0% 0% 
11 63% 38% N/A N/A 0% 68% 18% 14% N/A N/A N/A N/A N/A N/A N/A N/A 
Table 4.9. Summary of respiratory chain deficiency in the cerebellum. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts combined. One hundred neurons were counted with each antibody in 
each patient. Where FFPE tissue is unavailable or is known to have been fixed for longer than 6 months, no values are given. 
 
Key: N/A=not available 
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4.4.3 Occipital Lobe  
Brodmann Area 19 (BA19) of the occipital lobe was examined. 
4.4.3.1 Pyramidal Neurons of Layer V 
4.4.3.1.1 Complex I – NADH: Ubiquinone Oxidoreductase 
In a subset of patients, CI-19 and CI-20 antibodies were tested only, as it became 
apparent there was little additional information being added to the investigation through 
the inclusion of CI-30 and CI-39 antibodies. 
Patients with evidence for POLG mutations (Figure 4.12; images B) show little 
evidence of complex I deficiency in all four of the complex I subunits tested. 
Patients with no genetic diagnosis available (Figure 4.12; image D) show moderate 
levels of complex I deficiency in two of the complex I subunits tested. 
The patient without a POLG mutation (Figure 4.12; image C) shows a moderate level of 
deficiency with CI-39 and little evidence of deficiency with the other subunits. The 
occipital lobe in this patient had a fixation time of 1 month, so was therefore included 
for respiratory chain analysis. The cerebellum, parietal lobe, and basal ganglia had a 
fixation time of 14 years. 
There is a complex I deficiency in the occipital lobe of the POLG mutation-
undetermined group. The POLG mutation-positive group and POLG mutation-absent 
group show no deficiency or very few neurons with deficiency. The control shows no 
evidence of deficiency. 
The lack of respiratory chain deficiency in this brain area is in contrast to the 
neuropathology. Possible reasons for this are discussed in the Discussion section at 
the end of this chapter.  
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Figure 4.12. Staining with antibodies for complex I in the pyramidal neurons of 
the occipital lobe. 
Arrowheads indicate neurons. All sections stained with complex I antibody. A=Control 7 
CI-20, B=Patient 1 POLG mutation-positive group CI-20, C=Patient 12 POLG mutation-
absent group CI-20, D=Patient 10 POLG mutation-undetermined group CI-20. Scale 
bar = 100µm. 
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Deficiency values for all subunits are shown in Table 4.10. The brain area is 
unavailable for patients not listed in the table. 
POLG 
mutation Patient 
Complex I-
19 
Complex I-
20 
Complex I-
30 
Complex I-
39 
+ 
1 2% 2% 0% 3% 
2 2% 0% 0% 0% 
? 
8 14% 5% N/A N/A 
10 16% 8% N/A N/A 
11 2% 23% N/A N/A 
- 12 0% 1% 0% 19% 
Table 4.10. Table of complex I deficiency in the pyramidal neurons of the 
occipital lobe. 
Values are given for neurons of layer V. Percentage of deficiency defined as deficient (-
) and weak (+) neuron counts combined. One hundred neurons were counted with 
each antibody in each patient. Where FFPE tissue is unavailable or is known to have 
been fixed for longer than 6 months, no values are given. 
 
Key: N/A=not available 
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4.4.3.1.2 Complex II – Succinate: Ubiquinone Oxidoreductase 
Patients with evidence for POLG mutations, undetermined genetic diagnosis, or without 
a POLG mutation show no deficiency (Figure 4.13; images B, C and D). 
There is no evidence for complex II deficiency in these patients. The controls show no 
evidence of deficiency. 
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Figure 4.13. Staining with antibodies for complex II in the pyramidal neurons of 
the occipital lobe. 
Arrowheads indicate neurons. All sections stained with complex II subunit 70 antibody. 
A=Control 7, B=Patient 12 POLG mutation-absent group, C=Patient 1 POLG mutation-
positive group, D=Patient 2 POLG mutation-positive group. Scale bar = 100µm. 
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4.4.3.1.3 Complex III – Ubiquinol Cytochrome c Reductase 
Patients with evidence for POLG mutations or without a POLG mutation (Figure 4.14; 
image C) show no complex III deficiency. 
Patients with no genetic diagnosis available (Figure 4.14; images B and D) show 
moderate to high levels of complex III deficiency.  
The control shows no evidence of deficiency. 
Patient 10, no genetic diagnosis available, shows the highest complex III deficiency of 
80% of all patients in all brain areas. The occipital lobe of this patient shows a 
moderate complex I deficiency of 16% CI-19 deficiency. 
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Figure 4.14. Staining with antibodies for complex III Rieske subunit in the 
pyramidal neurons of the occipital lobe. 
Arrowheads indicate neurons. All sections stained with complex III Rieske subunit 
antibody. A=Control 7, B=Patient 8 POLG mutation-undetermined group, C=Patient 12 
POLG mutation-absent group, D=Patient 11 POLG mutation-undetermined group. 
Scale bar = 100µm. 
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Deficiency values are shown in Table 4.11. The brain area is unavailable for patients 
not listed in the table. This antibody stain could not be performed for Patient 2 as the 
supply of tissue was depleted. 
POLG 
mutation Patient Complex III-Rieske 
+ 1 0% 
? 
8 33% 
10 80% 
11 16% 
- 12 0% 
Table 4.11. Table of complex III deficiency in the pyramidal neurons of the 
occipital lobe. 
Values are given for neurons of layer V. Percentage of deficiency defined as deficient (-
) and weak (+) neuron counts combined. One hundred neurons were counted in each 
patient. Where FFPE tissue is unavailable or is known to have been fixed for longer 
than 6 months, no values are given. 
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4.4.3.1.4 Complex IV – Cytochrome c Oxidase 
Patients with evidence for POLG mutations show no complex IV subunit I deficiency 
(Figure 4.15; images B and C) and no complex IV subunit IV deficiency (Figure 4.16; 
images C and D). 
Patients with no genetic diagnosis available show little evidence of complex IV subunit I 
deficiency (Figure 4.15; image D). They show very little evidence of complex IV subunit 
IV deficiency. 
The patient without a POLG mutation shows little evidence of complex IV subunit I 
deficiency and no complex IV subunit IV deficiency (Figure 4.16; image B). The 
occipital lobe in this patient had a fixation time of 1 month, so was therefore included 
for respiratory chain analysis. The cerebellum, parietal lobe, and basal ganglia had a 
fixation time of 14 years. 
The control shows no evidence of deficiency for both subunits. 
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Figure 4.15. Staining with antibodies for complex IV subunit I in pyramidal 
neurons of the occipital lobe. 
Arrowheads indicate neurons. All sections stained with complex IV subunit I antibody. 
A=Control 7, B=Patient 1 POLG mutation-positive group, C=Patient 2 POLG mutation-
positive group, D=Patient 10 POLG mutation-undetermined group. Scale bar = 100µm. 
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Figure 4.16. Staining with antibodies for complex IV subunit IV in pyramidal 
neurons of the occipital lobe. 
Arrowheads indicate neurons. All sections stained with complex IV subunit IV antibody. 
A=Control 7, B=Patient 12 POLG mutation-absent group, C=Patient 1 POLG mutation-
positive group, D=Patient 2 POLG mutation-positive group. Scale bar = 100µm. 
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Deficiency values for both subunits are shown in Table 4.12. The brain area is 
unavailable for patients not listed in the table. 
POLG 
mutation Patient Complex IV-I Complex IV-IV 
+ 
1 0% 0% 
2 0% 0% 
? 
8 10% 1% 
10 18% 0% 
11 14% 1% 
- 12 3% 0% 
Table 4.12. Table of complex IV deficiency in the pyramidal neurons of the 
occipital lobe. 
Values are given for neurons of layer V. Percentage of deficiency defined as deficient (-
) and weak (+) neuron counts combined. One hundred neurons were counted with 
each antibody in each patient. Where FFPE tissue is unavailable or is known to have 
been fixed for longer than 6 months, no values are given. 
 
 
A summary of respiratory chain deficiency values for the occipital lobe is detailed in 
Table 4.13.
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   Occipital Lobe 
POLG mutation Patient CI-19 CI-20 CI-30 CI-39 CII-70 CIII CIV-I CIV-IV 
+ 
1 2% 2% 3% 0% 0% 0% 0% 0% 
2 2% 0% 0% 0% 0% N/A 0% 0% 
? 
8 14% 5% N/A N/A 0% 33% 10% 1% 
10 16% 8% N/A N/A 0% 80% 18% 0% 
11 2% 23% N/A N/A 0% 16% 14% 1% 
- 12 0% 1% 0% 19% 0% 0% 3% 0% 
Table 4.13. Summary of respiratory chain deficiency in the occipital lobe. 
Values are given for neurons of layer V. Percentage of deficiency defined as deficient (-) and weak (+) neuron counts combined. One hundred 
neurons were counted with each antibody in each patient. Where FFPE tissue is unavailable or is known to have been fixed for longer than 6 
months, no values are given. 
 
Key: N/A=not available 
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4.4.4 Parietal Lobe  
Brodmann Area 40 (BA40) of the parietal lobe was examined. 
4.4.4.1 Pyramidal Neurons of Layer V 
4.4.4.1.1 Complex I – NADH: Ubiquinone Oxidoreductase 
In a subset of patients, CI-19 and CI-20 antibodies were tested only, as it became 
apparent there was little additional information being added to the investigation through 
the inclusion of CI-30 and CI-39 antibodies. 
Patients with evidence for POLG mutations (Figure 4.17; images B, C and D) show 
either no deficiency or very few neurons with deficiency in complex I-30. The POLG 
mutation-undetermined group consisted of only one patient, Patient 8, which shows a 
particular deficiency in complex I-19.  
The control shows no evidence of deficiency. 
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Figure 4.17. Staining with antibodies for complex I in the pyramidal neurons of 
the parietal lobe. 
Arrowheads indicate neurons. All sections stained with complex I antibody. A=Control 7 
CI-30, B=Patient 2 POLG mutation-positive group CI-30, C=Patient 1 POLG mutation-
positive group CI-30, D=Patient 6 POLG mutation-positive group CI-30. Scale bar = 
100µm. 
 
  
230 
 
Chapter 4 Respiratory Chain Deficiency in Patients with Alpers’ Syndrome 
Deficiency values for all subunits are shown in Table 4.14. The brain area is 
unavailable for patients not listed in the table. 
POLG 
mutation Patient 
Complex I-
19 
Complex I-
20 
Complex I-
30 
Complex I-
39 
+ 
1 0% 0% 4% 2% 
2 5% 0% 9% 0% 
6 0% 1% 17% 0% 
? 8 53% 19% N/A N/A 
Table 4.14. Table of complex I deficiency in the pyramidal neurons of the parietal 
lobe. 
Values are given for neurons of layer V. Percentage of deficiency defined as deficient (-
) and weak (+) neuron counts combined. One hundred neurons were counted with 
each antibody in each patient. Where FFPE tissue is unavailable or is known to have 
been fixed for longer than 6 months, no values are given. 
 
Key: N/A=not available 
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4.4.4.1.2 Complex II – Succinate: Ubiquinone Oxidoreductase 
Patients with evidence for POLG mutations, undetermined genetic diagnosis, or without 
a POLG mutation show no deficiency (<2%) (Figure 4.18; images B, C and D). 
There is no evidence for complex II deficiency in these patients. The controls show no 
evidence of deficiency. 
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Figure 4.18. Staining with antibodies for complex II in the pyramidal neurons of 
the parietal lobe. 
Arrowheads indicate neurons. All sections stained with complex II subunit 70 antibody. 
A=Control 7, B=Patient 1 POLG mutation-positive group, C=Patient 2 POLG mutation-
positive group, D=Patient 8 POLG mutation-undetermined group. Scale bar = 100µm. 
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Deficiency values are shown in Table 4.15. The brain area is unavailable for patients 
not listed in the table. 
POLG 
mutation Patient Complex II-70 
+ 
1 2% 
2 0% 
6 0% 
? 8 0% 
Table 4.15. Table of complex II deficiency in the pyramidal neurons of the parietal 
lobe. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted in each patient. Where FFPE tissue is 
unavailable or is known to have been fixed for longer than 6 months, no values are 
given. 
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4.4.4.1.3 Complex III – Ubiquinol Cytochrome c Reductase 
Patients with evidence for POLG mutations (Figure 4.19; images B, C and D) show 
little evidence of complex III deficiency. 
There was one patient, Patient 8, from the group with no genetic diagnosis available 
where the parietal lobe could be assessed. Patient 8 shows little evidence of complex 
III deficiency.  
The control shows no evidence of deficiency. 
  
235 
 
Chapter 4 Respiratory Chain Deficiency in Patients with Alpers’ Syndrome 
 
Figure 4.19. Staining with antibodies for complex III Rieske subunit in the 
pyramidal neurons of the parietal lobe. 
Arrowheads indicate neurons. All sections stained with complex III Rieske subunit 
antibody. A=Control 7, B=Patient 6 POLG mutation-positive group, C=Patient 1 POLG 
mutation-positive group, D=Patient 2 POLG mutation-positive group. Scale bar = 
100µm. 
  
236 
 
Chapter 4 Respiratory Chain Deficiency in Patients with Alpers’ Syndrome 
Deficiency values are shown in Table 4.16. The brain area is unavailable for patients 
not listed in the table. 
POLG 
mutation Patient Complex III-Rieske 
+ 
1 0% 
2 15% 
6 1% 
? 8 13% 
Table 4.16. Table of complex III deficiency in the pyramidal neurons of the 
parietal lobe. 
Values are given for neurons of layer V. Percentage of deficiency defined as deficient (-
) and weak (+) neuron counts combined. One hundred neurons were counted in each 
patient. Where FFPE tissue is unavailable or is known to have been fixed for longer 
than 6 months, no values are given. 
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4.4.4.1.4 Complex IV – Cytochrome c Oxidase 
Patients with evidence for POLG mutations show little evidence of complex IV subunit I 
deficiency (Figure 4.20; images A, B and C) and no complex IV subunit IV deficiency 
(Figure 4.21; images A, B and C). 
There was only one patient, Patient 8, from the group with no genetic diagnosis 
available where the parietal lobe could be assessed. Patient 8 shows little evidence of 
complex IV subunit I deficiency and little evidence of complex IV subunit IV deficiency. 
The control shows no evidence of deficiency for both subunits. 
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Figure 4.20. Staining with antibodies for complex IV subunit I in pyramidal 
neurons of the parietal lobe. 
Arrowheads indicate neurons. All sections stained with complex IV subunit I antibody. 
A=Control 1, B=Patient 6 POLG mutation-positive group, C=Patient 1 POLG mutation-
positive group, D=Patient 2 POLG mutation-positive group. Scale bar = 100µm. 
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Figure 4.21. Staining with antibodies for complex IV subunit IV in pyramidal 
neurons of the parietal lobe. 
Arrowheads indicate neurons. All sections stained with complex IV subunit IV antibody. 
A=Control 1, B=Patient 1 POLG mutation-positive group, C=Patient 2 POLG mutation-
positive group, D=Patient 6 POLG mutation-positive group. Scale bar = 100µm. 
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Deficiency values for both subunits are shown in Table 4.17. The brain area is 
unavailable for patients not listed in the table. 
POLG 
mutation Patient Complex IV-I Complex IV-IV 
+ 
1 5% 0% 
2 3% 0% 
6 0% 0% 
? 8 4% 3% 
Table 4.17. Table of complex IV deficiency in the pyramidal neurons of the 
parietal lobe. 
Values are given for neurons of layer V. Percentage of deficiency defined as deficient (-
) and weak (+) neuron counts combined. One hundred neurons were counted with 
each antibody in each patient. Where FFPE tissue is unavailable or is known to have 
been fixed for longer than 6 months, no values are given. 
 
 
A summary of respiratory chain deficiency values for the parietal lobe is detailed in 
Table 4.18. 
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   Parietal Lobe 
POLG mutation Patient CI-19 CI-20 CI-30 CI-39 CII-70 CIII CIV-I CIV-IV 
+ 
1 0% 0% 4% 2% 2% 0% 5% 0% 
2 5% 0% 9% 0% 0% 15% 3% 0% 
6 0% 1% 17% 0% 0% 1% 0% 0% 
? 8 53% 19% N/A N/A 0% 13% 4% 3% 
 
Table 4.18. Summary of respiratory chain deficiency in the parietal lobe. 
Values are given for neurons of layer V. Percentage of deficiency defined as deficient (-) and weak (+) neuron counts combined. One hundred 
neurons were counted with each antibody in each patient. Where FFPE tissue is unavailable or is known to have been fixed for longer than 6 
months, no values are given. 
 
Key: N/A=not available
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4.4.5 Basal Ganglia  
4.4.5.1 Caudate, Putamen, and Globus Pallidus 
The basal ganglia is a structure of grey matter located deep in the white matter of the 
cerebrum. It functions in control of voluntary movement and cognitive functions. It 
consists of well-defined areas; the caudate, the putamen, the medial globus pallidus, 
and the lateral globus pallidus. The caudate and putamen are together named the 
striate nucleus because they contain the same inhibitory classes of neurons; medium 
spiny neurons, and both GABA-ergic and cholinergic interneurons. These two 
structures are separated by a tract of axons named the internal capsule. The striate 
nucleus receives input mainly from the frontal lobe and also from the cerebral cortex, 
and the output from the striate nucleus acts upon the substantia nigra and globus 
pallidus to regulate voluntary motor function. The caudate and putamen may have 
different functions: the caudate affecting eye movements and cognitive functions, and 
the putamen affecting motor control. The putamen and the globus pallidus together are 
named lentiform nucleus. The lentiform nucleus receives input from the striate nucleus 
and acts upon the subthalamic nucleus to modulate motor function.  
The availability of each of the caudate, putamen, and globus pallidus for analysis was 
dependent upon the precise location of the sample that was taken by the original 
pathology team. In some patients, this led to two of the three areas being available for 
analysis. 
4.4.5.1.1 Complex I – NADH: Ubiquinone Oxidoreductase 
In a subset of patients, CI-19 and CI-20 antibodies were tested only, as it became 
apparent there was little additional information being added to the investigation through 
the inclusion of CI-30 and CI-39 antibodies. 
Patients with evidence for POLG mutations (Figure 4.22; images C) show low to 
moderate levels of complex I deficiency in all four of the complex I subunits tested. 
Patients with no genetic diagnosis available (Figure 4.22; images B and D) show low to 
moderate levels of complex I deficiency in two of the complex I subunits tested. 
The POLG mutation-undetermined group shows a complex I deficiency in the basal 
ganglia in complex I-19 and complex I-20. The POLG mutation-positive group shows 
deficiency in complex I-20 and complex I-39. The control shows no evidence of 
deficiency. 
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Figure 4.22. Staining with antibodies for complex I in neurons of the basal 
ganglia. 
Arrowheads indicate neurons. All sections stained with complex I antibody. A=Control 6 
CI-19, B=Patient 11 POLG mutation-undetermined group CI-19, C=Patient 1 POLG 
mutation-positive group CI-19, D=Patient 10 POLG mutation-undetermined group CI-
19. All images are taken of the putamen. Scale bar = 100µm. 
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Deficiency values for all subunits are shown in Table 4.19. The brain area is 
unavailable for patients not listed in the table. Complex I-30 and complex I-39 results 
are not included as they were only available for Patient 1 and did not show extreme 
deficiency. 
POLG 
mutation Patient 
Complex I-
19 
Complex I-
20 
+ 1 
C – 0% C – 18% 
P – 2% P – 1% 
GP – 0% GP – 3% 
? 
8 
C – N/A C – N/A 
P – 10% P – 2% 
GP – 4% GP – 0% 
9 
C – 13% C – 14% 
P – 41% P – 7% 
GP – 26% GP – 0% 
10 
C – N/A C – N/A 
P – 0% P – 0% 
GP – 0% GP – 0% 
11 
C – 15% C – 12% 
P – 19% P – 19% 
GP – 18% GP – N/A 
Table 4.19. Table of complex I deficiency in the basal ganglia. 
Values are given for neurons from the caudate, putamen, and globus pallidus. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted with each antibody in each patient. 
Where FFPE tissue is unavailable or is known to have been fixed for longer than 6 
months, no values are given. 
 
Key: N/A=not available, C=caudate, P=putamen, GP=globus pallidus  
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4.4.5.1.2 Complex II – Succinate: Ubiquinone Oxidoreductase 
Patients with evidence for POLG mutations, undetermined genetic diagnosis, or without 
a POLG mutation show no deficiency (<6%) (Figure 4.23; images B, C and D). 
There is no evidence for complex II deficiency in these patients. The controls show no 
evidence of deficiency. 
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Figure 4.23. Staining with antibodies for complex II in neurons of the basal 
ganglia. 
Arrowheads indicate neurons. All sections stained with complex II subunit 70 antibody. 
A=Control 6 putamen, B=Patient 11 POLG mutation-undetermined group globus 
pallidus, C=Patient 1 POLG mutation-positive group globus pallidus, D=Patient 9 
POLG mutation-undetermined group putamen. Scale bar = 100µm. 
  
247 
 
Chapter 4 Respiratory Chain Deficiency in Patients with Alpers’ Syndrome 
Deficiency values are shown in Table 4.20. The brain area is unavailable for patients 
not listed in the table. 
POLG 
mutation Patient Complex II-70 
+ 1 
C – 0% 
P – 1% 
GP – 0% 
? 
8 
C – N/A 
P – 0% 
GP – 0% 
9 
C – 0% 
P – 1% 
GP – 6% 
10 
C – N/A 
P – 0% 
GP – 0% 
11 
C – 0% 
P – 0% 
GP – 0% 
Table 4.20. Table of complex II deficiency in the basal ganglia. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted in each patient. Where FFPE tissue is 
unavailable or is known to have been fixed for longer than 6 months, no values are 
given. 
 
Key: N/A=not available, C=caudate, P=putamen, GP=globus pallidus 
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4.4.5.1.3 Complex III – Ubiquinol Cytochrome c Reductase 
The availability of each of the caudate, putamen, and globus pallidus for analysis was 
dependent upon the precise location of the sample that was taken by the original 
pathology team. In some patients, this led to two of the three areas being available for 
analysis. 
Patients with evidence for POLG mutations (Figure 4.24; image D) show moderate 
levels of complex III deficiency. 
Patients with no genetic diagnosis available (Figure 4.24; images B and C) show low to 
moderate levels of complex III deficiency.  
The control shows no evidence of deficiency. 
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Figure 4.24. Staining with antibodies for complex III Rieske subunit in neurons of 
the basal ganglia. 
Arrowheads indicate neurons. All sections stained with complex III Rieske subunit 
antibody. A=Control 5 putamen, B=Patient 8 POLG mutation-undetermined group 
globus pallidus, C=Patient 10 POLG mutation-undetermined group putamen, D=Patient 
1 POLG mutation-positive group globus pallidus. Scale bar = 100µm. 
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Deficiency values are shown in Table 4.21. The brain area is unavailable for patients 
not listed in the table. This antibody stain could not be performed for Patient 11 as the 
supply of tissue was depleted. 
POLG 
mutation Patient Complex III-Rieske 
+ 1 
C – 14% 
P – 0% 
GP – 32% 
? 
8 
C – N/A 
P – 7% 
GP – 33% 
9 
C – 13% 
P – 40% 
GP – 17% 
10 
C – N/A 
P – 2% 
GP – 1% 
Table 4.21. Table of complex III deficiency in the basal ganglia. 
Values are given for neurons from the caudate, putamen, and globus pallidus. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted in each patient. Where FFPE tissue is 
unavailable or is known to have been fixed for longer than 6 months, no values are 
given. 
 
Key: N/A=not available, C=caudate, P=putamen, GP=globus pallidus 
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4.4.5.1.4 Complex IV – Cytochrome c Oxidase 
The availability of each of the caudate, putamen, and globus pallidus for analysis was 
dependent upon the precise location of the sample that was taken by the original 
pathology team. In some patients, this led to two of the three areas being available for 
analysis. 
Patients with evidence for POLG mutations show little evidence of complex IV subunit I 
deficiency (Figure 4.25; image B) and no complex IV subunit IV deficiency (Figure 4.26; 
image B). 
Patients with no genetic diagnosis available show low to moderate levels of complex IV 
subunit I deficiency (Figure 4.25; images C and D). They show little evidence of 
complex IV subunit IV deficiency (Figure 4.26; images C and D). 
The control shows no evidence of deficiency for both subunits. 
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Figure 4.25. Staining with antibodies for complex IV subunit I in neurons of the 
basal ganglia. 
Arrowheads indicate neurons. All sections stained with complex IV subunit I antibody. 
A=Control 6 putamen, B=Patient 1 POLG mutation-positive group caudate, C=Patient 9 
POLG mutation-undetermined group caudate, D=Patient 11 POLG mutation-
undetermined group caudate. Scale bar = 100µm. 
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Figure 4.26. Staining with antibodies for complex IV subunit IV in neurons of the 
basal ganglia. 
Arrowheads indicate neurons. All sections stained with complex IV subunit IV antibody. 
A=Control 6 putamen, B=Patient 1 POLG mutation-positive group caudate, C=Patient 
11 POLG mutation-undetermined group putamen, D=Patient 10 POLG mutation-
undetermined group putamen. Scale bar = 100µm. 
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Deficiency values for both subunits are shown in Table 4.22. The brain area is 
unavailable for patients not listed in the table. 
POLG 
mutation Patient Complex IV-I Complex IV-IV 
+ 1 
C – 5% C – 0% 
P – 1% P – 0% 
GP – 0% GP – 0% 
? 
8 
C – N/A C – N/A 
P – 2% P – 0% 
GP – 2% GP – 0% 
9 
C – 3% C – 0% 
P – 11% P – 4% 
GP – 2% GP – 0% 
10 
C – N/A C – N/A 
P – 2% P – 1% 
GP – 0% GP – 0% 
11 
C – 4% C – 0% 
P – 15% P – 10% 
GP – 0% GP – 0% 
Table 4.22. Table of complex IV deficiency in the basal ganglia. 
Values are given for neurons from the caudate, putamen, and globus pallidus. 
Percentage of deficiency defined as deficient (-) and weak (+) neuron counts 
combined. One hundred neurons were counted with each antibody in each patient. 
Where FFPE tissue is unavailable or is known to have been fixed for longer than 6 
months, no values are given. 
 
Key: N/A=not available, C=caudate, P=putamen, GP=globus pallidus 
 
 
A summary of respiratory chain deficiency values for the basal ganglia is detailed in 
Table 4.23.
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   Basal Ganglia 
POLG mutation Patient CI-19 CI-20 CII-70 CIII CIV-I CIV-IV 
+ 1 
C – 0% C – 18% C – 0% C – 14% C – 5% C – 0% 
P – 2% P – 1% P – 1% P – 0% P – 1% P – 0% 
GP – 0% GP – 3% GP – 0% GP – 32% GP – 0% GP – 0% 
? 
8 
C – N/A C – N/A C – N/A C – N/A C – N/A C – N/A 
P – 10% P – 2% P – 0% P – 7% P – 2% P – 0% 
GP – 4% GP – 0% GP – 0% GP – 33% GP – 2% GP – 0% 
9 
C – 13% C – 14% C – 0% C – 13% C – 3% C – 0% 
P – 41% P – 7% P – 1% P – 40% P – 11% P – 4% 
GP – 26% GP – 0% GP – 6% GP – 1% GP – 2% GP – 0% 
10 
C – N/A C – N/A C – N/A C – N/A C – N/A C – N/A 
P – 0% P – 0% P – 0% P – 2% P – 2% P – 1% 
GP – 0% GP – 0% GP – 0% GP – 1% GP – 0% GP – 0% 
11 
C – 15% C – 12% C – 0% C – N/A C – 4% C – 0% 
P – 19% P – 19% P – 0% P – N/A P – 15% P – 10% 
GP – 18% GP – N/A GP – 0% GP – N/A GP – 0% GP – 0% 
Table 4.23. Summary of respiratory chain deficiency in the basal ganglia. 
Values are given for neurons of layer V. Percentage of deficiency defined as deficient (-) and weak (+) neuron counts combined. One hundred 
neurons were counted with each antibody in each patient. Where FFPE tissue is unavailable or is known to have been fixed for longer than 6 
months, no values are given. 
Key: N/A=not available, C=caudate, P=putamen, GP=globus pallidus 
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A summary of the respiratory chain deficiency in all brain areas of all patients is detailed in Table 4.24.  
POLG 
Mutation Patient Cerebellum Occipital Lobe 
  I-19 I-20 I-30 I-39 II III IV-I IV-IV I-19 I-20 I-30 I-39 II III IV-I IV-IV 
+ 
1 PC-8% DN-0% 
PC-22% 
DN-10% 
PC-0% 
DN-53% 
PC-8% 
DN-11% 
PC-0% 
DN-0% 
PC-1% 
DN-0% 
PC-1% 
DN-2% 
PC-0% 
DN-0% 2% 2% 3% 0% 0% 0% 0% 0% 
2 PC-1% DN-0% 
PC-1% 
DN-9% 
PC-0% 
DN-14% 
PC-N/A 
DN-0% 
PC-1% 
DN-0% 
PC-39% 
DN-47% 
PC-0% 
DN-0% 
PC-0% 
DN-0% 2% 0% 0% 0% 0% N/A 0% 0% 
6 PC-11% PC-12% PC-25% PC-19% PC-5% PC-27% PC-15% PC-0% N/A N/A N/A N/A N/A N/A N/A N/A 
? 
7 PC-3% DN-2% 
PC-2% 
DN-0% N/A N/A 
PC-0% 
DN-0% 
PC-30% 
DN-49% 
PC-0% 
DN-22% 
PC-0% 
DN-0% N/A N/A 
N/A N/A N/A N/A N/A N/A 
8 PC-10% DN-0% 
PC-3% 
DN-0% N/A N/A 
PC-0% 
DN-0% 
PC-27% 
DN-10% 
PC-1% 
DN-0% 
PC-0% 
DN-0% 14% 5% 
N/A N/A 0% 33% 10% 1% 
9 PC-61% DN-68% 
PC-21% 
DN-89% N/A N/A 
PC-0% 
DN-0% N/A 
PC-33% 
DN-17% 
PC-0% 
DN-1% 
N/A N/A N/A N/A N/A N/A N/A N/A 
10 PC-44% DN-41% 
PC-13% 
DN-24% N/A N/A 
PC-28% 
DN-0% 
PC-60% 
DN-0% 
PC-10% 
DN-0% 
PC-8% 
DN-0% 16% 8% 
N/A N/A 0% 80% 18% 0% 
11 PC-63% PC-38% N/A N/A PC-0% PC-68% PC-18% PC-14% 2% 23% N/A N/A 0% 16% 14% 1% 
- 12 N/A 0% 1% 0% 19% 0% 0% 3% 0% 
C
hapter 4 
R
espiratory C
hain D
eficiency in P
atients w
ith A
lpers’ S
yndrom
e 
 
257 
 
 
 POLG 
Mutation Patient Parietal Lobe Basal Ganglia 
  I-19 I-20 I-30 I-39 II III IV-I IV-IV I-19 I-20 I-30 I-39 II III IV-I IV-IV 
+ 
1 0% 0% 4% 2% 2% 0% 5% 0% 
C-0% 
P-2% 
GP-0% 
C-18% 
P-1% 
GP-3% 
C-4% 
P-1% 
GP-3% 
C-23% 
P-2% 
GP-5% 
C-0% 
P-1% 
GP-0% 
C-14% 
P-0% 
GP-
32% 
C-5% 
P-1% 
GP-0% 
C-0% 
P-0% 
GP-0% 
2 5% 0% 9% 0% 0% 15% 3% 0% N/A N/A N/A N/A N/A N/A N/A N/A 
6 0% 1% 17% 0% 0% 1% 0% 0% N/A N/A N/A N/A N/A N/A N/A N/A 
? 
7 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
8 53% 19% N/A N/A 0% 13% 4% 3% P-10% GP-4% 
P-2% 
GP-0% N/A N/A 
P-0% 
GP-0% 
P-7% 
GP-
33% 
P-2% 
GP-2% 
P-0% 
GP-0% 
9 N/A N/A N/A N/A N/A N/A N/A N/A 
C-13% 
P-41% 
GP-
26% 
C-14% 
P-7% 
GP-0% 
N/A N/A 
C-0% 
P-1% 
GP-6% 
C-13% 
P-40% 
GP-
17% 
C-3% 
P-11% 
GP-2% 
C-0% 
P-4% 
GP-0% 
10 N/A N/A N/A N/A N/A N/A N/A N/A P-0% GP-0% 
P-0% 
GP-0% N/A N/A 
P-0% 
GP-0% 
P-2% 
GP-1% 
P-2% 
GP-0% 
P-1% 
GP-0% 
11 N/A N/A N/A N/A N/A N/A N/A N/A 
C-15% 
P-19% 
GP-
18% 
C-12% 
P-19% 
GP-N/A 
N/A N/A 
C-0% 
P-0% 
GP-0% 
N/A 
C-4% 
P-15% 
GP-0% 
C-0% 
P-10% 
GP-0% 
- 12 N/A N/A 
Table 4.24. Summary of respiratory chain deficiency in all brain areas.  
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 Values are given for neurons of layer V. Percentage of deficiency defined as deficient (-) and weak (+) neuron counts combined. One hundred 
neurons were counted with each antibody in each patient. Where FFPE tissue is unavailable or is known to have been fixed for longer than 6 
months, no values are given. 
 
Key: N/A=not available, PC=Purkinje cell, DN=dentate nucleus, C=caudate, P=putamen, GP=globus pallidus 
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4.4.6 Respiratory Chain Deficiency in Glial Cells 
Glial cells are ubiquitous cells of the CNS that perform many different functions. They 
support the functioning of neurons by providing simple sugars as an energy source for 
the neurons, insulate the axons of neurons, surround the neurons and physically 
support them, and provide an immune response. 
Respiratory chain deficiency is seen in the glial cells of two patients, described in the 
next paragraphs. A severe astrogliosis was noted in the pathological changes of these 
patients and so a stain for astrocytes has been included. Changes to the glial cells of 
the parietal lobe are described below. 
4.4.6.1 Patient 2 
Patient 2 shows evidence for POLG mutations, harbouring the p.Ala467Thr and 
p.Thr914Pro mutations. 
A stain for astrocytes, a common glial cell was used to assess the increase in cell 
population. Patient 2 shows normal staining with GFAP, showing the astrocyte 
population (Figure 4.27; image A). The parietal lobe shows a severe astrogliosis in the 
grey matter with many fewer astrocytes being present in the white matter. The 
astrocytes appear large and swollen. Porin staining of the glial cells (image B) shows 
only a slight deficiency, suggesting that many mitochondria are present in the glia. 
However, complex I (image C) and complex III (image D) staining of the glial cells 
shows a moderate deficiency. 
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Figure 4.27. Respiratory chain deficiency within glial cells in the parietal lobe of 
Patient 2. 
A=GFAP, B=porin, C=CI-19, D=CIII Rieske subunit. Image A shows a severe 
astrogliosis. Image B shows a slight deficiency in porin. Images C and D show a 
moderate deficiency in complex I and complex III. All images taken of Patient 2 POLG 
mutation-positive group. Scale bar = 100µm. 
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4.4.6.2 Patient 6 
Patient 6 shows evidence for POLG mutations, whose sibling harbours the 
p.Trp748Ser and p.Arg1096Cys mutations. 
A stain for astrocytes, a common glial cell was used to assess the increase in cell 
population. Patient 6 shows normal staining with GFAP, showing the astrocyte 
population (Figure 4.28; image A). The parietal lobe shows a severe astrogliosis in the 
grey and white matter. The astrocytes appear large and swollen. Porin staining (image 
B) shows a severe deficiency, suggesting extremely few mitochondria are present in 
the glial cells. Complex I (image D) staining and complex II (image C) staining of the 
glial cells both show a severe deficiency. 
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Figure 4.28. Respiratory chain deficiency within glial cells in the parietal lobe of 
Patient 6. 
A=GFAP, B=porin, C=CII-70, D=CI-30. Image A shows a severe astrogliosis. Image B 
shows a severe deficiency in porin. Image C shows a severe deficiency in complex II. 
Image D shows a severe deficiency in complex I. All images taken of Patient 6 POLG 
mutation-positive group. Scale bar = 100µm. 
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4.5 Discussion 
4.5.1 Respiratory Chain Deficiency In Relation to Neuropathology 
This chapter has examined the respiratory chain deficiency in neurons. In the previous 
chapter, I examined my cohort for features of neuropathology and now these are 
examined in relation to one another. The cerebellum shows the greatest changes in 
respiratory chain function and extensive neuropathology. The occipital lobe shows 
slight changes of the respiratory chain but moderate neuropathology. The parietal and 
basal ganglia show some changes of the respiratory chain and mild neuropathology.  
The occipital lobe shows an unexpected lack of correlation between the 
neuropathology and respiratory chain deficiency, even in patients where there was 
moderate neuropathology and a confirmed POLG mutation. There was neuron loss, 
predominantly seen in the upper grey matter layers, with moderate neuropathology 
throughout, yet extremely little respiratory chain deficiency is noted. This is very 
surprising in an area of the brain where there has been much reported involvement in 
patients with Alpers’ syndrome. The occipital lobe is an area of high metabolic activity 
and the neurons in this area may be more vulnerable to dysfunction of the respiratory 
chain. It is possible there may have been more pyramidal neurons than were assessed 
during this project and that these neurons may have had a respiratory chain 
dysfunction. If these neurons had died they could therefore not be examined and 
counted in this study. The remaining neurons may have been those that did not show a 
respiratory chain dysfunction and those were the neurons that were counted. An 
additional possibility considers that there are other neuronal subtypes present in the 
occipital cortex and some of these subtypes may have been too small to accurately 
examine and count at the highest magnification available, X100 magnification. These 
neurons may have shown respiratory chain dysfunction but were not counted. This may 
suggest that there are neurons that are differentially vulnerable to respiratory chain 
dysfunction and that this situation may be unique to the occipital lobe, as the lack of 
respiratory chain dysfunction was not seen in other brain areas. A third consideration 
may be given to the vascular regions of the occipital lobe, where a high metabolic 
demand requires a suitable vascular supply. There is evidence in other mitochondrial 
disorders with seizure involvement, e.g. MELAS, that infarcts, lesions and 
neurodegeneration may arise from vascular abnormalities after seizure activity (Iizuka 
et al., 2003). The neurons of the occipital lobe in patients with Alpers’ syndrome may 
be vulnerable to these vascular changes after seizure activity and this may result in an 
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imbalance between an increased energy demand and the ATP availability in the 
neuron. 
4.5.2 Respiratory Chain Deficiency in Neurons 
This is the first time that the respiratory chain has been studied at this level of detail in 
neurons in patients with Alpers’ syndrome. There was an overall trend that complex I 
and complex III showed the greatest deficiency in all brain areas of the patients. 
Complex IV subunit I shows a moderate deficiency which was always greater than the 
few neurons with complex IV subunit IV deficiency. Complex II deficiency was seen in a 
single patient. Respiratory chain deficiency will be discussed in more detail in the 
following sections. 
4.5.2.1 Complex I 
Complex I is the largest of the respiratory chain proteins, encoded by both nuclear and 
mitochondrial genes. Its assembly into a multi-subunit protein requires assembly 
factors and may progress through intermediate stages (Antonicka et al., 2003). There 
was a clear deficiency of complex I in seven of the patients investigated and in all brain 
areas. Four antibodies to complex I subunits were used: CI-19 (NDUFA13), CI-20 
(NDUFB8), CI-39 (NDUFA9), and one of the core subunits, CI-30 (NDUFS3). All of 
these subunits are nuclear-encoded and directly unaffected by mtDNA abnormalities. 
The most severe deficiencies were observed in the cerebellum, with both the Purkinje 
cells and neurons of the dentate nucleus exhibiting up to 89% complex I deficiency. 
Less severe deficiencies were noted in the occipital lobe, parietal lobe, and basal 
ganglia yet in some patients these were substantial; Patient 8 showed a 53% 
deficiency of CI-19 in the parietal lobe, and Patient 9 showed a 41% deficiency of CI-19 
in the putamen of the basal ganglia. Severe loss of a single complex I subunit was 
seen in Patient 1; 53% deficiency of the core subunit complex I-30 was seen in 
neurons of the dentate nucleus. Normal levels of staining are seen in the Purkinje cells 
of this patient. Greater levels of CI-30 deficiency are also seen in the parietal lobe of 
Patient 6 (17%) where there is no deficiency in other subunits. However, it is also clear 
that greater loss of any individual subunit of complex I can occur in neurons. This 
suggests that neurons may be more vulnerable to loss of the core subunits of complex 
I but that loss of an individual subunit can occur and may be tolerated if other subunits 
are intact. 
The most severe complex I deficiency of the Purkinje cells or dentate nucleus 
correlated with a greater degree of loss of that neuronal type. In Patient 9, Purkinje 
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cells showed a 61% and 21% deficiency with CI-19 and CI-20 subunits respectively, 
with no discernable neuron loss, while the dentate nucleus showed 68% and 89% 
deficiency with CI-19 and CI-20 subunits respectively, with moderate neuron loss. This 
suggests that surviving neurons show deficiency in areas where a greater number of 
neurons have already been lost and we may be seeing a snapshot of this process as 
further respiratory chain deficiency leads to increased neuronal cell death. 
Complex I deficiency, is the most common defect in mitochondrial patients (Darin et al., 
2001), yet it is an underdiagnosed condition and can occur in many heterogeneous 
disorders. A previous study in this lab has shown that patients with POLG mutations 
show a predominant complex I and complex IV deficiency of both Purkinje cells and 
neurons of the dentate nucleus in the cerebellum (Lax 2011). The study did not 
investigate for signs of complex III deficiency. 
Complex I deficiency may result in increased reactive oxygen species (ROS) 
production and it has been shown in fibroblast cell lines that those with a higher ROS 
production occurs in cells with the most severe complex I deficiency (Verkaart et al., 
2007). This increased ROS production may be contributing to neuron death and 
degeneration. 
Assembly of complex I, occurring through intermediate stages and facilitated by 
assembly factors, is dependent on the structure and integrity of both nuclear- and 
mitochondrially-encoded subunits in order to form the large complex (Lazarou et al., 
2007). Deficiency of subunits may reduce the efficacy of assembly, leading to a 
complex I deficiency. This may have a subsequent effect on other complexes within the 
supercomplex structure and compromise the respiratory chain’s capacity for ATP 
production. 
4.5.2.2 Complex II 
Complex II is a nuclear-encoded complex, involved in both the electron transport chain 
and the citric acid cycle. There was an obvious deficiency of complex II in one patient, 
Patient 10. This was apparent in the Purkinje cells of the cerebellum showing a 
deficiency of 28%, but not in neurons of the dentate nucleus which showed no 
deficiency. All other patients showed little or no complex II deficiency with <6% of the 
neurons revealing evidence of complex II dysfunction over all brain areas. This was 
expected as all four subunits of complex II are nuclear-encoded and therefore not 
directly affected by mtDNA deletions, mutations or mtDNA copy number. The complex 
II deficiency observed in Patient 10 is unusual and there may be other factors 
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influencing this observation in Purkinje cells. This patient also exhibited a very low 
mitochondrial density which was detected when staining with an antibody for porin (see 
Chapter 3 Neuropathological Features of Patients With Alpers’ Syndrome, 3.4.6 
‘Mitochondrial Localisation in Neurons’). 
4.5.2.3 Complex III 
There was an obvious and severe deficiency of complex III in most of the patients and 
in most brain areas. An antibody to the iron-sulphur protein (Rieske subunit), which has 
a direct role in electron transfer, was used in this study. Defects in complex III can lead 
to early-onset disorders associated with respiratory chain deficiency, including clinical 
signs of seizures, developmental delay and increased serum lactate levels (Fernandez-
Vizarra et al., 2007) and GRACILE syndrome (Visapää et al., 2002). 
Complex I and complex III are considered the main producers of ROS (Chen et al., 
2003) and disruption of these complexes within the supercomplex may increase ROS 
production (Maranzana et al., 2013). In addition, the core subunits, including the 
Rieske subunit, facilitate assembly of the complex. Defects of complex III assembly 
due to mutations in an assembly factor have been shown to lead to diminished 
incorporation of the Rieske subunit, leading to a loss of complex activity (Fernandez-
Vizarra et al., 2007). 
4.5.2.4 Complex IV 
This study examined two subunits of complex IV; the mitochondrially-encoded subunit I 
and the nuclear-encoded subunit IV. Complex IV subunit I (COX I) was the only 
mitochondrially-encoded subunit that was used to study respiratory chain deficiency. A 
low to moderate deficiency of COX I was seen in all brain areas and this subunit 
showed a greater deficiency in patients than subunit IV (COX IV). This suggests that 
damage to mtDNA has decreased COX I availability, a process that has not affected 
nuclear DNA and COX IV. However, the mitochondrially-encoded COX I subunit 
showed a milder deficiency than with nuclear-encoded complex I and complex III 
subunits. This was unexpected and it may be that other mitochondrially-encoded 
subunits of complex I and complex III were lost and that this destabilised the entire 
complex.  
COX IV shows little evidence of deficiency in some patients, yet this is always in 
concordance with a greater deficiency in COX I. This is associated with the loss of 
COX I and potentially a loss of structured assembly of the entire complex. In the 
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cerebellum, Patient 11 displayed a combined COX I and COX IV deficiency which has 
been seen previously in the cerebellum of patients with POLG mutations (Lax et al., 
2012), though a combined deficiency was not seen in the cerebellum of Patient 6 and 
Patient 9 which primarily showed a COX I deficiency. 
4.5.2.5 Patient Variability 
The patients in this cohort showed a wide variation in the level of respiratory chain 
deficiency. There was a clear decreased expression of complex I and complex III 
respiratory chain subunits in patients and many brain areas showed neurons that were 
weak or deficient in these complexes. 
Patient 1 was an interesting exception to the findings in the rest of the cohort. This 
patient showed the clinical signs of seizures, ataxia and liver failure. There was no 
neuron loss documented in any brain areas where the respiratory chain was 
investigated. There was a complex I deficiency but little complex III deficiency in the 
cerebellum. In the occipital and parietal lobes, there was no complex I or complex III 
deficiency. However, there was both a complex I and complex III deficiency in the basal 
ganglia. This suggests that the survival of neurons is linked to the integrity of the 
respiratory chain. 
Patient 2 showed moderate levels of complex III deficiency in the cerebellum (39% and 
47%) but there is little evidence of complex I deficiency (between 0% and 14%) in this 
part of the brain. In the parietal lobe, there is a slightly greater deficiency of complex III 
(15%) than complex I (between 0% and 9%). The comparison of complex I and 
complex III could not be made in the occipital lobe or basal ganglia due to a lack of 
suitable tissue. This finding is intriguing because deficiencies of complex I and complex 
IV are considered the most significant to mitochondrial disorders. This suggests that a 
complex III deficiency may be tolerated by the surviving neurons and could be an 
important indicator of mitochondrial disease. 
Patient 10, no genetic diagnosis available, showed the highest complex III deficiency in 
the occipital lobe, at 80%, of all patients in all brain areas. The occipital lobe of this 
patient showed a moderate complex I deficiency of 16% complex I-19 deficiency and a 
moderate complex IV-I deficiency of 18%. There was no complex IV-IV deficiency. In 
the cerebellum, there was a moderate complex II deficiency, at 28%, in Purkinje cells. 
Selective complex III deficiency in the occipital lobe is unusual. This suggests, as with 
Patient 2 above, that a complex III deficiency may be tolerated in neurons and it should 
not be overlooked when analysing respiratory chain deficiencies in patients with 
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mitochondrial disease. A selective complex II deficiency in Purkinje cells is also 
unusual. There may be other factors influencing this observation of complex II 
deficiency in Purkinje cells, such as very low mitochondrial density as mentioned above 
(see section 4.5.2.2 ‘Complex II’). 
Patient 11, no genetic diagnosis available, showed a complex IV-IV deficiency of 14%, 
comparable to the complex IV-I deficiency of 18% in the Purkinje cells of the 
cerebellum. The cerebellum showed a high complex I deficiency of 63% complex I-19 
deficiency and a high complex III deficiency of 68%. There was no complex II 
deficiency.  
4.5.2.6 Within-group Variation 
The POLG mutation-positive group showed deficiency in complex I and complex III in 
the cerebellum and parietal lobe. There were variable levels of complex III deficiency; 
Patient 1 shows little evidence of deficiency in the cerebellum and occipital lobe, while 
Patient 2 and Patient 6 show moderate levels of deficiency. Complex II did not show 
deficiency. Complex IV subunit I showed slightly weaker staining than subunit IV in the 
cerebellum and parietal lobe, but no deficiency of either subunit in the occipital lobe. 
The POLG mutation-undetermined group showed the most severe complex I deficiency 
in the cerebellum. The parietal lobe also showed a complex I deficiency with the single 
highest percentage of complex I deficiency being found in Patient 8; this was a 53% 
deficiency of complex I-19. There was no complex II deficiency. Complex III showed 
moderate to high levels of deficiency in the cerebellum and occipital lobe, with less 
evidence of deficiency in the parietal lobe and basal ganglia. Complex IV subunit I 
showed slightly weaker staining than complex IV subunit IV in the cerebellum and 
occipital lobe. 
The POLG mutation-absent patient could be studied for respiratory chain deficiency in 
the occipital lobe only, due to a fixation length of more than 6 months in all other brain 
areas. Complex I showed little evidence of deficiency in all subunit except CI-39 (19%). 
Complex II did not show deficiency. Complex III was not deficient in the occipital lobe 
(0%). Complex IV subunit I showed very slightly more deficiency (3%) than subunit IV 
(0%).  
4.5.2.7 Inter-group Variation 
The POLG mutation-positive group showed a moderate complex I and complex III 
deficiency. Patient 1 showed only a complex I deficiency in the cerebellum while 
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Patient 2 showed both a complex I and complex III deficiency. The occipital lobe 
showed little evidence of deficiency. This suggests a mixed pattern of respiratory chain 
deficiency that is variable between patients, though commonly showing a complex I 
deficiency. The POLG mutation-undetermined group showed the most severe complex 
I and complex III deficiencies in all four brain areas. The POLG mutation-absent patient 
could be studied for respiratory chain deficiency only in the occipital lobe. This patient 
showed little or no deficiency in all respiratory chain subunits (<3%), apart from 
complex I-39, in which there was a deficiency of 19%. 
In all groups, complex I deficiency was seen, often in association with a complex III 
deficiency which can be of the same severity. The POLG mutation-undetermined group 
showed the most severe deficiencies, which may reflect the unknown mutations 
present in this group. 
4.5.3 Respiratory Chain Deficiency in Glial Cells 
Glial cells are found throughout the brain, performing many vital functions and 
supporting the neurons within the brain tissue. The parietal lobe was examined in two 
patients and is considered in this discussion. Further brain areas and patients could not 
be examined in the time frame of this project. 
Patient 2 shows complex I and complex III deficiencies, though mitochondria appear to 
be present in the glial cells. This indicates a respiratory chain deficiency in the glial 
cells, despite little evidence of complex I deficiency (5% CI-19 and 9% CI-30) and 
moderate complex III deficiency (15%) in the neurons of the parietal lobe of Patient 2. 
Complex II shows no deficiency, which was expected as this is a nuclear-encoded 
subunit and unaffected by mtDNA mutations. 
Patient 6 shows mitochondrial deficiency and respiratory chain deficiencies of complex 
I and complex II. Staining with an antibody to porin shows low mitochondrial density in 
the glial cells while complex I and complex II-70 show moderate to high levels of 
deficiency. This highlights the loss of the respiratory chain and a low mitochondrial 
density which both reduces the capability of OXPHOS in the cell and increases the 
demand for energy from remaining mitochondria, increasing oxidative stress and 
damaging levels of ROS. This appears to only affect glial cells as complex II is intact in 
the neurons of Patient 6. 
Patient 2 was a child patient of 27 months old at death and had a relatively short 
course of disease progression of 10 months. By contrast, Patient 6 was a young adult 
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patient of 18 years old at death and had a longer course of disease progression of 2 
years. Both of these disease progressions are compatible with Alpers’ syndrome, and 
the severity of the glial cells respiratory chain deficiency may reflect the length of 
disease progression. A longer disease progression may result in a greater respiratory 
chain deficiency leading to a loss of mitochondria over time. 
Due to the large numbers of visible glial cells with or without respiratory chain 
deficiency, it is possible that the glial cells are a rapidly proliferating cell type, such as 
astrocytes or microglia (Janeczko 1991), that require increased energy to allow for the 
changes in the physiological state of the cell. Respiratory chain deficiency has been 
noted in the astrocytes of patients with mitochondrial disease (Lax et al., 2012) and 
cells positively identified as astrocytes through GFAP staining appeared swollen, an 
observation in rat models with chronic sodium valproate administration (Sobaniec-
Lotowska 2001). The activation of microglia requires increased energy and this may 
have an impact upon mitochondria within these cells, resulting in an increased 
respiration rate (Reichner et al., 1995). Electron microscopy investigation has shown 
changes to mitochondrial morphology in activated microglia, resulting in elongated, 
crescentiform, or ring-shaped mitochondria (Banati et al., 2004). 
Further analysis of this would be required, showing dual GFAP-positive staining or 
CD68-positive staining with additional respiratory chain antibody deficiency in the same 
cells. 
4.5.4 The Project’s Findings in the Context of the Literature 
The literature reports biochemical and histochemical studies of patient tissues which 
show a range of respiratory chain deficiencies. Liver, muscle, and fibroblasts are the 
most usual cell types to be studied in patients with POLG disorders, due to their 
relevance to the features of the disease or their ease of sampling. When tested, liver is 
often reported to show biochemical respiratory chain abnormalities whilst muscle and 
fibroblast samples may appear normal. It may be that defects in the POLG enzyme 
lead to secondary mtDNA mutations which may accumulate in post-mitotic tissues. As 
fibroblasts are mitotic cells, they may not develop the level of secondary mtDNA 
mutations seen in post-mitotic tissues. However, defective mtDNA replication may 
cause a more severely decreased oxidative phosphorylation in mitotic tissues as these 
cells require increased mtDNA replication during cell division. The mechanisms 
underlying tissue specificity in POLG disorders are currently unclear. 
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The previous literature on patients with POLG mutations contains mixed reports of 
respiratory chain abnormalities. This ranges from no reported respiratory chain 
deficiency in patients with a single POLG mutation (Hakonen et al., 2008) and no 
reported respiratory chain deficiency in patients with two recessive POLG mutations 
(Milone et al., 2008), to a severe deficiency involving multiple complexes in patients 
with two recessive POLG mutations (Isohanni et al., 2011). The cohort examined in this 
project is in agreement with the previous investigations that found a respiratory chain 
deficiency, primarily of complex I, in neurons of the brain. 
The previous literature on patients with Alpers’ syndrome describes respiratory chain 
deficiency of multiple complexes in a range of tissues, including liver, muscle, and 
fibroblasts (Table 4.25). Respiratory chain investigations in neurons from the brain 
have not previously been described in the literature. A 3 year old male patient with 
Alpers-Huttenlocher syndrome was reported with respiratory chain deficiencies in 
muscle tissue of complex I at 19%, complex II at 59%, complex III at 36%, and complex 
IV at 40% of control muscle values (Delarue et al., 2000). A 17 year old female patient 
with Alpers’ syndrome, harbouring the p.Thr851Ala and p.Arg1047Trp POLG 
mutations, showed normal levels of complexes I, II, II+III, III and IV in muscle 
homogenate (Wiltshire et al., 2008). In a liver biopsy from this patient, enzymes studies 
showed complex I at 8%, complex III at 33%, and complex IV at 19% of control values, 
with normal complex II and elevated citrate synthase. 
A range of tissues were affected by respiratory chain dysfunction. Interestingly, muscle 
was affected in two of these cases and unaffected in another despite other tissue types 
showing dysfunction. This highlights that muscle cannot be relied upon to be a 
diagnostic tissue when investigating Alpers’ syndrome (Gauthier-Villars et al., 2001; 
Nguyen et al., 2005; Delonlay et al., 2013). 
Variability in the complex deficiency between different brain areas, and different tissue 
types reported in the literature, suggests the possibility of epigenetic effects upon the 
mitochondria in these neurons. This is a recent area of investigation that will provide 
many new and interesting aspects of mitochondrial disease and may shed more light 
on the understanding of tissue specificity in mitochondrial disease (Byun and Baccarelli 
2014). 
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Respiratory Chain 
Abnormality (% of 
control value) 
Tissue 
Studied 
Type of 
Investigation 
POLG Mutation Publication 
Complex I 8% 
Complex III 33% 
Complex IV 19% 
Liver Biochemical 
p.Thr851Ala; 
p.Arg1047Trp 
(Wiltshire et 
al., 2008) 
Reduced complex I 
and IV 
Liver Biochemical 
p.Ala467Thr; 
c.3643+2T>C 
(Roels et al., 
2009) 
COX-deficiency Liver 
Histochemical test 
for enzyme 
activity 
Reduced complex I, 
III, and IV 
Liver Biochemical 
p.Ala467Thr; 
c.1251-2A>T 
(Schaller et 
al., 2011) 
Reduced complex I, 
III, IV 
Liver Biochemical 
p.Ala467Thr; 
p.Trp748Ser; 
p.Gly848Ser; 
p.Arg852Cys; 
p.Ser305Arg; 
p.Leu966Arg; 
p.Arg232His; 
p.His277Leu 
(Hunter et al., 
2011) 
Complex I 25% 
Complex III 31% 
Complex IV 52% 
Liver Biochemical 
p.Gly848Ser; 
p.Trp748Ser 
(Davidzon et 
al., 2005) 
COX-deficiency Liver 
Histochemical test 
for enzyme 
activity 
p.Ala467Thr; 
p.Ala467Thr 
(Boes et al., 
2009) 
COX-deficiency Liver 
Histochemical test 
for enzyme 
activity 
p.Ala467Thr; 
p.Leu605Arg 
(Stewart et al., 
2009) 
Reduced complex I Liver Biochemical Unknown 
(Gauthier-
Villars et al., 
2001) 
Reduced complexes Liver Biochemical 
p.Trp748Ser; 
p.I948fsX968 
(Sarzi et al., 
2007) 
p.Ala467Thr; 
p.T326fsX387 
p.Leu428Pro; 
p.Ala467Thr 
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Respiratory Chain 
Abnormality (% of 
control value) 
Tissue 
Studied 
Type of 
Investigation 
POLG Mutation Publication 
Reduced complex IV Liver Histochemical test 
for enzyme 
activity 
p.Ala467Thr; 
p.Ala467Thr (Nguyen et al., 
2005) 
Normal Liver 
p.Trp748Ser; 
p.Gly848Ser 
Complex I 19% 
Complex II 59% 
Complex III 36% 
Complex IV 40% 
Muscle Biochemical Not confirmed 
(Delarue et 
al., 2000) 
Partial COX-
deficiency 
Muscle 
Histochemical test 
for enzyme 
activity 
p.Ala467Thr; 
p.Thr914Pro 
(Morris et al., 
1996) 
COX-deficiency 
Muscle 
Histochemical test 
for enzyme 
activity 
p.Ala467Thr; 
p.Leu605Arg 
(Stewart et al., 
2009) 
COX-deficiency 
p.Ala467Thr; 
p.Gly848Ser 
5% COX-deficient 
fibres 
p.Ala467Thr; 
p.Gly848Ser 
Normal 
p.Gly11Asp; 
p.Ala467Thr; 
p.Arg852Cys 
Reduced complex IV Muscle Biochemical 
p.Ala467Thr; 
c.1251-2A>T 
(Schaller et 
al., 2011) 
Reduced complex I, 
III, IV 
Muscle 
Histochemical test 
for enzyme 
activity 
p.Arg227Trp; 
p.Ala467Thr; 
(de Vries et 
al., 2007) 
Reduced complex I, 
II, III 
p.Gly848Ser; 
p.Ala467Thr 
Reduced complex I, 
III 
p.Ala957Pro; 
p.Ala467Thr 
Normal 
Reduced complex I 
Reduced complex I-
III 
Reduced complex I-
IV 
COX-deficiency 
Muscle 
Biochemical and 
histochemical test 
for enzyme 
activity 
p.Ala467Thr; 
p.Arg574Trp; 
p.Gly848Ser; 
p.Trp748Ser; 
p.Gly303Arg; 
p.Ag232His; 
p.Met1163Arg 
(Sofou et al., 
2012) 
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Respiratory Chain 
Abnormality (% of 
control value) 
Tissue 
Studied 
Type of 
Investigation 
POLG Mutation Publication 
Normal Muscle Biochemical Unknown 
(Gauthier-
Villars et al., 
2001) 
Normal Muscle Biochemical p.Trp748Ser 
(Naess et al., 
2012) 
Normal Muscle Histochemical test 
for enzyme 
activity 
p.Ala467Thr; 
p.Ala467Thr (Nguyen et al., 
2005) 
Normal Muscle 
p.Trp748Ser; 
p.Gly848Ser 
Normal Muscle Biochemical 
p.Trp748Ser; 
p.Y1210fs1216X 
(Ferrari et al., 
2005) 
Normal Muscle 
Histochemical test 
for enzyme 
activity 
Not confirmed 
(Schwabe et 
al., 1997) 
Normal Muscle Biochemical 
p.Thr851Ala; 
p.Arg1047Trp 
(Wiltshire et 
al., 2008) 
Normal Muscle Biochemical 
p.Ala467Thr; 
c.3643+2T>C 
(Roels et al., 
2009) 
Normal Muscle Biochemical 
p.Trp748Ser; 
p.I948fsX968 
(Sarzi et al., 
2007) 
p.Ala467Thr; 
p.T326fsX387 
p.Ala467Thr; 
IVS20nt+2T>C 
Reduced complex I Fibroblasts Biochemical 
p.Ala467Thr; 
c.3643+2T>C 
(Roels et al., 
2009) 
Normal Fibroblasts Biochemical 
p.Ala467Thr; 
c.1251-2A>T 
(Schaller et 
al., 2011) 
Normal Fibroblasts 
Histochemical test 
for enzyme 
activity 
p.Arg227Trp; 
p.Ala467Thr; 
p.Gly848Ser; 
p.Ala957Pro 
(de Vries et 
al., 2007) 
Normal Fibroblasts Biochemical 
p.Trp748Ser; 
p.Y1210fs1216X 
(Ferrari et al., 
2005) 
Table 4.25. Published studies of respiratory chain investigations in patients with 
Alpers’ syndrome. 
275 
 
Chapter 4 Respiratory Chain Deficiency in Patients with Alpers’ Syndrome 
This table is a comprehensive list of publications. The list is extensive at the time of 
writing. Science publication databases Pubmed and Web of Knowledge were used with 
the search terms ‘Alpers syndrome’ and ‘Alpers syndrome respiratory chain deficiency’. 
 
Key: COX=cytochrome c oxidase  
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4.5.5 Novel Findings 
This is the first study to examine the severity of respiratory chain deficiency in single 
neurons in the brains of patients diagnosed with Alpers’ syndrome. This project has 
tested a battery of respiratory chain antibodies in single neurons in a large cohort of 
patients, which has not been published previously in the literature. 
In addition to neurons exhibiting a complex I deficiency, there was a complex III 
deficiency in all four brain areas. Complex III is rarely investigated in mitochondrial 
diseases and has revealed a new facet in the pathology of Alpers’ syndrome. Complex 
IV showed a slight deficiency in subunit I while subunit IV showed no change. The 
occipital lobe demonstrated little respiratory chain deficiency, though moderate 
neuropathology was shown in this area in patients with a POLG defect. This is 
surprising and may be due to the fact that neurons with a respiratory deficiency had 
already disappeared while neurons without any deficiency remained and were counted. 
The neurons in these young patients were small and it is also possible that some 
neuronal subtypes may have been too small to assess at the highest magnification of 
X100. If these neuronal subtypes showed respiratory chain deficiency, it would not 
have been possible to assess them during this project. 
The use of sodium valproate is not recommended in patients with a mitochondrial 
disease. Unfortunately, it may be administered prior to a full diagnosis. The chronic 
administration of sodium valproate to healthy rat models resulted in swollen astrocytes 
in the cerebellum (Sobaniec-Lotowska 2001). Although the mechanism by which 
sodium valproate becomes harmful in patients with a metabolic disorder is not fully 
understood, pathological features in healthy rat models suggests that similar pathology 
may occur in patients with mitochondrial disease. In patients of the cohort, the degree 
of swelling in the glial cells was different between the two patients examined, 
suggesting a progression of this pathological feature. In addition, the glial cells were 
found to have a respiratory chain deficiency which has not been reported in Alpers’ 
syndrome previously. In future projects, further brain areas could be examined for signs 
of glial cell pathology. 
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4.6 Future Work 
The work performed in this study has highlighted the need for large cohorts when 
examining respiratory chain deficiencies in Alpers’ syndrome. Bringing together many 
patients allows for deficiencies to be compared between groups of similar patients. 
Further assessment of complex I deficiencies in patients would be interesting, allowing 
research into the assembly of complex I and whether complex I deficiency in patients 
with Alpers’ syndrome is due, in part, to an assembly problem.  
Further investigations are needed into respiratory chain deficiencies in glial cell 
populations in different brain regions and in greater numbers of patients. Discovering 
the function of the respiratory chain deficient glial cells and correlating the severity of 
the respiratory chain deficiency, in neurons and glial cells, with the length of disease 
progression may give insight into the progression of Alpers’ syndrome and into POLG 
disorders. Astrocytes were seen that were greatly swollen while others had a milder 
swollen morphology. Research into whether the degree of swelling correlates with the 
severity of the disease features would aid understanding into the morphological change 
in these astrocytes. Whether multiple glial cell populations exhibit respiratory chain 
deficiencies may increase our knowledge of the pathology and progression of Alpers’ 
syndrome and give hope for possible therapies.  
This study has underlined the importance of quantifying the respiratory chain deficiency 
seen in the neurons of patients, and of examining all cells that play a role in supporting 
these neurons. 
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Chapter 5 Mitochondrial DNA Deletion and Depletion in Alpers’ 
Syndrome 
5.1 Introduction 
The integrity of mitochondrial DNA (mtDNA) is central to the functioning of the 
respiratory chain and the production of ATP. POLG is the sole DNA polymerase to 
replicate mtDNA in mammalian cells and is essential for life (Hance et al., 2005). POLG 
is encoded by a nuclear gene, mutations of which may result in dysfunction of the 
polymerase and inaccurate replication of mtDNA. This inaccurate replication has been 
reported to lead to deletions in the mtDNA (Van Goethem et al., 2001; Kollberg et al., 
2006) and to a depletion of mtDNA content (Naviaux et al., 1999; Uusimaa et al., 
2008). MtDNA deletion and depletion may result in a reduced expression of respiratory 
chain complexes, leading to respiratory chain deficiency and reducing the capacity for 
oxidative phosphorylation and ATP production, leading to cellular dysfunction. The 
CNS is very susceptible to changes in ATP levels, and both mtDNA deletion and 
depletion may act to decrease the amount of ATP produced and ultimately have a 
negative effect on the functioning of the CNS and brain. 
Previous studies have examined mtDNA deletion and depletion in patients with Alpers’ 
syndrome in a variety of tissues, including muscle, liver, brain, and fibroblasts, 
describing either mtDNA deletion, depletion, or a combination of both (Naviaux et al., 
1999; Ferrari et al., 2005; Kollberg et al., 2006). It is unclear whether one form of 
mtDNA damage is more prominent than the other, or whether they may occur together 
in a single cell. Unfortunately, many studies have been unable to answer this question. 
The method of tissue analysis is of great importance regarding what can be interpreted 
from the results of a study. The type of tissue is central to accurately assessing the 
health of mtDNA in neurons. The studies mentioned previously do not specify the type 
of tissue used to achieve the results, whether homogenate tissue or a single cell 
analysis. The analysis of single neurons allows for the increased sensitivity of a test 
and the accurate assessment of any mtDNA deletion and depletion. 
The previous chapters examined the neuropathology and respiratory chain deficiency 
in different brain areas of the cohort. This chapter will investigate mtDNA deletions and 
depletion and quantify this in single neurons from a subset of patients from the cohort. 
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5.2 Aims 
Patients with Alpers’ syndrome have shown clear respiratory chain dysfunction in 
neurons. The aims of this work are:  
1. To assess the mtDNA damage (mtDNA deletions and mtDNA depletion) in 
single neurons taken from frozen brain tissue. 
2. To investigate mtDNA damage in a wide age range of patients. MtDNA damage 
will be investigated in a young patient and in older teenage-adult patients, each 
with age-matched control tissue. 
5.3 Methodological Approach 
5.3.1 Patients and Controls 
Three patients and three age-matched controls were analysed to assess mtDNA 
damage (Table 5.1). These patients from the cohort were chosen based upon frozen 
tissue availability. 
Patient 
Age at 
Death 
(years) 
Sex POLG Mutation Available Brain Areas 
Patient 3 17 M p.Ala467Thr; p.Ala467Thr Frontal lobe 
Control 3 19 M N/A Parietal lobe, frontal lobe, temporal lobe 
Patient 4 24 F p.Ala467Thr; p.Trp748Ser 
Parietal lobe, occipital lobe, 
cerebellum, basal ganglia, 
frontal lobe, temporal lobe 
Control 4 27 M N/A Parietal lobe, frontal lobe, temporal lobe 
Patient 12 6 M None Parietal lobe, occipital lobe, basal ganglia 
Control 9 6 F N/A Parietal lobe, occipital lobe, cerebellum, basal ganglia 
Table 5.1. Details of the patients and controls used in the study of mtDNA 
abnormalities.  
Frozen tissue was used for patients and controls. 
Key: N/A=not applicable 
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5.3.2 SDH Histochemistry 
Frozen brain tissue sections from three patients and three controls (Table 5.1) were 
assessed by SDH histochemistry in order to visualise neurons. Sequential COX/SDH 
histochemistry was used to provide further information, highlighting neurons with a 
mtDNA defect which was shown by neurons that were COX-deficient and SDH-
positive. This was performed for one patient but could not be performed for all patients 
as the SDH reactivity proved to be low in most of the tissue samples, possibly due to 
the length of time in storage. 
20µm sections of frozen tissue were mounted on PEN slides (Leica Microsystems) and 
SDH histochemistry performed. After air drying, laser capture micro-dissection of single 
neurons was performed using the Zeiss Laser Microdissection System. Cells lysed 
overnight at 56oC using Tris-HCl buffer, Tween 1% and proteinase K. The next day, the 
proteinase K was deactivated at 95oC for 10 minutes before further applications. 
5.3.3 Real-time PCR 
The lysate from each neuron was tested in triplicate using quantitative real-time PCR 
with precise fluorogenic TaqMan probes (Applied Biosystems) to assess the 
amplification of the mitochondrial genes MT-ND1 and MT-ND4. The percentage of 
deletions in mtDNA was calculated using the relative proportions of amplified MT-ND4 
to MT-ND1, using the ΔCt method. The depletion of mtDNA (copy number) in single 
neurons was calculated using a standard curve derived from control samples of known 
copy number. The values were corrected to account for lysate volume and neuron area 
(µm2). A Ct value of less than 30 was considered to indicate DNA in the sample. 
A well-known limitation of real-time PCR is that it is inaccurate when detecting low 
levels of heteroplasmy, below 30%, as the sensitivity of the method does not allow for 
detection of these low levels. The technique may detect up to 30% heteroplasmy even 
if no mtDNA deletions are present. Suitable methods for detecting low levels of 
heteroplasmy are only available for specific mutations using PCR-based methods, for 
example SYBR Green. 
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5.3.4 Statistical Testing 
Both parametric and non-parametric statistical tests were used in this study. The 
normality of the data and the variance of the data were assessed using the Anderson-
Darling normality test and the F-test of Variances. If the data were statistically normal 
with normal variance, the unpaired two-tailed t-test was used. For data that were not 
statistically normal, the non-parametric Mann-Whitney U test was used. 
5.4 Results 
5.4.1 Mitochondrial DNA Deletion 
MtDNA deletion was assessed in single neurons subjected to SDH histochemistry and 
analysed with real-time PCR. Sequential COX/SDH histochemistry was not performed 
as the SDH reactivity proved to be low in most of the tissue, possibly due to the length 
of time in storage. 
Neurons were assessed from control tissues and showed values that were compatible 
with no mtDNA deletions being present. 
5.4.1.1 Young Adult Patients – Single Histochemistry 
Patient 3, a 17 year old male, was a POLG mutation-positive patient that was sex-/age-
matched to Controls 3 and 4. The frontal lobe only was available and neurons were 
tested from this region. The tissue was subjected to SDH histochemistry only. 
Patient 3 shows high levels of mtDNA deletions in a subset of neurons (Figure 5.1). 
The majority of neurons from Patient 3 had values within the experimental error of the 
assay (see above). This indicates that a subset of neurons from the patient may 
contain mtDNA deletions. The values in neurons from controls were compatible with no 
mtDNA deletions being present.  
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Figure 5.1. MT-ND4 deletions in frontal lobe of Patient 3 and Controls 3 and 4.  
The majority of neurons of the frontal lobe of Patient 3 have percentage values within 
the experimental error of the assay. A subset of neurons has high percentage values of 
MT-ND4 deletions. 
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Patient 4, a 24 year old female, was a POLG mutation-positive patient that was age-
matched to Controls 3 and 4. Neurons were tested from the parietal lobe, frontal lobe 
and temporal lobe. These three brain regions were chosen in order to have matching 
control brain regions to compare the patient results to, as other brain regions were not 
available for the controls. The tissue was subjected to SDH histochemistry only. 
Patient 4 shows evidence of mtDNA deletions in a small subset of neurons from the 
parietal lobe (Figure 5.2). The majority of neurons from Patient 4 had values within the 
experimental error of the assay. No mtDNA deletions were observed in the frontal lobe 
and temporal lobe. The values in neurons from controls were compatible with no 
mtDNA deletions being present. 
 
Figure 5.2. MT-ND4 deletions in Patient 4 and Controls 3 and 4.  
The majority of neurons of the parietal lobe of Patient 4 have percentage values within 
the experimental error of the assay. A subset of neurons in the parietal lobe has high 
percentage values of MT-ND4 deletions. The neurons of the frontal lobe and temporal 
lobe have percentage values within the experimental error of the assay. 
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5.4.1.2 Young Adult Patients – Sequential Histochemistry 
Sequential COX/SDH histochemistry was assessed for Patient 4 only. Patient 3 was 
not considered for this assessment as single SDH histochemistry was weak on the 
glass slides, so sequential COX/SDH histochemistry was not considered useful or 
informative. 
Only mtDNA deletions could be assessed when using sequential COX/SDH 
histochemistry as 3’ 3-diaminobenzidine (DAB), used in the visualisation of COX 
histochemistry, has been shown to interfere with the PCR method used in calculating 
DNA copy number (Murphy et al., 2012). 
Six different brain areas were available for Patient 4 and neurons were tested from the 
occipital lobe, parietal lobe, basal ganglia, cerebellum, frontal lobe and temporal lobe. 
The tissues were subjected to sequential COX/SDH histochemistry. 
The results show that both COX-positive and COX-deficient neurons contain mtDNA 
deletions. Whilst in many brain regions there was a slight increase in the number of 
cells with high levels of mtDNA deletion in COX-deficient neurons, a clear difference 
was only observed in the Purkinje cells of the cerebellum (Figure 5.3). In the basal 
ganglia, it was the lateral area of the globus pallidus that showed a clear difference 
(Figure 5.4). 
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Figure 5.3. MT-ND4 deletions in Patient 4 taken from slides with sequential 
COX/SDH histochemistry.  
The percentage of MT-ND4 deletions in COX-positive neurons are compared to COX-
deficient neurons in Patient 4. Purkinje cells were investigated from the cerebellum. 
Pyramidal neurons were investigated from the cerebral brain areas. A clear increase in 
the percentage of MT-ND4 deletions in COX-deficient neurons compared to COX-
positive neurons is seen in the cerebellum. 
Key: pos=COX-positive, def=COX-deficient  
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Figure 5.4. MT-ND4 deletions in Patient 4 taken from slides with sequential 
COX/SDH histochemistry from the basal ganglia.  
The percentage of MT-ND4 deletions in COX-positive neurons are compared to COX-
deficient neurons in Patient 4. This figure shows the percentage of MT-ND4 deletions 
in different areas of the basal ganglia. A clear increase in the percentage of MT-ND4 
deletions in COX-deficient neurons compared to COX-positive neurons is seen in the 
lateral globus pallidus. 
Key: pos=COX-positive, def=COX-deficient 
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5.4.1.3 Young Child Patient 
Patient 12, a 6 year old male without a POLG mutation, was age-matched to Control 9. 
Three different brain areas were available: the occipital lobe, the parietal lobe and the 
basal ganglia. The tissues were subjected to SDH histochemistry only.  
The neurons from Patient 12 and from Control 9 had mtDNA deletion values within the 
experimental error of the assay (Figure 5.5). These values were compatible with no 
mtDNA deletions being present. 
 
Figure 5.5. MT-ND4 deletions in Patient 12 and Control 9.  
The neurons of the occipital lobe, parietal lobe, and basal ganglia of Patient 12 have 
percentage values within the experimental error of the assay.  
Key: BG=basal ganglia, GP=globus pallidus  
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5.4.2 Mitochondrial DNA Depletion 
MtDNA depletion (copy number) was assessed in single neurons subjected to SDH 
histochemistry and assessed with real-time PCR. Sequential COX/SDH histochemistry 
was not performed as 3’ 3-diaminobenzidine (DAB), used in the visualisation of COX 
histochemistry, has been shown to interfere with the PCR method used in calculating 
DNA copy number. 
Neurons were assessed from control tissues. Some control neurons gave values that 
suggested they contained a low mtDNA copy number. This may be due to a variation 
produced by the real-time PCR method and due to this a large number of neurons were 
assessed for both controls and patients. The mean value of mtDNA copy number in the 
group of assessed neurons for a particular brain area was taken for controls and 
compared to the mean value of mtDNA copy number in the group of assessed neurons 
for the patient. 
5.4.2.1 Young Adult Patients 
Patient 3, a 17 year old male, was a POLG mutation-positive patient that was sex-/age-
matched to Controls 3 and 4. The frontal lobe only was available and neurons were 
tested from this region. The tissue was subjected to SDH histochemistry only. 
Patient 3 shows low mtDNA copy number (Figure 5.6) that is significantly different from 
the control values in the frontal lobe. 
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Figure 5.6. MtDNA copy number in frontal lobe of Patient 3 and Controls 3 and 4.  
The neurons of the frontal lobe of Patient 3 have a low mtDNA copy number that is 
significantly different to control values. The Mann-Whitney U test was used. * P<0.05, 
** P<0.01, *** P<0.001, **** P<0.0001. MtDNA copy number is expressed as the 
number of mtDNA molecules per neuronal cell body area (µm2). 
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Patient 4, a 24 year old female, was a POLG mutation-positive patient that was age-
matched to Controls 3 and 4. Neurons were tested from the parietal lobe, frontal lobe 
and temporal lobe. These three brain regions were chosen in order to have matching 
control brain regions to compare the patient results to, as other brain regions were not 
available for the controls. The tissues were subjected to SDH histochemistry only. 
Patient 4 shows low mtDNA copy number. This is significantly different from the control 
for both MT-ND1 and MT-ND4 in the parietal lobe (Figure 5.7) and the frontal lobe 
(Figure 5.8). MtDNA copy number is not significantly different between Patient 4 and 
both controls in the temporal lobe (Figure 5.9). 
 
Figure 5.7. MtDNA copy number in parietal lobe of Patient 4 and Controls 3 and 4.  
The neurons of the parietal lobe of Patient 4 have a low mtDNA copy number that is 
significantly different to control values. The Mann-Whitney U test was used. * P<0.05, 
** P<0.01, *** P<0.001, **** P<0.0001. MtDNA copy number is expressed as the 
number of mtDNA molecules per neuronal cell body area (µm2). 
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Figure 5.8. MtDNA copy number in frontal lobe of Patient 4 and Controls 3 and 4.  
The neurons of the frontal lobe of Patient 4 have a low mtDNA copy number that is 
significantly different to control values. The Mann-Whitney U test was used. * P<0.05, 
** P<0.01, *** P<0.001, **** P<0.0001. MtDNA copy number is expressed as the 
number of mtDNA molecules per neuronal cell body area (µm2). 
 
292 
 
Chapter 5 Mitochondrial DNA Deletion and Depletion in Alpers’ Syndrome 
 
Figure 5.9. MtDNA copy number in temporal lobe of Patient 4 and Controls 3 and 
4.  
The neurons of the temporal lobe of Patient 4 have a mtDNA copy number that is not 
significantly different to control values. An unpaired two-tailed t-test was used. The 
Mann-Whitney U test was used to determine the values for Patient 4 MT-ND4 vs 
Control 3 MT-ND4, and Patient 4 MT-ND1 vs Control 4 MT-ND1 as the variances 
differed significantly. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. MtDNA copy 
number is expressed as the number of mtDNA molecules per neuronal cell body area 
(µm2). 
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5.4.2.2 Young Child Patient 
Patient 12, a 6 year old male without a POLG mutation, was age-matched to Control 9. 
Three different brain areas were available and neurons were tested from the occipital 
lobe, parietal lobe and basal ganglia. The tissues were subjected to SDH 
histochemistry only. 
Patient 12 shows low mtDNA copy number. This is significantly different between the 
range of neuronal values of the patient and the range of neuronal values of the control 
in the occipital lobe (Figure 5.10), the parietal lobe (Figure 5.11) and the putamen 
(Figure 5.12). 
 
 
Figure 5.10. MtDNA copy number in occipital lobe Patient 12 and Control 9.  
The neurons of the occipital lobe of Patient 12 have a low mtDNA copy number that is 
significantly different to control values. An unpaired two-tailed t-test was used. * 
P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. MtDNA copy number is expressed as 
the number of mtDNA molecules per neuronal cell body area (µm2). 
294 
 
Chapter 5 Mitochondrial DNA Deletion and Depletion in Alpers’ Syndrome 
 
Figure 5.11. MtDNA copy number in parietal lobe Patient 12 and Control 9.  
The neurons of the parietal lobe of Patient 12 have a low mtDNA copy number that is 
significantly different to control values. An unpaired two-tailed t-test was used. * 
P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. MtDNA copy number is expressed as 
the number of mtDNA molecules per neuronal cell body area (µm2). 
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Figure 5.12. MtDNA copy number in the putamen of the basal ganglia from 
Patient 12 and Control 9.  
The neurons of the putamen of the basal ganglia of Patient 12 have a low mtDNA copy 
number that is significantly different to control values. An unpaired two-tailed t-test was 
used to determine the values for MT-ND1. The Mann-Whitney U test was used to 
determine the values for MT-ND4 as the variances differed significantly. * P<0.05, ** 
P<0.01, *** P<0.001, **** P<0.0001. MtDNA copy number is expressed as the number 
of mtDNA molecules per neuronal cell body area (µm2). 
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5.5 Discussion 
This chapter has examined for the presence of mtDNA abnormalities in neurons of 
patients with confirmed POLG mutations and a patient with no mutations in POLG. 
5.5.1 Inter-group Variation 
Patient 12, a 6 year old male, is a young child patient with no mutation in POLG (Table 
5.1). In the occipital lobe, parietal lobe, and caudate and putamen of the basal ganglia, 
the patient shows levels of mtDNA deletion within the experimental error of this assay 
(<30%). 
Patients 3 and 4 are young adult patients with common mutations in POLG; Patient 3, 
a 17 year old male, is homozygous for the p.Ala467Thr mutation and Patient 4, a 24 
year old female, is compound heterozygous for the p.Ala467Thr and p.Trp748Ser 
mutations (Table 5.1). 
Patient 3 shows both low levels (<30%) and high levels (>70%) of mtDNA deletion in 
subsets of neurons. There are two clear groupings of neurons with either low or high 
levels of mtDNA deletions. This may indicate a changing level of mtDNA loss in some 
neurons and a change towards an increased number of neurons with high levels of 
mtDNA deletions over time. The two populations have very distinct mtDNA deletion 
levels which may also indicate different neuronal subtypes that were sampled. It is not 
possible to morphologically distinguish different neuronal subtypes in a frozen tissue 
sample and neuronal subtypes that are more vulnerable to mtDNA damage may be 
present in the sample. Patient 3 shows moderate levels of mtDNA depletion in the 
frontal lobe. 
Patient 4 shows levels of mtDNA deletion within the experimental error of this assay 
(<30%) in the parietal lobe, frontal lobe, and temporal lobe. The parietal lobe shows 
some neurons with moderate levels of deletion (>30% and <70%). The patient shows 
moderate levels of mtDNA depletion in the parietal lobe and frontal lobe. The temporal 
lobe is relatively spared and does not show any mtDNA depletion, which agrees with 
the general clinical description of Alpers’ syndrome of there being no features of the 
disease directly correlating with temporal lobe damage. It is possible that neurons in 
this area of the brain are not as susceptible to damage as neurons in the occipital lobe 
and frontal lobe. 
  
297 
 
Chapter 5 Mitochondrial DNA Deletion and Depletion in Alpers’ Syndrome 
Depletion of mtDNA appears to play a greater role in Alpers’ syndrome and results in 
reduced expression of respiratory chain complexes and impaired OXPHOS 
capabilities. Both the young patient and adult patients have more significant levels of 
mtDNA depletion than mtDNA deletion. MtDNA deletions do not appear to be 
consistently at high levels in any of the patients. However, the adult patients show a 
subset of their neurons with high levels of mtDNA deletion, suggesting that these 
deletions increase in some neurons over time. 
5.5.2 COX-Positive and COX-Deficient Neurons 
MtDNA deletions were assessed in COX-positive and COX-deficient neurons from 
Patient 4, in order to investigate whether there is a difference between mtDNA deletion 
levels in neurons showing mitochondrial abnormalities. MtDNA depletion was not 
assessed as 3’ 3-diaminobenzidine (DAB), used in the visualisation of COX 
histochemistry, has been shown to interfere with the PCR method used in calculating 
DNA copy number (Murphy et al., 2012). 
All the brain regions studied showed a trend of a higher percentage of deletions in the 
COX-deficient neurons when compared to the COX-positive neurons. Unsurprisingly, 
this suggests that COX-deficient neurons harbour more mtDNA deletions than COX-
positive neurons and that these mtDNA deletions could have affected the 
mitochondria’s capability to perform oxidative phosphorylation. Neurons that are COX-
deficient and show levels of mtDNA deletion within the experimental error of this assay 
(<30%) may have a true deletion level that is higher because low levels are not 
accurately detected by the real-time PCR method. Alternative methods to quantify low 
levels of mtDNA deletions and depletion currently include other PCR-based 
techniques, such as nested real-time PCR. 
5.5.3 The Project’s Findings in the Context of the Literature 
The previous literature on patients with Alpers’ syndrome contains many reports of 
mtDNA depletion (Naviaux et al., 1999; Naviaux and Nguyen 2004; Ferrari et al., 2005; 
Scalais et al., 2012). The findings in this study are in agreement with previous 
investigations that found mtDNA depletion in patient tissues. Additionally, mtDNA 
deletions have been reported in muscle tissue of patients with Alpers’ syndrome 
(Kollberg et al., 2006), however mtDNA deletions are not as commonly reported as 
mtDNA depletion. This study found mtDNA depletion seemed to be more prevalent 
than mtDNA deletions in terms of the mtDNA defect detected. 
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A study assessing patient groups both with POLG mutations and without POLG 
mutations suggested differences in mtDNA abnormalities. Patients with POLG 
mutations showed more mtDNA deletions and/or mtDNA depletion but patients without 
POLG mutations showed no mtDNA deletions or depletion (Sofou et al., 2012). My 
study does not agree with this as both patient groups with either POLG mutations or 
without POLG mutations showed mtDNA damage. However, greater numbers of 
patients and controls are needed to confirm this. The lack of mtDNA damage in the 
patients without a POLG mutation in the published study is odd and may be attributable 
to the use of skeletal muscle and blood tissue samples to analyse the mtDNA, 
extracting mtDNA from homogenate tissue as opposed to single cells. The data 
compiled in this thesis chapter have been derived from single cell analysis of neurons 
from different regions of the brain, allowing for a much more sensitive test for the 
presence of mtDNA deletions and depletion in patients. The inclusion of neurons from 
a greater number of controls per patient group would further increase the accuracy of 
the test. 
Studies investigating both mtDNA deletion and depletion have primarily looked at 
muscle and liver tissues, with fewer studies including brain tissue for examination. 
Investigations into a patient with Alpers’ syndrome showed reduced mtDNA content of 
15% and 33% in liver and muscle respectively with a normal mtDNA content in brain, 
relative to controls (Uusimaa et al., 2008). It is unusual that brain tissue appeared to 
have no mtDNA deletions or depletion. However, if a homogenate tissue sample was 
used for the analysis then a mixture of neurons and other less susceptible cell types 
would have been included in the sample and this may explain the result of no mtDNA 
depletion.  
Other studies have examined non-CNS tissues including skeletal muscle, liver, and 
fibroblast cells and these have shown variable and tissue-specific mtDNA damage. A 
reported case exhibited a reduced mtDNA content of 8% in skeletal muscle and 8% in 
liver, and in another patient reduced mtDNA content of 23% in liver compared to the 
control (Taanman et al., 2009). In a separate study, a patient showed severely reduced 
mtDNA content of 78% and 15% in skeletal muscle and liver respectively with a normal 
mtDNA content of fibroblasts, relative to controls (Schaller et al., 2011). A patient 
showed reduced mtDNA content of 21%, 27%, and 98% in skeletal muscle, liver and 
blood respectively, compared to controls (Scalais et al., 2012). These studies show 
severely reduced mtDNA content in liver, variably reduced mtDNA content in skeletal 
muscle, and near normal mtDNA content in fibroblast and blood samples. 
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Fibroblasts rarely show mtDNA depletion or acquire the mtDNA defects to the same 
levels seen in post-mitotic cells. The liver shows moderate to high levels of mtDNA 
depletion which coincides with the severe pathology seen during the course of the 
disease. Skeletal muscle shows moderate levels of mtDNA depletion which suggests a 
level of pathology that does not manifest itself during the early stages of the disease. 
Symptoms in skeletal muscle are rarely described in the literature and may indicate a 
sub-pathological role for mtDNA abnormalities in muscle. 
5.5.4 Novel Findings 
This study performed real-time PCR analysis on single neurons from a young patient 
and two teenage-adult patients with POLG disorders. The analysis of individual 
neurons, as opposed to a homogenate tissue sample, has increased the sensitivity of 
the test and allowed the assessment of questions about neuronal vulnerability. MtDNA 
depletion appeared to be a more significant defect in the patients than mtDNA deletion 
levels, signifying that depletion plays a greater role in the disease progression of 
Alpers’ syndrome. Greater levels of mtDNA depletion occur in both the young patient 
and in adult patients suggesting mtDNA depletion is a prominent feature at all ages. 
MtDNA deletions are seen in a subset of neurons from the adult patients but not in the 
young patient, suggesting that mtDNA deletions can accumulate to higher levels over 
time. MtDNA depletion affects neurons in the parietal and frontal lobes in adult patients, 
and the parietal and occipital lobes, as well as the putamen of the basal ganglia in a 
young patient. MtDNA depletion is not detected in the temporal lobe when assessed in 
adult patients. This is a rarely studied brain area in patients as the general clinical 
description of Alpers’ syndrome does not necessarily correlate with temporal lobe 
damage and there is no neuropathological evidence in the pathologist’s report to 
suggest that there is temporal lobe damage in these patients; a finding reiterated in this 
study. 
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5.6 Future Work 
The work performed in this study has highlighted the need for further cellular studies of 
mtDNA abnormalities in patients with POLG mutations and Alpers’ syndrome. The 
effect of mtDNA abnormalities on the respiratory chain and on oxidative 
phosphorylation is not fully understood. Further studies into the mechanism of this will 
add to our understanding of how the disease pathology progresses, particularly in 
patients with clinically diagnosed Alpers’ syndrome where no POLG mutations are 
present. Also, a greater number of controls are required to compare with patient 
results. Suitable control tissue is extremely difficult to obtain due to the sensitivity of the 
age of the control, and this should be taken into account for timescale considerations of 
a study. 
MtDNA depletion appears to play a greater role in disease progression, though mtDNA 
deletions are present in older patients. The types of deletion present in the mtDNA of 
affected neurons will be highly informative of what is happening in the cells and may 
lead to studies of cell therapy that could benefit patients in the early stages of disease. 
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6.1 Introduction 
Mitochondrial disorders represent a significant burden of disease on the population. It 
is estimated that at least one in every two hundred members of a healthy population 
may carry a pathogenic mitochondrial mutation (Elliott et al., 2008) and the risk of 
developing a mitochondrial DNA disease is determined to be on average 16.5 in 
100,000 individuals (Schaefer et al., 2008). The first mitochondrial disease was 
described in 1962 describing a patient with a hypermetabolism disorder (Luft et al., 
1962). Hundreds of mitochondrial disorders have since been described and our 
understanding of the aetiology and mechanisms leading to these disorders has grown. 
Alpers’ syndrome is an early-onset, autosomal recessive disorder primarily affecting 
the CNS and liver. The first report describing the syndrome was made in 1931 (Alpers 
1931) with additional clinical signs of liver involvement described in 1976 (Huttenlocher 
et al., 1976). The discovery that this disorder was primarily due to mutations in POLG 
polymerase (Naviaux et al., 1999) was quickly followed by the report of damage to the 
mtDNA in patients (Naviaux and Nguyen 2004). Previous studies have reported 
neuropathological features that include neuron loss, astrogliosis, and capillary 
proliferation affecting the cerebellum and occipital lobe (Harding 2008; Uusimaa et al., 
2008). White matter abnormalities are investigated much less frequently yet reports of 
myelin loss are intriguing and require much closer scrutiny in future studies (Bao et al., 
2008). Respiratory chain deficiency has been described in a variety of tissue types, 
including skeletal muscle, liver, and fibroblasts (Wiltshire et al., 2008; Schaller et al., 
2011). However, the characterisation of respiratory chain deficiency in single neurons 
has not been previously described in the literature. MtDNA damage has been 
described in patients in the form of mtDNA deletions, mtDNA depletion, or a 
combination of both (Ferrari et al., 2005; Kollberg et al., 2006). However, much of these 
data are based upon the findings in homogenate tissue samples, comprising all cell 
types, which is not considered to be accurate in determining mtDNA damage in 
neuronal cells. 
The aims of this study were to characterise the neuropathological features in four brain 
regions, explore the nature of respiratory chain deficiencies in neurons, and determine 
the predominant type of mtDNA damage in the single neurons of twelve patients with 
Alpers’ syndrome and POLG disorders. 
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6.2 Major Findings 
6.2.1 Neuropathological Features 
A number of histological stains and immunological antibodies were employed to 
investigate a variety of neuropathological features in both patients and controls. These 
were used to explore morphological features, neuron loss, astrogliosis, white matter 
abnormalities, microglial activation, and mitochondrial mass and abnormal 
mitochondrial localisation. 
The cerebellum was the most severely affected area of the brain, with the occipital lobe 
exhibiting moderate pathology. The parietal lobe showed mild pathology and the basal 
ganglia showed almost no pathology but strikingly, this region did show severe white 
matter loss. The most severe neuropathological feature was dependent upon the 
POLG group investigated. The POLG mutation-positive group displayed a more severe 
astrogliosis and severe microglial activation, with low mitochondrial density, while the 
POLG mutation-absent group displayed a more severe myelin loss in all areas. The 
neuropathological differences between groups with or without POLG mutations 
demonstrate differences in the underlying mechanisms of disease formation due to the 
possible different gene mutations. 
Neuron loss was seen in all patients, except stillbirth Patient 5. Neuron loss was found 
to be most severe in the cerebellum and in the upper cortical layers of the occipital lobe 
and parietal lobe. Neuron loss was correlated with astrogliosis in the occipital lobe only. 
Astrogliosis was severe across all groups and there were swollen astrocytes noted in 
some patients. A number of patients showed a reduced mitochondrial mass in neurons, 
most notably Patient 10, where all Purkinje cells showed low mitochondrial density. 
Abnormal mitochondrial localisation was also seen, which was categorised as either a 
perinuclear distribution, distribution around the periphery of the soma, or a weak 
staining of porin at the periphery of the soma. Abnormal localisation was most 
noticeable in the larger Purkinje cells and neurons of the globus pallidus of the basal 
ganglia due to their size and the volume of cell cytoplasm visible. Myelin loss in the 
white matter was a prominent feature and was seen in the cerebellum, occipital lobe, 
and the basal ganglia in 3 of the 4 patients studied. The myelin loss appeared to be 
primary, although in some instances in Patient 12, with no detected POLG mutation, 
there was possible secondary loss of myelin due to axonal loss. The Bielschowsky 
silver stain is difficult to perform and analyse and the results of this method have been 
taken as a guide. Microglial activation was present in most patients and the severity 
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correlated with the severity of astrogliosis. Extremely swollen microglia were seen in 
the occipital lobe of Patient 2, which corresponded with microvacuolation and severe 
myelin loss, possible indicators of the phagocytosis of degenerating cells and large 
amounts of material. Severe neuropathology can be seen in all patients, whether the 
POLG mutation is known or unknown. The posterior areas of the brain, the cerebellum 
and the occipital lobe, are the more severely affected areas. The parietal lobe and 
basal ganglia show less pathology. The neuropathology seen in this cohort suggests 
that the extent and pattern of pathology is variable in patients and that severe 
pathology of the basal ganglia is uncommon. 
Studies using electron microscopy (EM) techniques investigated an Alpers’ syndrome 
patient and controls matched for the length of formalin fixation time. The patient had 
sparser cytoplasm and fewer visible cellular organelles than both controls, suggesting a 
more rapid cellular breakdown due to pre-fixation factors. Electron-dense inclusions 
were seen within the mitochondria of brain tissue examined from a patient diagnosed 
with Alpers’ syndrome and in control tissue, which was tested at the same time. 
Investigations of control tissue have not been previously reported in the literature, 
possibly due to the testing of patient tissue only. 
It is important to investigate and record the neuropathology present in patients with 
Alpers’ syndrome. It provides clear guidelines of the pathology found in the CNS of 
patients, allowing neuropathologists to confirm a patient diagnosis and to expand the 
diagnostic criteria for future use. 
6.2.2 Respiratory Chain Deficiency 
A battery of antibodies was used to all four complexes in the electron chain in order to 
investigate respiratory chain deficiency in single neurons of patients. A semi-
quantitative assessment of Purkinje cells and pyramidal neurons of cortical layer V was 
performed. These are large neurons with a relatively large area of visible cytoplasm by 
which to visually evaluate respiratory chain dysfunction. 
A predominant loss of complex I and complex III in the cerebellum, parietal lobe and 
basal ganglia was seen. The occipital lobe showed almost no respiratory chain loss in 
neurons. This was very surprising and it is possible that there has been a loss of 
deficient neurons, while neurons with a relatively intact respiratory chain remain. It is 
also possible that the respiratory chain deficiency may be present in smaller neurons of 
a different subtype which are too small to accurately examine in the setting of this 
project. The most severe respiratory chain deficiency was seen in patients of the POLG 
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mutation-undetermined group, reflecting the effect of unknown mutations that are 
present in this group. 
Complex I and complex III showed a more severe deficiency over all brain areas. This 
may be due to the large size and relative instability of complex I. Complex I is reported 
to interact with complex III in the formation of the supercomplex (Acín-Pérez et al., 
2004) and that disruption of these complexes can lead to increased ROS production 
(Maranzana et al., 2013). This may lead to damaged mitochondria and mtDNA, leading 
to further respiratory chain deficiency. In some patients, complex III deficiency was 
severe with a much milder complex I deficiency. In Patient 2 and Patient 10 this severe 
complex III deficiency with a milder complex I deficiency is clear. This suggests that a 
complex III deficiency may be tolerated by the surviving neurons and could serve as an 
indicator of respiratory chain dysfunction in surviving neurons. It is possible that the 
variability in antibody staining may be partly due to other factors, including antibody 
staining technique and the analysis of different brain regions. 
Complex II showed a moderate deficiency in the Purkinje cells of Patient 10. This was 
the only patient to exhibit a complex II deficiency. In Patient 10, this deficiency is linked 
to low mitochondrial density which is present in all Purkinje cells. In a number of 
patients, complex IV-I (COX I) showed a slight deficiency, and always a greater 
deficiency than complex IV-IV (COX IV). This may be due to mtDNA damage that has 
decreased COX I availability, a mitochondrially-encoded subunit. This damage would 
not have directly affected COX IV, a nuclear-encoded subunit. However, the 
mitochondrially-encoded COX I subunit showed a milder deficiency than with nuclear-
encoded complex I and complex III subunits. This was unexpected and it may be that 
other mitochondrially-encoded subunits of complex I and complex III that had not been 
examined had been lost and that this destabilised the entire complex. 
Respiratory chain deficiency represents an important pathological phenotype of 
mitochondrial disease. Multiple deficiencies of complex I, III, and IV have been found in 
neurons of this cohort of patients, with a wide variability in antibody staining exhibited 
across all patients. This variability and deficiency over different brain areas suggests 
the possibility of an epigenetic effect upon the mitochondria in these neurons. 
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6.2.4 MtDNA Deletion and Depletion 
Both SDH staining and real-time PCR was used to assess mtDNA damage in single 
neurons obtained through laser-capture microdissection. From the current literature, it 
is unclear whether mtDNA damage is predominantly mtDNA deletion, mtDNA 
depletion, or a combination of both mtDNA deletion and depletion. Homogenate tissue 
samples are often used to assess this damage. 
In the neurons of both young and adult patients, mtDNA depletion is more severe than 
mtDNA deletion. This occurs in patients irrespective of the POLG mutation status. 
MtDNA deletions were seen at low levels; however these were unlikely to be accurately 
detected by the method of real-time PCR. In a subset of neurons in the adult patients, 
mtDNA deletion levels were detected at high levels of above 70% mtDNA deletion. This 
may indicate a dynamic level of mtDNA loss and a move towards increased numbers of 
neurons with increasing levels of mtDNA deletions. 
MtDNA deletions were assessed in COX-positive and COX-deficient neurons from a 
single adult patient. The COX-deficient neurons were found to harbour greater levels of 
mtDNA deletions than COX-positive neurons. Neurons that displayed both COX-
deficiency and showed levels of mtDNA deletion within the experimental error of this 
assay (<30%), may have a true deletion level that is higher. This is because low levels 
of mtDNA deletions cannot be accurately detected by the real-time PCR method. 
MtDNA damage is linked to respiratory chain deficiency, which has been shown by this 
study to predominantly consist of mtDNA depletion, demonstrating the first report of 
mtDNA abnormalities in single neurons of patients with Alpers’ syndrome. 
6.3 Strengths and Limitations 
This study was carried out with ethical approval from the Newcastle and North Tyneside 
Local Research Ethics Committees, ethical approval number 2002/205. CNS tissue 
donated to the NBTR, University of Vienna, and University of Bonn was used. A major 
strength of this study lies in the large cohort used for the investigations, inclusive of a 
wide age range of patients which reflects the increasing number of reports in the 
literature that describe clinically diagnosed cases of Alpers’ syndrome in older teenage 
patients. Patients both with POLG mutations and without POLG mutations have been 
included to reflect the growing number of cases of Alpers’ syndrome that are clinically 
diagnosed and yet do not harbour a mutation in POLG. Genes currently reported to 
lead to an Alpers’ syndrome-like phenotype include the FARS2 gene (Elo et al., 2012) 
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and C10orf2 gene that codes for the helicase Twinkle (Hunter et al., 2011). There may 
be other genes that lead to an Alpers’ syndrome-like phenotype to be reported in the 
future and next-generation sequencing techniques may be beneficial in these cases, to 
determine the underlying molecular basis of the disorder. 
This study describes the investigation of respiratory chain deficiency in single neurons. 
This is the first time that this has been investigated in single neurons from the brains of 
patients with Alpers’ syndrome and allows for examination of respiratory chain 
deficiencies in the neurons only, as opposed to a mixture of cell types, possibly each 
with a different level of deficiency. This method allows for the assessment of the 
surviving neuronal population exclusively. 
A limitation of this study is the rarity of the disease and the sensitive nature of the tissue 
required, which resulted in considerable difficulty in acquiring suitable tissue from 
young patients and control subjects in all brain areas being investigated. Tissue was 
acquired from a number of facilities and applications were made to many more 
facilities. The suitability of the tissue for each particular branch of investigations was an 
important factor to consider. The tissue that was used for genetic investigations was 
found to be not suitable due to the length of fixation in formalin and embedding in 
paraffin wax. Frozen tissue or a previously extracted DNA sample would have been 
more suitable if available. The tissue for EM studies was of limited suitability due to a 
long fixation time in formalin. Tissue from patients with a short formalin fixation time or 
free from fixation in formalin would have been more suitable if available. There were 
limitations of some of the technique used. Semi-quantitative assessments were 
performed as more fully quantitative methods were not optimised for the retrieval of 
data, as with assessment of the white matter. The employment of quantitative 
densitometric methods would be useful to future studies of myelin loss and respiratory 
chain deficiency. 
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6.5 Future Work 
This research has examined the neuropathological features in a large cohort of patients 
with a range of ages and underlying genetic mutations. In some cases the genetic 
mutation could not be fully assessed, and this highlights the importance of the facilities 
that look after and provide these resources to researchers. 
Efforts to explore the underlying genetic mutations in all patients diagnosed with Alpers’ 
syndrome will allow for a better understanding of the spectrum of POLG disease. 
Patients with clinical signs of Alpers’ syndrome and no mutation in POLG expand the 
genetic classification of Alpers’ syndrome and stress the importance of a genetic 
diagnosis. The use of next-generation sequencing techniques and whole exome 
sequencing may be advantageous in determining the genetic mutations in these 
patients. The finding and categorisation of novel mutations in POLG can further aid our 
understanding of the effect of mutations upon the function of the POLG polymerase. 
Abnormalities of the white matter are infrequently reported in cases of Alpers’ 
syndrome. This study has reported considerable myelin loss in patients, including 
severe loss in the basal ganglia, an area not often associated with evidence of 
neuropathology. This highlights the importance of examining myelin loss, and other 
white matter abnormalities, in brain areas that may show no other neuropathological 
features, such as the basal ganglia. In addition, the use of fully quantitative techniques, 
including densitometric measurements, may remove the investigator bias and allow for 
a more rigorous comparison between patients and controls and between different 
patients. 
A predominant complex I and complex III deficiency of the respiratory chain was 
observed in neurons. The use of cell studies, such as induced pluripotent stem cells 
(iPSCs), may prove beneficial in future investigations to explore any further 
mechanisms behind respiratory chain deficiency, for example whether impaired 
complex assembly is involved. The respiratory chain deficiency seen in glial cells 
warrants further investigation and poses many interesting questions regarding the cell 
type or cell types with a respiratory chain deficiency and the role played by these cells 
in the disease progression of Alpers’ syndrome. iPSC culture systems may be applied 
to both these avenues of further research, having the potential to further explore the 
mechanisms involved in respiratory chain deficiency and possible abnormalities of the 
supercomplex, and allowing these to be studied in different cell types. 
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MtDNA depletion was the more severe consequence of mtDNA damage seen in all 
patients studied. MtDNA deletions were present at high levels in a small subset of 
neurons tested. The types of mtDNA deletions present in neurons, whether mostly 
large-scale deletions or smaller rearrangements, will be of interest and may shed light 
on the function and survival of neurons susceptible to the effect of POLG mutations. 
6.6 Conclusions 
The investigation of patients, from the neuropathology occurring in the brain and the 
presence of respiratory chain dysfunction, to the integrity of mtDNA in a single neuron 
has revealed a variable complex I and complex III deficiency in neurons and glial cells. 
Predominant mtDNA depletion in single neurons with mtDNA deletions occurring in a 
smaller subset of neurons leads us closer to understanding the mechanism of POLG-
induced mtDNA damage, though further investigations are needed to understand the 
mechanism of respiratory chain deficiency and its tissue-specific manifestation. The 
progress towards understanding the mechanism of POLG mutations in the aetiology of 
Alpers’ syndrome is leading us forward, to possible new therapies where there is hope 
for many children and their families. 
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